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The epigenome dynamically regulates chromatin structure to control cellular function and 
homeostasis in a highly specific fashion and mediates the complex interaction between the 
DNA and our environment. Epigenetic mechanisms such as DNA methylation and post-
translational histone modifications contribute to the maintenance of cellular structure, identity, 
and plasticity in a cell type specific manner. Despite the key role epigenetics has in the 
regulation of the genome, there have been relatively few studies that have characterised the 
epigenome in neurons, neither in the healthy aging brain nor in neurodegenerative disease. 
Alzheimer’s disease (AD) is a terminal progressive neurodegenerative disorder. While familial 
mutations account for approximately 10% of cases, the cause of 90% of AD cases is unknown. 
In the absence of highly penetrant risk alleles, epigenetics is well poised to contribute to the 
pathogenesis and progression of AD, but this role is yet to be fully explored. The research in 
this thesis has characterised DNA methylation in post-mortem human AD brains in a cell type 
specific manner, and is the first to characterise key histone modifications in neurons across a 
time-course of healthy aging, and across a time-course in a model of AD.  
Firstly, global DNA methylation (5mC) and hydroxymethylation (5hmC) levels were assessed 
in neuronal and glial cell types in the inferior temporal gyrus of human AD cases and age-
matched controls. Neurofilament (NF)-labelled pyramidal neurons, known to be vulnerable to 
AD pathology were deficient in extranuclear 5mC in AD cases compared to controls. This work 
also demonstrated that fewer astrocytes exhibited nuclear 5mC and 5hmC marks in AD cases 
compared to controls. However, there were no alterations in global levels of 5mC and 5hmC 
in disease-resistant calretinin-interneurons or microglia in AD. Furthermore, no alteration in 
the density of 5mC or 5hmC labelled nuclei was detected in near-plaque versus plaque-free 
regions in late-AD cases. 5mC and 5hmC were present in a high proportion of neurofibrillary 
tangles, suggesting no loss of DNA methylation marks in tangle bearing neurons. This 
demonstrated that global epigenetic dysregulation may be occurring in astrocytes and NF-
positive pyramidal neurons in AD.  
Histone modifications aid in the regulation and compaction of DNA into chromatin. The 
second part of this PhD study was the first to characterise H3K27ac and H3K4me3 markers of 
active enhancer and promoter elements, using chromatin immunoprecipitation and next-
generation sequencing (ChIP-seq) in neurons from the forebrain of C57/BL6 mice at 3, 6, 12, 
and 24 months of age (n=5 per genotype). H3K27ac marking was enriched in young neurons 
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at 3 months of age and old neurons at 24 months of age at a range of genomic regulatory regions 
including promoters proximal to transcriptional start sites, CpG islands around transcriptional 
start sites, enhancers distal to transcriptional start sites, and at known cortical super enhancers. 
H3K4me3 was also enriched at promoters in neurons at 3, 12, and 24 months of age, and at 
enhancers at 3 months of age. Gene ontology analysis predicted that H3K27ac and H3K4me3 
aid in the regulation of neuronal processes including synaptic plasticity, ion channel binding, 
transporter activity, calcium channel activity and cellular metabolic processes. These data also 
point towards a partial recapitulation of a juvenile-like epigenetic state in late aging and 
demonstrate the dynamic nature of the histone landscape in neurons in the aging brain. 
APP/PS1 AD mice closely recapitulate the pathology present in human early-AD cases, 
including beta-amyloid plaque deposition, neuritic dystrophy and plaque-associated synapse 
loss. APP/PS1 mice allow for the examination of the earliest pre-pathology epigenetic changes 
that occur in AD, as well as measurement across a time course of disease progression. The third 
part of this PhD thesis used neuronal nuclei from the forebrain of APP/PS1 mice and age-
matched wild-type control mice (n=5 per genotype) at 3, 6 and 12 months of age that were 
subject to ChIP-seq using antibodies detecting H3K27ac and H3K4me3. These data identified 
enrichment of H3K27ac marking at the transcriptional start site and at cortical super enhancers, 
but depletion from enhancers, in neurons prior to pathology onset in APP/PS1 mice. H3K4me3 
marking was also enriched at the transcriptional start site in neurons prior to pathology onset, 
and in pathology rich cases in APP/PS1 mice. Gene ontology analysis predicted that key 
neuronal specific pathways were disrupted early in AD. These included pathways involved in 
synaptic plasticity, membrane depolarisation and protein localisation, as well as pathways 
involved in cellular maintenance. Both H3K27ac and H3K4me3 marking evolved over time in 
APP/PS1 neurons. In addition, these data point towards a partial recapitulation of a juvenile-
like epigenetic state epigenome in pathology rich neurons, with numerous H3K27ac and 
H3K4me3 marked sites shared between 3 and 12 months of age and the results have also 
identified several novel genes and pathways yet to be investigated in AD. 
In summary, the data presented here show the complex nature of the neuronal epigenome and 
its dynamic response to neuropathology. The neuronal epigenome undergoes dramatic change 
in early adulthood and undergoes a partial recapitulation of a juvenile-like epigenetic state in 
late aging. The epigenome undergoes cell-type specific global loss of DNA methylation, 
occurring in both NF+ pyramidal neurons and astrocytes in AD. Furthermore, the neuronal 
epigenome is dysregulated prior to pathology onset in AD mice, and major restructuring of the 
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histone landscape occurs with dense AD pathology. Taken together, the data presented within 
this thesis demonstrate the evolution of the neuronal epigenome in aging, and dysregulation of 
both DNA methylation and histone modifications in AD.  
9 
Acknowledgements 
I would first and foremost like to thank my supervisors Dr Adele Woodhouse, Dr Phillippa 
Taberlay and Prof James Vickers for their patience, enthusiasm, generosity, support, guidance 
and friendship throughout my PhD. I could not have completed this journey without their 
support, and I am forever grateful for their guidance through my PhD.  
Thank you to Mr Graeme McCormack and Mr Justin Dittmann for their technical support and 
guidance while I was optimising the many protocols for this project. A special thanks to Dr 
Terry Pinfold from the University of Tasmania and Dr Kate Giles, Dr Eric Lam and Mr Rob 
Salomon from the Garvan Institute of Medical Research for their support with flow cytometry, 
and for being welcoming and accommodating during my time at Garvan. I would also like to 
thank the animal care staff and the CFF for their assistance with animal work. Thanks also to 
Mr Aidan Bindoff, Professor Michael Charleston and Prof Mark Robinson for their assistance 
with bioinformatics and programming while I jumped head first into the analysis of ChIP-seq 
data.  
To the members of the Wicking Dementia Research and Education Centre, you have all become 
like a second family to me and provided so much encouragement and friendship throughout 
this journey and made it truly enjoyable. I have learnt so much from all of you. I would also 
like to show my utmost appreciation to all my friends and family for their continued support, 
love, patience and friendship throughout the highs and lows of my PhD.   
Finally, this project could not have happened without the funding and support from the JO and 
JR Wicking Trust (Equity Trustees), Dementia Australia Research Foundation, Yulgilbar 
Foundation, and the Judith Jane Mason & Harold Stannett Williams Memorial Foundation 
(ANZ Masons).  
10 
Contents 
Copyright Statement .................................................................................................................. 2
Statement of Authority of Access .............................................................................................. 3
Statement of co-authorship ........................................................................................................ 4




Common Abbreviations ........................................................................................................... 18
Chapter 1: Introduction ............................................................................................................ 19
Introduction .............................................................................................................................. 20
1.1 Dementia and Alzheimer’s disease ................................................................................ 20
Figure 1.1: Common Alzheimer’s disease pathology ...................................................... 22
1.2 Beta amyloid production, processing & the ‘amyloid cascade hypothesis’ .................. 23
1.3 Tau hypothesis and Neurofibrillary Tangles.................................................................. 24
1.4 Neuropathological stages of Alzheimer’s disease ......................................................... 25
1.5 Transgenic models of Alzheimer’s disease .................................................................... 27
1.6 Cell type specific vulnerability in Alzheimer’s disease ................................................. 30
Figure 1.2: Cell types of the brain ................................................................................... 32
1.7 Genetics, Environment and Alzheimer’s disease ........................................................... 35
Epigenetics ............................................................................................................................... 37
1.8 Regulation of transcription ............................................................................................ 37
1.9 DNA Methylation .......................................................................................................... 38
1.10 Histone modifications .................................................................................................. 40
Figure 1.3: Regulation of chromatin structure through epigenetic modifications ........... 47
11 
Epigenetics in the brain ............................................................................................................ 48
1.11 Dynamic epigenetic regulation in the brain ................................................................. 48
1.12 Epigenetics in the aging brain ...................................................................................... 53
Epigenetics in Alzheimer’s disease ......................................................................................... 56
1.13 DNA methylation in Alzheimer’s disease ................................................................... 56
Table 1.1: DNA methylation alterations in Alzheimer’s disease .................................... 58
1.14 Histone modifications in Alzheimer’s disease ............................................................. 62
Table 1.2: Histone modifications, HAT and HDAC in Alzheimer’s disease .................. 65
1.15 Limitations and challenges of current epigenetic approaches ..................................... 66
Aims & Hypothesis .................................................................................................................. 68
Hypothesis............................................................................................................................ 68
Aim 1: Characterise DNA methylation of specific cell types in Alzheimer’s disease ........ 69
Aim 2: Charting histone modifications in neurons across aging ......................................... 70
Aim 3: Identifying histone modification alterations in neurons in Alzheimer’s disease mice
.............................................................................................................................................. 71
Chapter 2: Methods .................................................................................................................. 72
2.1 Human brain tissue sources and processing................................................................... 73
2.2 Tissue sectioning ............................................................................................................ 73
Table 2.1: Human brain cases used for immunohistochemistry and analysis ................. 74
2.3 Immunohistochemistry .................................................................................................. 75
Table 2.2: Antibodies ....................................................................................................... 76
2.4 Autofluorescence quenching .......................................................................................... 77
2.5 Microscopy .................................................................................................................... 77
2.6 Immunohistochemistry image analysis .......................................................................... 77
2.7 Immunohistochemistry Statistical Analysis ................................................................... 79
2.8 Mouse tissue source and processing .............................................................................. 79
2.9 Genotyping ..................................................................................................................... 79
12 
 
2.10 Isolation of neuronal nuclei ......................................................................................... 80 
2.11 Neuronal nuclei immunolabelling................................................................................ 80 
2.12 Fluorescence activated cell sorting .............................................................................. 81 
Figure 2.1: Gating strategy for isolation of neuronal nuclei ............................................ 84 
Figure 2.2: Difference in histone marking between whole brain homogenate and purified 
neuronal nuclei in wild-type mice and APP/PS1 mice. ................................................... 86 
2.13 Sonication .................................................................................................................... 87 
2.14 DNA purification ......................................................................................................... 87 
2.15 Chromatin immunoprecipitation .................................................................................. 88 
Next-generation sequencing..................................................................................................... 89 
2.16 Library preparation ...................................................................................................... 89 
2.17 Sequencing ................................................................................................................... 89 
Table 2.3: ChIP-seq sequencing depth............................................................................. 90 
Bioinformatic analysis ............................................................................................................. 91 
2.18 Sample pre-processing ................................................................................................. 91 
2.19 Sequence alignment ..................................................................................................... 91 
2.20 Pseudoreplicate generation .......................................................................................... 92 
2.21 Peak Calling ................................................................................................................. 92 
2.22 Differential enrichment analysis with CSAW ............................................................. 93 
2.23 Gene ontology analysis ................................................................................................ 94 
2.24 Putative enhancer track generation .............................................................................. 94 
2.25 Percentage breadth of genomic coverage .................................................................... 95 
2.26 CpG island analysis...................................................................................................... 96 
2.27 Plot generation ............................................................................................................. 96 
2.28 Venn diagram analysis ................................................................................................. 96 
2.29 RNA-seq overlap analysis............................................................................................ 97 
Chapter 3: Neurofilament-labelled pyramidal neurons and astrocytes are deficient in DNA 
methylation marks in Alzheimer's disease ............................................................................. 100 
13 
3.1 Introduction ...................................................................................................................... 101
3.2 Results .............................................................................................................................. 103
3.2.1 Less extranuclear 5mC labelling in pyramidal neurons in cortical layer 5 of late-AD 
cases ................................................................................................................................... 103
Table 3.1: Power Calculations ....................................................................................... 104
Figure 3.1: A significantly lower proportion of NF-rich pyramidal neurons co-localised 
with 5mC in cortical layer 5 of late-AD cases ............................................................... 105
3.2.2 No difference in the percentage of calretinin-labelled interneurons co-localised with 
5hmC/5mC between case types ......................................................................................... 106
Figure 3.2: No significant difference in calretinin-labelled interneurons co-localised with 
5mC or 5hmC through the progression of AD............................................................... 107
3.2.3 No difference in the percentage of microglia that co-localised with 5mC and 5hmC 
between case types ............................................................................................................. 108
Figure 3.3: No significant difference in microglia co-localised with 5mC or 5hmC through 
the progression of AD .................................................................................................... 109
3.2.4 Less nuclear 5mC and 5hmC in astrocytes in late-AD cases compared to control and 
early-AD cases ................................................................................................................... 110
3.2.5 A high proportion of NFT’s co-localised with 5mC and 5hmC ............................... 110
Figure 3.4: A significantly lower proportion of astrocytes co-localised with 5mC and 
5hmC in late-AD cases compared to control ................................................................. 111
Figure 3.5: No significant difference in NFTs co-localised with 5mC or 5hmC through the 
progression of AD .......................................................................................................... 112
3.2.6 No difference in the density of 5mC and 5hmC positive nuclei in near-plaque and 
plaque-free regions of interest in late-AD cases ................................................................ 113
Figure 3.6: No difference in the density of 5mC and 5hmC positive nuclei in near-plaque 
and plaque-free regions of interest in late-AD cases ..................................................... 114
3.3 Discussion ........................................................................................................................ 115
Table 3.2: Change in labelling of late-AD cases compared to controls......................... 115
Chapter 4: Alteration of the neuronal epigenome in the aging brain ..................................... 120
14 
 
4.1 Introduction ...................................................................................................................... 121 
4.2 Results .............................................................................................................................. 123 
4.2.1 Histone acetylation changes in neurons during development and aging .................. 123 
Figure 4.1: H3K27ac is enriched during development and in aging neurons ................ 124 
4.2.2 H3K27ac is enriched at TSS in neurons during development and late aging ........... 125 
Figure 4.2: H3K27ac is enriched at the TSS in neurons during development and late aging
........................................................................................................................................ 127 
4.2.3 H3K27ac marking is enriched at putative enhancers and cortical super enhancers in 
development and late aging ............................................................................................... 128 
Figure 4.3: H3K27ac is enriched at enhancers and super-enhancers in neurons in 
development and aging .................................................................................................. 130 
4.2.4 H3K27ac marking of the epigenome annotates to synaptic pathways in aging ....... 131 
Figure 4.4: H3K27ac alterations in neurons annotate to pathways involving synaptic 
plasticity and RNA modifications in the aging brain..................................................... 132 
4.2.5 H3K27ac marking is evolving in neurons, and demonstrate a partial recapitulation of 
development in neurons from the aging brain ................................................................... 133 
Figure 4.5: Evolution of differential H3K27ac marking and partial recapitulation of a 
juvenile-like epigenetic state in aging neurons .............................................................. 134 
4.2.6 H3K4me3 marking is enriched in neurons in the developing and aged brain of C57/BL6 
mice .................................................................................................................................... 135 
Figure 4.6: H3K4me3 is enriched in neurons of the developing and aging brain ......... 137 
4.2.7 H3K4me3 marking at promoters in neurons is enriched at 3 months, depleted at 6 
months, and re-established with age .................................................................................. 138 
Figure 4.7: H3K4me3 is enriched in promoters in neurons during development and aging
........................................................................................................................................ 140 
4.2.8 Enhancers exhibit minimal H3K4me3 enrichment in neurons across ages .............. 141 
Figure 4.8 Enhancers in neurons exhibit minimal H3K4me3 marking across aging .... 142 
4.2.9 H3K4me3 is annotated to pathways involving cellular function, maintenance, and post-
translational modifications in aging neurons ..................................................................... 143 
15 
 
Figure 4.9 In neurons differential H3K4me3 marking across aging occurs at promoters 
responsible for core molecular and post-transcriptional functions ................................ 144 
4.2.10 Sites of H3K4me3 enrichment are shared between the developing and aging brain
............................................................................................................................................ 145 
Figure 4.10 Sites of H3K4me3 enrichment are shared between the developing and aging 
neurons ........................................................................................................................... 147 
4.3 Discussion ........................................................................................................................ 148 
Chapter 5: Alteration of the neuronal epigenome occurs prior to pathology onset and is altered 
throughout Alzheimer’s disease progression ......................................................................... 161 
5.1 Introduction ...................................................................................................................... 162 
5.2 Results .............................................................................................................................. 164 
5.2.1 Histone acetylation is enriched in neurons early in the APP/PS1 mouse model of AD
............................................................................................................................................ 164 
Figure 5.1: Global dysregulation of H3K27ac in neurons prior to pathology onset in 
APP/PS1 mice ................................................................................................................ 165 
5.2.2 H3K27ac is enriched at TSS in neurons prior to pathology onset in the APP/PS1 mice
............................................................................................................................................ 166 
Figure 5.2: H3K27ac enrichment occurs at transcriptional start sites in neurons from 
APP/PS1 mice prior to pathology onset......................................................................... 167 
5.2.3 H3K27ac is reduced at enhancers genome-wide, but enriched at the majority of cortical 
super-enhancers in neurons prior to pathology onset in APP/PS1 mice ............................ 169 
Figure 5.3: H3K27ac is depleted from putative enhancers in APP/PS1 neurons prior to 
pathology onset .............................................................................................................. 172 
Figure 5.4: A subset of cortical super-enhancers are enriched for H3K27ac in APP/PS1 
neurons at 3 months ....................................................................................................... 173 
5.2.4 H3K27ac marking of the epigenome changes in neurons at sites associated with 
synaptic plasticity and post-translational modification pathways ..................................... 174 
Figure 5.5: H3K27ac alterations affects synaptic plasticity and post-translational 
modification regulatory pathways in neurons in APP/PS1 neurons .............................. 175 
16 
 
5.2.5 H3K27ac reprogramming occurs early and changes over time in APP/PS1 neurons
............................................................................................................................................ 176 
Figure 5.6: Alteration of H3K27ac marking in neurons across pathology accumulation in 
APP/PS1 neurons ........................................................................................................... 178 
Table 5.1: H3K27ac marking is consistently enriched in pre-pathology and pathology rich 
neurons ........................................................................................................................... 179 
5.2.6 Differential enrichment of H3K4me3 marking prior to pathology onset, and with 
increasing age in APP/PS1 neurons ................................................................................... 179 
Figure 5.7: H3K4me3 is dysregulated prior to pathology onset, and with increasing age in 
APP/PS1 neurons ........................................................................................................... 181 
5.2.7 H3K4me3 is enriched at TSS at pre-pathology and pathology-rich time-points in 
APP/PS1 neurons ............................................................................................................... 182 
Figure 5.8: H3K4me3 is enriched at TSS at pre-pathology and pathology-rich timepoints 
in APP/PS1 neurons ....................................................................................................... 184 
5.2.8 H3K4me3 is not dysregulated at enhancers in APP/PS1 neurons ............................ 185 
Figure 5.9: H3K4me3 marking is not dysregulated at enhancers in APP/PS1 neurons 186 
5.2.9 H3K4me3 marking is enriched at sites associated with core molecular processes in 
APP/PS1 neurons ............................................................................................................... 187 
Figure 5.10: H3K4me3 marking occurs at promoters responsible for core molecular and 
post-transcriptional modification pathways ................................................................... 188 
5.2.10 H3K4me3 differential enrichment peaks at pre-pathology and pathology rich time-
points in APP/PS1 neurons ................................................................................................ 189 
Figure 5.11: H3K4me3 differential enrichment peaks at pre-pathology and pathology-rich 
time-points in APP/PS1 neurons .................................................................................... 190 
Table 5.2: H3K4me3 marking is consistently enriched in pre-pathology and pathology 
rich neurons .................................................................................................................... 191 
5.2.11 H3K27ac and H3K4me3 are enriched in known AD risk variants ......................... 192 
Table 5.3: H3K4me3 and H3K27ac are differentially enriched at AD risk loci ........... 193 
5.2.12 H3K27ac and H3K4me3 enriched sites are transcribed in human AD cases ......... 194 
17 
 
Figure 5.12: Genes differentially enriched for H3K27ac and H3K4me3 marking are also 
differentially expressed in human AD ........................................................................... 195 
5.3 Discussion ........................................................................................................................ 196 
Chapter 6: Discussion ............................................................................................................ 211 
Table 6.1: Pathways of H3K27ac and H3K4me3 enrichment in aging neurons ........... 214 
Table 6.2: Pathways enriched for H3K27ac and H3K4me3 marking in APP/PS1 neurons
........................................................................................................................................ 216 
Table 6.3: Many pathways of H3K27ac and H3K4me3 marking are shared between aging 
and AD ........................................................................................................................... 219 
6.1 Strengths, limitations and future directions ................................................................. 220 
6.2 Conclusions .................................................................................................................. 224 
References .............................................................................................................................. 226 
Appendix 1 ............................................................................................................................. 265 
General solutions ............................................................................................................... 265 
Immunohistochemistry solutions ....................................................................................... 266 
Nuclei extraction solutions ................................................................................................ 267 
Appendix table 1: Nuclei extraction buffer solution ...................................................... 268 
Chromatin Immunoprecipitation buffers ........................................................................... 269 
Appendix table 2: Chromatin immunoprecipitation buffers .......................................... 269 
Appendix 2 ............................................................................................................................. 270 
Appendix 2: Supplementary Figure 1: Polyclonal 5hmC antibody versus mouse 
monoclonal 5hmC antibody labelling ............................................................................ 271 
Appendix 2: Supplementary Figure 2: Correlations detected between cell-type specific 
DNA methylation data and PMI or Age ........................................................................ 272 
Appendix 2: Supplementary Figure 3: Dysregulation of H3K27ac marking at enhancers 






AD  Alzheimer’s disease 
APP  Amyloid protein precursor 
ApoE  Apoliopoprotein E 
Aβ  Amyloid beta 
BACE  Beta secretase 
CBP  Calcium binding protein 
CpG  Cytosine guanine dinucleotides 
CrBP  Creb binding protein 
CREB   Cyclic-AMP response binding protein 
DN  Dystrophic neurite 
DNA  Deoxyribonucleic acid  
DNMT DNA methyltransferase 
EGR1  Early-growth-response protein 1 
FACS  Fluorescence activated cell sorting 
IBA1  Ionised calcium-binding adapter 1 
LOAD  Late-onset AD 
LTD  Long-term depression 
LTP  long-term potentiation 
MAPT  Microtubule associated protein tau 
MCI  Mild cognitive impairment 
MFG  Middle frontal gyrus 
MTG  Middle temporal gyrus 
NF+  Neurofilament positive  
NeuN  Neuronal nuclei antibody 
NFT  Neurofibrillary tangle 
NT  Neuropil threads 
NMDA N-methyl-D-aspartate 
PS1  Presenilin 1 
PS2  Presenilin 2 
TET  Ten eleven translocase 
5mC  5-methylcytosine 










1.1 Dementia and Alzheimer’s disease 
Dementia is a syndrome that covers a range of neurological disorders, including frontotemporal 
lobar dementia, dementia with Lewy bodies and Alzheimer’s disease. These disorders manifest 
as progressive cognitive decline and memory loss. Since its discovery by Alois Alzheimer in 
1906, Alzheimer’s disease (AD) has been identified as the most common form of dementia, 
accounting for more than 70% of all dementias, with an estimated 46.8 million people living 
with dementia globally (Alzheimer's Disease International, 2015). Alzheimer’s disease is a 
terminal, progressive, neurodegenerative disorder, that represents a large financial and 
socioeconomic burden, with dementia expenditure in Australia increasing to an estimated 
$14.67 billion per annum in 2017 (Brown, Hansnata, & La, 2017).   
Although AD develops and progresses differently in each person living with dementia, there 
are general similarities that can be used for diagnosis of the disease. Common clinical 
symptoms for AD include cognitive impairment, memory loss, changes to emotion, and 
changes in sensory perception (Förstl & Kurz, 1999), each reflecting underlying pathological 
changes in the brain. The pathological hallmarks of AD include extracellular beta-amyloid 
plaques (Aβ), intraneuronal neurofibrillary tangles (NFTs) of microtubule associated protein 
tau, aberrant neuronal processes of neurofilaments, scaffolding or signalling proteins termed 
dystrophic neurites (DNs), and neuropil threads (NTs), which are aggregates of tau and 
ubiquitin (Braak & Braak, 1991; G. Perry et al., 1991) (Figure 1.1). Widespread cortical 
atrophy, neuronal and synaptic loss are also observed in late-stage AD cases (Braak & Braak, 
1991; Brun & Englund, 1981; P. R. Hof, Cox, & Morrison, 1990; L. F. Lue, Brachova, Civin, 
& Rogers, 1996; Mitew, Kirkcaldie, Dickson, & Vickers, 2013b; Terry et al., 1991). There are 
a number of familial, dominantly inherited genetic alleles that contribute to the early onset of 
AD (EOAD), which leads to clinical symptoms prior to 65 years of age and a more aggressive 
phenotype when compared with late-onset AD (LOAD) (Chartier-Harlin et al., 1991; van Duijn 
et al., 1994). The key pathological features of AD consist of accumulations of abnormal 
insoluble protein aggregates within the brain, however, the driving mechanisms for disease 








Figure 1.1: Common Alzheimer’s disease pathology 
Schematic of the pathology characteristic of AD. Extracellular Aβ plaques (orange), 
intracellular NFTs (green) in excitatory neurons (blue). Tau and ubiquitin pathology 
accumulate in the extracellular space as dystrophic neurites (green around plaques) proximal 
to Aβ plaques, and neuropil threads. Insoluble NFT pathology persists as ghost tangles (green, 
hollow) after the neuron has deteriorated, some of which are engulfed by astrocytes. Images 
depicting neurofibrillary tangles (left, green), Aβ plaques (middle, red), and dystrophic neurites 




1.2 Beta amyloid production, processing & the ‘amyloid cascade hypothesis’ 
The major constituent of the insoluble protein aggregates in AD is from the amyloid beta (Aβ) 
protein. Aβ is formed as a product from the processing and cleavage of the amyloid precursor 
protein (APP), which is a membrane bound protein with roles in neuronal survival, neurite 
outgrowth and in signal transduction (review: (Dawkins & Small, 2014)). Proteolytic cleavage 
of APP is accomplished by two pathways: APP is cleaved by α-secretase and γ-secretase 
complexes, generating sAPPα and P3 fragment. Amyloid precursor protein can also be cleaved 
by β-secretase (BACE) in the extracellular domain (n terminus) generating sAPPβ (Vassar et 
al., 1999). The sAPPβ fragment is then cleaved by the γ-secretase complex to generate Aβ 1-
40 and 1-42, which are prone to aggregation and lead to the formation of plaques (review: 
(Rajendran & Annaert, 2012; Thinakaran & Koo, 2008)). Early onset AD (EOAD) is associated 
with mutations in the presenilin protein genes (PS1, PS2) and APP genes; highly penetrant 
autosomal dominant mutations which lead to increased generation of Aβ 1-40 and 1-42 and 
contribute to plaque accumulation in AD (review:(Czech, Tremp, & Pradier, 2000)). These 
mutations form the basis of many in vivo models of AD (De Strooper et al., 1998; Scheuner et 
al., 1996). Increased Aβ 1-40 and 1-42 also lead to a rise of soluble, oligomeric Aβ within the 
brain (James P. Cleary et al., 2004; C. A. McLean et al., 1999). Studies have implicated 
oligomeric Aβ to cause much of the toxicity and synaptic loss seen in AD, rather than fibrillar 
plaques (James P Cleary et al., 2005; Koffie et al., 2009a; C. A. McLean et al., 1999). 
Dystrophic neurites (DN) are another common pathology formed from inclusions of 
neurofilament processes, APP, ubiquitin, and tau, and can aggregate to form neuritic plaques 
(Tracey C. Dickson, King, McCormack, & Vickers, 1999; Mitew et al., 2013b; J. C. Vickers 
et al., 1996; Adele Woodhouse, James C. Vickers, Paul A. Adlard, & Tracey C. Dickson, 2009).  
The ‘amyloid cascade hypothesis’ posits that the accumulation of Aβ acts as the driving 
mechanism for AD onset and progression, likely through an imbalance between Aβ production 
and clearance, with intracellular changes in tau, neuronal loss and vascular damage occurring 
as a secondary consequence (J. A. Hardy & Higgins, 1992). The clearest evidence in support 
of the amyloid cascade hypothesis is that genetic mutations in genes associated with EOAD 
are all involved in APP processing, including APP (Citron et al., 1992; Goate et al., 1991), 
S182/PS1 (Sherrington et al., 1995), PS2 (Levy-Lahad et al., 1995), and the ApoE ε4 mutation 
(Strittmatter et al., 1993), all of which have been established as autosomal dominant risk factors 
for AD (review: (Czech et al., 2000)). Indeed, some studies have identified stronger 
correlations between Aβ peptides (including soluble Aβ40,42) cognitive decline, and synaptic 
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alterations, rather than Aβ deposits (L.-F. Lue et al., 1999; Näslund, Haroutunian, Mohs, & et 
al., 2000) (review:(Selkoe, 2008)). While it has also been shown that mutations in APP are 
protective against AD (Jonsson et al., 2012). Neuritic plaque load has also been shown to be 
associated with the severity of cognitive impairments in AD (Cummings & Cotman, 1995). 
Strong support for the amyloid cascade hypothesis is also present within Down syndrome. The 
genetic basis of Down syndrome is trisomy of chromosome 21, which is the chromosome 
containing the APP gene (Kang et al., 1987; St George-Hyslop et al., 1987). Subsequent over-
expression of proteins on chromosome 21 results in accumulation of Aβ pathology consistent 
between AD and Down syndrome (Masters et al., 1985). While the Aβ hypothesis provides a 
strong framework for the onset and progression of AD there are several concerns worth noting, 
including that Aβ deposits do not correlate with the rate of cognitive decline (Berg, McKeel, 
Jr, Miller, & et al., 1998). Amyloid beta plaques have also been observed in patients with no 
cognitive impairment (Crystal et al., 1988), though this may be due to individuals having a 
higher cognitive reserve (review: (J. Hardy, 2002)). In the absence of Aβ driving disease 
pathogenesis, studies have developed an alternative hypothesis of tau driving AD based 
neurodegeneration. 
 
1.3 Tau hypothesis and Neurofibrillary Tangles 
The tau hypothesis stipulates that mutations altering the composition or function of tau lead to 
abnormal phosphorylation of the protein. The key component of the NFT aggregates observed 
in AD is paired helical filaments of hyperphosphorylated tau, usually present in the soma of 
some subsets of excitatory neurons (Grundke-Iqbal et al., 1986). The protein accumulation and 
cellular dysfunction leads to the development of Aβ plaques as a downstream consequence. 
Tau is a microtubule-associated protein that is well established in the development and stability 
of microtubules (Cleveland, Hwo, & Kirschner, 1977; Weingarten, Lockwood, Hwo, & 
Kirschner, 1975). The microtubule-associated protein tau (MAPT) gene is alternatively spliced 
to form tissue and cell-type specific isoforms (Goedert, Spillantini, Jakes, Rutherford, & 
Crowther, 1989). Studies have identified loss of tau to increase Aβ autophagy and deposition 
in vivo (Lonskaya, Hebron, Chen, Schachter, & Moussa, 2014). While other studies have 
shown a reduction in tau improves cognitive outcome in APP expressing mice with a Aβ 
burden, and reduces excitotoxicity in those models (Roberson et al., 2007). Studies have shown 
tau accumulation and NFTs to correlate with progressive cognitive decline in AD (Arriagada, 
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Growdon, Hedley-Whyte, & Hyman, 1992; Berg et al., 1998; M. E. Murray et al., 2015). 
Recently, positron-emission tomography imaging of tau in human temporal lobe correlated 
with cognitive decline and AD severity (Brier et al., 2016).  
Tau-mediated neurodegeneration in AD has been hypothesised to occur because of either a 
toxic gain-of-function, or because of a loss of normal function of the tau protein, leading to cell 
loss and subsequent clinical symptoms. Hyperphosphorylation of tau leads to tau aggregating 
in the form of NFTs. Neurofibrillary tangles prevent the normal transport of vesicles, leading 
to a toxic loss of function and detachment of tau molecules from microtubules. This causes an 
overall compromise of normal axonal transport (review:(Ballatore, Lee, & Trojanowski, 
2007)). Despite progress in detection of AD and longitudinal studies of disease progression, 
correlations between amyloidosis, tauopathies and AD clinical symptoms are contradictory and 
the underlying cascade of events that leads to AD onset and subsequent neurodegeneration 
remain unknown (Berg et al., 1998). 
 
1.4 Neuropathological stages of Alzheimer’s disease  
Extracellular Aβ plaques and intraneuronal NFTs accumulate throughout AD progression and 
can be characterised into several stages (Braak & Braak, 1991). The most widely accepted 
classification has been produced by Braak & Braak (1991), who characterised plaque and NFT 
formation in post-mortem AD tissue (Braak & Braak, 1991). Braak & Braak (1991) detected 
inter-individual differences in plaque formation and distribution that were highly variable, but 
could be characterised into three stages as follows: In the first stage (A) low density Aβ deposits 
are present in basal areas of the frontal, temporal and occipital cortices, with some deposition 
in the presubiculum and entorhinal cortex, however no Aβ deposits are present in the 
hippocampus. In stage (B), there is an increased density of Aβ in the neocortex, with mild 
deposition in the hippocampal formation and relatively little involvement of the of primary 
sensory and motor cortex. Aβ deposition accumulates in cortical layers V and VI of in the basal 
parts of the frontal, temporal and occipital cortical regions, while layers II/III contain fewer 
plaques than V and VI but feature more densely packed cores. In the final, and most severe 
stage (C) neocortical areas exhibit dense packed Aβ with moderate amyloid deposition of 
primary neocortical areas, that are mainly localised in layer II, III and V (Braak & Braak, 1991). 
Another major study has utilised positron-emission tomography to confirm amyloid deposition 
through AD progression in living participants, confirming Aβ progression to start in the 
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temporobasal cortices, then spreading through association areas of the neocortex, and finally 
through primary sensory, motor cortex and medial temporal lobe and striatum (Grothe et al., 
2017). The hippocampus contains limited amyloid pathology early in disease (stage A), but has 
limited Aβ accumulations by stage B, and is fully involved by stage C. Striatum and other 
subcortical structures gradually accumulate Aβ pathology, however substantia nigra and pars 
compacta rarely show Aβ deposits. 
Braak & Braak (1991) were also able to produce a pathological classification of AD based on 
intracellular NFT pathology, and six stages were established for classification: Stage I: Very 
few NFTs are detected in cortical areas, with only limited accumulations in excitatory 
projection neurons in regions between the entorhinal cortex and the temporal cortex (termed 
‘trans-entorhinal cortex’) (Braak & Braak, 1985, 1991). Stage II: The trans-entorhinal cortex 
exhibits numerous NFTs. NFTs begin to accumulate in the CA1 hippocampal sub-region. Stage 
III: NFTs progress through the entorhinal cortex, with numerous dendrites containing NTs. 
Few NFTs are present in the basal frontal, temporal and occipital cortex in layers II/III and V. 
Ghost NFTs are present in the trans-entorhinal region. Stage IV: NFTs are widely dispersed 
throughout the CA1 region of the hippocampus, while still only having mild isocortical 
involvement. Stage V: Ghost tangles can be found in pre-α projection neurons, and numerous 
NFTs are seen in all regions of the hippocampus. In stage V, the occipital and temporal 
neocortex is affected by NFT pathology, however there is resistance in the occipital and 
temporal neocortices, Stage VI: In stage VI, NFTs are more pronounced, wide accumulations 
of ghost tangles are present within the entorhinal pre-α subregion. Ghost NFTs may also be 
degraded and glial populations are present at the site of debris. The CA1 region of hippocampus 
has severe loss of neuronal cells, and vast NT presence. The major distinguishing feature of 
stage VI is that isocortical regions are severely affected with dense NT formations, ghost 
tangles and glial formations (Braak & Braak, 1991). 
Another method for staging AD was established in 1989 which included psychological 
assessment from mild cognitive impairment (MCI) through to post-mortem analysis. The 
Consortium to Establish a Registry for Alzheimer’s disease (CERAD) includes a battery of 17 
clinical and neuropsychological assessments including the Mini-Mental State Examination, 
measurements of episodic memory, and immediate and delayed recall for assessment of 
clinically diagnosed AD, often followed by post-mortem analysis of plaque load and tangle 
pathology (Moms et al., 1989). 
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The use of pathological and clinical staging allows for measurement of disease progression, 
allowing for study of the healthy, preclinical, MCI, and late-stage AD. However, as the first 
pathological changes in AD can occur up to 17 years prior to clinical symptoms, it is difficult 
to identify mechanistic changes occurring during the onset and early progression of AD 
(Rodriguez-Vieitez et al., 2016).  
 
1.5 Transgenic models of Alzheimer’s disease 
Despite current research with post-mortem human tissue, it is not possible to detect the first 
changes associated with disease onset and there is difficulty identifying changes that occur in 
the earliest stages of AD progression using post-mortem human tissue. Thus, several key 
murine models have been developed to investigate the onset and mechanisms of early AD 
pathology progression. These transgenic AD models are based on human familial AD 
mutations in App, Ps1/Ps2 and Mapt, some of which are detailed below:  
 Tg2576 – The Tg2576 is an over-expression of the Swedish mutation KM670/671 
familial APP gene (APPswe) (Lys670-Met, Met671-Leu), driven by a hamster prion protein 
promoter (hPRP) vector, with expression present throughout the CNS (Hsiao et al., 1996). This 
model expresses APP with 5-fold increase compared to endogenous mouse APP, and a 14-fold 
increase Aβ 1-40/1-42, has behavioural deficits in spatial learning and working memory by 9-
10 months, and plaque deposition at 11 months of age. (Elder, Gama Sosa, & De Gasperi, 2010; 
Hsiao et al., 1996). There is no tau pathology or overt neuronal loss present in this model, 
though synaptic deficits have been noted  
 APP22/23 – This mouse model is based on over-expression of mutant human APPswe 
leading to Aβ deposition in the neocortex by 6 months of age (Sturchler-Pierrat et al., 1997). 
Key differences between APP22/23 and the Tg2576 is the promoter used for driving over-
expression, with APP22/23 utilising the Thy1 promoter to drive over-expression, which is a 
neuronal house-keeping gene. This model exhibited cognitive impairment in spatial memory 
from 3 months of age (P. H. Kelly et al., 2003; Van Dam et al., 2003), with neuronal loss 
reported in adult mice from 12 months of age (Calhoun et al., 1998).  
 APP/PS1 – This model is based on the C57/BL6 background harbouring familial AD 
mutations: human APPswe (KM670/671NL or K595N/M596L APP695swe mutations 
depending on strain) and PS1 (L166P/dE9) under the Thy1 or mouse Pnrp promoter 
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(Jankowsky et al., 2004; Spanopoulou, Giguere, & Grosveld, 1991). Plaque deposition begins 
from 6 months of age, with dense plaque deposition by 12 months of age (Garcia-Alloza et al., 
2006; Jankowsky et al., 2004)). Global neuronal loss is not observed, with only limited 
neuronal loss occurring at 8 months of age (Radde et al., 2006). Studies have reported cognitive 
deficits in spatial awareness and memory with the Morris water maze by 6 months (Gallagher, 
Minogue, & Lynch, 2013; Serneels et al., 2009). Studies have shown increased levels of tau in 
the CSF of APP/PS1 mice, and tau labelled neuritic accumulations, but no NFT accumulation 
(Maia et al., 2013; Radde et al., 2006). Synaptic loss occurs for Vglut-1, VGAT, and GAD65 
immunopositive boutons in 12-month APP/PS1 mice, closely recapitulating human disease 
(Mitew, Kirkcaldie, Dickson, & Vickers, 2013a). Synaptic loss has also been reported to occur 
in dendritic spines with proximity to Aβ plaques at 3 months of age from in vivo live imaging 
(Bittner et al., 2012). 
5xFAD – A subsequent model has been developed based around the APPswe 
KM670/671NL and Ps1 (M146L), but also incorporating 3 more familial AD mutations: App 
I716V, App V717I and PS1 L286V. This model has a more aggressive pathogenic phenotype, 
with interneuronal accumulations of Aβ observed by 1.5 months of age, and plaque deposition 
detected by 2 months of age (Oakley et al., 2006). This model also features synaptic loss and 
neuronal loss by 6 months, however no NFT formation occurs in this model (Oakley et al., 
2006). 
 HTau – Murine models have been developed of human tau accumulation, featuring 
multiple isoforms of non-mutated human tau. Key pathology includes age dependent 
accumulation tau, resulting in the redistribution and hyperphosphorylation of tau in cell bodies 
and dendrites of the hippocampus and cortex (Andorfer et al., 2003; Maeda et al., 2016). 
Intraneuronal accumulations of hyperphosphorylated tau were present between 3-5 months of 
age, particularly in the hippocampus, with NFT formation evident by 15 months of age 
(Andorfer et al., 2003). Spatial learning and memory deficits were observed at 12 months of 
age, measured by novel object recognition, and Morris water maze (Polydoro, Acker, Duff, 
Castillo, & Davies, 2009). 
Tau P301S – This model develops NFT-like pathology due to the expression of a 
transgene of mutant human tau, driven by a mouse prion protein promoter (Allen et al., 2002; 
Yoshiyama et al., 2007). NFTs were reported in hippocampus, neocortex and entorhinal cortex 
at 4 months of age, and synaptic loss and gliosis have been observed in the hippocampus by 3 
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months. Cortical atrophy (loss of up to 25%) and hippocampal atrophy of (loss of 45%) has 
been observed at 12 months of age, with neuronal loss starting at 3 months of age (Hampton et 
al., 2010; Yoshiyama et al., 2007).  
Knock in AD mice (AppNL and AppNLF, AppNLGF) –  More recently, genetic knock-in AD 
mice have been established in an attempt to minimise the artefact generation that feature in 
genetic over-expression models, that often result in disruption of endogenous gene expression, 
and over-express other APP products as well as Aβ (Saito, Matsuba, Yamazaki, Hashimoto, & 
Saido, 2016). Knock in AD mouse models expressed mutant human App (Swedish KM670/671 
in AppNL, and Swedish KM670/671 with beyreuther/Iberian mutations I716F in AppNLF), which 
increase both the expression of Aβ and increase the proportion of Aβ1-42 in comparison to Aβ1-
40 (Takashi Saito et al., 2014). The AppNLF model generated Aβ plaques in the cortex by 6 
months that also exhibited immunoreactivity for activated astrocytes and microglia (Takashi 
Saito et al., 2014). AppNLF mice also exhibited memory loss at 18 months. AppNLGF mice 
exhibited Aβ plaque accumulation at 2 months of age, and greater microglial and astrocyte 
activity (Takashi Saito et al., 2014).  
Triple transgenic models have also been developed to provide more comprehensive disease 
modelling, recapitulating Aβ deposition and tau accumulation together. These models allow 
for the investigation of the complex interactions between amyloid and tau neuropathology and 
subsequent degeneration.  
 3xTG – This overexpression model features three key human familial AD mutations, 
including the APPswe KM670 Swedish, MAPT P0311, and the PS1 M146V, driven by Thy1.2 
promoter (Oddo et al., 2003). It is one of the most widely studied triple transgenic models, 
featuring Aβ plaque and NFT pathology. Intracellular accumulations of tau have been reported 
by 3-4 months within the neocortex and hippocampus, that were often accompanied by synaptic 
loss, Aβ deposition by 6 months of age, and NFT pathology was present in the hippocampus 
by 12 months (Oddo et al., 2003). Cognitive deficits in long term retention occurred by 4 
months (Billings, Oddo, Green, McGaugh, & LaFerla, 2005), while spatial learning and 
working memory deficits were observed at 7 months of age (Oddo et al., 2003). 
Animal models of AD have been very successful in identifying the key impacts of disease 
pathology in the cortex. Studies have been able to identify the impact of amyloid and tau 
deposition on the surrounding neuropil and study potential therapeutic targets in a model of the 
disease (B. Zhang et al., 2012). Many of the AD mouse models closely recapitulate the 
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pathologies seen in human AD, including neuronal and plaque associated DN pathology of 
post-mortem human preclinical AD (A. Woodhouse, J. C. Vickers, P. A. Adlard, & T. C. 
Dickson, 2009), and synaptic loss similar to human AD (Mitew et al., 2013a). The use of these 
models allows for examination of the earliest physiological changes as a result of Aβ or tau 
deposition in the cortex. The initial effects of AD pathology are currently impossible to study 
in post-mortem human tissue, as it is not possible to identify the earliest stages of AD, where 
cortical changes are occurring more than 17 years prior to the onset of clinical symptoms 
(Rodriguez-Vieitez et al., 2016). 
Despite the success of the transgenic mouse models of AD there are some limitations that need 
to be considered when using them for research. Limitations of these models include the 
dependency on over-expression of familial AD associated mutations, which can generate 
phenotypes unrelated to the disease, and due to the lifespan of rodents, these are not models of 
the time-frame of human AD. Many of the transgenic models do not feature all pathologies of 
human AD, including substantial neuronal loss (Irizarry, McNamara, Fedorchak, Hsiao, & 
Hyman, 1997; Irizarry, Soriano, et al., 1997), and only few models exhibit NFT like pathology 
(Elder et al., 2010).  
 
1.6 Cell type specific vulnerability in Alzheimer’s disease 
The brain consists of a wide range of cell types, each with specialised functions to allow for 
normal homeostasis and proper function. Pioneering work by Santiago Ramón y Cajal (1852-
1934) provided the framework for modern neuroscience, illustrating the anatomical landscape 
of the brain. Cajal (1909) utilised the Golgi staining method to present the first histological 
images of the brain, illustrating that the brain is made up of individual neurons, rather than a 
global network as hypothesised in the reticular theory (Cajal, 1909) (review: (de Castro, López-
Mascaraque, & De Carlos, 2007; López-Muñoz, Boya, & Alamo, 2006)). Broadly, these cells 
can be split into two main classes: neurons – classically thought of as the functional cells of 
the brain; and glial cells – the supporting cells in the brain. There are a range of neuronal 
subtypes including excitatory neurons and interneurons. Excitatory neurons generate a positive 
charge in response to stimuli, generating an action potential to transmit to post-synaptic 
neurons. Interneurons can be both excitatory or inhibitory, maintaining or limiting the 








Figure 1.2: Cell types of the brain 
Schematic showing pyramidal neurons (green), interneurons (red), oligodendrocytes (yellow), 
microglia (purple), and astrocytes (blue) in the brain. Pyramidal neurons have been shown to 
be selectively vulnerable to AD pathology, whereas interneurons have been shown to be 
resistant to AD pathology. Microglia and astrocytes respond to AD pathology and promote the 





A vast network of glial cells support and maintain homeostasis within the brain. Microglia act 
as resident macrophages and are the main immune cell type in the brain. Microglia feature 
highly ramified, motile processes that survey the local environment for CNS damage, 
dynamically interacting with neurons and astrocytes. Microglia clear metabolic and cellular 
debris from the surrounding extracellular space, and can mobilise to initiate a localised pro-
inflammatory state in response to homeostatic imbalance and injury, promoting phagocytosis 
and apoptotic pathways (Khandelwal, Herman, & Moussa, 2011; Nimmerjahn, Kirchhoff, & 
Helmchen, 2005). Astrocytes are star-like glial cells identified by Cajal (1909) that also play a 
role in maintenance of homeostasis in the brain alongside microglia (Cajal, 1909). Astrocytes 
maintain and remove cellular and synaptic debris and they also have functional roles in synaptic 
plasticity and neuronal activity (Araque, Parpura, Sanzgiri, & Haydon, 1999) (review:(Perea, 
Navarrete, & Araque, 2009)). Astrocytes are capable of long range Ca2+ signalling from 
mechanical stimulation and in response to synaptic transmission (Araque et al., 1999; Charles, 
Merrill, Dirksen, & Sanderson, 1991). 
Neuronal cells exhibit differential vulnerability to AD pathology. Analysis of neuronal cell loss 
and synaptic loss in AD brains has shown a subset of pyramidal neurons containing 
neurofilament-triplet proteins (NF+) to be selectively vulnerable to AD pathology. 
Neurofilament positive pyramidal neurons residing in cortical layers II/III and V in the 
prefrontal and temporal cortex, and in the CA1 and CA3 regions of the hippocampus, have all 
been shown to be vulnerable to AD pathology (P. R. Hof et al., 1990; Patrick R. Hof & 
Morrison, 1990; Koffie et al., 2009b; Thangavel, Sahu, Van Hoesen, & Zaheer, 2009; J. C. 
Vickers et al., 1994). Neurofilaments are the structural and functional unit of the neuronal 
cytoskeleton that assist in maintaining the morphology of neurons. Combinations of 
neurofilament light, medium and heavy heteropolymers form elastic cores to assist normal 
cellular function including axonal transport and synaptic plasticity (reviews: (M. K. Lee & 
Cleveland, 1996; J. C. Vickers, Kirkcaldie, Phipps, & King, 2016)). Dysregulation of the 
neuronal cytoskeleton is frequently seen in neurodegenerative diseases, including AD, 
Parkinson’s disease, and Lewy body dementia. It has been suggested that NF+ pyramidal 
neurons may be particularly susceptible to AD pathology due alterations in calcium buffering, 
long range projections, metabolic stress, and to the loss or hyperphosphorylation of cytoskeletal 
proteins such as tau to be key to the cell-type specific vulnerability (P. R. Hof et al., 1990; 




In contrast, studies have indicated that a subset of calcium binding protein (CBP) interneurons 
expressing calretinin are resistant to excitotoxicity and to AD pathology (Fonseca & Soriano, 
1995; P. R. Hof, Nimchinsky, Celio, Bouras, & Morrison, 1993; Lukas & Jones, 1994; 
Sampson, Morrison, & Vickers, 1997). While, other research has shown parvalbumin and 
calretinin interneuron loss in the hippocampus of knock-in APP/PS1 mouse models and the 
dentate gyrus of post-mortem human AD cases (Takahashi et al., 2010). Interneurons 
expressing gamma-aminobutyric acid (GABA) are also implicated in the hippocampus of 
Tg2576 mice (review: (Y. Li et al., 2016)). Calretinin immunopositive interneurons show lower 
dystrophic neurite accumulation than neurofilament positive neurons in plaque dense regions 
in transgenic AD mice, and in post-mortem inferior temporal gyrus of AD cases (Mitew et al., 
2013b). Indeed, Mitew et al., (2013) determined that NF+ DN pathology, but not calretinin 
associated DNs, correlated with Aβ load, and plaque size in post-mortem human tissue and in 
APP/PS1 or Tg2576 mice (Mitew et al., 2013b). It has been suggested that interneurons have 
an enhanced ability to process calcium, and are resistant to oxidative damage (Pike & Cotman, 
1995). It is also possible that calretinin interneurons are resistant to physical damage from Aβ 
plaques, or feature a strengthened ability for structural and functional remodelling in 
comparison to NF+ pyramidal neurons (Blizzard et al., 2011; Mitew et al., 2013b ). 
Neuroinflammation is also a commonly accepted hallmark of AD, however it is not known 
whether the neuroinflammation is acting as a protective mechanism, or is detrimental to 
neurodegeneration (L. F. Lue et al., 1996) (review: (Mosher & Wyss-Coray, 2014)). In AD, 
microglia undergo phenotypic changes to become amoeboid, and have been identified 
surrounding dense-core Aβ plaques, from early stages of AD pathogenesis (Bornemann et al., 
2001; Itagaki, McGeer, Akiyama, Zhu, & Selkoe, 1989; Sasaki, Yamaguchi, Ogawa, Sugihara, 
& Nakazato, 1997). Surface receptors including TLRs, and a range of immune related genes 
including Cd36, Cd47, Clu, Cr1, Cxcr2, Tgf-β, Trem2 and Mcp-1 are expressed in microglia 
surrounding Aβ plaques, however, the pathway for microglial activation is unknown 
(Bamberger, Harris, McDonald, Husemann, & Landreth, 2003; Karch & Goate, 2015; Reed-
Geaghan, Savage, Hise, & Landreth, 2009). Recently, studies utilising single-cell 
transcriptomics have identified sub-populations of microglia that reacted to AD pathology, via 
TREM2 dependent and independent pathways (Keren-Shaul et al., 2017). Activated astrocytes 
have also been shown to surround Aβ plaques alongside microglial activation, and bind and 
degrade Aβ and dysfunctional synaptic dystrophies (T. Wyss-Coray et al., 2003). 
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It has been recently hypothesised that astrocytic dysfunction leads to the accumulation of 
dystrophic neurites and presynaptic protein aggregations in vivo (Gomez-Arboledas et al., 
2018). 
 
1.7 Genetics, Environment and Alzheimer’s disease 
Individual risk for sporadic AD is determined by both genetic and environmental factors; it is 
a multifactorial disease. There are multiple physiologic and molecular pathways altered during 
the progression of AD. The ApoE ε4 allele has been implicated in AD, attributable for up to 
60% of late-onset AD cases, making it the strongest genetic risk factor for late onset AD 
(Ashford, 2004; Strittmatter et al., 1993). Apolipoprotein E ε4 is known to regulate lipid 
transport and is primarily produced in the liver, however its role in the brain is less well 
understood. Studies have shown that carriers of the ApoE ε4 allele have more abundant Aβ 
plaques than non-carriers (Kok et al., 2009). It has been hypothesised that the ApoE protein 
has roles in APP membrane insertion, processing and Aβ clearance (Corder et al., 1993; Tokuda 
et al., 2000), and the ε2 allele has been shown to be protective against AD (Tokuda et al., 2000). 
APOE ε4 has also been shown to downregulate cleavage and secretion of a key neurotrophin 
in the brain; brain derived neurotrophic factor (BDNF) in vitro, while ApoE ε2 and ε3 increased 
BDNF secretion (Sen, Nelson, & Alkon, 2017). In the healthy brain, BDNF has been implicated 
in long-term potentiation (LTP), synaptogenesis, and memory formation (review:(Bramham & 
Messaoudi, 2005)), and BDNF mRNA is downregulated in transgenic models of AD (Peng et 
al., 2009), and in post-mortem AD (Phillips et al., 1991). Other risk alleles have been 
implicated in late-onset AD including Clu, Picalm, Bin1, Cr1, Abca7 and Cd33, but have a low 
prevalence in AD (Bamberger et al., 2003; Hu et al., 2011; Karch & Goate, 2015; Lambert et 
al., 2009; Reed-Geaghan et al., 2009). Many of the alleles implicated in AD are associated with 
endocytosis of synaptic vesicles (review: (Ridge, Ebbert, & Kauwe, 2013)). Despite numerous 
genetic risk factors for AD, their penetrance and prevalence do not account for the total number 
of AD cases seen today, which implicates other external risk factors in the development of AD.  
Environmental factors have also been implicated as a key contributor for AD development and 
may account for the cause of late-onset AD. Some examples of environmental risk factors for 
developing sporadic AD include cardiovascular health, diet, obesity and diabetes, traumatic 
brain injury, trace metal levels and heavy metal exposure, vitamin B, and education 
level/cognitive reserve.   
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Cardiovascular health – Cardiovascular health has been implicated in AD. Studies have 
shown regular physical activity (exercise equal to or greater than walking more than three times 
a week) to reduce the risk of AD in people aged 65 and older (Laurin, Verreault, Lindsay, 
MacPherson, & Rockwood, 2001). Subsequently, studies have correlated obesity and diabetes 
(type II) with altered risk of AD (W. L. Xu et al., 2011); being underweight, or overweight 
between the ages of 30-45 led to increased risk of AD in one study (Beydoun et al., 2008), 
however other studies have shown higher body-mass-index to correlate with lower risk of AD 
(Atti et al., 2008).  
Diet – Lifestyle factors like diet have been shown to impact AD. A Mediterranean 
influenced diet has been associated with reduced risk of AD, as opposed to western style diets 
(M. C. Morris et al., 2015; Scarmeas, Stern, Tang, Mayeux, & Luchsinger, 2006). Excessive 
consumption of alcohol has been linked with increased risk of dementia, potentially due to 
neurotoxic effects in later life, but moderate consumption of alcohol is thought to be protective 
against dementia (Anttila et al., 2004). 
Traumatic Brain Injury – Epidemiological studies and meta-analysis have identified a 
history of head injury to increase the risk for Alzheimer’s disease (Fleminger, Oliver, 
Lovestone, Rabe-Hesketh, & Giora, 2003; Mortimer et al., 1991). Head injury occurring in 
later life, or more severe head injury with periods of loss of consciousness or memory loss have 
been shown to also increase risk for AD. Some studies have implicated repeat head injury with 
more severe or earlier onset of AD (Plassman et al., 2000). 
Metal Homeostasis – An imbalance in metal homeostasis is seen in AD, potentially due 
to changes in redox-activity leading to cytotoxicity. A concentration of trace metals, including 
zinc, copper, and iron has been identified in the core of Aβ plaques, and surrounding neuropil 
of the amygdala (Lovell, Robertson, Teesdale, Campbell, & Markesbery, 1998). In particular, 
zinc and iron is highly concentrated in the core of plaques and surrounding neuropil (Connor, 
Menzies, St Martin, & Mufson, 1992; Lovell et al., 1998), and a disruption in iron homeostasis 
has been observed in post-mortem AD cases (Connor, Snyder, Beard, Fine, & Mufson, 1992). 
Studies have identified significantly decreased levels of DNMT1 and MeCP2, and significantly 
increased Ser 396, 235 phosphorylated tau mRNA and protein in C57/BL6 mice exposed to 
environmental lead (Bihaqi, Bahmani, Adem, & Zawia, 2014; Eid, Bihaqi, Renehan, & Zawia, 
2016). It has been suggested that an imbalance in environmental exposure to trace metals can 
increase the risk for AD, though the mechanism is poorly understood, but might indicate a role 
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of oxidative stress in AD pathogenesis (review: (George Perry, Cash, Srinivas, & Smith, 2002; 
Peters, Connor, & Meadowcroft, 2015)).  
Vitamin B – Vitamin B deficiency is thought to alter Aβ production, with longitudinal 
studies showing that folate deficiency increases the risk of AD (Ho et al., 2003; H. X. Wang et 
al., 2001). Vitamin b deficiency has also led to changes in PS1, BACE and APP gene 
expression (Andrea Fuso et al., 2008).  
Education/cognitive reserve – Education level and occupation, or social/leisure 
activities that promote neuronal activity and consolidate cortical connections are thought to 
delay the onset of AD (Brayne et al., 2010; Karp et al., 2009; Stern et al., 1994). There is often 
a discrepancy between observed neuropathology and functional deficits seen in AD, which is 
thought to be due to a cognitive reserve generated from occupational and educational level 
(Barulli & Stern, 2013). Genetics may also influence the base level of cognitive reserve (Ward 
et al., 2017).  
In the absence of genetic mutations, epigenetic factors may link environmental risk in the onset 
and development of AD. 
 
Epigenetics 
1.8 Regulation of transcription 
Described by Waddington in 1942, the term epigenetics was defined as a change in phenotype 
without change in genotype (Waddington, 1942a, 1942b). There have been numerous studies 
of the role of epigenetics, chromatin structure and gene regulation since 1942 through to today 
(Britten & Davidson, 1969; Kornberg, 1974) (review: (Allis & Jenuwein, 2016)). Epigenetics 
has since been refined to describe changes to the DNA environment, or changes to 
transcription, without directly altering the DNA sequence. Regulation of the DNA by 
epigenetic modifications such as DNA methylation and histone modifications allows for 
complex interaction between the environment and the DNA by regulating chromatin structure 
(review: (Allis & Jenuwein, 2016)). Appropriate packaging of the DNA in the nucleus is 
essential for proper gene expression. DNA is packaged with equal mass of proteins (histones) 
into chromatin (Kornberg, 1974). Repeating units of DNA and histones (~146bp DNA wrapped 
1.65 times around a histone octamer) form nucleosome subunits (Carter, 1978; Kornberg, 
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1974), which interact with linker DNA to form euchromatin or heterochromatin (Figure 1.3) 
(Carter, 1978; Luger, Mader, Richmond, Sargent, & Richmond, 1997; McGhee & Felsenfeld, 
1980; Mirsky & Silverman, 1972; Olins & Olins, 1974; Waddington, 1942a). Epigenetic 
modifications such as histone modifications and DNA methylation allows for the modification 
of chromatin structure by altering nucleosome positioning and their affinity to compact, thus 
increasing or decreasing accessibility to the DNA (Figure 1.3). The presence of densely packed 
nucleosome subunits and heterochromatin limits the binding of transcriptional machinery to 
promoter sequences and the initiation of transcription at the transcriptional start sites (TSS). 
This occurs in a highly regulated, cell-type specific and gene specific fashion. Thus, epigenetic 
processes allow cells to be genetically homogeneous, but structurally and functionally 
heterogeneous (Ryan Lister et al., 2013; Maruyama et al., 2011; Mo et al., 2015; Stedman & 
Stedman, 1950) (review: (Rudolf Jaenisch & Adrian Bird, 2003)).  
The two most commonly studied epigenetic modifications are DNA methylation (Bird, 
Taggart, Frommer, Miller, & Macleod, 1985; Holliday & Pugh, 1975; Hotchkiss, 1948; Razin 
& Riggs, 1980), and post-translational histone modifications (Vincent G. Allfrey & Mirsky, 
1964; Britten & Davidson, 1969; N. D. Heintzman et al., 2009; Nathaniel D. Heintzman et al., 
2007; S. A. Morris et al., 2007; Stedman & Stedman, 1950) (Figure 1.3). Epigenetic 
modifications alter the accessibility for determining whether regions of chromatin will 
generally be active (euchromatin) or repressed (heterochromatin) (Heitz, 1928). Epigenetic 
control of cis-regulatory elements including promoters and enhancers also alter the chromatin 
accessibility for transcriptional machinery to bind and initiate gene transcription (Banerji, 
Olson, & Schaffner, 1983; Banerji, Rusconi, & Schaffner, 1981) (review: (Andersson, 2015)). 
Next-generation sequencing technologies, the ability to sequence rare populations of cells, and 
even single-cell analysis has improved our understanding of the complexity of epigenetic 
regulation within cell types and between individual cells (Ryan Lister et al., 2013; R. Lister et 
al., 2009; Luo et al., 2017; Meissner et al., 2008; Mo et al., 2015). Epigenetic processes are 
now being implicated in neurodegenerative diseases as potential mechanisms for disease onset 
and progression. 
 
1.9 DNA Methylation 
DNA methylation is the most widely studied epigenetic modification. Chemical modifications 
to DNA were hypothesised by Avery & McCarty (1944), and Hotchkiss (1948) (Avery, 
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Macleod, & McCarty, 1944; Hotchkiss, 1948). The role of DNA methylation in gene regulation 
and differentiation was hypothesised independently by Holliday, and Riggs in 1975, with the 
discovery of its roles in repression and subsequently the identification of cytosine-guanine 
dinucleotide (CpG islands) and shores occurring shortly after (Bird et al., 1985; Holliday & 
Pugh, 1975; P. A. Jones & Taylor, 1980; Razin & Riggs, 1980). In mammalian species, DNA 
methylation involves the addition of methyl groups at CpG sites (5-methylcytosine – 5mC), by 
DNA methyltransferases (DNMTs) (L. Chen et al., 1991; Klimasauskas, Kumar, Roberts, & 
Cheng, 1994; Okano, Bell, Haber, & Li, 1999). These CpG sites are often found in clusters, 
called CpG islands (typically unmethylated), and the distribution of methylation across CpG 
islands can regulate transcription. However, methylation can also accumulate in non-CpG sites 
(Guo et al., 2013; Ryan Lister et al., 2013; Ramsahoye et al., 2000). Methylation of CpG islands 
at TSS is generally associated with repression and subsequent gene silencing, by preventing 
transcription factor access to DNA (Antequera, Boyes, & Bird, 1990; Watt & Molloy, 1988). 
Thus, heavily methylated CpG islands often co-localise with heterochromatin and are 
inhibitory to transcription (Choy et al., 2010; Razin & Riggs, 1980)(review: (J. Y. Lee & Lee, 
2012; Suzuki & Bird, 2008)). CpG islands are often present at promoter regions (with as many 
as 50-60% of promoters contain CpG islands), but can also be observed within gene bodies and 
in intergenic regions resulting different (often permissive) transcriptional profiles (Ioshikhes 
& Zhang, 2000; Jjingo, Conley, Yi, Lunyak, & Jordan, 2012). However distal regulatory 
elements are generally less methylated than promoters, and are CpG poor regions (~30% of 
distal elements are methylated) (Stadler et al., 2011). Interestingly, DNA methylation has also 
been identified to occur at non-CpG dinucleotides (CC, CA, CT), which accounts for up to 
approximately 0.02% of all methylated cytosines, and was first described in the plant genome 
(Lindroth et al., 2001) with DNMT3A/B both involved in the maintenance of non-CpG sites 
(reviews: (R. Jaenisch & A. Bird, 2003; Peter A. Jones, 2012; Peter A. Jones & Liang, 2009)). 
However non-CpG methylation may regulate neuronal differentiation and function (Ryan 
Lister et al., 2013). It should be noted that association of DNA methylation and silencing is not 
always absolute. A recent study has shown that DNA methylation may not be enough to silence 
gene promoter elements in human MCF7 cells (Ford et al., 2017). 
Conversely, the removal of 5mC allows for permissive, or stimulated gene expression, and can 
be achieved through passive or active mechanisms. Passive demethylation occurs through 
depletion during replication, with DNMTs withholding methylation on selected bases.  A key 
pathway of active demethylation involves ten-eleven-translocase proteins (TET) (Ito et al., 
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2010; Tahiliani et al., 2009). In mammalian species, TET proteins catalyse the conversion of 
5mC to 5-hydroxymethylcytosine (5hmC), which is a marker of active demethylation and is 
associated with gene transcription (Ito et al., 2010; Tahiliani et al., 2009). Proteins can bind to 
methylated genomic regions and regulate transcription. Methyl-CpG-binding proteins (MeCP) 
bind to 5mC and particularly 5hmC, and can act to enhance or repress transcription (Lewis et 
al., 1992; Mellen, Ayata, Dewell, Kriaucionis, & Heintz, 2012). Methyl-CpG-binding proteins 
are involved in many different aspects of gene regulation. They can facilitate interaction 
between DNA methylation and other chromatin modifiers, and are also involved in processing 
mRNA, alternative splicing, x-inactivation, gene imprinting, and limits 5hmC labelling within 
gene bodies (Cheng et al., 2017; X. Nan et al., 1998). Interestingly, methyl-CpG-binding 
proteins are highly expressed in the brain and regulate neuronal chromatin structure (Skene et 
al., 2010).   
The function of DNA methylation requires understanding of the distribution of DNA 
methylation across the genome: the sum of methylated regions across promoter, enhancer and 
gene bodies, and unmethylated regions, or CpG shores. Recent advances in bisulphite treatment 
of DNA and next-generation sequencing (whole genome bisulphite sequencing; WGBS) has 
allowed for single base resolution of 5mC across the genome (R. Lister et al., 2009). 
Techniques have also advanced to include nucleosome positioning with simultaneous 
methylation sequencing of the same strand of DNA. Nucleosome occupancy with next 
generation sequencing (NOMe-seq) allows for simultaneous measurement of methylation and 
nucleosome positioning and has been adapted for single cell analysis (T. K. Kelly et al., 2012; 
Phillippa C. Taberlay, Statham, Kelly, Clark, & Jones, 2014, Pott, et al., 2017). Utilising these 
advances in technology, sequencing of cell populations and single cells has been accomplished, 
showing that DNA methylation is both tissue and cell-type specific (R. Lister et al., 2009; Luo 
et al., 2017; Mendizabal & Yi, 2016; Mo et al., 2015). 
 
1.10 Histone modifications 
Post-translational modifications to the histone N-terminus tail domain were first described by 
Allfrey et al., (1964), and it was hypothesised that acetylation and methylation play a role in 
the regulation of RNA synthesis (V. G. Allfrey, Faulkner, & Mirsky, 1964). It is now known 
that a core octamer of histone proteins (two copies each of H2A, H2B, H3, and H4) forms 
nucleosomes, which act as the dynamic building blocks of chromatin (Luger et al., 1997), while 
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histone H1 binds to the outside of the histone octamer aiding in structural stabilisation (Finch 
& Klug, 1976; Thoma & Koller, 1977) (Figure 1.3). The modifications on the tail domains of 
the histone proteins can alter charge, binding affinity and facilitate chromatin restructuring 
through interaction with other nucleosomes, and the recruitment of chromatin remodelling 
enzymes resulting in changes to gene expression (Hong, Schroth, Matthews, Yau, & Bradbury, 
1993). Post-translational histone modifications are now documented to include methylation, 
acetylation, phosphorylation and ubiquitination, where methylation and acetylation have been 
most widely studied; however, there are more than 100 possible known histone modifications 
that can modify chromatin structure on lysine and arginine residues (M. Tan et al., 2011). 
Histone modification nomenclature is denoted by histone number, followed by residue and 
modification; for example, histone 3 lysine 9 can be acetylated (H3K9ac), or methylated 
H3K9me3. These modifications do not occur in isolation, with combinations of histone 
modifications working together to adapt nucleosome structure and regulate gene expression. 
Histone modifications alter the access for transcriptional machinery to regulatory elements 
such as the TSS, promoters and enhancer elements. A histone code hypothesis has been 
postulated, in which the combination of post-translational histone modifications and overall 
profile of the nucleosome structure lead to diverse biological outcomes (Dion, Altschuler, Wu, 
& Rando, 2005; Jenuwein & Allis, 2001) (reviews: (Bannister & Kouzarides, 2011; 
Kouzarides, 2007; Zentner & Henikoff, 2013)). 
Histone modifications are actively catalysed by a suite of enzymes including histone 
methyltransferases and acetyltransferases and can be actively removed with demethylases and 
deacetylases. The first histone lysine methyltransferases (HKMT) to be discovered were the 
SUV39H1 and SUV39H2 complexes, responsible for methylation of lysine residues on histone 
H3 (Aagaard et al., 1999; O'Carroll et al., 2000). In 1996, Brownwell and colleagues identified 
the functional role for histone acetyltransferases (HATs) and histone deacetylases (HDACs), 
which act as a switch for transcriptional regulation (Brownell et al., 1996). There is now a wide 
range of known methyltransferases/demethylases and acetylases/deacetylases, each modifying 
specific histone modification substrates (Allis et al., 2007). One of the many effects of 
modifying histones is to allow for nucleosome remodelling and alternative splicing. 
Transcriptional activity is dependent on nucleosome positioning, which changes through active 
(ATP-dependent) pathways. The SWI/SNF nucleosome remodelling complex was found to 
regulate chromatin structure, and subsequently transcription, in 1992 (Hirschhorn, Brown, 
Clark, & Winston, 1992). The SWI/SNF complex removes histones from DNA by nucleosome 
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disassembly, or by transferring histone octamers to another position on the DNA (Hirschhorn 
et al., 1992; Whitehouse et al., 1999).  
Single nucleosome resolution mapping of histone methylation and acetylation was first 
accomplished with chromatin immunoprecipitation on microarrays (ChIP-chip), giving the first 
analysis of histone distribution across the genome (C. L. Liu et al., 2005). However, advances 
in the use of next-generation technology for chromatin immunoprecipitation and next-
generation sequencing (ChIP-seq) has allowed for modification specific analysis at a high 
resolution across the genome (Johnson, Mortazavi, Myers, & Wold, 2007; Robertson et al., 
2007; Schmid & Bucher, 2007). Limitations of ChIP-seq protocols include the large sample 
size required and antibody quality limitations. Adaptations to the ChIP-seq protocol have 
allowed for higher resolution mapping, indexing and multiplexing of rare samples and low cell 
number (van Galen et al. 2015), and protocols have been developed for single cell ChIP-seq 
experiments to reveal cellular heterogeneity for the epigenome (Rotem et al., 2015). High 
sensitivity and specificity antibodies to transcription factors and histone modifications have 
improved the quality and resolution of ChIP-seq experiments (Kidder, Hu, & Zhao, 2011). 
Histone acetylation:  
Histone acetylation was first described by Allfrey and colleagues in 1964 (V. G. Allfrey et al., 
1964; Vincent G. Allfrey & Mirsky, 1964). Histones have a positive ionic charge, which is 
weakened through the addition of acetyl groups, subsequently reduces the attraction between 
histones and DNA, and increasing access for transcription factors to bind to DNA open reading 
frame (Hong et al., 1993). This function plays a vital role in the maintenance of DNA integrity, 
with early studies finding loss of histone H4, or replacement of the lysine residue leading to 
cell cycle defects in G2 and M phase (Megee, Morgan, & Smith, 1995). Acetyl groups are 
added to histone tails by HATs, a class of enzymes that catalyse the transfer of acetyl groups 
from acetyl-CoA to lysine on the N-terminus of histone proteins (Belikoff, Wong, & Alberts, 
1980; Kleff, Andrulis, Anderson, & Sternglanz, 1995) (review: (Zentner & Henikoff, 2013)). 
Histone deacetylases transfer acetyl groups from acetylated histone proteins to coenzyme-A 
(CoA), producing a more condensed chromatin state (Taunton, Hassig, & Schreiber, 1996).  
Histone acetylation is generally associated with active chromatin and is permissive to gene 
expression.  H3K9ac is highly correlated with active promoters, and is often found around TSS, 
and may recruit elongation complexes for transcription (Gates et al., 2017). While H3K27ac is 
a modification that marks active from poised enhancers, is also present around transcriptional 
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start sites of active genes and may have a role in the elongation of transcription (Creyghton et 
al., 2010a). Morris and colleagues (2007) determined H3K36ac to be located at the promoters 
of RNA polymerase II (RNA pol II) transcribed genes (S. A. Morris et al., 2007). To further 
illustrate the regulatory control histone modifications have on gene expression, Shogren-Knaak 
et al., (2006) showed that H3K16ac inhibited the compaction of chromatin fibres, 
demonstrating the control that histone modifications have over higher order chromatin structure 
and subsequent gene expression (Shogren-Knaak et al., 2006b). Distal regulatory elements also 
aid in the regulation of transcription. Broad regions involved in the trans-regulation of genes 
are usually identified by enrichment of H3K27ac, and have been defined as putative super 
enhancers (Khan & Zhang, 2016; Pott & Lieb, 2014). Super enhancers are genomic regulatory 
regions that are responsible for cellular identity  (Hnisz et al., 2013; Whyte et al., 2013). Only 
a small percentage of super enhancers have been identified through initiatives like the Super 
Enhancer Database (Khan & Zhang, 2016), however the functional role of many super 
enhancer regions remains to be elucidated. 
 
Histone methylation:  
Histone methylation can occur to both lysine and arginine residues of the N-terminus residues. 
Histone methyltransferase enzymes can recognise and bind lysine and arginine residues and 
catalyse the addition of one, two or three (mono-, di- or tri-) methyl groups to the N-terminus 
tail of histone residues. Unlike histone acetylation, the addition of methyl groups does not alter 
the charge of the histone DNA complex in the nucleosome. H3K4me1 marking at the TSS has 
been shown to be associated with the promoters of actively transcribed genes (Barski et al., 
2007; B. E. Bernstein et al., 2005; Nathaniel D. Heintzman et al., 2007). While H3K4me1 
marking present outside of promoter regions is associated with functional enhancers (Nathaniel 
D. Heintzman et al., 2007). Histone 3 lysine 4 methylation can also act as an initiator for 
downstream histone acetylation (Z. Wang et al., 2009). One of the most comprehensively 
studied histone methylation marks is histone 3 lysine 4 tri-methyl (H3K4me3), which has been 
shown to mark transcriptional start sites of active genes (B. E. Bernstein et al., 2005; Nathaniel 
D. Heintzman et al., 2007; Santos-Rosa et al., 2002). Studies have also identified interactions 
between demethylation complexes and H3K4me3, where they couple (including both chromo- 
and bromo- domains) to the N-terminus of tri-methylated histones and initiate chromatin 
remodelling (Huang, Fang, Bedford, Zhang, & Xu, 2006; Wysocka et al., 2006). H3K27me3 
is a marker of repressive chromatin and inactive gene promoters (Barski et al., 2007; P. C. 
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Taberlay et al., 2011; Young et al., 2011). Polycomb repressive complex 2, containing EZH2 
add methyl groups to histone residues such as H3K27 (Cao et al., 2002; Ferrari et al., 2014). 
The co-localisation of H3K4me3 and H3K27me3 marking indicate bivalent chromatin domains 
(Azuara et al., 2006; B. E. Bernstein et al., 2006). This has been implicated in higher global 
chromatin structure by facilitating interactions with chromatin and transcription factors, and by 
interacting with chromatin assembly and remodelling complexes to regulate chromatin 
compaction (Shogren-Knaak et al., 2006a; Blosser, 2009 #973; Zhou & Grummt, 2005). 
Histone modifications both influence and are influenced by the histone modification signature 
of neighbouring nucleosomes and protein complexes that are recruited to DNA (Fischle et al., 
2005)(reviews: (Kouzarides, 2007). 
 
Histone and DNA methylation interactions:  
To aid appropriate gene transcription, regions of the genome are partitioned into accessible 
euchromatin and dense compact heterochromatin. A growing body of evidence supports cross 
talk between DNA methylation and histone modifications (Hisashi Tamaru & Selker, 2001; H. 
Tamaru et al., 2003). Mutations in genes encoding histone methyltransferases have been 
associated with reduced DNA methylation (Hisashi Tamaru & Selker, 2001; H. Tamaru et al., 
2003), and subsequent studies have identified DNMT domains and co-binding proteins 
(SIN3A, UHRF1, MeCP2) that bind to histone modifications (Dhayalan et al., 2010; Q. Zhao 
et al., 2016). Functional mapping of DNA methylation and histone modifications has identified 
prerequisites for the establishment of DNA methylation. The addition of H3K9me1 by 
Suv39hp1 is required to recruit Dnmt3b for subsequent DNA methylation in mammalian 
species (Lehnertz et al., 2003). Another key example of the interactions occurring between 
histone modifications and DNA methylation is during differentiation when de-novo 
methylation is happening within the embryo. Histone methylation on lysine 4 such as 
H3K4me1/2/3 act as mediators for the establishment of de-novo methylation in the embryo 
during development, preventing DNA methyltransferase 3L (DNMT3L) from binding and 
recruiting DNMT3A and DNMT3b (Jia, Jurkowska, Zhang, Jeltsch, & Cheng, 2007; Ooi et al., 
2007).  
DNA methylation silences transcription by changing nucleosome structure and subsequent 
formation of heterochromatin. In 1998, two studies identified a role for methyl CpG-binding 
protein 2 (MeCP2) in the regulation of chromatin structure through interactions with DNA 
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methylation and histone modifications (P. L. Jones et al., 1998; Xinsheng Nan et al., 1998). 
These studies showed that the MeCP2 complex recruited the HDAC/SIN3A co-repressors to 
remove histone acetylation and lead to transcriptional silencing and heterochromatin formation 
(P. L. Jones et al., 1998; Xinsheng Nan et al., 1998). SIN3A acts as a scaffolding protein for 
HDACs and other transcriptional regulators to bind target promotors (Yi Zhang, Iratni, 
Erdjument-Bromage, Tempst, & Reinberg, 1997). Recruitment of HDAC/SIN3A complex by 
MeCP2 was specific to methylated DNA located in a nucleosome, rather than CpG or site 
specific recruitment (Fuks et al., 2003; P. L. Jones et al., 1998). It has also been shown that 
MeCP2 can drive methylation of H3K9, regulate learning and memory formation, and is 
associated with Rett syndrome and other neurological disorders (Ambigapathy, Zheng, & 
Keifer, 2015; Amir et al., 1999; Fuks et al., 2003). These examples demonstrate the complexity 
and interaction between DNA methylation and histone modifications, establishing the need to 
integrate the research on each form of epigenetic modification (reviews: (Cedar & Bergman, 








Figure 1.3: Regulation of chromatin structure through epigenetic modifications 
Dynamic regulation of the genome through epigenetic mechanisms including DNA 
methylation (5mC: red – repressive; 5hmC: green – permissive), post-translational histone 
modifications (eg:H3K4me3 - active, H3K27ac – permissive; H3K27me3 – repressive), and 
subsequent changes to nucleosome positioning. Each of these result in changes to chromatin 




Epigenetics in the brain 
1.11 Dynamic epigenetic regulation in the brain 
The study of epigenetics in the brain has recently expanded, demonstrating epigenetic 
regulation plays key roles in neural development, the formation of memory, synaptic plasticity, 
axonal pathfinding, aging and AD (Ambigapathy et al., 2015; Calfa et al., 2012; Fischer, 
Sananbenesi, Wang, Dobbin, & Tsai, 2007a; Ryan Lister et al., 2013; Mo et al., 2015). 
Understanding the role of epigenetic regulation in the healthy developing and aging brain is 
essential to understand how disease will dysregulate the system.    
 
The epigenome is highly specific in neurons of the developing brain 
Distinct sub-types of excitatory and inhibitory neurons communicate in intricate networks to 
govern higher thought processes, emotion and behaviour. Neuronal diversity is associated with 
differences in synaptic plasticity, electrophysiological properties, and morphology. This is 
accomplished partially through epigenetic regulation of gene expression in stem-cells as they 
differentiate into neurons (Ryan Lister et al., 2013). Neural progenitor cells (NPCs) generate 
terminally differentiated cells in a distinct order, with key signalling pathways activated during 
gestation and post-birth to promote neural development; for example, platelet derived growth 
factor and Wnt signalling drive neural differentiation in the mammalian cortex (Erlandsson, 
Enarsson, & Forsberg-Nilsson, 2001; Y. Hirabayashi et al., 2004) (reviews: (Yusuke 
Hirabayashi & Gotoh, 2005; Molyneaux, Arlotta, Menezes, & Macklis, 2007)). Neural 
progenitor cells also give rise to oligodendrocytes and astrocytes through activation of 
alternative signalling pathways (including the STAT3/JAK cascades for intracellular 
signalling) (Magistri et al., 2016; Raff, Miller, & Noble, 1983; Yanagisawa et al., 2000). 
Studies have shown that histone modifications (H3K9me3) and DNA methylation are involved 
in the regulation of cellular differentiation from neural progenitor cells into astrocytes and 
neurons (Singh, Shiue, Schomberg, & Zhou, 2009; Takizawa et al., 2001; S.-L. Tan et al., 
2012). For example, Kraus, et al., (2016) measured core epigenetic modifiers of DNA 
methylation (including Dnmt1, Dnmt3a, Dnmt3b, Tet1, Tet2, Tet3, and Apobec1-3) across an 
early life time-course in the frontal cortex and cerebellum of C57/BL6 mice, ranging from 
postnatal day 0, 7, 15, 30 to 120, utilising immunohistochemistry (T. F. J. Kraus et al., 2016). 
This study observed the percentage of 5hmC positive cells in the frontal cortex to significantly 
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increase through post-natal development to adulthood, however 5mC remained consistent with 
age (T. F. J. Kraus et al., 2016). Similar to other studies, methylation was more abundant in 
neuronal cells compared to non-neuronal cells of the brain (T. F. Kraus, Guibourt, & 
Kretzschmar, 2015; T. F. J. Kraus et al., 2016; Ryan Lister et al., 2013; Wagner et al., 2015). 
The cellular outcomes of neural progenitor cells are associated with diverse epigenetic 
landscapes, which are established early in development (Ryan Lister et al., 2013; Mo et al., 
2015).  
Initial difficulties in the isolation of neuronal nuclei have limited cell-type specific epigenetic 
analysis in the brain. Jiang and colleagues (2008) developed new methods utilising the FOX-3 
transcription factor (NeuN - (Kee K. Kim, Robert S. Adelstein, & Sachiyo Kawamoto, 2009; 
R. J. Mullen, C. R. Buck, & A. M. Smith, 1992)), which is present in the vast majority of 
neuronal nuclei, to assess the default epigenetic landscape for mammalian neuronal cells with 
flow cytometry (Jiang, Matevossian, Huang, Straubhaar, & Akbarian, 2008). Neuronal nuclei 
isolated with this technique were shown to maintain nucleosomes and chromatin structure 
compared to unsorted nuclei, making the method of isolation ideal for epigenetic based NGS 
protocols (Jiang et al., 2008). More recently, Lister et al., (2013) isolated neuronal and glial 
cell populations from mouse and human frontal cortex at four time-points representing 
embryonic, juvenile, adolescent and adult ages, and performed whole genome bisulphite 
sequencing (WGBS) and ChIP-seq. This study found that non-CG specific methylation 
accumulated throughout the genome in neurons across age, but not in glial populations across 
life (Ryan Lister et al., 2013). Key timepoints for non-CG methylation occurred alongside 
synaptogenesis and synaptic pruning in a highly conserved fashion between mouse and human 
brain (Ryan Lister et al., 2013).  
 
The epigenome defines cell-type specificity 
To date there is no standard ‘reference epigenome’, as epigenetics regulates gene transcription 
in a cell type specific manner; however, consortiums are working to establish a framework and 
database of the epigenome (The, 2012). Recent studies have concentrated on identifying 
distinct epigenetic patterns of neuronal sub-types (Alexey Kozlenkov et al., 2016; Mo et al., 
2015). To address the lack of cell-type specific maps of the neuronal epigenome, a seminal 
study by Mo et al., (2015) isolated and separated Camk2a fast acting excitatory neurons, 
parvalbumin interneurons, and vasoactive-intestinal peptide expressing interneurons from the 
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neocortex of transgenic mice, and performed WGBS, ChIP-seq, ATAC-seq (measuring 
chromatin accessibility), and RNA-seq on the isolated populations (Mo et al., 2015). This study 
demonstrated that DNA methylation, in particular non-CpG methylation to be highly specific 
to particular neuronal subtypes, with almost half of all differentially methylated regions were 
hypomethylated in excitatory neurons, and cell-type specific transcription factors and promoter 
regions contained low levels of methylation (Mo et al., 2015) Only 13.4% of ATAC-seq peaks 
shared across parvalbumin, Camk2a and VIP neurons (Mo et al., 2015).  
The advent of single-cell sequencing has demonstrated that the epigenome and transcriptome 
are highly cell-type specific (Buenrostro et al., 2015; Clark et al., 2017; Farlik et al., 2015; 
Islam et al., 2014; Pott, 2017; Smallwood et al., 2014). Single-cell RNA-seq experiments and 
unsupervised clustering based on sequence similarity (t-distributed stochastic neighbour 
embedding) have allowed for the molecular identification of seven distinct sub-types of 
pyramidal neurons and glial cells within the somatosensory cortex and hippocampus of mouse, 
with layer 5 pyramidal neurons clustering into two distinct sub-types (Zeisel et al., 2015). The 
application of single-cell WGBS in the brain has also resulted in the identification of new 
neuronal cell-types. Luo, et al., (2017) utilised single-cell WGBS in 8-week mouse and human 
(25 years) frontal cortex to sequence over 6000 methylomes from single cells (Luo et al., 2017). 
By utilising t-SNE based clustering analysis, Luo identified novel parvalbumin expressing 
inhibitory neuron and layer 6 excitatory neuron subtypes; and showed inhibitory neurons have 
conserved regulatory regions across species in comparison to excitatory neurons (Luo et al., 
2017). A key difficulty with single-cell WGBS is achieving high coverage and sequencing 
depth from a single cell. The single-cell WGBS study from Luo et al., (2017) achieved 5% 
coverage of the reference genome from a single cell, with approximately 1.55 million mapped 
reads per cell (Luo et al., 2017). This is further supported by mRNA profiling of 
excitatory/inhibitory neuronal subtypes and glial populations in the CNS, showing significant 
translational diversity between neuronal sub-types (Doyle et al., 2008).  
Several studies have also highlighted the importance for brain region specific analysis when 
studying epigenetics (Davies et al., 2012; Rizzardi et al., 2017). Techniques such as MeDIP-
seq and HumanMethylation450K arrays in human brain have shown region specific differences 
in methylation between the visual cortex, entorhinal cortex, superior temporal cortex, 
cerebellum, pons and blood (Davies et al., 2012; Hernandez et al., 2011). One study has 
demonstrated that the methylation status of the frontal and temporal cortex to be similar, but 
both dissimilar to cerebellum when measured with HumanMethylation 27 arrays (Hernandez 
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et al., 2011). Whereas studies in post-mortem schizophrenic brain have shown region and loci 
specific differences of methylation in dorsolateral prefrontal cortex and hippocampus (Alelú-
Paz et al., 2016; Viana et al., 2016). Differentially hydroxymethylated regions also exist 
between hippocampus and cerebellum in murine models (Szulwach et al., 2011). However, all 
studies of 5hmC to date have discovered region specific differences in mixed cell populations 
and haven’t investigated cell-type specific epigenetic landscapes. 
 
Epigenetics, memory and synaptic plasticity 
Synaptogenesis, long-term potentiation and long-term depression are essential for learning and 
memory. Synapses form between neurons allowing for communication throughout the brain. 
The formation, maintenance, extinction and dynamic regulation of synapses (synaptic 
plasticity) occurs throughout life. These processes require changes to gene expression and 
appropriate regulation of chromatin structure to assist in the formation of memories (Dickey et 
al., 2003). Initial studies of the epigenetic regulation of memory formation demonstrated 
chromatin-level regulation of learning and memory in a learned taste aversion paradigm 
(Swank & Sweatt, 2001). Swank, et al., (2001) showed that mitogen-activated protein kinase 
activity regulated histone acetyltransferases in the insular cortex during long-term memory 
formation (Swank & Sweatt, 2001).  
To date, numerous studies have reported changes in the epigenetic states of specific signalling 
pathways or genes associated with learning and memory. Methylation maintenance molecules 
are essential for synaptic plasticity, learning and memory (Feng et al., 2010b; Levenson et al., 
2006). Studies have demonstrated that experience dependent plasticity in the brain correlates 
with a changing methylation landscape around genes involved in synaptic plasticity (Leighton 
et al., 2018; X. Li et al., 2014; Widagdo et al., 2016). For example, neuronal activity has been 
shown to alter genome-wide expression of epigenetic regulators for DNA maintenance and 
repair in vitro (for example the Ing1 pathway) (Leighton et al., 2018). While other studies have 
shown upregulation of transcriptional regulators Egr1 and Fos mRNA in the ventral tegmental 
area in vivo after auditory associated reward learning, associated with decreased promoter 
methylation of Egr1, but increased gene body methylation for Egr1 and Fos (Day et al., 2013). 
Other transcriptional regulators such as Tet3, which mediates the deposition of 5hmC, has been 
shown to accumulate around genes associated with synaptic plasticity in the prefrontal cortex 
and hippocampus during learning and behavioural adaptation (X. Li et al., 2014; Widagdo et 
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al., 2016). DNA methyltransferases have also been implicated in the regulation of synaptic 
plasticity. Conditional knockdown of Dnmt1 and Dnmt3a postnatally in post-mitotic neurons 
have led to long term deficits in LTP and long-term depression (LTD), hippocampal atrophy, 
and cognitive dysfunction (Feng et al., 2010b). In vitro studies have shown the Gadd45 gene 
to rapidly demethylate in response to synchronised therapeutic stimulus or in response to 
exercise based neuronal stimulation (Guo et al., 2011; Ma et al., 2009). Similarly, studies have 
also shown histone modifications to be important for memory consolidation and retention in 
mice (Pavlopoulos et al., 2013; Peleg et al., 2010). Much of the research into synaptic plasticity 
and epigenetics has centred around brain derived neurotrophic factor (BDNF). BDNF is a key 
gene in the regulation of synaptic plasticity and has been implicated in memory formation. 
Neuronal depolarisation has been shown to reduce CpG methylation around the Bdnf gene 
promoter in vitro, regulated by a complex of MeCP2/HDAC/SIN3a (Martinowich et al., 2003). 
While histone acetylation at Bdnf gene promoters in the mouse prefrontal cortex is associated 
with consolidation of long-term memory (Bredy et al., 2007; Lubin, Roth, & Sweatt, 2008). In 
summary, epigenetic regulation of memory formation and retention, and underlying changes 
to synaptic plasticity correlate with changes to the epigenome.   
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1.12 Epigenetics in the aging brain 
Aging is widely accepted as the leading risk factor associated with AD (review: (Ghosh, 
Agarwal, & Haggerty, 2011; Yankner, 2000)); however, AD is not a normal part of cognitive 
aging. Epigenetics has an established role in synaptic plasticity, long term potentiation and 
depression, and memory formation; however, there have been few studies of the epigenome in 
the aging brain. The transcriptional profile of genes involved in synaptic plasticity and memory 
formation are altered in the aging brain, which occur alongside significant DNA damage in 
promoter regions in neural and glial cells (Tao Lu et al., 2004; Soreq et al., 2017). Epigenetic 
changes may be the cause of underlying cognitive impairment occurring in the aging brain.  
 
DNA methylation in the aging brain 
Cortical aging has been associated with a variety of methylation states. Genome-wide studies 
have illustrated a complex landscape of both accumulation of DNA methylation in the aging 
brain (Ryan Lister et al., 2013; Yu et al., 2012), hypomethylation in the aging brain 
(Christensen et al., 2009; Penner et al., 2011), while other studies have shown both hyper- and 
hypomethylation in the aging brain (Bakulski et al., 2012). An epigenome wide association 
study utilising HumanMethylation27 Beadchip arrays identified 2,227 genes differentially 
methylated with aging in the mid-frontal gyrus of the post-mortem human prefrontal cortex, 
with ~50% of sites hypermethylated and ~50% of sites hypomethylated with increasing age 
(Bakulski et al., 2012). Other genome-wide array based studies have identified correlations 
between aging and increased methylation at CpG islands in the frontal and temporal cortex 
noting that dramatic changes to methylation occur early in life and are stabilised through aging 
(Hernandez et al., 2011; Numata et al., 2012). Non-CpG methylation also accumulates in 
neurons throughout later life (Ryan Lister et al., 2013; Szulwach et al., 2011). Interestingly, 
cortical CpG methylation has been shown to predominantly accumulate throughout life, in 
genomic regions separate from non-CpG methylation (Ryan Lister et al., 2013; Yu et al., 2012). 
While non-CpG methylation also accumulates in the cortex throughout later life (Ryan Lister 
et al., 2013; Szulwach et al., 2011). Studies using bead based arrays have observed age related 
hypomethylation for CpGs around Igf2, Hdac5, Ercc1 and Myod1 loci; specifically and an age 
related decrease in Arc promoter methylation in the CA1 region of the hippocampus, and 
increased Arc promoter methylation in the dentate gyrus of aged (24+ months) rats (Christensen 
et al., 2009; Penner et al., 2011). Studies in murine models have shown accumulation of 5hmC 
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in neuronal cells during development that is conserved through aging in cerebellum and 
hippocampus, while others have shown an increase of 5hmC in dopaminergic neurons in the 
aging substantia nigra (H. Chen, Dzitoyeva, & Manev, 2012; Fasolino, Liu, Wang, & Zhou, 
2017).The different results reported by these studies may be due to different sampling and 
molecular techniques, brain regions examined and cellular heterogeneity within the samples 
analysed (Davies et al., 2012; Ryan Lister et al., 2013; Mo et al., 2015). 
While there have been some genome-wide DNA methylation studies in the aging brain, many 
studies have focused on candidate pathways or genes of interest in the aging brain. For instance, 
quantitative PCR-based studies of DNA methylation across age in neuronal nuclei from the 
anterior and lateral temporal lobe from human cases have shown increased DNA methylation 
in promoter CpG islands of PGR, SYK and HOXA1 genes, but decreased methylation in S100A2 
with age (Siegmund et al., 2007). The study also found 8 loci in whole brain homogenate to 
have increased methylation with aging, including GABRA2, GAD1, HOXA1, NEUROD1, 
NEUROD2, PGR, STK11, and SYK (Siegmund et al., 2007). Another study of post-mortem 
human parietal cortex reported that CpGs of the Tau promoter were hypomethylated with 
increasing age (Tohgi et al., 1999). However, mass spectrometry analysis of DNA methylation 
binding sites in the post-mortem human prefrontal cortex have shown no significant aging 
related changes in promoter CpG sites for APP, NCSTN, BACE, SIN3A and DNMT1, but 
detected a negative drift in promoter methylation for APOE and PS1 with increasing age (S.-
C. Wang, Oelze, & Schumacher, 2008).  
 
Histone modifications in the aging brain 
There have been few studies of histone modifications in the aging brain. Much of the literature 
is not in agreement regarding the role of histone modifications in the aging brain. Likely, a 
complex combination of enrichment and depletion of histone modifications occurs through 
aging (Benito et al., 2015; Cheung et al., 2010; Nativio et al., 2018; Peleg et al., 2010; 
Rodrigues, Souza, Ghiraldini, Mello, & Moraes, 2014). Indeed, one study has identified histone 
modifications to be dynamic in the developing brain, but stabilise through aging (Shulha, 
Cheung, Guo, Akbarian, & Weng, 2013). Animal models allow for the study of a time-course 
of histone modification changes in aging in a controlled environment that is difficult to mirror 
with post-mortem human tissue. Cognitive aging results in a global loss of H3K9me3 and gain 
in H3K9ac in the cortex of Balb/c mice, indicative of increased euchromatin and transcriptional 
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activity with aging (Rodrigues et al., 2014). Depletion of H3K9 methylation has been 
correlated with the decreased expression of BDNF from aged hippocampal and cortical 
neuronal cultures (Walker, LaFerla, Oddo, & Brewer, 2013). While other studies have shown 
no difference in H3K9ac, H3K14ac, H4K5ac, H4K8ac, and H4K16ac in 16 month old 
hippocampal neurons from the C57/BL6 mice compared to 3 month old littermates, there was 
an age associated depletion of H4K12ac (localises to promoters/intron-exon boundaries and 
correlates with gene expression in neurons (Benito et al., 2015)), which suggests a reduction in 
transcription and subsequent loss of memory consolidation in aged animals (Peleg et al., 2010). 
When measured with ChIP-seq, H4K12ac was depleted from 20 month old CA1 hippocampal 
neurons compared to 3 month old counterparts in a murine model (Benito et al., 2015). 
H4K12ac depletion in aged neurons was associated with dysregulation of RNA metabolic 
process, splicing, apoptosis and autophagic cell death when measured with RNA-seq (Benito 
et al., 2015). 
There have been few studies of the aging brain in post-mortem human tissue. These studies 
have identified a complex pattern of enrichment and depletion in the aging brain. A ChIP-seq 
study of neurons (NeuN+ FACS) in the human prefrontal cortex in 11 samples from 0.5-14 and 
68-69 years investigated H3K4me3 alterations with age (Cheung et al., 2010). Analysis of 3 
samples less than 1 year old with 3 samples greater than 60 years of age showed 589 sites of 
enrichment present in infant, but not aged samples, and 101 peaks were unique to the aged 
samples (Cheung et al., 2010). In accordance with previous literature, another genome-wide 
study in post-mortem prefrontal cortex has identified rapid developmental changes to 
H3K4me3 at 1157 loci in neurons at sites pertaining to neuronal development, synaptogenesis, 
and intracellular signalling, but few changes to adult or aging neurons (Shulha et al., 2013). A 
recent study highlighted the importance for genome wide histone modification analysis in the 
aging brain. Nativio et al. (2018) performed ChIP-seq for H4K16ac (associated with promoter 
activation) in young and aged temporal lobe with mixed neuron and glial cell populations. The 
study utilised ChIP-seq and identified an increase in H4K16ac in aged individuals compared 
to younger cognitively healthy controls (Nativio et al., 2018). Gene ontology analysis showed 
that the top genes associated with aging were within pathways associated with respiration 
processing, insulin stimulus and the inflammatory response (Nativio et al., 2018). Alongside 
studies characterising histone modifications in the aging brain, others have trialled histone 
deacetylase inhibitors (HDACi) as a potential treatment to improve memory performance in 
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the aging brain (Dagnas, Guillou, Prévôt, & Mons, 2013; Pavlopoulos et al., 2013; Peleg et al., 
2010; Walker et al., 2013).  
 
Epigenetics in Alzheimer’s disease 
A wide range of evidence exists to support the notion of epigenetic dysregulation in AD. 
Recently studies have identified epigenetic alterations present in post-mortem AD cases and in 
AD mouse models, which provide support for epigenetic dysregulation in AD, however it is 
not known whether epigenetic dysregulation causes AD, or is a downstream consequence of 
the disease. Indeed, seminal studies of epigenetics in AD identified changes to DNA 
methylation that occur in tandem with neuritic plaque load and Braak staging, occurring at 
some of the earliest detectable stages of the disease (P. L. De Jager et al., 2014; Lunnon et al., 
2014). 
Several methods have been utilised for assessing epigenetic modifications in AD. Many studies 
have investigated global levels of DNA methylation and histone modifications with 
immunohistochemistry or various blotting techniques to determine total protein or methylation 
levels (A. I. Bernstein et al., 2016; Bradley-Whitman & Lovell, 2013; Coppieters et al., 2013; 
Lashley et al., 2014; D. Mastroeni et al., 2015; D. Mastroeni et al., 2010; Narayan, Lill, Faull, 
Curtis, & Dragunow, 2015). Others have used next generation sequencing to identify changes 
at a base-pair resolution, through genome-wide association studies, WGBS, or ChIP-seq 
(Benito et al., 2015; P. L. De Jager et al., 2014; Gjoneska et al., 2015; Lunnon et al., 2014). 
Coordinated changes in DNA methylation and histone modifications may explain the 
dysfunction seen in AD. 
 
1.13 DNA methylation in Alzheimer’s disease 
DNA methylation is the most widely studied epigenetic modification in AD. Global DNA 
methylation is altered through the progression of AD, however the results of current research 
have not been in agreeance as to the nature of change occurring in AD (Table 1.1). Some studies 
have shown global hypermethylation (Bradley-Whitman & Lovell, 2013; Coppieters et al., 
2013; Lardenoije et al., 2018), while others have reported global hypomethylation in AD 
(Chouliaras et al., 2013; A. Fuso, Seminara, Cavallaro, D'Anselmi, & Scarpa, 2005; D. 
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Mastroeni et al., 2010; S.-C. Wang et al., 2008; West, Lee, & Maroun, 1995) (Table 1.1). 
Indeed, other studies have not found any change to global DNA methylation in AD (Lashley 
et al., 2014).  For example, immunohistochemistry and dot-blot based analysis have detected 
an increase in global 5mC, 5hmC and TET1 intensity in the middle-frontal gyrus, middle-
temporal gyrus and hippocampus of late-onset AD cases compared to age-matched controls 
(Bradley-Whitman & Lovell, 2013; Coppieters et al., 2013). While a study of the post-mortem 
human hippocampus with immunohistochemistry presented a decrease of 5mC in CA1 and 
CA3 hippocampal subregions and a decrease of 5hmC in the dentate gyrus and CA3 region of 
the hippocampus in AD cases (Chouliaras et al., 2013). However, other research has shown no 
change in 5mC and 5hmC in the entorhinal cortex of post-mortem AD brains when measured 
with immunohistochemistry and ELISA (Lashley et al., 2014). DNA methylation has also been 
identified in the cytoplasm of AD middle frontal gyrus and middle temporal gyrus, but has not 




Table 1.1: DNA methylation alterations in Alzheimer’s disease 
Author 











Increased levels of TET1, 5mC and 5hmC in the hippocampus of preclincal and late stage 
AD compared to control cases 
Chouliaras, 





Decreased 5mC in glia but not neurons in hippocampal CA3, decreased 5mC intensity in 
neurons and glia in hippocampal CA1 in AD vs control. 5hmC decreased in neurons and glia 
in dentate gyrus, and in glia of CA3, but not CA1 in AD vs control cases.  
Coppieters, 
et al., (2013) 
Immunohistochemi
stry  
Human MFG and 
MTG 
No difference in 5mC or 5hmC immunolabelling in neurons, astrocytes or microglia in the 




stry and ELISA 
Human 
entorhinal cortex 
No difference in 5mC or 5hmC immunolabelling in neurons in entorhinal cortex of control 
and AD cases, confirmed with ELISA 
Mastroeni, 
et al., (2010) 
Immunohistochemi
stry Human EC Decrease in 5mC labelled neurons in the EC of AD cases compared to controls 
Sanchez-






human FC & 
Mouse brains 
DNA hypermethylation associated silencing of 3 target genes: TBXA2R, SORBS3 and 
SPTBN4 in AD compared to control 
Siegmund, 
et al., (2007) 
5' methylation 
status of 50 genes 
of CNS growth and 
development 







5hmC differentially methylated in PFC of AD cases. 5431 sites hyper-hydroxymethylated, 
2170 hypo-hydroxymethylated, genes identified to be differentially hydroxymethylated in 
post-mortem AD were confirmed in fly model 
Rao, et al 
(2012) 
Methylation CpG 
qPCR, RNA qPCR Human FC 
Both hypermethylation and hypomethylation in AD cases compared to control and 
preclinical. Hypermethylation of Bdnf and Nf-κβ gene promoter, hypomethylation of Cox-2 




27, RNAseq Human FC 
Hypomethylation of TMEM59, PS1 and PS2, transcriptional changes in TMEM59, and no 
differences for APOE, BACE1, BDNF, BIN1, PICALM and TOMM40 in AD samples. No 
global difference in DNA methylation between AD samples and controls 
De Jager, et 
al., (2014) 
HumanMethylation
450K Human PFC 
Correlation between DNA methylation and neuritic plaque load. Changes occur early in AD 
progression 
Gasparoni, 
et al., (2018) 
HumanMethylation 
450k 
FC and TC (bulk), 
occipital cortex 
(FACS NeuN) 







cortex, PFC, STG 
ANK1 hypermethylation correlates with Braak staging and neuritic plaque load in EC, STG 







CpG hypermethylation was associated with neuritic plaque load in AD (including including 
Bin1, Clu, ABCA7, Ms4a6a, and Apoe). Hypermethylated SNP risk loci correlated with 
increased neuritic plaque load in AD 





Human STG Trem2 promoter methylation increased in 3 separate cohorts of AD, and correlated with Braak staging 
Sanchez-
Mut, et al 
(2014) 




DUSP22, CLDN15, QSCN6 enriched in AD hippocampus compared to control.  Linear 
correlation between DNA methylation of Dusp22 and plaque load 
Sanchez-







DNA methylation changes are common across neurodegenerative disease including AD, 
Parkinson’s disease, FTD, and Lewy body dementia. Neurodegenerative diseases have shared 
sites that are  hypo- and hypermethylated 
    







Age associated global hypomethylation, but transcription factor binding site (SP1) specific 
hypermethylation in AD vs control cases 
West, et al., 
(1995) Southern blot Human cortex APP gene hypomethylated in AD cortex, but not age matched controls 






 Differentially hydroxymethylated regions to correlate with neuritic plaques. Differentially 
methylated regions associated with cellular and synaptic activity 




bisulfite sequencing  
Various human 
tissue including 
AD cortex  
12408 differentially methylated AD CpGs overlapped with developmental methylation 
landscape 
FC – frontal cortex, TC – temporal cortex, PFC – prefrontal cortex, MFG – middle frontal 




With the advent of next generation sequencing, it is now possible to measure CpG site specific 
changes in DNA methylation with arrays or at a genome-wide level. However, many previous 
genome-wide association studies (450k/HumanMethylation) and whole-genome bisulphite 
sequencing studies have presented contradictory results. Some studies have shown a mix of 
hypomethylation and hypermethylation in AD compared to control cases (Bakulski et al., 2012; 
Rao, Keleshian, Klein, & Rapoport, 2012; Sanchez-Mut et al., 2016), while others have 
detected predominately hypomethylation (Watson et al., 2016), and others have reported 
hypermethylation in the AD brain (Chibnik et al., 2015; P. L. De Jager et al., 2014; Lunnon et 
al., 2014; Siegmund et al., 2007; M. J. Ziller et al., 2013). Bakulski, et al. (2012) performed 
genome wide DNA methylation analysis of a heterogenous cell population from human frontal 
cortex using the HumanMethylation27 array. This study identified 948 CpGs to be 
differentially methylated in late-onset AD, including hypomethylation of TMEM59, PS1 and 
PS2 with associated transcriptional changes in TMEM59, but no differences in methylation or 
transcriptomics for APOE, BACE, BDNF, BIN1, PICALM and TOMM40 in AD samples 
(Bakulski et al., 2012). The difference in global coverage of DNA methylation between late-
onset AD cases and cognitively normal controls was within 2.9% of each other, regions of 
chromosome 3 were hypomethylated, and chromosome 10 and 17 were hypermethylated in 
AD compared to control (Bakulski et al., 2012). Lunnon, et al., (2014) utilised 
HumanMethylation450 array and bisulphite pyrosequencing in the post-mortem entorhinal 
cortex, superior temporal gyrus, and prefrontal cortex of AD cases and age-matched controls 
to identify AD associated differentially methylated loci. This study identified hypermethylation 
of ANK1, PCBD1, SLC15A4, SIRT6, MEST, MLST8, ZNF512, and TMX4 in AD cases (Lunnon 
et al., 2014). Early research using WGBS in the frontal cortex of two severe AD cases reported 
that more than 60% of known ENCODE transcription factor binding sites showed high levels 
of methylation in the AD cases compare to age-matched controls (M. J. Ziller et al., 2013). In 
particular, AD samples had DMRs within regions of non-conserved genomic regions as well 
as intergenic regions compared to controls (M. J. Ziller et al., 2013). More recently, genome-
wide analysis of hypermethylated CpG regions identified correlations of H3K4me3 and 
H3K27me3 marked promoters with known AD loci including CLU, DIP2C, FRMD4A, HLA-
DRB1, HLA-DQB1, CTNNA2, and KLK7 (Watson et al., 2016).  A recent study has highlighted 
the importance of cell sorting to identify AD related changes in DNA methylation in neurons. 
Gasparoni and colleagues sorted human neuronal and glial nuclei from the occipital cortex and 
assessed DNA methylation alterations in AD using the HumanMethylation 450k array 
(Gasparoni et al., 2018). This study demonstrated that isolated neurons and glia were 
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hypomethylated (60% of differentially methylated CpGs) in AD cases compared to controls 
(Gasparoni et al., 2018). Interestingly, neurons and glia had different methylation profiles that 
dynamically progressed with increasing Braak stage of AD cases (Gasparoni et al., 2018). Gene 
ontology analysis demonstrated that differential methylation was occurring at pathways for 
neurological processes including synaptic transmission, neurotransmitter levels and neuron 
projection morphogenesis (Gasparoni et al., 2018). The changes to DNA methylation in AD 
may also be shared across other dementias, with one study utilising WGBS to identify a core 
set of genes being differentially methylated across AD, Parkinson’s disease, and Lewy body 
dementia (Sanchez-Mut et al., 2016).  
DNA hydroxymethylation has also been implicated in AD, however techniques have only 
recently been developed to measure it at a genome-wide level. There have been two studies 
that have performed genome-wide sequencing of 5hmC in post-mortem human AD brain (A. 
I. Bernstein et al., 2016; J. Zhao et al., 2017). Bernstein, et al., (2016) identified a range of 
5hmC DMRs to be enriched at intergenic regions of the prefrontal cortex of 10 post-mortem 
AD samples, with a mix of both hypo-hydroxymethylation and hyper-hydroxymethylation (A. 
I. Bernstein et al., 2016). Gene ontology analysis demonstrated significant enrichment in 
pathways of cell polarity, synaptic activity and cellular maintenance, and differentially 
hydroxymethylated regions included AD associated single nucleotide polymorphisms such as 
ANK1, MAPK1, BIN1 and CAMK1D (A. I. Bernstein et al., 2016). This study tested gene loci 
from the findings of the human data to follow up in Drosophila, showing the genes associated 
with 5hmC DMRs to alter tau-associated neurotoxicity (A. I. Bernstein et al., 2016). 
Additionally, genome wide analysis of 5hmC in the post-mortem human dorsolateral prefrontal 
cortex has shown global enrichment in exons, introns, TSS and promoter regions but global 
loss at intergenic regions of AD cases (J. Zhao et al., 2017).  
Some studies have concentrated on characterising DNA methylation in brain specific or disease 
specific loci, predominantly at genes involved in memory formation and familial AD risk loci. 
These studies show gene specific hypermethylation of genes associated with synaptic plasticity 
(Rao et al., 2012), and generally hypomethylation at AD risk loci (S.-C. Wang et al., 2008; 
West et al., 1995). An early study of DNA methylation in AD showed the APP locus to be 
hypomethylated in in the AD brain with Southern blot (West et al., 1995). Mass spectrometry 
analysis of DNA methylation binding sites in the human prefrontal cortex detected a loss in 
promoter methylation for APOE and PS1 in AD samples (S.-C. Wang et al., 2008). Gene and 
transcript specific analysis of Bdnf, Creb, Synaptophysin, Cox-2 and Nf-κβ through qPCR 
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analysis showed hypermethylation of CpGs in the BDNF and NF-κβ gene promoters, and 
hypomethylation of CpGs in the COX-2 gene promoter in frontal cortex of post-mortem AD 
cases (Rao et al., 2012). Moreover, a study of DNA methylation of 50 genes related to CNS 
growth and development of the anterior temporal cortex (including a subset analysis of 
neuronal nuclei for 10 genes) has identified hypomethylation of S100a2 and increased 
methylation of Sorbs3 in AD (Siegmund et al., 2007). 
Among the most convincing evidence for epigenetics being critical to the progression of AD 
lies in the correlations between epigenetic data and AD pathology. Multiple studies have 
correlated loss of DNA methylation with Braak staging or neuritic plaque load, while others 
have reported positive correlations between DNA methylation and increased pathology load. 
The different cortical regions, fixation strategy, and methods of analysis may have led to 
inconsistent results between studies (Table 1.1). For instance, Coppieters et al., (2013), 
reported positive correlations between Aβ, tau and ubiquitin (dystrophic neurite) loads and both 
5mC and 5hmC intensity in AD. However, Chouliaras, et al., (2013) described negative 
correlations between global 5mC and 5hmC levels and Aβ plaque load in the hippocampus, but 
did not observe any correlation with NFT load (Chouliaras et al., 2013). Recently, a study in 
the 3xTG and APP/PS1 mice and primate models of AD, and observed negative correlations 
between global levels of 5mC, 5hmC and DNMT3A and plaque load in dentate gyrus and CA3 
region of the hippocampus in APP/PS1 and 3xTg AD models (Lardenoije et al., 2018). One 
seminal study correlated DNA methylation with pathological staging in AD (P. L. De Jager et 
al., 2014). De Jager, et al., (2014) performed DNA methylation analysis of a large suite of 
samples from the prefrontal cortex of two major post-mortem studies (totalling over: 2700 
samples), and a replicate study of 117 individuals. This study used 
InfiniumHumanMethylation450 array to show that DNA methylation at a set of genes, 
including Bin1, Abca7, Ank1, Cdh23, Dip2a, Rhbdf2, Rpl13, and Serpinf1/2, correlated with 
neuritic plaque load; and that DNA methylation alterations were present early in AD 
progression (P. L. De Jager et al., 2014). A follow up study using HumanMethylation 450k 
arrays confirmed that hypermethylation of a range of CpGs including BIN1, CLU, ABCA7, 
MS4A6A, and APOE correlated with increased neuritic plaque load in human AD prefrontal 
cortex (Chibnik et al., 2015). Other studies have shown linear correlations between DNA 
methylation of the DUSP22, ANK1 and TREM2 genes and neuritic plaque load, and Braak 
staging in the superior temporal gyrus (Lunnon et al., 2014; Sanchez-Mut et al., 2014; Smith 
et al., 2016). Differential hydroxymethylation correlated with neuritic plaque load in the human 
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dorsolateral prefrontal cortex at genomic sites associated with cellular and synaptic activity 
(including DUSP22, SYN2, ATXN1, and APC2) (J. Zhao et al., 2017). Furthermore, four 
differentially hyroxymethylated sites, ABAT, CAMK1D, HTRA3, and LRRN1, also correlated 
with NFTs, in the human dorsolateral prefrontal cortex (J. Zhao et al., 2017). Interestingly, data 
suggests that the correlations between DNA methylation at certain sites and pathology load 
may also be cell type specific. Recent research indicates that different loci exhibited DNA 
methylation that changed in tandem with Braak staging in neurons (e.g. HOXA3, APP and 
ADAM17) compared to glia (ANK1) in the human occipital cortex (Gasparoni et al., 2018). 
 
1.14 Histone modifications in Alzheimer’s disease 
Histone acetylation and methylation are dysregulated in AD, however there have been few 
studies to that performed genome-wide analysis of histone modifications to ascertain the 
molecular underpinnings of AD (Benito et al., 2015; Gjoneska et al., 2015; A. Kozlenkov et 
al., 2014).  
Studies of global histone modifications utilising immunohistochemistry or blotting are not in 
agreeance, demonstrating either enrichment or depletion of various histone modifications in 
AD (Table 1.2) (Francis et al., 2009; D. Mastroeni et al., 2015; Narayan et al., 2015). Francis, 
et al., (2009) demonstrated that APP/PS1 mice performed worse in fear conditioning than WT 
controls, and identified that after fear conditioning there is a global loss of histone H4 in the 
hippocampus of 3-4-month-old APP/PS1 mice compared to WT control mice (Francis et al., 
2009). In contrast, total H3, H4, H3ac and H4ac are enriched in neurons of the middle-temporal 
gyrus of post-mortem AD brains, and correlate GFAP, tau and Aβ load (Narayan et al., 2015). 
Mastroeni, et al., (2015) performed immunohistochemical analysis of H3K4me3 marking. This 
study observed that intracellular changes in H3K4me3 to occurred early in AD progression by 
correlating with Braak staging, and showed a shift in the intracellular location of H3K4me3 
from the nucleus to the soma of neurons (D. Mastroeni et al., 2015).  
Alongside changes to histone modifications, research has also illustrated that HDACs are 
enriched as a result of AD pathogenesis in vivo (Table 1.2) (Govindarajan et al., 2013; Graff et 
al., 2012). In particular, HDAC2 was increased in neurons of the CA1 hippocampus in an AD-
like mouse model (Graff et al., 2012). Furthermore 8-month transgenic APP/PS1-21 mice 
recover cognitive deficits to wild-type levels after knocking out HDAC6 (Govindarajan et al., 
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2013). Another study has identified AD risk loci, including ApoE €4, to induce nuclear 
translocation of HDACs in the hippocampus of C57/BL6 mice resulting in a reduction of 
BDNF expression. However, mice exposed to ApoE €3 increased histone acetylation within 
the nucleus and upregulated BDNF (Sen, Nelson, & Alkon, 2015). Subsequently, a number of 
studies have investigated the use of HDACi in AD to improve behavioral outcomes in animal 
models of the disease (Francis et al., 2009; Govindarajan et al., 2013; Kilgore et al., 2009; 
Vecsey et al., 2007). Histone deacetylase inhibitors have been shown to increase learning and 
memory performance in a contextual fear paradigm using 6-month APP/PS1 transgenic mice 
(Kilgore et al., 2009). Additionally, treatment with HDACi prior to a fear conditioning 
paradigm restored histone H4 in the APP/PS1 mice, rescued behavioral performance and 
improved long-term potentiation in hippocampal slice recordings (Francis et al., 2009).  
There have been five studies investigating histone modifications in AD at a genome-wide scale 
(Table 1.2) (Benito et al., 2015; Gjoneska et al., 2015; Klein et al., 2019; Marzi et al., 2018; 
Nativio et al., 2018). The limited literature that is available regarding histone modifications in 
AD points towards depletion of certain histone modifications at putative enhancers and 
promoters associated with synaptic plasticity along with enrichment at immune response genes 
(Gjoneska et al., 2015), and genome-wide depletion of H4K16ac and H4K12ac (both indicative 
of transcriptional activity) at transcriptional start sites (TSS) (Benito et al., 2015; Nativio et al., 
2018). An early ChIP-seq study by Gjoneska, et al., (2015) was a significant advance for the 
field at the time, performing ChIP-seq and RNA-seq of hippocampal homogenate in CK-p25 
inducible neurodegeneration mouse model measuring H3K4me1, H3K4me3, H3K9me3, 
H3K27me3, H3K27ac, H3K36me3 and H4K20me1 (Gjoneska et al., 2015). The CKp25 mouse 
model accumulates plaques rapidly with dense accumulation 6 weeks after induction of p25. 
There was widespread downregulation of genes involved in synaptic plasticity by 6 weeks post 
p25 induction, and widespread enrichment of H3K4me1 and H3K27ac at both promoters and 
enhancers for genes associated with immune activity and stimuli response, that was present at 
pre-symptomatic timepoints (2 weeks post-induction of p25) (Gjoneska et al., 2015). 
Interestingly, Gjoneska noted only a small number of peaks were present for polycomb-
repressed regions labelled by H3K27me3 (Gjoneska et al., 2015). A seminal study by Benito 
and colleagues (2015) used a combination of FACS and ChIP-seq in 3-month and 20-month 
APP/PS1-21 mice to analyse histone modifications in neurons from the hippocampus. The 
authors report that Aβ plaque accumulation resulted in both depletion of H4K12ac and 
transcriptional loss of genes associated with synaptic plasticity (Benito et al., 2015). This loss 
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of synaptic plasticity associated transcripts occurred in conjunction with impaired synaptic 
function, inflammation, and behavioral deficits in APP/PS1 mice (Benito et al., 2015). Histone 
deacetylase inhibitor (SAHA) administration was able to alleviate behavioral deficits and 
reduce inflammation and partially restore H4K12ac marking in neurons but not glia (Benito et 
al., 2015). However, SAHA did not reduce plaque load in 20-month-old APP/PS1 mice (Benito 
et al., 2015). Nativio, et al., (2018) has demonstrated genome-wide depletion of H4K16ac from 
the post-mortem human lateral temporal lobe compared to age-matched controls (Nativio et 
al., 2018). This study also characterized age associated epigenetic changes as well as disease 
related changes and correlated H4K16ac marking with pathology load, leading to the 
identification of three separate classes of change in H4K16ac marking; age-regulated, age-
dysregulated and age-independent changes, many of which overlapped AD-associated 
quantitative trait loci curated from previous genome-wide association studies, with 143 age-
regulated, 231 age-dysregulated and 220 disease specific overlaps (Nativio et al., 2018). A 
recent genome-wide study of H3K27ac (active enhancers; indicative of activation) identified 
4162 sites of differential enrichment between post-mortem entorhinal cortex from AD cases 
and age-matched control cases (Marzi et al., 2018). H3K27ac was increased in promoter and 
enhancer regions of genes associated with AD, including Mapt, App, Ps1, and Ps2 (Marzi et 
al., 2018). In accordance with other recent literature, genome-wide analysis of H3K9ac 
(indicative of activation) with ChIP-seq in the prefrontal cortex of post-mortem AD cases have 
shown that tau, but not Aβ correlates with altered H3K9ac profile at promoters and enhancers 
(Klein et al., 2019). This study detected 5990 differentially H3K9ac marked sites leading to 
transcriptional changes in AD measured by RNA-seq (Klein et al., 2019). While the knowledge 
of the histone modifications in AD is expanding, further research is required to generate 
comprehensive multilayered epigenetic maps, particularly in specific cell types in AD.  
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Table 1.2: Histone modifications, HAT and HDAC in Alzheimer’s disease 
Author 
(year) Methodology Tissue source Key findings 







Loss of H4K12ac in neurons of hippocampus. Associated with impaired 
synaptic function, increased inflammation  
Francis, et al., 
(2009) 




Global loss of histone H4 in APP/PS1 mice. HDACi improved histone 
acetylation and improved behavioural deficits and long-term potentiation 
Gjoneska, et 
al., (2015) ChIP-seq/RNA-seq 
CKp25 mouse 
hippocampus 
Changes to histone landscape at promoters and enhancers. Increased 
transcription of genes associated with immune response, decreased 
expression genes associated with synaptic plasticity.  
Govindarajan, 







HDAC6 KO restores behavioural deficits in APP/PS1-21 mice 




CKp25 mouse CA1 
hippocampus  HDAC2 increased in neuronal nuclei of CA1 hippocampus of AD mice 
Hendrickx, et 
al., (2014) ChIP-qPCR, qRT-PCR, 
APP mice prefrontal 
cortex and 
hippocampus 
APP+ mice have decreased histone H4, APP- mice showed increased 
H4K5ac and H4K12ac at the same promoters. APP- mice have reduced 
capability to learn, and associated hypoacetylation 
Klein, et al., 
(2019) ChIP-seq, RNA-seq 
Human prefrontal 
cortex 
Tau, but not Aβ, correlates with altered H3K9ac profile and leads to 
transcriptional  
Koldamova, 
et al., (2014) ChIP-seq 
APP23 mouse 
pooled forebrain 
EGR1 correlates with histone methylation and acetylation. Total levels of 
EGR1 were reduced in APP23 mice when compared to WT controls. 
Depletion in AD risk loci: Picalm, Ps2, App 




4162 H3K27ac marked sites differentially enriched in AD: 35% were 
enriched for H3K27ac marking, while 65% were depleted for H3K27ac 









H3K4me3 labelling moves from nucleus to cytoplasm in – correlates with 
Braak staging 
Narayan, et 
al., (2015) Immunohistochemistry 
Human inferior 
temporal gyrus 
Correlations between total histone H3, total histone H4, H3ac and H4ac 
with GFAP, tau and Aβ load, hyperacetylation of neurons labelled with 
NeuN 




AD associated loss of H4K16ac, associated with dysregulation of REST, 





1.15 Limitations and challenges of current epigenetic approaches  
There are many challenges to address with the current techniques available to analyse 
epigenetic alterations in AD. There is a lack of cell type, brain region, or cortical layer specific 
quantitative analysis in immunohistochemical studies within the literature (Bradley-Whitman 
& Lovell, 2013; Chouliaras et al., 2013; Coppieters et al., 2013; D. Mastroeni et al., 2010). 
Meanwhile, there have been few true genome-wide studies of epigenetic alterations in AD 
(Sanchez-Mut et al., 2016; J. Zhao et al., 2017; Michael J Ziller et al., 2013; M. J. Ziller et al., 
2013). Most DNA methylation studies have performed HumanMethylation 450K or similar 
arrays (Bakulski et al., 2012; Chibnik et al., 2015; P. L. De Jager et al., 2014; Gasparoni et al., 
2018; Lunnon et al., 2014) that are not genome-wide but provide a reference of candidate loci 
across the genome and as a result do not assess many CpG sites and intergenic regions. WGBS 
addresses this by analyzing at base pair resolution throughout the entire genome, however, 
there have been few studies to date to incorporate WGBS into their experiments (Sanchez-Mut 
et al., 2016; J. Zhao et al., 2017; M. J. Ziller et al., 2013). While new research is incorporating 
a range of single-cell RNA-seq, ChIP-seq and WGBS technologies to show ever increasing 
complexity of the epigenetic landscape, as illustrated by DeJager and colleagues’ (2018) 
landmark multi-omics map of the frontal cortex in the aging and AD brain (Philip L. De Jager 
et al., 2018). However, there are still many factors that need to be taken into consideration 
when performing these experiments including sequencing depth and analytical methods. Many 
genomic regions are still difficult to sequence with current technology producing artifacts in 
output and therefore, are excluded from many analyses (Consortium, 2012). There are few 
bioinformatics based pipelines for addressing biological replicates (A. T. L. Lun & Smyth, 
2016; M. D. Robinson, McCarthy, & Smyth, 2010), and there are few standardized procedures 
that recognize inter-individual variation between samples (Landt et al., 2012). There are also 
impeding issues in cost for genome-wide next-generation sequencing in large experiments.  
Advances in cell sorting, multiplexed ChIP-seq, and single-cell WGBS have provided new 
resolution at a cell-type specific and genome-wide level (Luo et al., 2017), and studies are now 
using such methodologies to characterize the aging and AD brain (Nativio et al., 2018). The 
vast majority of studies investigating epigenetic changes in AD have used whole brain 
homogenate (Bakulski et al., 2012; P. L. De Jager et al., 2014; Gjoneska et al., 2015; 
Koldamova et al., 2014; Lunnon et al., 2014; Marzi et al., 2018; Nativio et al., 2018; Sanchez-
Mut et al., 2014; Sanchez-Mut et al., 2016; Siegmund et al., 2007; J. Zhao et al., 2017; M. J. 
Ziller et al., 2013), including a mixture of neuronal and glial cell types. Two studies have 
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performed next-generation sequencing in neurons and glia (Benito et al., 2015; Gasparoni et 
al., 2018), potentially masking neuron specific changes to the epigenome. Indeed, the isolation 
of neurons demonstrated differential methylation between neurons and glia with increasing 
Braak stage in the occipital cortex (Gasparoni et al., 2018), while neurons were selectively 
depleted for H4K12ac marking with increasing age and in AD (Benito et al., 2015). Histone 
deacetylase inhibitors were able to selectively reinstate H4K12ac marking in neurons. These 
two studies highlight the importance of generating cell type specific epigenetic data to 
understand how AD impacts vulnerable or disease resistant cell types.  
Many questions remain unanswered in the burgeoning field of epigenetics and Alzheimer’s 
disease. Studies have shown that the epigenome is both region and cell-type specific (Luo et 
al., 2017), however it is not known whether different cortical regions exhibit differential DNA 
methylation or histone modification patterns in AD. Although initial studies have shown that 
neurons and glia exhibit different epigenetic landscapes in AD (Benito et al., 2015; Gasparoni 
et al., 2018), there have been no studies of the epigenome in neuronal sub-types that are 
vulnerable or resistant to AD pathology. Finally, despite the correlations with Braak or neuritic 
plaque load, it is still unknown whether epigenetic alterations in AD are an early consequence 




Aims & Hypothesis 
Alzheimer’s disease is a terminal condition and affects the lives of more than 26 million people 
globally and is estimated to impact more than 100 million people by 2050 (Brookmeyer, 
Johnson, Ziegler-Graham, & Arrighi, 2007). Despite current research, there is little 
understanding of the onset and progression of sporadic AD, which account for ~90% of all AD 
cases. Known familial gene loci, including PS1, PS2, APOE, and APP, are involved in familial 
AD onset and progression. In the absence of highly penetrant risk alleles, epigenetic alterations 
are well poised to contribute to the pathogenesis and progression of AD, but this role is yet to 
be fully explored. Despite the key role epigenetics has in the regulation of the genome, there 
have been relatively few studies that have characterised the epigenome of neurons, neither in 
the healthy aging brain nor in neurodegenerative diseases. With this in mind, there is a need to 
incorporate a range of techniques to characterise epigenetic alterations in AD including 
quantitative immunohistochemistry at a cell-type specific and layer specific level and genome-
wide next-generation sequencing.  
 
Hypothesis 
The hypothesis for this PhD study is that the epigenome will be cell-type specific, and the 
neuronal epigenome will evolve with age and be dysregulated in AD. 
The research in this thesis will characterise DNA methylation in post-mortem human AD brains 
in a cell type specific manner, and will characterise key histone modifications in neurons across 




Aim 1: Characterise DNA methylation of specific cell types in Alzheimer’s 
disease  
Assess global alterations in common DNA methylation marks in specific cell types in post-
mortem human control, early-sporadic AD, and late-sporadic AD cases using 
immunohistochemistry. Studies have implicated DNA methylation alterations through the 
progression of AD, however few have performed quantitative analysis in a cell-type specific 
manner, or quantified changes in tandem with AD pathology. With this in mind, the aim of this 
study was to investigate global alterations in DNA methylation (5mC) and DNA 
hydroxymethylation (5hmC) in different neuronal and glial cell types including neurofilament-
labelled pyramidal neurons, calretinin positive interneurons, microglia and astrocytes using 
immunohistochemistry in post-mortem human tissue in early-sporadic AD (Braak stages I-III) 
and late-sporadic AD (Braak stages IV-VI) cases compared to age matched controls. This study 
also investigated whether the cells adjacent to Aβ plaques or tangle-bearing neurons were more 
susceptible to global alterations in DNA methylation. Immunohistochemistry is the only 
technique available to date that can determine global DNA methylation changes in specific 





Aim 2: Charting histone modifications in neurons across aging 
Generate temporal maps of histone modifications in aging neurons using ChIP-seq. 
Aging is widely accepted as the greatest risk factor for AD, however, there have been few 
studies to characterise histone modifications in neurons in the aging brain. Hence, this study 
characterised histone modifications in neurons from 3- , 6- , 12- , and 24-month old C57/BL6 
mice using chromatin immunoprecipitation and next generation sequencing (ChIP-seq). These 
timepoints corresponded to juvenile, young, adult and old mice and enabled the assessment of 
the alterations in neuronal histone modifications to occur as the result of healthy aging. 
Neuronal nuclei were purified by fluorescence activated cell sorting with NeuN from the 
forebrain of C57/BL6 mice. The histone modifications examined included those that 
commonly mark enhancers (H3K27Ac) and promoters (H3K4me3). The ChIP-seq technique 
allowed for the generation of temporal maps of active and repressive epigenetic marks and 
whether alterations exist at gene regulatory regions (gene promoters/enhancers) in early life 




Aim 3: Identifying histone modification alterations in neurons in 
Alzheimer’s disease mice 
Generate temporal maps of histone modifications in neurons in a mouse model of AD using 
ChIP-seq. There have been four studies to date investigating histone modifications at base-pair 
resolution in AD, with most performing ChIP-seq on a single histone modification, and few 
have characterised histone modifications in specific cell-types. Hence, this study characterised 
histone modifications in neurons from 3- , 6- , and 12-month old APP/PS1 mice and age-
matched wild-type control mice using Chromatin Immunoprecipitation and next generation 
sequencing (ChIP-seq). These timepoints corresponded to pre-pathology, pathology onset and 
dense-pathology time points in the APP/PS1 model and enabled the assessment of the earliest 
neuronal histone modification alterations to occur in this mouse model of amyloidosis. 
Neuronal nuclei were isolated by cell sorting with NeuN from the forebrain of APP/PS1 and 
wild type mice. This study generated temporal maps of histone modifications that commonly 












2.1 Human brain tissue sources and processing  
Human post-mortem tissue was sourced from the Victorian Brain Bank Network (Melbourne, 
Victoria, Australia), and the South Australian Brain Bank (Adelaide, South Australia, 
Australia). Informed consent for the collection of tissue was obtained prior to death and 
institutional approval for the use in research was granted by the University of Tasmania’s 
Human Research Ethics Committee, consistent with the Declaration of Helsinki (Tracey C. 
Dickson et al., 1999). Permission for brain autopsy and use for research was obtained by the 
original tissue sources. Tissue blocks of the inferior temporal gyrus were immersion fixed in 
10% formalin, or perfusion fixed in picric acid and 4% paraformaldehyde. Tissue was stored 
in 0.01 PBS with 0.01% sodium azide (Table 2.1).  
Human cases included the inferior temporal gyrus (ITG) of 5 control (mean age, age range; 
mean PMI, PMI range: 74.2±4.0 years, 58-84 years; 44.4±6.0 hours, 27-57 hours), 5 early-AD 
(80.6±2.8 years, 74-91 years; 49.2±5.2 hours, 32-68 hour) and 6-8 late-AD cases (76.5±2.7 
years, 60-91 years; 30.2±6.0 hours, 5-65 hours; Table 2.1). Late-AD cases conformed to 
CERAD criteria (Murayama & Saito, 2004), and exhibited Braak stage IV-VI pathology (Braak 
& Braak, 1991). Control cases exhibited no AD pathology. Early-AD cases did not conform to 
CERAD criteria and were representative of Braak stage III pathology (Braak & Braak, 1991). 
There was no significant difference in the age or PMI of control, early-AD and late-AD cases.  
 
2.2 Tissue sectioning 
Blocks of human ITG were incubated in an 18% sucrose solution overnight, followed by a 30% 
sucrose solution (Appendix 1) overnight. Tissue was then submerged and frozen in Tissue-Tek 
Optimum Cutting Temperature (O.C.T) compound (VWR, Radnor, Pennsylvania, USA), and 
sections were cut coronally at 40µm on the Leica CM 1850 cryostat (Leica Microsystems, 






Table 2.1: Human brain cases used for immunohistochemistry and analysis 
SABB – South Australian Brain Bank; VBBN – Victorian Brain Bank Network; MI – 
myocardial infarction; PE - pulmonary embolism; DVT – deep vein thrombosis; COAD – 
chronic obstructive airways disease 
  
Type Source Fixative Cause of Death 
PMI 








AD VBBN Formalin mesothelioma 64 F 91 4.83 52.0 
AD VBBN Formalin COAD 65 M 60 9.95 21.3 
AD VBBN Formalin Respiratory 31 M 67 10.48 35.1 
AD VBBN Formalin Respiratory 24 M 79 2.75 19.7 
AD VBBN Formalin Cardiac 24 M 81 4.50 20.2 
AD SABB PFA & picric acid AD 13 F 71 6.10 24.5 
AD SABB PFA & picric acid AD 26 F 76 9.40 44.2 
AD SAAB PFA & picric acid AD 5 F 83 4.05 56.7 
AD SABB PFA & picric acid 
Heart 
failure 17 F 84 7.58 32.0 
AD SABB PFA & picric acid Pneumonia 34 M 73 7.10 61.5 
Early 
AD VBBN Formalin Cardiac 32 M 74 0.35 - 
Early 
AD VBBN Formalin Cardiac 68 M 74 3.98 - 
Early 
AD VBBN Formalin 
Renal 
failure 48 M 91 0.05 - 
Early 
AD VBBN Formalin Cardiac 50 M 82 1.68 - 
Early 
AD VBBN Formalin MI 49 M 82 1.30 - 
Control VBBN Formalin Asthma 30 F 58 - - 
Control VBBN Formalin PE, DVT 27 F 73 - - 
Control VBBN Formalin Cardiac 54 M 77 - - 
Control VBBN Formalin Respiratory 57 M 79 - - 




Immunohistochemistry was performed to assess astrocytes, microglia, calretinin-positive 
interneurons, NF-positive pyramidal neurons, NFTs, Aβ plaques, 5mC and 5hmC marks (Table 
2.2).  Optimal concentrations were determined for each primary antibody, with positive control 
single-immunolabelling experiments performed for each antibody. Negative control 
experiments were performed, in which the primary antibody was omitted eliminating all 
immunosignal. The specificity of the rabbit polyclonal anti-5hmC antibody was verified with 
a mouse monoclonal 5hmC antibody (GTX629765, GenTex/Sapphire Bioscience, Michigan 
USA) which demonstrated analogous extranuclear immunofluorescence signal (Appendix 2:  
Supplementary Figure 1)  
Tissue sections were incubated in 3% horse serum in 0.01M PBS for 60 minutes at room 
temperature, washed 3X in 0.01M PBS and incubated in primary antibodies (Table 2.2) diluted 
in 0.01M PBS-X (Appendix 1) for 24 hours at room temperature. Following 3X washes in 
0.01M PBS, tissue sections were incubated with AlexaFluor488 and AlexaFluor594 (1:1000; 
Invitrogen/Life technologies, Carlsbad, CA) secondary antibodies diluted in 0.01M PBS-X for 
two hours at room temperature. Sections were washed 3X in 0.01M PBS and were mounted, 
dried, and coverslipped with DAKO fluorescent mounting medium (DAKO, USA). 90% 
formic acid was used as antigen retrieval for immunolabelling Aβ plaques (Tracey C. Dickson 
et al., 1999), while thioflavin-S staining (Sigma-Aldrich, Missouri, USA) was used to stain 
fibrillar plaques in conjunction with 5mC/5hmC and GFAP immunolabelling (T. C. Dickson 
& Vickers, 2001). The fluorescent signal was amplified via biotin/streptavidin 
immunofluorescence for the mouse anti-IBA1 antibody: immunolabelling was performed as 
detailed above, but following primary antibody incubation tissue sections were incubated in 
goat anti-mouse/rabbit biotinylated secondary antibodies (1:200, 5mg/mL; DAKO) in 0.01M 
PBS-X for two hours at room temperature, washed 3X in 0.01M PBS and incubated in 
Streptavidin AlexaFluor488 (1:500) diluted in 0.01M PBS for two hours at room temperature. 
Antibodies penetrated the entire depth of tissue sections, both with and without formic acid 
antigen retrieval; clear double immunolabelling with optimal intensity was present at a depth 
of 12.8-18.4µm in formic acid treated tissue sections and at a depth of 12.4-17.7µm in non-




Table 2.2: Antibodies 
A summary of the primary antibodies utilised within this study:  























(Glostrup, Denmark) A 0024 
Rabbit 
polyclonal 1:4000 




MN1020 Mouse monoclonal 1:1000 









AB5054 Rabbit monoclonal 1:500 




Ab7332 Rabbit polyclonal 1:1000 
GFAP GFAP isolated from cow spinal cord 
Dako 





GFAP Clone 4A11 BD Bioscience 556327 Mouse IgG2b 1:500 




Ab5076 Goat polyclonal 1:250 




AB9568 Rabbit polyclonal 1:250 
Pan-beta 




44-136 Rabbit polyclonal 1:1000 




SIG-39320 Mouse monoclonal 1:1000 




SMI-32R-500 Mouse monoclonal 1:500 




MAB377 Mouse monoclonal 1:1000 




39159 Rabbit polyclonal 
2µg/ml (2µl per 
sample) 




39133 Rabbit polyclonal 
2µg/ml (2µl per 
sample) 




07-449 Rabbit polyclonal 





2.4 Autofluorescence quenching 
Autofluorescence quenching was used to remove lipofuscin autofluorescence and lower 
background autofluorescence to enhance clarity for analysis. Free floating or mounted sections 
were incubated in potassium permanganate solution (Appendix 1) for 20 minutes at room 
temperature on an orbital shaker, before being washed twice in 0.01M PBS for two minutes at 
room temperature. Samples were then incubated in a solution containing potassium 
metabisulphite and oxalic acid (Appendix 1) for approximately two minutes to clear the 
potassium permanganate from the region of interest. Samples were then washed three times in 
0.01M PBS for ten minutes at room temperature on the orbital shaker. 
 
2.5 Microscopy 
Cell counts were performed on a Leica DM LB2 fluorescent microscope (Leica microsystems, 
Wetzlar, Germany) for NF-positive pyramidal neurons and NFTs. For astrocytes, microglia 
and calretinin-labelled interneurons cell counts were performed on images of whole tissue 
sections collected on Perkin Elmer’s Ultraview VoX spinning disk confocal microscope 
(Nikon Ti Eclipse microscope (Minato, Tokyo, Japan), Yokogawa Electric Corporation CSU-
X1 spinning disk confocal scanner (Musashino, Tokyo, Japan) and Volocity software 6.3 
(Perkin Elmer, Massachusetts, USA). All image acquisition and cell counts were performed 
blinded to case type. 
 
2.6 Immunohistochemistry image analysis 
Cell counts were performed systematically by starting at the edge of tissue section in the 
appropriate layer of the ITG at a Z plane (between 12.4-18.4µm depth) in the tissue 
corresponding to clear double-immunolabelling, and counting the first 50 cells encountered on 
that Z plane in the correct cortical layer. Cells were defined as having extranuclear labelling if 
any labelling for 5mC or 5hmC was observed in the cytoplasm of the cell outside of the nucleus.  
Neurofilament positive pyramidal neurons: 50 NF-positive pyramidal neurons in layers 2/3 and 
layer 5 were counted with 5mC/5hmC co-localisation recorded, in each control (n=5), early-
AD (n=5) and late-AD (n=8; n= 6, respectively) case.  
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Interneurons: Whole tissue sections were imaged. 50 calretinin-positive neurons were counted 
in layers 2/3; 25 calretinin-positive neurons were counted in layer 4 (due to the limited number 
of calretinin-positive cells in layer 4) with 5mC/5hmC labelling recorded in each control (n=5), 
early-AD (n=5) and late-AD (n=8) case.  
Microglia: Whole tissue sections were imaged. 50 microglia were counted in layers 2/3 and in 
layer 4 with 5mC/5hmC co-localization noted in each control (n=5), early-AD (n=5) and late-
AD (n=7) case.   
Astrocytes: Whole tissue sections were imaged. 50 astrocytes were counted across cortical 
layers 2-6 with 5mC/5hmC co-localization noted in each control (n=5), early-AD (n=5) and 
late-AD (n=8) case.  
NFTs: 50 NFTs in layers 2/3 and layer 5 were counted with 5mC/5hmC co-localisation 
recorded in early- and late-AD cases (n=7 and 6, respectively).  
Aβ plaques and 5mC/5hmC nuclei: 10 plaques were imaged in layer 2/3 of late-AD cases (n=8) 
and 10 plaque-free zones were imaged in layer 2/3 of control (n=5) and late-AD cases (n=8). 
Images were obtained systematically, by starting at the edge of the tissue section and taking 
images of the first 10 isolated plaques or plaque free zones encountered in layer 2/3. 5mC and 
5hmC labelled nuclei were counted in near-plaque donut shaped region of interest (ROI) that 
was 150% of the plaque diameter (Chapter 3 - Figure 6; (Mitew et al., 2013b). The average 
area of the near-plaque ROI was used to define equivalent plaque-free ROI ((Fernandez-
Martos, King, Atkinson, Woodhouse, & Vickers; Mitew et al., 2013b).  
Aβ plaque load: This analysis was performed as previously (Woodhouse et al., 2009); briefly 
four systematically selected 1200μm wide strips of the ITG from the pia to the white matter 
were imaged for each early-AD and late-AD case, and the percentage area occupied by Aβ 
plaques was then calculated (Image J, version 1.39p).  
NFT density: This analysis was performed as previously (Woodhouse et al., 2009); briefly one 
systematically selected 1200μm wide strip of the ITG from the pia to the white matter was 
imaged for each late-AD case, the number of NFTs in the sampled area was counted and the 
NFT density calculated (Image J, version 1.39p). Representative images for figures were taken 




2.7 Immunohistochemistry Statistical Analysis 
Image data was analysed in SigmaPlot (Version 12.0, Systat Software Inc.) with one-way 
ANOVAs; different post-hoc tests were performed depending on the distribution and normality 
of the data including: Kruskal-wallis one-way ANOVA on ranks and Holm-sidak one-way 
ANOVA. Statistical significance was defined as p<0.05. All data is presented as the mean with 
the standard error of the mean.  
 
2.8 Mouse tissue source and processing  
All animal procedures were undertaken with ethical approval from the Animal Ethics 
Committee of the University of Tasmania (A12780/A15120) and all experiments abided by the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (Council, 
2013). The AD mouse model used for this study was the APPSWE/PSENdE9 (APP/PS1) 
(B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax; stock number: 34832-JAX). APP/PS1 mice 
and age matched wild-type control littermates were aged to 3 months (pre-pathology), 6 months 
(pathology onset), and 12 months (advanced pathology), with n = 5 biological replicates per 
genotype, per time-point. An additional cohort of 5 wild-type mice were aged to 24 months. 
Animals were housed in standard conditions (12hr day/night cycle, housing temperature of 
20oC, ad-libatum access to food). Mice were sacrificed with an intraperitoneal injection of 
Lethobarb (pentobarbitol) at 110mg/kg body weight. Animals were tested for pain response 
before undergoing cardiac perfusion with 0.01M PBS (Appendix 1). The forebrain was then 




Genotyping was performed as previously described (Collins, King, Woodhouse, Kirkcaldie, & 
Vickers, 2015). Tail clippings were taken from mice at weaning for initial genotyping, and at 
perfusion for replicate genotyping of all animals. Tails were incubated in 45µL of extraction 
solution (95091-025, QUANTA Biosciences, Beverly, Massachusetts, USA) for 30 minutes at 
95°C to extract genomic DNA. Genotypes were identified by PCR using MyTaq Red Mix 
(BIO-25044, Bioline, London, UK) and primers (GeneWorks, Thebarton, South Australia, 
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Australia) to amplify PS1 and an internal control gene (IL-2) as per the manufacturer’s 
protocol. PCR products were electrophoresed against Hyperladder V 100bp ladder (BIO-
33031, Bioline, London, UK)  on a 2% agarose gel (BIO-41025, Bioline, London, UK) 
containing 0.0001% SYBR safe DNA gel stain (S33102, Invitrogen, Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) at 110V for 4five minutes and imaged using the Amersham 
Imager 600 (GE Healthcare Life Sciences, South Logan, Utah, USA) image station. 
 
2.10 Isolation of neuronal nuclei 
Squares (2cm2) of cheesecloth (9338918004577, Ogilvies Designs, Belmont, Western 
Australia, Australia) were pre-soaked in nuclei extraction buffer (NEB) (Appendix 1) and 
placed in 15ml falcon tubes (Thermo Fisher Scientific, Waltham, MA, USA) until required. 
Fresh-frozen mouse forebrains were sectioned along the midline, and half of the forebrain was 
immersed in 4.8mL of freshly prepared NEB, while the other half of the forebrain was frozen 
for future analysis. The forebrain was then homogenised on ice using a dounce tissue 
homogeniser (357544, Wheaton, Millville, New Jersey, USA) for one minute with a loose-
fitting pestle with 0.114mm clearance. Homogenised tissue was then filtered through four 
layers of cheesecloth, followed by 70µm and 40µm Falcon cell strainers (Thermo Fisher 
Scientific, Waltham, MA, USA) on ice. Homogenate was then centrifuged at 500g for  minutes 
at 4oC and the supernatant was then discarded. The nuclei pellet was resuspended in 5mL of 
0.22µm filtered 0.01M PBS, centrifuged at 500g for five minutes at 4oC, and the pellet 
resuspended in 500µL 0.01M PBS for downstream processing. 10µL of each sample was 
diluted 1:5 in 0.01M PBS, then diluted 1:1 with trypan blue (15250061, Thermo Fisher 
Scientific, Waltham, MA, USA). Haemocytometer counts were performed to calculate the 
number of nuclei per sample and to ensure a consistent number of nuclei were being isolated 
between samples.  
 
2.11 Neuronal nuclei immunolabelling 
To provide secondary antibody only control solutions for downstream nuclei sorting, 50µL of 
each nuclei sample was incubated with Alexafluor 647 at 1:2000 (A31571, Invitrogen/Life 
technologies, Carlsbad, CA, USA), 10µL of blocking solution containing 0.5% BSA (B4287-
25G, Sigma-Aldrich, St Louis, Missouri, USA), 10% normal goat serum (G9023-10, Sigma-
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Aldrich, St Louis, Missouri, USA), and 35µL 0.01M PBS, for a total of 100µL on a slow rotator 
in the dark for 40 minutes at 4oC. DAPI working stock (10µL; Appendix 1) was added to the 
secondary antibody solution for the last five minutes of the incubation. For primary samples, 
mouse anti-NeuN antibody (A60) (MAB377, Merk Millipore, Billerica, Massachusetts, USA) 
at 1:1000 (Table 2.2) was conjugated with donkey anti-mouse AlexaFluor 647 secondary 
antibody at 1:2000 (1:10 stock was prepared previously for accurate pipetting) (A31571, 
Invitrogen/Life technologies, Carlsbad, CA, USA), 100µL 0.5% BSA (B4287-25G, Sigma-
Aldrich, St Louis, Missouri, USA) and 10% normal goat serum (G9023-10, Sigma-Aldrich, St 
Louis, Missouri, USA), and 394µL 0.01M PBS for a total of 500µL. Primary antibody solutions 
were incubated for five minutes at room temperature on an orbital shaker in the dark. 50µL 
0.01M PBS was added to the remaining nuclei, then combined with the preconjugated 
block/NeuN/AlexaFluor 647 solution for a total volume of 1000uL and incubated for 40 
minutes at 4oC on a slow rotator in the dark. After 40 minutes, the nuclei solution was 
centrifuged at 500g for five minutes at 4oC, the supernatant was discarded and the sample was 
then resuspended in 1000µL ice cold 0.01M PBS for further experimentation. 
 
2.12 Fluorescence activated cell sorting 
Fluorescence activated cell sorting (FACS) was performed on a BD Biosciences FACSAria III 
(Becton Dickinson Biosciences, Franklin Lakes, NJ, USA). Falcon tubes (15mL; Thermo 
Fisher Scientific, Waltham, MA, USA) were coated with a small amount of foetal calf serum 
(SH30084.02, Hyclone, GE Healthcare Life Sciences, South Logan, Utah, USA) prior to use. 
DAPI and secondary antibody only negative control samples were used to identify nuclei on 
fluorescence and forward/side scatter plots to eliminate cellular debris, and to set a threshold 
for background secondary antibody fluorescence for each sample (Figure 2.1a,c). Doublet 
discrimination was set (Figure 2.1b). NeuN labelled samples were then sorted with the 
established gates (Figure 2.1c-f). Sample purity was determined by re-running a small amount 
of sorted sample through the FACS. Sorted samples all exhibited >97% purity from their 
respective gates. NeuN+ and NeuN- samples were collected, fixed in 1% methanol-free 
formaldehyde (28906, Pierce, Thermo Fisher Scientific, Waltham, MA, USA) for 1five 
minutes at room temperature then quenched with 0.125M glycine (G8898, Sigma-Aldrich, 
Missouri, USA) for five minutes at room temperature, prior to freezing at -80oC for 
downstream processing. Parameters for FACS were extensively optimised, including testing: 
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multiple nozzle sizes (70µM, 100µM, 130µM), sheath pressures, primary and secondary 
antibody concentrations, secondary fluorophores (AlexaFluor 488, 546, 594, 647), nuclei 
solution concentration, forward/side-scatter gating strategies, blocking solutions, and testing 
jet-in-air and cuvette-based flow cytometers. To assess whether NeuN expression alters across 
aging, the number of NeuN+ nuclei from the FACS results was analysed, showing that there 
was no significant difference in the number of neuronal nuclei collected between time-points 
for WT mice (3 months old: 2.75x106 ± 0.15 nuclei, 6 months old: 2.59x106 ± 0.13 nuclei, 12 
months old mean: 2.51x106 ± 0.04 nuclei, 24 months old: 2.149x106 ± 0.18; all mean±SEM) 
(One way ANOVA, p=>0.05, Tukey's multiple comparisons test). To confirm the differences 
between whole forebrain homogenate samples (n=3 per genotype, 12 months of age) and 
NeuN+ nuclei purified from the forebrain (n = 2 per genotype, 12 months of age).  ChIP-qPCR 
was performed for H3K4me3, H3K27me3 and H3K27ac at known enhancers for AD risk factor 
genes and compared in wildtype and APP/PS1 mice demonstrating distinct differences between 






Figure 2.1: Gating strategy for isolation of neuronal nuclei 
(a) DAPI labelled nuclei and, (b) doublet discrimination used to determine pure, single nuclei 
sub-population on (c) forward scatter (linear) and side scatter (log). (d) Forward scatter and 
side scatter gate for DAPI + nuclei were used to gate out debris. (e, f) Gating strategy applied 
to NeuN labelled sample to reduce the amount of debris collected in sorted samples and NeuN 
fluorescence determined from secondary only gate. (f) The distance between NeuN negative 







Figure 2.2: Difference in histone marking between whole brain homogenate and purified 
neuronal nuclei in wild-type mice and APP/PS1 mice.  
Differential enrichment was detected for H3K4me3 (top), H3K27me3 (middle) and H3K27ac 
(bottom) between chromatin from whole forebrain (left) and neuronal nuclei purified from 
forebrain (right) in both wildtype (black/blue) and transgenic AD (pink/red) mice. Data = % 





Sorted neuronal nuclei (NeuN+) were pelleted in at 52000g, 4oC for 25 minutes using the 
Sorvall WX Ultra 90 ulracentrifuge and TH-641 swinging bucket rotor (54295, Thermo Fisher 
Scientific, Waltham, MA, USA). Nuclei pellets were resuspended in 300µL of SDS lysis buffer 
(Appendix 1) and transferred to 1.5ml Bioruptor+ TPX microtubes (C30010010-300, 
Diagenode, Seraing, Belgium) for sonication. Sonication was optimised to obtain DNA 
fragments between 200-500bp length. Sonication was performed on a Bioruptor Plus next-gen 
ultrasonicator (Diagenode, Seraing, Belgium) under the following conditions: 10 cycles of 30s 
on/30s off, repeated 5 times, replacing ice-water every 10 cycles. Fragment size was confirmed 
using a sample of purified DNA electrophoresed on a 2% agarose gel and additionally tested 
on a Agilent 4200 tape-station (Agilent Technologies, California, USA). After sonication, 
samples of 500,000 nuclei were aliquoted for chromatin immunoprecipitation (ChIP) 
experiments.  
 
2.14 DNA purification 
DNA samples were purified using the following protocol modified from (Sambrook & Russell, 
2006). Samples (300µL in 0.01M PBS) were incubated with 1µL Proteinase K (50µg/mL 
(MPRK092, Epicentre, Middleton, Wisconsin, USA) per 200,000 nuclei at 65oC overnight. 
Equal volume of phenol:chloroform solution (P0269-100M, Sigma-Aldrich, Missouri, USA) 
was added to each sample and vortexed for one minute until an emulsion formed. Samples 
were then centrifuged at 6,000g for five minutes at room temperature. The aqueous layer was 
collected and combined with 2.5 volumes of ethanol (E7023-1L, Sigma-Aldrich, Missouri, 
USA). Sodium chloride (NaCl) was added to 0.3M final concentration in the sample solution. 
Samples were precipitated overnight at -20oC. Samples were then centrifuged at 16,000g for 
30 minutes to pellet purified DNA. The supernatant was discarded, the pellet was washed in 
70% ethanol and centrifuged at 16,000g for five minutes. The pellet was then dried at room 
temperature five minutes to remove residual ethanol. Samples were then resuspended in 20µL 




2.15 Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed as previously described (Oakford et al., 
2010; P. C. Taberlay et al., 2011; Phillippa C. Taberlay et al., 2014) with minor modifications. 
Briefly, samples containing approximately 500,000 nuclei were adjusted to 1mL with IP 
dilution buffer (Appendix 1), mixed gently by pipetting and 1% of the total sample was 
removed for total input control samples (TI) and frozen at -20oC. Antibodies utilised for ChIP-
seq experiments included: anti-H3K4me3 (39160; Active Motif, Carlsbad, CA, USA), anti-
H3K27me3 (07-449; Millipore Massachusetts, USA) and anti-H3K27ac (39134; Active Motif, 
Carlsbad, CA, USA). All antibodies have been previously validated for specificity and use in 
ChIP assays. All samples (n = 35) were processed in parallel for each ChIP antibody to 
eliminate batch effects. Samples were incubated with primary antibodies overnight at 4oC with 
rotation with a concentration of 2µg or 2µL of antibody per sample. Samples were then 
incubated with 20µL ChIP grade magnetic A/G beads (26162, Pierce, Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) for two hours at 4oC with rotation. Samples were 
then placed on a MagnaRack (CS15000; Invitrogen/Life technologies, Carlsbad, CA, USA) for 
one minute and supernatant was removed. Samples were washed in 1mL low salt wash buffer 
(Appendix 1) for three minutes at room temperature. After incubation samples were placed on 
a magnetic rack for one minute, and supernatant was removed and discarded. This process was 
repeated for one high salt buffer wash, one LiCl buffer wash, and two TE buffer washes 
(Appendix 1). After the final TE buffer wash, samples were incubated for 1five minutes at 
room temperature in 50µL of freshly prepared ChIP elution buffer (Appendix 1). The 
supernatant was collected and the elution step was repeated with an additional 50µL ChIP 
elution buffer for a total volume of 100µL. Chromatin samples and TI control samples were 
then incubated with 4µL 5M NaCl and 1.5µL (50µg/mL) Proteinase K (MPRK092, Epicentre, 
Middleton, Wisconsin, USA) overnight at 65oC to reverse crosslinks. RNase A (1µL of 
10mg/mL; EN0531, Thermo Fisher Scientific, Waltham, Massachusetts, USA) was then added 
to each sample and incubated for 1 hour at 37oC. ChIP samples and TI control samples were 
further purified using the Chromatin IP DNA Purification Kit (58002, Active Motif, Carlsbad, 
California, USA) according to the manufacturer’s instructions, and eluted in 50µL of elution 
buffer. ChIP experiments were performed for 500,000 nuclei for H3K4me3, H3K27ac, and in 
technical duplicate for H3K27me3. H3K27me3 ChIPs were pooled prior to library preparation 






2.16 Library preparation 
Libraries were prepared using the Nugen Ovation Ultralow V2 (0347 V2 1-96/0344 V2 1-16, 
Redwood City, CA, USA) library preparation kits as per the manufacturer’s protocol with 
minor modification. Cycling conditions for PCR amplification were optimised using EvaGreen 
dye 20X (31000-T, Biotium, Fremont, CA, USA), with H3K27ac samples amplified for 17 
cycles, H3K4me3, H3K27me3 and total input control samples amplified for 18 cycles. 
 
2.17 Sequencing 
Libraries were subjected to quality control and normalisation with the Agilent 4200 tape-station 
system and D1000 tapes (Agilent, Santa Clara, CA, USA), and qPCR analysis performed at 
Australian Genomics Research Facility. Illumina flow-cell adaptors were added prior to 
sequencing (Illumina, San Diego, CA, USA). An equal amount of DNA was added from each 
sample to normalise all samples across the flow lanes. Samples were sequenced on the Illumina 
Hi-Seq 2500 Next-Generation-Sequencer (Illumina, San Diego, CA, USA) using 50bp single-
end sequencing parameters. Primary image analysis was performed in real time by HiSeq 
Control Software v2.2.68 and Real Time Analysis v 1.18.66.3. The Illumina bcf2fastq 
2.20.0.422 pipeline was used to generate FASTQ files for downstream analysis. Prior to 
sequencing, all samples from H3K27ac and H3K4me3 were pooled to minimise batch effects 
and all sequenced equally across 7 lanes. Mean sequencing depth for these samples was 
29,235,684 single-end reads with a range of 14,772,920 – 52,363,200 single-end reads (Table 
2.3). H3K27me3 samples were similarly pooled to minimise lane effects, then sequenced over 
7 lanes. Mean sequencing depth for H3K27me3 was 54,193,632 single-end reads with a range 
of 39,039,879 – 65,999,514 single-end reads (Table 2.3). An input control was sequenced from 
one sample of each time-point and genotype. The input control samples were and sequenced 
across one lane, with mean sequencing depth of 37,412,073 single-end reads and a range of 




Table 2.3: ChIP-seq sequencing depth 
A summary table of the sequencing depth for each histone modification used in this study: 
Samples Minimum read depth Maximum read depth Mean read depth 
H3K27ac 9,576,466 24,491,555 16,223,033 
H3K27me3 26,531,221 45,023,509 34,992,581 






The bioinformatic analysis included in the results chapter of this thesis required extensive 
optimisation. Included below is the final parameters used for each part of the analysis. 
 
2.18 Sample pre-processing 
FASTQ files generated from Illumina HiSeq 2500 were imported onto the Nectar research 
cloud for all processing running Ubuntu 16.0.4.3 LTS Xenial Server Edition. Raw reads were 
checked for quality control with FASTQC version 0.11.7 and MultiQC (Andrews, 2010; Ewels, 
Magnusson, Lundin, & Kaller, 2016). Illumina flow-cell adaptors were trimmed from all 
sequences using the Trim Galore wrapper version 0.4.3 for Cutadapt (version 1.15) (Martin, 
2011). Nugen Ovation Ultralow v2 adaptors were trimmed from individual samples with 
Cutadapt (Martin, 2011) prior to sequence alignment. Any samples not meeting quality control 
standards were removed from further analysis.  
 
2.19 Sequence alignment 
Bowtie2 is a highly efficient hardware accelerated alignment tool frequently utilised in read 
mapping for ChIP-seq experiments (Langmead & Salzberg, 2012). ChIP-seq samples were 
aligned with Bowtie2 version 2.3.4 Linux distribution (accessed 30/1/2018). Samples were 
mapped to Mus musculus reference genome mm10 (accessed 08/12/2017 at UCSC 
http://hgdownload.cse.ucsc.edu/downloads.html#mouse) using default parameters (Waterston 
et al., 2002). The mean percentage of aligned reads was 95.63%, with a minimum of 87.41%. 
Samples containing more than 9.5 million uniquely aligned reads were utilised for downstream 
analysis. After mapping, samples were converted to BAM file format and indexed with 
SAMtools version 1.7, then visualised with Integrated Genomics Viewer (IGV) version 2.4.8 
(H. Li et al., 2009). Further quality control was performed with deepTools multibamSummary 
and plotPCA version 3.0, and bigwig files were generated with bamCompare for visualisation 
on IGV (Diaz, Nellore, & Song, 2012; Ramírez et al., 2016). Total input control samples were 
merged using SAMtools merge, then sorted and indexed prior to peak calling.  
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2.20 Pseudoreplicate generation  
Two pseudoreplicates were generated for each time-point and genotype (Gjoneska et al., 2015; 
Landt et al., 2012) prior to performing differential enrichment analysis. Biological replicates 
were merged into a single file using samtools merge, read with samtools view, shuffled and 
separated into files containing equivalent numbers of randomly distributed reads, then sorted 
with samtools sort utilising the following code (based off ENCODE IDR analysis): 
samtools merge -u -@62 
/NGS_Data/Andrew/Pseudoreplicate_BAM/H3K27me3_inter
mediate/H3K27me3_WT3_merged.bam *WT3*.bam  
for file in *.bam ; do 
echo ""$file" "is being processed..."" 
samtools view -H $(Akiyama et al.) > 
${file}_header.sam  
nlines=$(samtools view -@62 ${file} | wc -l) 
#identify the number of reads in a bam file 
echo "total number of reads:" 
echo "$nlines"  
nlines=$(( (nlines + 1) / 2 )) 






2.21 Peak Calling 
Peaks were called for H3K4me3 and H3K27ac against a merged input control utilising MACS2 
with a Q value cut-off of 0.05 (Yong Zhang et al., 2008). H3K27me3 peaks were also called 
with MACS2, with –broad option enabled to composite broad genomic regions into wider 
peaks and analysed with both Q value cut off of 0.05, and also a relaxed Q value cut-off of 0.01 
as described in (Gjoneska et al., 2015). ENCODE blacklisted regions for mm10 (downloaded: 




2.22 Differential enrichment analysis with CSAW 
Differential enrichment analysis was performed within R using the ChIP-seq Analysis with 
Windows (csaw) package (A. T. L. Lun & Smyth, 2016). Briefly, mapped reads from 
pseudoreplicate samples were imported into csaw as bam files, setting the fragment size to 
250bp as identified from sonication and tape-station quality control. The ENCODE mm10 
blacklist file was imported and reads were filtered from blacklisted regions (Consortium, 
2012). Reads were then counted into bins of 2000bp, then log count-per-million reads were 
filtered by an average of log2(3) for H3K4me3, log2(4) for H3K27ac, and log2(2) for 
H3K27me3 to remove low abundance regions of non-specific binding. The background 
filtering was optimised for each histone modification to ensure removal of the bulk of 
background reads, subsequently increasing detection power and reducing multiple testing bias. 
Filtered reads were then binned into 10kb bins, and used for removal of library composition 
bias, and trended biases based on the scaling normalisation strategy of trimmed mean of M 
values (TMM) from EdgeR (A. T. L. Lun & Smyth, 2016; M. D. Robinson et al., 2010; Mark 
D. Robinson & Oshlack, 2010). Differential enrichment analysis was then performed with a 
quasi-likelihood framework and negative binomial modelling from the EdgeR package (M. D. 
Robinson et al., 2010). Trends in read variance were estimated from the total read number with 
negative binomial dispersions from all 10kb binned reads. Read counts were then fitted to a 
generalised linear model that accounted for the negative binomial dispersions, quasi-likelihood 
dispersions, and effective (log) library size. The variance within samples was reduced to the 
previously determined dispersion test using an empirical Bayes strategy, and P-values were 
then assigned to each bin using a quasi-likelihood F-test (A. T. L. Lun & Smyth, 2016; M. D. 
Robinson et al., 2010; Mark D. Robinson & Oshlack, 2010). Binned reads were then clustered 
into 2000bp tolerance regions for H3K4me3 and H3K27ac, or 6000bp tolerance regions for 
H3K27me3, and false discovery rate error control was established with Benjamini Hochberg 
correction for multiple testing (Benjamini & Hochberg, 1995). Gene annotation was then 
established for each region based on intron/exon and promoter data from the 
TxDb.Mmusculus.UCSC.mm10.KownGene library, where promoters were defined as 3000bp 
upstream + 1000bp downstream of a transcriptional start site, and annotated regions within 
5000bp the TSS were also reported. Differentially enriched sites were saved as .bed files with 
rtracklayer for downstream analysis (Lawrence, Gentleman, & Carey, 2009). Tables were 
generated for all data, also including logCPM and logFC as identified from ‘getBestTest’ for 
the top enriched window from each tolerance clustered region for descriptive plotting and 
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downstream analysis. For scripts on csaw see the following link: 
https://github.com/ajphipps/EpiAD/blob/master/csaw_example_script.rd     
 
2.23 Gene ontology analysis  
BED files of significantly differentially enriched sites generated from differential enrichment 
analyses were uploaded to the Genomic Regions Enrichment of Annotations Tool (GREAT), 
by Stanford University (C. Y. McLean et al., 2010). Samples were compared against ‘whole 
genome background’ using the UCSC mm10 genome assembly. Genomic regions were 
associated with ‘basal+extension’ (5000bp upstream and 1000bp downstream, with max 
extension of 1000kb), included curated regulatory domains, and samples that covered a large 
proportion of the genome were corrected with the ‘significant by region-based binomial’ option 
when prompted. All raw GO data, and the top 20 terms ranked by ‘observed hypergeometric 
hits’ from each GO analysis was downloaded from GREAT as .tsv files and imported into R 
studio for visualisation with ggplot2.  
 
2.24 Putative enhancer track generation 
H3K27ac pseudoreplicate files previously generated (Section 2.20) were subjected to peak 
calling with MACS2 as specified in (Section 2.21). All H3K27ac peak bed files (from both 
genotypes and time points) were concatenated to generate a single track with all potential 
HK27ac binding sites from neuronal nuclei. The track was sorted by chromosome and start 
position, and overlapping sites were merged with BEDTools 2.25 (Quinlan, 2014). The UCSC 
mm10 KnownGene track was downloaded from the UCSC table browser (downloaded 
20/7/2018), and start locations for both strands were padded with ±2000bp from the TSS using 
the following script:  
awk '($6 == "+") { print $0 }' input bed12file.bed | 
awk 'BEGIN{ OFS="\t" }($2 > 2000){ print $1, ($2 - 
2000), ($2 + 2000), $4, $5, $6, $7, $8, $9, $10, $11, 
$12}' > UCSCKnowngene.tss.for.padded2kb.bed 
awk '($6 == "-") { print $0 }' 
mm10_knowngene_edited.bed | awk 'BEGIN{ OFS="\t" }($3 > 
2000){ print $1, ($3 - 2000), ($3 + 2000), $4, $5, $6,  







bedtools sort -i UCSCKnowngene_5kb_padded12.bed > 
UCSCKnowngene_5kb_padded.sorted12.bed 
bedtools merge -i UCSCKnowngene_5kb_padded.sorted12.bed 
> UCSCKnowngene_5kb_final_merged_sorted.bed 





The forward and reverse padded KnownGene bed files were then concatenated, sorted by 
chromosome and start position, then merged with BEDTools 2.25. The resulting padded 
KnownGene bed file was used with BEDTools to subtract the TSS ±2000bp from the H3K27ac 
merged bam file, leaving only H3K27ac binding sites that were outside of the TSS ±2000bp 
window, resulting in 73,610 putative enhancer binding sites. These sites were saved as a bed 
file and used for mean signal plots and heatmap generation.  
 
2.25 Percentage breadth of genomic coverage 
The percentage genomic coverage at 5× sequencing depth was determined from the .bam files 
with Samtools mpileup, then converted to a percentage of the mm10 genomic coverage 
(calculated from bowtie2-inspect-s and counted with unix wc), which was then calculated in 
Microsoft Excel.  
for file in *.bam 
samtools mpileup ${file} | awk -v X="${5}" '$4>=5' | wc 
-l > K27ac_breadth.txt 
done 
 
#total number of reads in reference genome 
 
bowtie2-inspect-s /NGS_Data/Andrew/mm10/mm10btref | awk 
'-F "\t" BEGIN{L=0}; {L=L+$2}; END{print L}' 
 
#calculate total number of characters in the mm10 bt2 




bowtie2-inspect-s -n /NGS_Data/Andrew/mm10/mm10btref | 
wc -m  
 
#912 characters to subtract from reference genome 
output - base 2776387315 subtract 912 = final size 
2776386403 
 
The genomic coverage was then plotted as histograms in GraphPad prism 6. 
 
2.26 CpG island analysis 
Tracks for CpG islands in mm10 were downloaded from the UCSC table browser. This data 
was subset against UCSC KnownGene TSS for mm10 with BEDTools 2.25 to be able to 
identify TSS that contained CpG islands. H3K4me3 and H3K27ac marking was then mapped 
against these tracks as heatmaps.  
 
2.27 Plot generation 
Heatmaps and mean profile data intersecting histone modifications with UCSC KnownGene 
TSS and putative enhancer tracks were generated with deepTools (version 3.0) computeMatrix, 
plotProfile, and plotHeatmap (Ramírez et al., 2016), or Seqplots v1.12.1 (Stempor & Ahringer, 
2016). Combined profile plots for APP/PS1 and WT control mice samples were generated with 
Seqplots v1.12.1 (Stempor & Ahringer, 2016). Representative genomic regions of interest of 
pseudoreplicates were exported from IGV (H. Li et al., 2009) and with edited with Adobe 
Illustrator. Volcano plots were generated with ggplot2 utilising the logFC from ‘getBestTest’ 
generated in csaw (2.23).  
 
2.28 Venn diagram analysis 
To determine whether sites of differential H3K27ac and H3K4me3 enrichment were shared 
between time-points, venn diagrams were generated with BEDTools 2.25 multi-intersect and 
gplots in the R studio environment (Quinlan, 2014). BED files generated from pairwise 
differential enrichment analysis were analysed with bedtools:  
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bedtools multiinter -header -i 
H3K4me3_3FC_AD3_DBsites.bed H3K4me3_3FC_AD6_DBsites.bed 
H3K4me3_3FC_AD12_DBsites.bed -names K4me3_AD3 K4me3_AD6 
K4me3_AD12 > K4me3_intersect.txt 
The output of the mutli-intersect analysis was then imported into Rstudio and venn diagrams 




escape_double = FALSE, trim_ws = TRUE) 
View(K27ac_intersect) 
K27ac_sub <- data.frame(K27ac_intersect$K27ac_AD3, 
K27ac_intersect$K27ac_AD6, K27ac_intersect$K27ac_AD12) 
colnames(K27ac_sub) <- c("3m APP/PS1 DB sites", "6m 
APP/PS1 DB sites", "12m APP/PS1 DB sites") 
venn(K27ac_sub) 
To identify whether H3K4me3 or H3K27ac marked sites that were shared across time-points 
were consistently enriched or depleted, differential enrichment data was subset into 
significantly enriched or significantly depleted, then analysed pairwise with bedtools 
BEDTools 2.25 intersect (Quinlan, 2014). 
 
2.29 RNA-seq overlap analysis 
RNA-seq data was obtained from (Mathys et al., 2019). All neuronal RNA-seq data (excitatory 
and inhibitory neurons) was compiled and filtered for unique genes to be comparable with the 
NeuN+ ChIP-seq enrichments. Human gene symbols were converted to mouse symbols with 
the MGI database. Genes enriched for H3K27ac and H3K4me3 were also filtered for unique 




















#split the overlaps column 
# find commas positioned after + or - and replace with a space 
H3K4me3_12m_AD12_allresults$overlap <- gsub("([+-]),", "\\1 ", 
H3K4me3_12m_AD12_allresults$overlap)  
# count number of regions per observation 
H3K4me3_12m_AD12_allresults$n_regions <- 
ifelse(!is.na(H3K4me3_12m_AD12_allresults$overlap), 
str_count(H3K4me3_12m_AD12_allresults$overlap,' ') + 1,NA)  
#find the maximum amount of regions found in an observation 
max_regions <- max(H3K4me3_12m_AD12_allresults$n_regions, na.rm = TRUE)  
#partition into multiple coloumns 
H3K4me3_12m_AD12_allresults <- H3K4me3_12m_AD12_allresults %>% 
separate(col = overlap, into = paste0('overlap', 1:max_regions), sep = ' 












#subset both datasets by significance 
unique.mathys_nopath_path <- 
unique(sig_Mathys_all_neuron_no_path_vs_path$Symbol) 
H3K4me3_AD12_sig <- subset(H3K4me3_12m_AD12_allresults, FDR <=0.05) 
d <- H3K4me3_AD12_sig 
 
#isolate gene names without the pipes and tidy  
d[, 14:38] <- apply(d[, 14:38], 2, function(x) stringr::str_extract(x, 
"[^|]*")) 
 
#convert long form columns into short form rows 
k <- reshape2::melt(d[, c(1, 13:38)], id.vars = c("X1", "overlap")) %>%  
  mutate(genes = value) %>% 
  select(-c(variable, value)) %>% 
  na.omit() %>% 
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  left_join(select(d, -starts_with("overlap")), by = "X1") %>% 
  arrange(X1) 
 
#make the mouse genes lowercase 
mouse_genes <- (unique(k$genes)) 
 
#find the overlapping genes in mouse and human datasets 
keep <- mouse_genes[mouse_genes %in% unique.mathys_nopath_path] 
 
#join the human and mouse data together into a single datatable 
j <- left_join(k, sig_Mathys_all_neuron_no_path_vs_path , by = c("genes" = 
"Symbol")) 
 
write.csv(j, file = "H3K4me3_AD12_overlap_nopath_vs_path.csv") 
 






Chapter 3: Neurofilament-labelled pyramidal neurons and 






Despite increasing research efforts, the underlying cause of sporadic AD remains unknown. In 
the absence of genetic aberrations, it is possible that epigenetic alterations may contribute to 
the multiple pathological pathways implicated in the onset and progression of AD (Coppieters 
et al., 2013; Diego Mastroeni, McKee, Grover, Rogers, & Coleman, 2009; Siegmund et al., 
2007). The epigenome encompasses a variety of components that act in concert, such as DNA 
methylation and post-translational histone modifications (Christensen et al., 2009; Narayan et 
al., 2015). The epigenetic machinery exerts exquisite control over gene regulation programs 
and allows for all cell types to be genetically homogenous, while structurally and functionally 
heterogeneous. Importantly, the epigenome also provides a link between environmental factors 
and sporadic AD risk (D. Mastroeni et al., 2010).  
A number of studies have investigated changes in DNA methylation marks 5mC (usually 
associated with gene silencing) and 5hmC (associated with active de-methylation and increased 
gene expression) throughout the progression of AD at specific genes or genome-wide using 
whole brain homogenate (A. I. Bernstein et al., 2016; Chouliaras et al., 2013; P. L. De Jager et 
al., 2014; Lunnon et al., 2014). The location of 5mC/5hmC methylation marks on the genome 
has differential effects on transcription, and the outcome further depends on interplay with 
other epigenetic modifications such as the presence or absence of particular histone marks 
(Cedar & Bergman, 2009; Narayan et al., 2015). The majority of studies investigating DNA 
methylation in AD have shown that AD is associated with global DNA hypermethylation 
relative to control cases (Bradley-Whitman & Lovell, 2013; P. L. De Jager et al., 2014; 
Sanchez-Mut et al., 2013; Siegmund et al., 2007), while some studies have detected DNA 
hypomethylation (West et al., 1995). Other studies report that DNA hypo- and hyper-
methylation can co-occur in AD brain but at different loci (Bakulski et al., 2012). Two 
independent studies recently reported similar sets of differentially methylated regions that 
changed in tandem with neuritic plaque load or Braak staging, clearly showing that epigenetic 
alterations occur early in AD (P. L. De Jager et al., 2014; Lunnon et al., 2014). However, the 
cell types in which these alterations occur remain to be determined.  
There is increasing interest in cell type specific alterations in DNA methylation in AD. This is 
due to the cell-type specific vulnerability that exists in different subsets of neuronal cells. For 
example, neurons that contain the neurofilament (NF) ‘triplet’ proteins in layers 2/3 and 5 of 
the cortex are selectively vulnerable to NFT pathology (Patrick R. Hof & Morrison, 1990; 
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Thangavel et al., 2009; J. C. Vickers et al., 1994). Whereas, a subset of calretinin-positive 
interneurons are resistant to AD pathology (P. R. Hof et al., 1993; Mitew et al., 2013b). Seminal 
studies have characterized the epigenome of different neuronal populations, identifying 
different DNA methylation patterns between neurons and non-neuronal cells in the CNS 
(Coppieters et al., 2013; Ryan Lister et al., 2013; Mo et al., 2015). Cell type specific alterations 
in DNA methylation have also been implicated in the progression of AD (Coppieters et al., 
2013; D. Mastroeni et al., 2010), however few studies have quantitated cell type specific 
changes in DNA methylation (Chouliaras et al., 2013; Gasparoni et al., 2018). Additionally, no 
study to date has determined whether the cells adjacent to Aβ plaques or tangle-bearing neurons 
are more susceptible to epigenetic alterations.  
There is emerging evidence of a role for epigenetic aberrations in the pathophysiology of AD. 
There is, however, little information regarding cell type specific epigenetic alterations in the 
brain, or whether there is any direct association between epigenetic modifications and AD 
pathology. This study characterises 5mC and 5hmC methylation in subsets of cortical neurons 
with differential vulnerability to degeneration in AD, including NF-positive pyramidal neurons 
and calretinin-labelled interneurons, as well as in microglia and astrocytes. This study has also 
examined DNA methylation changes in close proximity to Aβ plaques, as well as in NFT-




3.2.1 Less extranuclear 5mC labelling in pyramidal neurons in cortical layer 
5 of late-AD cases 
Initially, 5mC and 5hmC was examined in NF-rich pyramidal neurons that are vulnerable to 
AD pathology. The majority of NF-positive pyramidal neurons co-localised with nuclear 5mC 
(Figure 3.1a-c) and 5hmC (Figure 3.1d-f) immunolabelling, and, in a subset of NF-rich 
pyramidal neurons, this labelling extended into the cell body and proximal processes. There 
was no significant difference in the percentage of NF-rich pyramidal neurons that co-localised 
with nuclear 5mC labelling in layers 2/3 or 5 across control (mean±SE; 98.4± 0.7%; 94.8± 
2.1%), early-AD (99.6± 0.4%, 93.6± 1.4%) and late-AD cases (97.3± 0.9%, 98.5± 0.6%; Figure 
3.1j,k). Similarly, there was no significant difference in the percentage of NF-labelled 
pyramidal neurons in layers 2/3 or 5 with nuclear 5hmC labelling between control (100.0 ± 
0.0%, 98.0± 1.0%), early-AD (98.0± 0.8%, 98.0± 1.0%) and late-AD (96.8± 1.7%, 97.0± 1.2%) 
cases (Figure 1j,k). Interestingly, significantly less NF-positive pyramidal neurons contained 
extranuclear 5mC labelling in layer 5 in late-AD cases (14.8± 1.3%) compared to control and 
early-AD cases (28.8± 3.0%, 31.2± 4.1%, respectively; Kurskal-Wallis one way ANOVA on 
ranks; p=<0.05; Figure 3.1k). There was no significant difference in the proportion of NF-
positive pyramidal neurons in layer 2/3 with extranuclear 5mC across control (33.6± 7.1%), 
early AD (36.8± 4.3%) and AD cases (26± 3.2%; Figure 3.1j). There was no significant 
difference in extranuclear labelling in layer 2/3 or layer 5 for 5hmC between control (78± 2.3%; 
58.8± 8.3), preclinical (65.6± 7.5%; 55.6± 13.7%), and AD (57.2± 4.0%; 45.3± 11.4%; Figure 




The samples required to power this investigation could not be predicted a priori, thus, for the 
value of change detectable for each of the datasets within Chapter 3 refer to Table 3.1. To 
ensure that variations in PMIs and age had not impacted this study, linear regression analysis 
was performed on all datasets. There were no correlations between the data presented and PMI 
or age with the exception of: a negative correlation between the percentage of microglia with 
nuclear 5hmC and age in layer 2/3 (but not in layer 4), and a positive correlation between the 
proportion of pyramidal neurons with nuclear 5mC and extranuclear 5mC and PMI in layer 2/3 
(see Appendix 2: Supplementary Figure 2). In addition, no gender effects were present in cell 
type specific datasets.  
Table 3.1: Power Calculations 
Dataset 
Change detected with 90% 
power* 
% NF pyramidal neurons with 5hmC L2/3 6.8% 
% NF pyramidal neurons with 5hmC L5 5.9% 
% NF pyramidal neurons with 5mC L2/3 4.4% 
% NF pyramidal neurons with 5mC L5 9.6% 
% Calretinin interneurons with 5hmC L2/3 19.9% 
% Calretinin interneurons with 5hmC L4 21.3% 
% Calretinin interneurons with 5mC L2/3 28.6% 
% Calretinin interneurons with 5mC L4 24.3% 
% Microglia with 5hmC L2/3 31.7% 
% Microglia with 5hmC L4 30.9% 
% Microglia with 5mC L2/3 29.7% 
% Microglia with 5mC L4 17.7% 
% Astrocytes 5hmC 23.6% 
% Astrocytes 5mC 25.5% 
Density 5hmC nuclei (near plaque vs plaque 
free) 0.0019 nuclei/μm2 
Density 5mC nuclei (near plaque vs plaque free) 0.0015 nuclei/μm2 
 








Figure 3.1: A significantly lower proportion of NF-rich pyramidal neurons co-localised 
with 5mC in cortical layer 5 of late-AD cases 
(a-f, green) The majority of NF labelled pyramidal neurons in layer 2/3 of the ITG exhibited 
nuclear (a-c, red) 5mC and (d-f, red) 5hmC labelling (arrows) in (a,d) control, (b,e) early-AD 
and, (c,f) late-AD cases. (g-i) High magnification representative images show the co-
localisation of (g) 5hmC, (h) NF positive pyramidal neurons and, (i) merge in a control case.  
(j) histogram showing the percentage of NF-positive pyramidal neurons in Layers 2/3 of the 
ITG that co-localised with nuclear/extranuclear 5mC or 5hmC in control (white), early AD 
(grey) and late AD (black) cases. (k) histogram of the percentage of NF-positive pyramidal 
neurons in Layers 5 of the ITG that co-localised with 5mC or 5hmC in (white) control, (grey) 
early AD and (black) AD cases. Bar graphs represent the mean value for each case type; error 




3.2.2 No difference in the percentage of calretinin-labelled interneurons co-
localised with 5hmC/5mC between case types 
Next, 5mC and 5hmC immunolabelling was assessed in calretinin-labelled interneurons that 
are resistant to AD pathology. There was no significant difference in the proportion of 
calretinin-positive interneurons co-localised with nuclear 5mC immunoreactivity within 
pathology-rich cortical layers 2/3 or in relatively pathology-poor layer 4 between control 
(mean±SE: layer 2/3: 76.0± 4.7%; layer 4: 70.4± 5.6%), early-AD (67.2± 3.4%; 72.8± 3.5%) 
and late-AD case types (70.0± 5.8%; 77.1± 2.1%; Figure 3.2j,k). There was also no significant 
difference in the percentage of calretinin-positive interneurons in layers 2/3 or 4 with nuclear 
5hmC labelling between control (77.2 ± 1.9%; 70.4± 1.4%), early-AD (80.4± 5.0%; 77.6± 
5.6%) and late-AD (85.3± 2.7%; 82.0± 3.4%, respectively) cases (Figure 3.2j,k). A small 
number of calretinin-labelled interneurons contained extranuclear 5mC labelling, with no 
significant difference in layer 2/3 or layer 4 between control (5.6± 1.5%; 10.4± 2.9%), early-
AD (6.4± 1.0%; 13.6± 2.4%) or late-AD (4.6± 1.3%; 10.9± 1.9%) case types (Figure 3.2j,k). 
There was also no significant difference in extranuclear 5hmC labelling (Figure 3.2j,k) in 
cortical layers 2/3 and layer 4 across control (4.8± 1.7%; 8.8± 2.9%), early-AD (9.6± 1.9%; 
7.2± 1.6%) and late-AD cases (7.3± 1.9%; 6.0± 2.3%; Figure 3.2j,k).  
Comparison of calretinin-positive interneurons between pathology-rich layer 2/3 and 
pathology-poor layer 4 showed no significant difference in nuclear or extranuclear 5mC 
labelling between the layers. Interestingly, there was a significantly higher percentage of 
calretinin immunopositive interneurons with nuclear 5hmC in control, early AD and AD cases 
in layers 2/3 compared to layer 4 (one way ANOVA; all p=<0.001), but no significant 
difference in the percentage of calretinin positive neurons that had extranuclear 5hmC 
immunoreactivity in cortical layers 2/3 compared to layer 4 any of the case types. Comparative 
analysis identified inherent differences in 5mC and 5hmC marks between NF-positive neurons 
and calretinin-labelled interneurons. In layer 2/3 a significantly higher percentage of NF-
positive pyramidal neurons exhibited nuclear 5mC in control cases compared to calretinin-
positive interneurons in layer 2/3 (Mann-Whitney Rank Sum T-test; p=<0.05). Additionally, a 
significantly higher proportion of NF-positive pyramidal neurons contained nuclear 5hmC 










Figure 3.2: No significant difference in calretinin-labelled interneurons co-localised with 
5mC or 5hmC through the progression of AD 
(a-f, i, green) Calretinin labelled interneurons in layer 2/3 of the ITG exhibited nuclear (a-c, 
red) 5mC and (d-f, i, red) 5hmC labelling (arrows) in (a,d) control, (b,e) early AD and, (c,f) 
late AD cases. (g-i) High magnification representative images of (g) 5hmC, (h) calretinin and, 
(i) merge in an early-AD case. (j) Bar graph showing the percentage of calretinin-labelled 
interneurons in layers 2/3 of the ITG that co-localised with nuclear/extranuclear 5mC or 5hmC 
in (white) control, early AD (grey) and late AD (black) cases. (k) Bar graph of the percentage 
of calretinin-labelled interneurons in layers 4 of the ITG that co-localised with 5mC or 5hmC 
in (white) control, (grey) early AD and, (black) AD cases. Bar graphs represent the mean value 




The percentage of NF-rich pyramidal neurons with extranuclear 5mC in layer 2/3 was 
significantly greater than that of calretinin-positive interneurons in control cases (Mann-
Whitney Rank Sum T-test; p=<0.05), while the proportion of NF-positive pyramidal neurons 
co-localised with extranuclear 5hmC in layer 2/3 was also significantly higher than that of 
calretinin-positive interneurons in control cases (Mann-Whitney Rank Sum T-test; p = <0.05).  
 
3.2.3 No difference in the percentage of microglia that co-localised with 5mC 
and 5hmC between case types 
There was no significant difference in the percentage of microglia that contained nuclear 5mC 
in layers 2/3 or layer 4 across control (layer2/3: 77.6± 2.9%; layer4: 75.2± 3.2%), early-AD 
(78.4± 5.2%; 72.8± 3.42%) and late-AD cases (74.6± 5.8%; 66.9± 3.2%, respectively, Figure 
3.3j,k). There was also no significant difference in nuclear 5hmC in microglia in layer 2/3 or 
layer 4 in control (77.2± 6.8%; 76.4± 4.7%), early-AD (68.0± 5.2%; 65.6± 6.2%) and late-AD 
cases (72.0± 4.6%; 70.6± 6.8%; Figure 3.3j,k). There was limited extranuclear 5mC/5hmC 
labelling observed in microglia (Figure 3.3g-i). There was no significant difference in the 
proportion of microglia that contained extranuclear 5mC labelling across control (13.2± 2.6%; 
9.2± 1.6%), early-AD (12.8 ± 2.5%;9.2± 0.9%), and late-AD (18.0± 2.3%;13.7± 2.1%; Figure 
3.3j,k) case types, as well as extranuclear 5hmC in layer 2/3 or layer 4 across control (12.8± 
3.1%; 11.6± 2.1%), early-AD (19.6± 3.6%; 15.6± 4.1%) and late-AD cases (17.4± 4.0%; 15.1± 
3.0%, Figure 3.3j,k). A comparison of microglia between pathology-rich layers 2/3 and 
pathology-poor layer 4 showed that there was no significant difference in the percentage of 
microglia co-localised with nuclear or extranuclear 5mC or 5hmC between the layers in 











Figure 3.3: No significant difference in microglia co-localised with 5mC or 5hmC through 
the progression of AD  
(a-f, i, green) Microglia in layer 2/3 of the ITG exhibited (a-c, i, red) nuclear 5mC and (d-f, 
red) 5hmC labelling (arrows) in (a, d) control, early (b, e) AD and, (c,f) late AD cases. (g) High 
magnification representative images of 5mC, (h) ferritin labelled microglia and (i) merge in a 
control case. (j) Bar graph showing the percentage of  microglia in layers 2/3 of the ITG that 
co-localised with nuclear/extranuclear 5mC or 5hmC in (white) control, (grey) early AD  and 
(black) late AD cases. (k) Bar graph of the percentage of microglia in layer 4 of the ITG that 
co-localised with 5mC or 5hmC in (white) control, (grey) early AD and, (black) AD cases. Bar 
graphs represent the mean value for each case type; error bars represent the SEM. Scale bars: 




3.2.4 Less nuclear 5mC and 5hmC in astrocytes in late-AD cases compared 
to control and early-AD cases 
A significantly lower percentage of astrocytes exhibited co-localisation with nuclear 5mC in 
late-AD cases (64.5± 3.9%) when compared to control cases (83.2± 5.4%, Holm Sidak one 
way ANOVA; p=<0.05; Figure 3.4), however there was no significant difference between the 
proportion of astrocytes with nuclear 5mC in early-AD cases (72.8± 4.3%) and late-AD or 
control case types. Similarly, a significantly lower proportion of astrocytes contained nuclear 
5hmC in late-AD (67.5± 5.0%) cases compared to control cases (85.2± 0.9%; Kruskal-Wallis 
one way ANOVA on ranks; p=<0.05; Figure 3.4j,k), and again there was no difference in the 
proportion of astrocyte with nuclear 5hmC between early-AD (74.4± 1.8%) and the other case 
types. There was no significant difference in extranuclear 5mC or 5hmC labelling between 
control (14.8± 4.5%; 17.6± 2.2%), early-AD (14.0± 2.5%; 15.2± 3.8%) and late-AD (7.3± 
1.2%; 22.0± 5.1%, respectively; Figure 3.4j,k) case types. Qualitative analysis of astrocytes 
showed no robust differences in 5mC or 5hmC labelling of astrocytes located in close 
proximity to Aβ plaques.  
 
3.2.5 A high proportion of NFT’s co-localised with 5mC and 5hmC 
Analysis of NFTs with 5mC/5hmC in late-AD cases showed a high proportion of NFTs co-
localised with 5mC and 5hmC in cortical layers 2/3 and layer 5 (Figure 3.5). There was no 
significant difference in the percentage of NFTs that contained nuclear 5mC between layers 
2/3 and layer 5 (76.3± 7.6%; 66.9± 8.5%), and no difference in extranuclear 5mC labelling 
between layers 2/3 and layer 5 (8.9± 2.2%, 8.6± 1.96%; Figure 3.5). In comparison, a 
significantly higher proportion of NFTs co-localised with nuclear 5hmC in layer 2/3 compared 
to layer 5 (99.3% ± 0.38, 92.8% ± 1.37, respectively; one way ANOVA; p = <0.05), but there 
was no significant difference in NFTs with extranuclear 5hmC in layer 2/3 when compared to 
layer 5 (22.6% ± 7.68, 22.8% ± 9.82; Figure 3.5c). The NFT density was also determined for 
each late-AD case (Table 1). There were no correlations detected between the NFT density and 
the proportion of specific cell types (NF-labelled pyramidal neurons, calretinin-labelled 










Figure 3.4: A significantly lower proportion of astrocytes co-localised with 5mC and 
5hmC in late-AD cases compared to control 
(a-f, i, green) Astrocytes in layer 2/3 of the ITG exhibited nuclear (a-c, i, red) 5mC and (d-f, 
red) 5hmC labelling (arrows) in (a,d) control, (b,e) early AD and (c,f) late AD cases. High 
magnification representative images of (g) 5mC, (h) GFAP positive astrocytes and (i) merge 
in a control case. (j) Bar graph showing the percentage of astrocytes in layers 1-6 of the ITG 
that co-localised with nuclear/extranuclear 5mC in (white) control, (grey) early AD and, 
(black) late AD cases. (k) Bar graph of the percentage of astrocytes in layers 1-6 of the ITG 
that co-localised with 5hmC in (white) control, (grey) early AD and, (black) late-AD cases. 
Bar graphs represent the mean value for each case type; error bars represent the SEM. Scale 





Figure 3.5: No significant difference in NFTs co-localised with 5mC or 5hmC through the 
progression of AD 
A high proportion of NFTs co-localised with 5mC and 5hmC. (a,b, green) NFTs in layer 2/3 
and layer 5 of the ITG exhibited nuclear/extranuclear (a) 5mC, and (b) 5hmC in late AD cases. 
Bar graph showing the percentage of NFTs with nuclear/extranuclear 5mC and 5hmC in (black) 
layer 2/3 and (grey) layer 5 in late AD cases. Bar graphs represent the mean value for each case 
type; error bars represent the SEM. Scale bars: (a,b) 35μm. 
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3.2.6 No difference in the density of 5mC and 5hmC positive nuclei in near-
plaque and plaque-free regions of interest in late-AD cases 
To determine if the density of 5mC and 5hmC labelled nuclei was altered near Aβ plaques in 
layer 2/3, the density 5mC and 5hmC labelled nuclei in near-plaque regions of interest (ROI) 
in late-AD cases, as well as in equivalent plaque-free ROI in late-AD and control cases was 
quantitated (Figure 3.6). There was no significant difference in the density of 5hmC positive 
nuclei in near-plaque ROI in late-AD cases (0.003555±0.000354 cells/µm2) compared to 
plaque-free ROI in late-AD cases (0.003516±0.000390 cells/µm2) and control cases 
(0.002405± 0.000195 cells/µm2). Similarly, no significant difference was detected between the 
density of 5mC labelled nuclei in near-plaque ROI (0.003812±0.000267 cells/µm2) and plaque-
free ROI (0.003769±0.000314 cells/µm2) in late-AD cases. However, plaque-free ROI in 
control cases exhibited a lower density of 5mC positive nuclei (0.002305±0.000166 cells/µm2) 
compared to near-plaque and plaque-free ROI in late-AD cases (One way ANOVA;Holm-
Sidak method, p= 0.007). The Aβ plaque load was determined for each AD case (Table 3.1). 
There were no correlations between the Aβ plaque load and the proportion of specific cell types 
(NF-labelled pyramidal neurons, calretinin-labelled interneurons, microglia or astrocytes) 











Figure 3.6: No difference in the density of 5mC and 5hmC positive nuclei in near-plaque 
and plaque-free regions of interest in late-AD cases 
Example images of (red) 5mC labelled nuclei in layer 2/3 of a plaque-free (a) control ROI, (b) 
plaque-free ROI in a late-AD case and (c, green) a near-plaque ROI in a late-AD case.  
Representative images showing (a-f, red) 5mC and (g-i, red) 5hmC labelled nuclei in (e-f, h-i) 
near-plaque (green) ROI in (d-i) late-AD cases. (j) Bar graph of the density of 5mC labelled 
nuclei in plaque-free ROI in control cases compared to plaque-free ROI and near-plaque ROI 
in late-AD cases. (k) Bar graph of the density of 5hmC labelled nuclei in plaque-free ROI in 
control cases compared to plaque-free ROI and near-plaque ROI in late-AD cases. Bar graphs 





Given the small proportion of sporadic AD cases that have identifiable genetic risk factors, the 
pathogenesis of sporadic AD remains unknown. Epigenetics provides a potential link between 
environmental and pathological exposures and gene expression; thus, understanding epigenetic 
alterations in AD may help to elucidate mechanisms of pathogenesis and disease progression. 
Previous studies have detected correlations between AD pathology and DNA methylation in 
all cell types/whole brain homogenate, however the nature of the change in DNA methylation 
from many of these investigations is inconsistent (Bradley-Whitman & Lovell, 2013; 
Chouliaras et al., 2013; Coppieters et al., 2013; P. L. De Jager et al., 2014; Lunnon et al., 2014; 
D. Mastroeni et al., 2010; Sanchez-Mut et al., 2013; Siegmund et al., 2007).  
This study investigated global levels of 5mC and 5hmC methylation in NF-positive pyramidal 
neurons, calretinin-labelled interneurons, microglia, astrocytes and methylation marks 
associated with disease pathology. There was no significant difference in the global levels of 
nuclear 5mC or 5hmC in NF-positive pyramidal neurons, calretinin-positive interneurons and 
microglia across disease progression, and no significant differences in extranuclear 5mC or 
5hmC in calretinin-positive interneurons, microglia (Table 3.2). A significantly lower 
percentage of astrocytes exhibited nuclear 5mC or 5hmC in late-AD cases compared to 
controls. Interestingly, there were significantly less NF-pyramidal neurons with extranuclear 
5mC in layer 5 of late-AD cases compared to control and early-AD cases. Finally, a high 
proportion of NFTs contained nuclear 5mC and 5hmC, while no specific association was 
observed between 5mC- and 5hmC-positive nuclei and Aβ plaques. 
Table 3.2: Change in labelling of late-AD cases compared to controls 
      Nuclear Labelling Extranuclear Labelling 
Cell type 5mC 5hmC 5mC 5hmC 
NF-positive pyramidal neurons   ↓  
Calretinin-positive interneurons     
Microglia     
Astrocytes ↓ ↓   




This study was conducted using all cases available that were of sufficient quality and quantity 
(12 tissue sections spanning 1.0-1.5cm of the ITG). A common caveat of working with post-
mortem human tissue is its limited availability due to its precious nature, thus, the number of 
cases of each case type examined is one of the limitations of the current study. The value of 
change detectable for each of the datasets presented in this study has been reported in Table 
3.1. The current study was able to detect a change of 4.4% for NF pyramidal neurons co-
localised with nuclear 5mC in layers 2/3, and of 31.7% of microglia containing nuclear 5hmC 
in layers 2/3 with 90% power. The number of cases analysed in this study is consistent with 
the current literature (Ahmadian et al., 2015; J. Liu & Jia, 2014; D. Mastroeni et al., 2015).  
A number of epigenome-wide association studies have identified changes at a gene specific 
level, however, they have not taken into account artefacts caused by cell type specific 
differences in DNA methylation and as a result have reported wide variation in DNA 
methylation profiles (Bakulski et al., 2012; Bradley-Whitman & Lovell, 2013; Sanchez-Mut et 
al., 2013; Siegmund et al., 2007). More recently, two studies reported that DNA methylation 
alterations correlated with pathology load in AD, and differential CpG methylation occurred 
early in AD progression (P. L. De Jager et al., 2014; Lunnon et al., 2014), however both studies 
used whole brain homogenate, thus identifying the cell types in which these DNA methylation 
changes occur is crucial for understanding the pathological processes in AD (Lord & Cruchaga, 
2014a). Cell type specific resolution for DNA methylation alterations is critical as cell type 
specific differences in DNA methylation between NF-, calretinin- and parvalbumin-positive 
neuronal populations were observed in mouse brain (Mo et al., 2015).  Gasparoni and 
colleagues (2018) have also identified differences in DNA methylation between neurons and 
glia in the occipital lobe of AD cases after isolation with FACS. Although the study 
demonstrated that both neurons and glia were hypomethylated in AD, they had different 
methylation profiles that dynamically progressed with increasing Braak stage of AD cases 
(Gasparoni et al., 2018).  
A number of studies have investigated changes in DNA methylation in neurons using 
immunohistochemistry. Coppieters et al. (2013) identified increased 5mC and 5hmC 
immunoreactivity in nuclei from the human medial frontal gyrus (MFG) and the medial 
temporal gyrus (MTG) with intensity based analysis (Coppieters et al., 2013). Chouliaras et al. 
(2013) also observed a global decrease in 5mC and 5hmC in neurons and glia in the 
hippocampus of AD cases compared to age matched controls (Chouliaras et al., 2013). Sub-
region analysis of the hippocampus showed decreased 5mC in neurons of CA1, but not CA3 
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or dentate gyrus, and also a decrease in 5hmC in neurons in the dentate gyrus, but not in CA1 
or CA3 (Chouliaras et al., 2013). In contrast this study did not detect a difference in nuclear 
5mC or 5hmC localization in either NF-positive pyramidal neurons or in calretinin labelled 
interneurons in the ITG across disease progression. Similar to the current study, no significant 
difference in 5mC and 5hmC in neuronal nuclei of the entorhinal cortex was detected in AD 
cases compared to controls (Lashley et al., 2014). The differences between studies may be due 
to different methods of analysis (cell counts, immunofluorescence intensity analysis), different 
regions studied, and different cell populations being analysed. Differential DNA methylation 
patterns exist in different brain regions in the normal and disease brain (Sanchez-Mut et al., 
2013), while distinct DNA methylation profiles also characterise different neuronal 
subpopulations (Mo et al., 2015). The data presented in this study also show inherent 
differences in DNA methylation patterns between distinct neuronal subtypes in the ITG. For 
example, >95% of NF-rich pyramidal neurons in control cases exhibit nuclear 5mC/5hmC 
labelling, while significantly less (~76%) calretinin-positive interneurons co-localised with 
5mC/5hmC nuclei. However, it is important to note that although global measurements of DNA 
methylation can provide an indication of overall changes occurring in the AD brain, DNA 
methylation can finely control gene expression at a gene specific level. Recently, studies have 
demonstrated cell-type specific DNA methylation profiles in mouse and human cortex using 
genome wide approaches (Luo et al., 2017). Luo and colleagues (2017) characterised 
methylation profiles using single-cell DNA methylation sequencing, identifying 21 different 
excitatory and inhibitory neuronal sub-populations based on methylation status in the human 
frontal cortex (Luo et al., 2017). In contrast to the current study, Luo et al.,(2017) showed that 
interneuron populations were generally enriched to a greater level than NF+ excitatory neurons. 
Immunohistochemistry has a detection limit and can not detect gene or base specific differences 
in methylation status. It is also important to note that bisulphite sequencing cannot differentiate 
between 5mC and 5hmC, which may explain some of the differences between the two studies 
(Luo et al., 2017). Interestingly, both Luo, et al., (2017) and the current study showed layer 
specific differences in DNA methylation in excitatory and inhibitory neurons, however it 
should be noted that there were many gene specific differences in DNA methylation based on 
cortical layer and neuronal cell-type in Luo’s study.  Despite the differences in studies, the use 
of single cell sequencing can allow for visualization and analysis of methylation states at a 
gene specific level, which should be expanded upon in future studies. This PhD study also 
detected significant differences in the same neuronal subtype between cortical layers, with a 
significantly higher percentage of calretinin-positive interneurons co-localised with nuclear 
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5hmC in layers 2/3 compared to layer 4 in control cases. These inherent differences in DNA 
methylation marks between neuronal cell types is likely related to the diverse functions of 
different neuronal populations. Pyramidal neurons and interneurons play different roles in 
learning and memory (A. J. Murray et al., 2011), which cause DNA methylation changes in 
neurons (Day et al., 2013; Feng et al., 2010a; Levenson et al., 2006), thus it is likely that 
differential levels of epigenetic plasticity exist in neuronal sub-populations (Mo et al., 2015). 
Interestingly, a similar percentage of calretinin-labelled interneurons, astrocytes and microglia 
had nuclear 5mC and 5hmC (70%-80% of the population). In contrast, extranuclear 5mC and 
5hmC were also observed in all cell types at varying levels. A higher proportion of NF-positive 
neurons contained extranuclear 5mC and 5hmC than calretinin-positive interneurons in the 
control cases in layer 2/3. Coppieters et al. (2013) also described extranuclear 5mC and 5hmC 
labelling in the processes of cells in the MFG and MTG of control and late AD cases 
(Coppieters et al., 2013). 5mC and 5hmC labelling has been detected in RNA and 
mitochondrial DNA and studies have characterised methylation of RNA as a novel mechanism 
of translational modification (Bradley-Whitman & Lovell, 2013; J. Liu & Jia, 2014; Squires et 
al., 2012). This study has shown a significant reduction in the percentage of NF-rich pyramidal 
neurons with extranuclear 5mC in layer 5 in late-AD cases compared to early-AD and control 
cases (Table 2), which may indicate altered RNA methylation in this vulnerable subset of 
neurons in AD. 
This study detected a significantly lower percentage of astrocytes with nuclear 5mC and 5hmC 
in late-AD cases compared to controls, but no significant differences in 5mC or 5hmC labelling 
in microglia across case types (Table 2). Previous studies reported that astrocytes and microglia 
had weak 5mC and 5hmC labelling compared to neurons in the MTG and MFG (Coppieters et 
al., 2013), and that 5mC and 5hmC were decreased in glial cells in hippocampal subregions of 
AD cases compared to controls (Chouliaras et al., 2013). Astrocytes become activated and 
respond to the presence of Aβ plaques in AD (Itagaki et al., 1989), thus, it is perhaps not 
surprising that the epigenetic profile of astrocytes differs between control and AD cases. 
Studies have identified a core set of genes to be up-regulated in reactive astrocytes, however 
there are a range of different genes that are up-regulated depending on disease state (Zamanian 
et al., 2012). There were no robust differences in 5mC or 5hmC labelling of astrocytes located 
in close proximity to Aβ plaques in the current study, suggesting an alteration in the state of 
the epigenome of astrocytes throughout the cortex. The differences in astrocyte 5mC and 5hmC 
labelling was interesting to detect in this PhD study. However, immunohistochemistry has an 
inherent detection limit which is a caveat of the technique. The findings of the current study 
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could be further characterized and expanded upon with genome-wide approaches such as single 
cell sequencing. Such approaches would allow for analysis of redistribution of DNA 
methylation at a base specific level in control, early AD, and late stage AD cases rather than 
global presence or absence as found in the current study.  
Several studies have reported significant positive correlations between 5mC and 5hmC levels 
and AD pathology load globally (Coppieters et al., 2013; P. L. De Jager et al., 2014; Lunnon 
et al., 2014), while other studies have reported negative or no correlations between 5mC and 
5hmC levels and pathology load (Bradley-Whitman & Lovell, 2013; Chouliaras et al., 2013). 
There were no correlations between plaque load or NFT density and the proportion of specific 
cell types (NF-labelled pyramidal neurons, calretinin-labelled interneurons, microglia or 
astrocytes) that were positive for nuclear or extranuclear5mC or 5hmC.  In addition, there was 
no alteration in the density of 5mC or 5hmC labelled nuclei in near-plaque versus plaque-free 
ROI in late-AD cases. This study has also observed a high proportion (>97%) of NF-positive 
pyramidal neurons with 5mC compared to the proportion of NFTs with nuclear 5mC (~75%) 
in AD cases. NFTs form in NF-rich pyramidal neurons, however, the NFT population measured 
in our study contained both intracellular NFTs and extracellular ‘ghost’ tangles that correspond 
to the death of some neurons. As extracellular NFTs in the ITG accounted for 27% of all NFTs, 
(James C. Vickers, Tan, & Dickson, 2003), this suggests that there is little or no loss of nuclear 
5mC or 5hmC in tangle bearing neurons.  
This study clearly demonstrates that there are cell type specific differences in DNA 
methylation, and highlights the importance of cell type specific analysis to better understand 
the DNA methylation profiles of neural and glial cell types in both the healthy brain and disease 
states. The data presented in this study indicate that epigenetic alterations occur in NF-positive 
pyramidal neurons and astrocytes in late-AD cases, and such epigenetic changes may play a 
role in AD progression. To develop a complete picture of the epigenetic changes and their role 
in AD both DNA methylation and histone modifications will need to be examined in different 











Aging is the leading risk factor for development of AD, however there have been few studies 
to characterise histone modifications within the healthy aging brain (Chapter 1.12). This is 
particularly important as epigenetic regulation is a dynamic process in the brain, with roles in 
neuronal development, maintenance, memory formation and consolidation, synaptic 
maintenance, and long-term potentiation, many of which are disrupted in AD (Feng et al., 
2010b; Levenson et al., 2006; Lubin et al., 2008).   
There have been few studies to characterise global levels of histone modifications within the 
aging brain (Peleg et al., 2010; Rodrigues et al., 2014; Walker et al., 2013). The most widely 
studied histone modification has been H3K9 methylation and acetylation. Of the few studies 
to measure global histone modifications, the data suggest that different cell-types and cortical 
regions exhibit different global levels for histone modifications such as H3K9ac and H3K9 
methylation (Rodrigues et al., 2014; Walker et al., 2013). Rodrigues and colleagues (2014) 
showed enrichment of H3K9ac marking in the aged mouse cortex, but depletion of H3K9me3, 
indicative of increased chromatin accessibility and transcriptional activity when measured with 
Western blot and immunocytochemistry (Rodrigues et al., 2014). While an in vitro study 
identified no change in total H3 acetylation, but depletion of H4 acetylation and H3K9 
methylation in aging hippocampal and cortical neurons across a time-course from 2-21 months 
of age (Walker et al., 2013). Interestingly, depletion of H3K9ac marking correlated with 
decreased expression of BDNF in cultured neurons (Walker et al., 2013). However, another 
study demonstrated that there was no global change in H3K9ac, H3K14ac, H4K5ac, H4K8ac, 
H4K12ac and H4K16ac in 16 month old hippocampal neurons from the C57/BL6 mice, 
compared to 3 month controls when measured with immunoblot (Peleg et al., 2010).  
Although global measurements of histone modifications can provide an indication of overall 
changes occurring within the aging brain, epigenetic regulation of the genome is finely 
controlled at specific promoters and enhancers to regulate gene expression. To date, there have 
been 4 studies that have characterised histone modifications in the aging brain at a genome-
wide level (Benito et al., 2015; Cheung et al., 2010; Nativio et al., 2018; Shulha et al., 2013). 
These studies have identified a redistribution of histone acetylation with increasing age. For 
example, Nativio, et al., (2018) performed ChIP-seq for H4K16ac in post-mortem human 
lateral temporal lobe from cases in the ‘young’ (mean age 52) and ‘old’ (mean age 68) cohorts. 
Nativio and colleagues identified an enrichment of H4K16ac genome-wide, with 127000 peaks 
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unique to old cases compared to 50000 peaks unique to young cases, and ~156000 peaks shared 
by young and old cases (Nativio et al., 2018). Gene ontology analysis further elucidated that 
the top aging associated genes were annotated to pathways involving respiration processing, 
insulin stimulus and inflammatory response (Nativio et al., 2018). Interestingly, the study also 
identified a linear correlation between aging and neurodegenerative disease, implicating a 
component of normal aging in disease (Nativio et al., 2018).  
To date, only 3 studies have utilised FACS to isolate neuronal nuclei from the cortex to identify 
neuron specific changes to histone modifications in the aging brain (Benito et al., 2015; Cheung 
et al., 2010; Shulha et al., 2013). A ChIP-seq study of neurons in the post-mortem human 
prefrontal cortex from 0.5-69 years demonstrated an age associated depletion of H3K4me3 
(Cheung et al., 2010). Analysis of developmental (<1 year old) and aged (>60 years of age) 
neuronal samples showed 589 significant H3K4me3 peaks enriched in the developmental 
neurons, but not aged neurons, while 101 peaks were enriched in the aged neurons (Cheung et 
al., 2010). The study demonstrated that enrichment of H3K4me3 in all samples was specific to 
key neuronal pathways involving neurogenesis, neurite development, and synaptic 
transmission, however there were no significant gene ontology terms identified from the 101 
peaks specific to aged neurons (Cheung et al., 2010). In accordance with Cheung, another 
genome-wide study in neurons from the prefrontal cortex has identified rapidly occurring 
developmental changes to H3K4me3 at 1157 loci in neurons at sites pertaining to neuronal 
development, synaptogenesis, and intracellular signalling, but few changes to H3K4me3 
marking in adult or aging neurons (Shulha et al., 2013). Finally, Benito and colleagues (2015) 
identified genome-wide depletion of H4K12ac in neurons from the hippocampus of C57/BL6 
mice at 20 months of age compared to 3 months of age, at sites involved in RNA modifications, 
metabolic processes, apoptosis, and RNA localisation (Benito et al., 2015). Interestingly, 
H4K12ac depletion with age was specific to neuronal cells, and reversed by administration of 
a HDACi (Benito et al., 2015). The studies to date have demonstrated both enrichment and 
depletion of histone modifications associated with transcription in the aging brain.  
The current study sought to characterise the histone landscape of neurons within healthy aging 
brain in a time-course by utilising chromatin immunoprecipitation and next-generation 
sequencing (ChIP-seq) of H3K27ac and H3K4me3 from the forebrain of C57/BL6 mice at 3, 
6, 12, and 24 months of age. These data present the first comprehensive genome-wide 




4.2.1 Histone acetylation changes in neurons during development and aging  
The epigenome is regulated through a wide range of epigenetic modifiers. Here, H3K27ac; a 
key marker of active promoters and active enhancers, was characterised in forebrain neurons 
from C57/BL6 animals at 3 months of age, 6 months of age, 12 months of age, and 24 months 
of age.  
An assessment of the total genomic coverage can provide an indication of the changes to 
H3K27ac marking in aging neurons at a global level. Here, an analysis of the total genomic 
coverage was performed of neurons from mice at 3, 6, 12, and 24 months of age by determining 
the percentage of the genome that contained greater than 5× depth for H3K27ac. At 3 months 
of age, H3K27ac marking was present in approximately 2.23% of the neuronal genome, 
similarly 6 month old neurons exhibited approximately 2.46% genome coverage for H3K27ac 
(Figure 4.1a). By 12 months of age, neurons were depleted for H3K27ac compared to the 
previous time-points (12 months: 1.86% genome coverage; Figure 4.1a). Strikingly, 24 month 
old neurons sustained a ~50% increase in H3K27ac marking compared to the earlier time-
points (24 months: 3.70%; Figure 4.1a).  
Next, a pairwise analysis of differential enrichment for H3K27ac was performed genome-wide 
across 3, 6, 12, and 24 month old neurons. This analysis demonstrated an evolution of H3K27ac 
marking in aging neurons (Figure 4.1b-d). Initially, there were 11901 sites significantly 
enriched for H3K27ac in 3 month old neurons compared to 6 months old neurons, and 122 sites 
that were depleted in 3 month old neurons compared to 6 month old neurons (Benjamini 
Hochberg FDR adjusted p-value <0.05; Figure 4.1b). There were 1230 differentially enriched 
and 103 depleted H3K27ac marked sites in neurons at 12 months of age compared to those at 
6 months of age (Benjamini Hochberg FDR adjusted p-value <0.05; Figure 4.1c). Interestingly, 
11823 sites were enriched for H3K27ac in 24 month old neurons compared to those at 12 
months of age, and 155 sites were depleted for H3K27ac marking in 24 month old neurons 
compared to 12 months of age (BH FDR adjusted p-value <0.05; Figure 4.1d). Differential 
enrichment for H3K27ac peaked in 3 month, and 24 month old neurons (Figure 4.1b-d). The 
top ranked differentially enriched sites from the neuronal aging time-course were visualised 
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Figure 4.1: H3K27ac is enriched during development and in aging neurons 
(a) Percentage 5× genomic coverage of H3K27ac in 3 month (light blue), 6 month (blue), 12 
month (dark blue), and 24 month old (dark grey) neurons from C57/BL6 mice. (b-d) Volcano 
plots show the logFC and FDR adjusted P-value of H3K27ac marking through a time-course 
of aging in neurons. (b) LogFC and FDR adjusted P-value of 3 month versus 6 month old 
neurons, (c) 6 month versus 12 month old neurons and, (d) 12 month versus 24 month old 
neurons; positive logFC (light green) represents enrichment in the older time-point of pairwise 
comparison, and negative logFC (dark green) depletion from the older time-point of the 
pairwise comparison (i.e. enrichment in the younger time-point). (e-g) Representative tracks 
visualised in IGV showing the top-ranked sites of enrichment in pseudoreplicates between (e) 
3 (light blue) and 6 (blue) month old neurons at an enhancer across the Eml6 gene; (f) 6 (blue) 
and 12 (dark blue) month old neurons at the Vav3 enhancer and; (g) 12 (dark blue) versus 24 
(dark grey) month old neurons at the Osbp2 enhancer. (h-j) Histograms showing the logFC of 
the best window within the normalised region of H3K27ac marking in neurons from the 




For example, an enhancer for Eml6 encoding Echinoderm Microtubule Associated Protein Like 
6, was enriched in 3 month old neurons compared to neurons in 6 month old mice. Eml6 is a 
member of a protein family reported to stabilise microtubules in the mammalian brain 
(Houtman, Rutteman, De Zeeuw, & French, 2007). Interestingly, Vav3; Vav Guanine 
Nucleotide Exchange Factor 3, a protein involved in actin cytoskeletal rearrangements and 
axon guidance, (Sauzeau et al., 2010) was depleted in 6 month old neurons compared to those 
at 12 months of age. Vav3 has also been implicated in neurological disorders such as 
schizophrenia (Aleksic et al., 2013). Similarly, H3K27ac was enriched at a putative enhancer 
for Osbp2; Oxysterol Binding Protein 2 in 24 month old neurons compared neurons at 12 
months of age. Oxysterol binding proteins are known to regulate lipid and cholesterol 
metabolism and are thought to interact with intermediate filaments (C. Wang, JeBailey, & 
Ridgway, 2002),. To further illustrate the dynamic nature of H3K27ac marking in aging 
neurons, the LogFC of Eml6, Vav3, and Osbp2 were plotted as histograms across the aging 
time-course, demonstrating the dynamic nature of H3K27ac marking over time (Figure 4.1e-
j). 
Taken together, these data demonstrate a global enrichment of H3K27ac marking in aging 
neurons, and differential enrichment of H3K27ac marking in 3 and 24 month old neurons, 
while there was little change in neuronal H3K27ac marking between 6 and 12 months of age.   
 
4.2.2 H3K27ac is enriched at TSS in neurons during development and late 
aging 
H3K27ac marking is generally present at active enhancers, and to a lesser degree at the TSS of 
active genes (Creyghton et al., 2010b; Rada-Iglesias et al., 2011). Initially, the average 
distribution of H3K27ac marking was plotted around a 2kb region upstream and downstream 
of TSS. Here it was identified that H3K27ac marking was enriched in neurons around the TSS 
particularly during development and late aging (Figure 4.2a). The marking exhibited a bimodal 
distribution, with the greatest signal identified at the +1 nucleosome sitting immediately 3’- to 
the TSS (Figure 4.2a). The average H3K27ac marking was approximately 2-fold greater in 3 
month old neurons compared to 6 month old neurons (3 month max: 2.04, 6 month max: 1.13, 
respectively; Figure 4.2a). At 12 months of age, H3K27ac marking was slightly enriched in 
neurons at the TSS compared to 6 month old neurons (12 month max: 1.34; Figure 4.2a). 
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Interestingly, in 24 month old neurons, H3K27ac marking was approximately 2-fold greater 
than 12 month old neurons (24 month max: 2.90; Figure 4.2a).   
Next, heatmaps of H3K27ac marking were plotted against UCSC KnownGene TSS. This 
analysis showed that approximately 33% of TSS contained H3K27ac marking in neurons at 3 
months of age. The magnitude and distribution of H3K27ac marking was depleted in neurons 
by 6 months of age, then increased at 12 months of age. By 24 months of age, the proportion 
of TSS and magnitude of H3K27ac marking in neurons was enriched to a greater level than in 
3 month old neurons (Figure 4.2b).  
CpG islands are key regulatory regions of the genome, predominantly found at the TSS, and 
are key sites for DNA methylation to regulate transcription (review: (Deaton & Bird, 2011)).  
To further elucidate the distribution of H3K27ac marking at TSS and to identify if the changes 
seen at the TSS were predominantly found at CpG islands, the data was subset into CpG islands 
containing TSS and non-CpG island TSS. Interestingly, approximately 40% of all TSS 
contained CpG islands. At 3 months of age H3K27ac marking covered approximately 2/3 of 
all CpG islands containing TSS in neurons (Figure 4.2c). By 6 months of age, the proportion 
of H3K27ac marked CpG island TSS and the magnitude of H3K27ac marking were depleted 
in neurons (Figure 4.2c). While at 12 months of age, the proportion of CpG islands containing 
TSS marked with H3K27ac in neurons increased to a similar number as observed in 3 month 
old neurons, however the magnitude of H3K27ac marking was still lower than in 3 month old 
neurons (Figure 4.2c). Interestingly, 24 month old neurons were enriched in both the proportion 
of CpG island containing TSS marked and the magnitude of H3K27ac marking to a level 
greater than in 3 month old neurons. Moreover, the distribution of H3K27ac marking shifted 
slightly downstream of the TSS in 24 month old neurons compared to neurons at all the other 
ages examined (Figure 4.2c). In contrast to CpG island containing TSS, non-CpG island 
containing TSS exhibited a lower proportion and magnitude of H3K27ac enrichment in 
neurons (Figure 4.2d). At 3 months of age, approximately 1/5 of non-CpG island TSS contained 
H3K27ac marking in neurons (Figure 4.2d). However, by 6 months of age, the proportion of 
non-CpG island TSS enriched for H3K27ac and the magnitude of enrichment were depleted in 
neurons (Figure 4.2d). At 12 months of age, there was a slight increase in the proportion and 
magnitude of H3K27ac marking at non-CpG island TSS compared to 6 months of age, which 
was then further increased in 24 month old neurons, back to the levels seen in 3 month old 
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Figure 4.2: H3K27ac is enriched at the TSS in neurons during development and late aging 
(a) Average enrichment plots for H3K27ac within a 2kb window of TSS for the UCSC 
KnownGene track in neurons at 3 (light blue), 6 (blue), 12 (dark blue) and 24 months of age 
(dark grey). (b) Heatmaps of H3K27ac marking at TSS for UCSC KnownGene sorted by 
strongest (blue) to weakest (red) signal in neurons from 3, 6, 12 and 24 months of age. (c) 
Heatmaps of H3K27ac marking at CpG island containing TSS from the UCSC mm10 CpG 
island track sorted by strongest (blue) to weakest (red) signal in neurons from 3, 6, 12 and 24 
month old C57/BL6 mice. (d) Heatmaps of H3K27ac marking at non-CpG containing TSS 
from the UCSC mm10 KnownGene track sorted by strongest (blue) to weakest (red) signal in 




Taken together, these data demonstrate that H3K27ac marking is enriched at TSS in 3 and 24 
month old neurons and H3K27ac marking is depleted from adult neurons at 6 and 12 months 
of age. TSS are enriched for H3K27ac marking in 24 month old neurons, to levels similar to 
those observed at 3 months of age. The majority of differential H3K27ac marking in neurons 
across aging is occurring at CpG island containing TSS.  
 
4.2.3 H3K27ac marking is enriched at putative enhancers and cortical super 
enhancers in development and late aging 
There are a range of transcriptional elements that are responsible for appropriate cellular 
identity and function. Enhancers are key distal regulatory elements that allow for appropriate 
cellular identity and function. To identify epigenetic modifications occurring at enhancers 
specifically, a track of all H3K27ac marking outside of a 2kb window of UCSC KnownGene 
TSS was generated and used to map ‘putative enhancers’. Herein, ‘putative enhancers’ as 
defined above will be referred to as enhancers.  
The average distribution of H3K27ac at enhancers was measured by visualising the mean 
abundance of reads around a 2kb window of the enhancer mid-point. Initially, H3K27ac 
marking at enhancers were collated and mapped. 3 month old neurons were highly enriched 
for H3K27ac marking (3 month max: 37.98; Figure 4.3a), which was similar at 6 months of 
age (6 month max: 31.32; Figure 4.3a). Interestingly, at 12 months of age, the magnitude of 
marking for H3K27ac at enhancers was increased in neurons (12 month max: 45.60; Figure 
4.3a). Interestingly, the magnitude of enhancer H3K27ac marking was depleted in 24 month 
old neurons (24 month max: 30.56; Figure 4.3a). The average enrichment of enhancers was 
highly dynamic throughout the aging time-course.  
Next, H3K27ac marking was mapped against enhancers by visualising the data with heatmaps. 
Enhancers were highly enriched in neurons at 3 months of age, with the vast majority of 
enhancers containing H3K27ac marking at the mid-point of the 2kb window (Figure 4.3b). By 
6 months of age, only a small proportion of enhancers in neurons were highly enriched for 
H3K27ac marking, however the mid-point of all enhancers showed weak marking for H3K27ac 
(Figure 4.3b). Enhancers were slightly enriched in the magnitude of H3K27ac marking in 
neurons at 12 months of age compared to 6 months of age (Figure 4.3b), and by 24 months of 
age, the proportion and magnitude of H3K27ac marking at enhancers were further enriched. 
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Interestingly, at 24 months of age, H3K27ac marking was widely distributed across the 2kb 
window in a small subset of enriched enhancers in neurons (Figure 4.3b). 
Super-enhancers are recently discovered regulatory regions responsible for cell-type specific 
gene expression that aid in the determination of cellular identity ((Hnisz et al., 2013; Whyte et 
al., 2013); Chapter 1.10). A cortical super-enhancer track was obtained from dbSUPER; a 
database of known super-enhancers, to map changes in H3K27ac enrichment around known 
cortical super-enhancers (Khan & Zhang, 2016). The majority of known cortical super-
enhancers were enriched for H3K27ac marking, with approximately 25% of all super enhancers 
highly enriched for H3K27ac marking in neurons at 3 months of age (Figure 4.3c). However, 
in 6 month old neurons, the magnitude and proportion H3K27ac marking at super enhancers 
was lower than in 3 month old neurons (Figure 4.3c). At 12 months of age, neurons showed 
slight enrichment for H3K27ac at super-enhancers compared to the 6 month time-point (Figure 
4.3c). Interestingly, the magnitude and proportion of H3K27ac enrichment at super-enhancers 
increased in 24 month old neurons to levels seen at 3 months of age (Figure 4.3c).  This was 
further illustrated with example tracks of H3K27ac marking at the top ranked sites enriched for 
H3K27ac overlapping cortical super-enhancers.  
Next, an overlap analysis for differentially enriched H3K27ac sites (from Figure 4.1a) was 
performed with the cortical super-enhancer track. There were 1165 differentially marked 
H3K27ac sites that were enriched in 3 month versus 6 month old neurons that overlapped 
cortical super-enhancers. However, there were only 5 differentially marked H3K27ac sites that 
intersected cortical super-enhancers that were enriched in 6 month old versus 3 month old 
neurons. The top ranked H3K27ac marked site from 3 month old versus 6 month old neurons 
was at the super-enhancer overlapping the Bsn gene (Figure 4.3d). While 277 differentially 
enriched H3K27ac sites were overlapping super-enhancers in 12 month old neurons, with the 
top ranked H3K27ac site was at the super-enhancer at the Celf2 gene (Figure 4.3e). There were 
9 H3K27ac marked sites that were overlapping super-enhancers in 6 month old neurons 
compared to 12 months of age. Interestingly, there were 1028 H3K27ac differentially marked 
sites enriched in 24 month old neurons compared to 12 month old neurons that were also sites 
for known cortical super-enhancers, as well as 16 sites of H3K27ac enrichment in 12 month 
old versus 24 month old neurons. The top ranked H3K27ac marked site was overlapping a 





































































































































































































































































































































































































































































































Figure 4.3: H3K27ac is enriched at enhancers and super-enhancers in neurons in 
development and aging 
(a) Average enrichment plots for H3K27ac within a 2kb window of putative enhancers in 
neurons at 3 (light blue), 6 (blue), 12 (dark blue) and 24 (dark grey) months of age. (b) 
Heatmaps for H3K27ac marking at putative enhancers sorted by strongest (blue) to weakest 
(red) signal in 3, 6, 12 and 24 month old neurons from the forebrain of C57/BL6 animals. (c) 
Heatmaps for H3K27ac marking against the Super-Enhancer Database (dbSUPER) track were 
sorted by strongest (blue) to weakest (red) signal in neurons at 3, 6, 12 and 24 months of age. 
(d-f) Representative tracks visualised using the IGV browser are shown. H3K27ac signal 
overlap was evident in neurons at super-enhancers overlapping the top ranked differentially 
enriched sites including between pseudoreplicates at; (d) 3 and 6 months of age at the Bsn loci, 




Taken together, these data demonstrate that H3K27ac marking is dynamically regulating 
enhancers and super-enhancers throughout the genome in aging neurons. There is enrichment 
of H3K27ac at both enhancers and super enhancers in neurons at 3 months of age, which is 
then depleted at 6 and 12 months of age, before becoming enriched in 24 month old neurons. 
 
4.2.4 H3K27ac marking of the epigenome annotates to synaptic pathways in 
aging 
Next, the underlying molecular and biological pathways associated with the differential 
enrichment of H3K27ac in neurons was assessed with gene ontology using the Genomic 
Regions Enrichment of Annotations Tool (GREAT) (C. Y. McLean et al., 2010). H3K27ac 
marking was dynamically enriched in a range of molecular and biological processes. For 
example, H3K27ac marked sites that were differentially enriched in neurons between 3 and 6 
months of age were annotated to ‘GO molecular functions’ such as ‘calmodulin binding’, 
‘divalent inorganic cation transmembrane transporter activity’, ‘calcium channel activity’ and 
‘actin filament binding’, while annotation to ‘GO biological process’ identified pathways such 
as ‘regulation of synaptic transmission’, ‘metal ion transport’, ‘calcium ion transport’ and 
‘learning’ (Figure 4.4a,d). H3K27ac marked sites that were differentially enriched between 6 
and 12 month old neurons were annotated to ‘GO molecular functions’ including ‘protein N-
terminus binding’, ‘ankyrin binding’ and ‘voltage-gated sodium channel activity’. H3K27ac 
marked sites were also annotated to ‘GO biological processes’ of ‘synapse organisation’, 
‘regulation of synaptic plasticity’, and ‘protein localisation to membrane’ (Figure 4.4b,e). 
Between 12 and 24 months of age, H3K27ac marking in neurons was annotated to ‘GO 
molecular functions’ including ‘actin filament binding’, ‘unfolded protein binding’, ‘SNARE 
binding’ and ‘polyubiquitin binding’, and annotations to ‘GO biological processes’ included 
‘regulation of RNA splicing’, ‘maintenance of protein location in cell’, ‘regulation of receptor 
activity’ and ‘execution phase of apoptosis’ (Figure 4.4c,f).  
Together these data identified a transition from synaptic and ion transport pathways in juvenile 
neurons, while cortical aging led to enrichment in pathways for the maintenance of cellular 
function and cellular senescence such as RNA splicing, protein localisation and apoptosis. 
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Figure 4.4: H3K27ac alterations in neurons annotate to pathways involving synaptic 
plasticity and RNA modifications in the aging brain 
(a-f) The top 10 gene ontology annotations, ranked by hypergeometric observed gene hits for 
sites of significant (FDR adjusted P value <0.05) H3K27ac differential enrichment in neurons 
at (a,d) 3 versus 6 months of age (b,e), 6 versus 12 months of age and (c,f) 12 versus 24 months 
of age. Gene ontology analysis predicts annotated pathways in (a, b, c) molecular function and, 




4.2.5 H3K27ac marking is evolving in neurons, and demonstrate a partial 
recapitulation of development in neurons from the aging brain  
To determine whether enrichment of H3K27ac occurred at similar or different loci in aging 
neurons an intersection analysis of bed files containing all sites of significant differential 
enrichment at each time-point was performed. 
Initially, there were 10209 differentially enriched H3K27ac sites specific to the 3 month old 
versus 6 month old neuron comparison, with only 112 sites were shared with the analysis 
performed on 6 versus 12 month old neurons (Figure 4.5a). Strikingly, there were 7203 sites 
(>33% of the sites) of H3K27ac differential binding that were shared between young (3 versus 
6 months) and old (12 versus 24 months) neurons (Figure 4.5a). There was also a group of 
1225 differentially enriched H3K27ac sites in neurons that were present in all pairwise 
timepoint comparisons (Figure 4.5a). The majority of H3K27ac differentially marked sites 
between the 6 versus 12 month old neurons were shared with the other time-points, with only 
75 sites of differential H3K27ac marking specific to this pairwise comparison. The majority 
(12747) of H3K27ac differentially marked sites in neurons from the 12 versus 24 month old 
comparison were specific to that time-point (Figure 4.5a).  
Next, gene ontology analysis was performed for the sites identified in the intersection analysis 
to assess the biological pathways in neurons that were common across time-points or specific 
to certain ages. Sites of differential H3K27ac marking specific to 3 versus 6 month old neurons 
were annotated to ‘GO biological processes’ including ‘ion transmembrane transport’, 
‘regulation of neurological system process’, ‘regulation of transmission of nerve impulse’ and 
‘divalent metal ion transport’ (Figure 4.5c). Interestingly, differentially H3K27ac marked sites 
shared between the 3 versus 6 month old neurons and 12 versus 24 month old neurons were 
annotated to ‘GO biological processes’ including the ‘regulation of synaptic plasticity’, 
‘regulation of transporter activity’, ‘regulation of phosphatase activity’, and ‘regulation of 
dendrite development’ (Figure 4.5d). Sites that were unique to the 12 versus 24 month time-
point were annotated to pathways involving the ‘regulation of mRNA processing’, ‘regulation 
of ARF protein signal transduction’, ‘execution phase of apoptosis’, ‘vacuolar transport’, and 
‘oxidative phosphorylation’ among others (Figure 4.5e).  
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Figure 4.5: Evolution of differential H3K27ac marking and partial recapitulation of a 
juvenile-like epigenetic state in aging neurons  
(a) Venn diagram plotting the overlap in sites that were differentially enriched in neurons from 
the 3 months versus 6 months, 6 months versus 12 months and 12 months versus 24 months 
old pairwise comparisons. (b) Functional annotations for ‘GO biological process’ for the 1225 
sites that were differentially enriched in neurons at all time points, (c) the 10209 H3K27ac sites 
unique to the 3 versus 6 months of age differential enrichment analysis, (d) the 7203 sites 
shared between the 3 versus 6 months of age and 12 versus 24 months of age pairwise 
comparison and, (e) the 12747 H3K27ac marked sites unique to 12 versus 24 month old 
comparison. There were no pathways enriched for H3K27ac marking between 3 versus 6 
month old neurons and 6 versus 12 month old neurons, unique to 6 versus 12 month old 




While the differentially H3K27ac marked sites that were common across all ages were 
annotated to pathways such as ‘regulation of synaptic transmission’, ‘regulation of metal ion 
transport’, ‘synapse organisation’, ‘regulation of synaptic plasticity’, ‘protein localisation to 
membrane’, and ‘neurotransmitter transport’ (Figure 4.5b). There were no pathways that were 
annotated for H3K27ac marking between 3 versus 6 month old and 6 versus 12 month old, 
unique to 6 versus 12 month old, or shared between 6 versus 12 month old and 12 versus 24 
month old pairwise comparisons, which all had less than 200 differentially marked sites. 
To determine whether sites of differential H3K27ac enrichment that were shared across time-
points in neurons exhibited a consistent pattern of depletion or enrichment over time; 
differential enrichment data from csaw was separated into enriched or depleted at each time-
point and the data was analysed with BEDTools intersect to determine the number and direction 
of H3K27ac marked sites over time. When the enrichment or depletion of H3K27ac marking 
at sites was analysed for neurons across 3, 6 and 12 months of age the vast majority (92%) of 
sites were enriched for H3K27ac at 3 and 12 months of age compared the 6 month time-point. 
Furthermore, when the enrichment or depletion of H3K27ac was assessed in neurons across 6, 
12 and 24 months of age most (87%) sites exhibited a progressive increase in the enrichment 
of H3K27ac across 6-24 months of age. Interestingly, there was a small proportion of H3K27ac 
marked sites (7.5%) that demonstrated enrichment in neurons at 12 months of age compared to 
at 6 and 24 months of age.  
Taken together these analyses indicate that the majority of sites that are dynamically marked 
for H3K27ac in neurons across aging exhibit enrichment of H3K27ac at 3 months of age, 
depletion of H3K27ac at 6 months of age followed by a progressive enrichment of H3K27ac 
between 6 and 24 months of age.  
 
4.2.6 H3K4me3 marking is enriched in neurons in the developing and aged 
brain of C57/BL6 mice 
One key histone modification that increases transcription factors accessibility to chromatin and 
subsequent gene expression is H3K4me3. H3K4me3 marking predominantly located at the 
promoter elements of active genes (B. E. Bernstein et al., 2005; Nathaniel D. Heintzman et al., 
2007; Rada-Iglesias et al., 2011).  H3K4me3 was sequenced genome wide in neurons from 
C57/BL6 mice to identify differential enrichment across a time-course of brain aging 
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incorporating 4 time-points: 3 months of age,6 months of age, 12 months of age, and 24 months 
of age. 
Initially, the total genomic coverage of H3K4me3 marking was measured by quantitating the 
percentage of the genome that contained more than 5× reads. This analysis gave an indication 
of gross changes occurring in the aging brain. Initially, in 3 month old neurons H3K4me3 
marking was present in approximately 2.94% of the genome (Figure 4.6a). While in 6 month 
old neurons H3K4me3 marking was depleted covering only 1.85% of the genome (Figure 
4.6a). H3K4me3 marking then remained relatively stable in 12 month old and 24 month old 
neurons with a total genomic coverage of 1.92% and1.77%, respectively (Figure 4.6a). Neurons 
initially had enrichment for H3K4me3, which then depleted in young adult neurons and was 
stable through aging (Figure 4.6a).  
Next, differential enrichment analysis of H3K4me3 was performed genome-wide. There was 
an evolution of H3K4me3 marking over time in aging neurons (Figure 4.6b-d). Initially, there 
were 23258 sites that were enriched in 3 month old neurons compared to 6 month old neurons, 
while only 623 H34me3 marked sites were enriched in 6 month neurons (Figure 4.6b). There 
were 16018 H3K4me3 marked sites that were enriched in 12 month old neurons compared to 
those at 6 months of age, with 406 sites were enriched in 6 month old neurons compared to 12 
month old neurons (Figure 4.6c). When comparing 12 and 24 month old neurons, there were 
15271 H3K4me3 marked sites significantly enriched in 24 month old neurons compared to 12 
months of age, while 1341 sites were enriched in 12 month old neurons compared to 24 months 
of age (Figure 4.6d). To further elucidate the change in H3K4me3 marking, the top ranked 
differentially enriched H3K4me3 marked sites were visualised with IGV (Figure 4.6e-g). For 
example, the promoter of the Grin1 gene was enriched in 3 month old neurons compared to 
neurons that were 6 months of age. Grin1 encodes the Glutamate Ionotropic Receptor NMDA 
Type 1 Subunit, which is an essential subunit of N-methyl-D-aspartate receptors, and important 
for normal brain function ((W. Chen et al., 2017) Figure 4.6e). The top differentially enriched 
site between 6 and 12 months old neurons was at the promoter for the Brsk1gene, which 
encodes the Brain-Specific Serine/Threonine Kinase 1 protein, which regulates the polarisation 
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Figure 4.6: H3K4me3 is enriched in neurons of the developing and aging brain 
(a) Percentage 5× genomic coverage of H3K4me3 in neurons of 3 (light blue), 6 (blue), 12 
(dark blue) and 24 (dark grey) months of age from C57/BL6 mice. (b-d) Volcano plots show 
the logFC and FDR adjusted P-value of H3K4me3 marking through a time-course of aging in 
neurons. (b) LogFC and FDR adjusted P-value of 3 month versus 6 month old neurons, (c) 6 
month versus 12 month old neurons and (d) 12 month versus 24 month old neurons. Positive 
logFC (light green) represents enrichment in the older time-point of pairwise comparison, and 
negative logFC (dark green) depletion from the older time-point of the pairwise comparison 
(enrichment in the younger time-point). (e-g) Representative tracks visualised in IGV showing 
the top-ranked sites of enrichment in neuronal pseudoreplicates between: (e) 3 (light blue) and 
6 (blue) months of age at the promoter of the Grin1 gene; (f) 6 (blue) and 12 (dark blue) months 
of age at the Brsk1 promoter and (g) 12 (dark blue) versus 24 (dark grey) months of age at the 
Actn4 promoter. (h-j) Histograms showing the logFC of the best window within the normalised 
region of H3K4me3 marking in neurons from the pairwise differential enrichment analysis at 




Similarly, the top differentially enriched site between 12 and 24 month old neurons was at the 
promoter for Actn4, which encodes the Actinin Alpha 4 protein, a member of the spectrin 
family of cytoskeletal proteins, which has been shown to influence spine morphology 
((Kalinowska et al., 2015) Figure 4.6g). To illustrate the dynamic nature of H3K4me3 marking 
at specific loci in neurons over time, the logFC from the differentially enriched sites was plotted 
as a histogram across the aging time-course (Figure 4.6h-j).   
 
4.2.7 H3K4me3 marking at promoters in neurons is enriched at 3 months, 
depleted at 6 months, and re-established with age 
H3K4me3 marking is predominantly found at the TSS and promoter of active genes in 
mammalian species (B. E. Bernstein et al., 2005; Nathaniel D. Heintzman et al., 2007; Rada-
Iglesias et al., 2011). To identify if the differential enrichment of H3K4me3 marking was 
occurring at promoters, H3K4me3 was plotted against tracks for UCSC KnownGene TSS and 
then further subset into CpG island containing TSS and non-CpG island containing TSS. The 
mean abundance of reads was mapped within a 2kb window either side of TSS (Figure 4.7a). 
H3K4me3 marking was enriched at the +1 and -1 nucleosomes proximal and distal to the TSS 
in neurons. Quantitation of the mean enrichment plots showed that H3K4me3 marking was 
strongest at the TSS in 3 months old neurons (3 month max: 7.12; Figure 4.7a), while at 6 
months of age neurons the TSS were depleted for H3K4me3 marking (6 month max: 3.24; 
Figure 4.7a). At 12 months of age the mean abundance of H3K4me3 marking at the TSS in 
neurons increased (12 month max: 5.17; Figure 4.7a), before plateauing at the TSS of 24 month 
old neurons (24 month max: 5.17; Figure 4.7a). To further assess the change in H3K4me3 over 
time, heatmaps were generated against UCSC KnownGene TSS. At 3 months of age, 
H3K4me3 marking was present at approximately 50% of TSS in neurons (Figure 4.7b), 
however by 6 months of age the proportion of TSS marked by H3K4me3 slightly decreased, 
and the magnitude of H3K4me3 marking was depleted from the TSS of neurons (Figure 4.7b). 
At 12 months of age, the proportion of H3K4me3 marked TSS remained constant in neurons, 
however, there was an increase in the magnitude of H3K4me3 marking.  
The proportion of TSS enriched for H3K4me3 and the magnitude of the H3K4me3 marking 
remained consistent in 24 month old neurons (Figure 4.7b). Further analysis indicated that the 
majority of H3K4me3 marking was present at CpG island containing TSS (Figure 4c,d). 
Approximately 4/5 of CpG island containing TSS were enriched for H3K4me3 marking in 3 
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month old neurons (Figure 4.7c). At 6 months of age, the proportion of CpG island containing 
TSS marked with H3K4me3 in neurons was slightly lower than at 3 months of age, hand the 
magnitude of marking H3K4me3 was also depleted (Figure 4.7c). In 12 and 24 month old 
neurons, the proportion (~80%) of CpG island containing TSS enriched for H3K4me3 
remained relatively stable, with a sustained increase in the magnitude of H3K4me3 marking 
compared to 6 month old neurons. Interestingly, at 24 months of age, the distribution of 
H3K4me3 marking around CpG island containing TSS changed, with a loss of marking 
upstream of the TSS (Figure 4.7c). In comparison, H3K4me3 marking at non-CpG containing 
TSS in neurons was more stable. At 3 months of age, approximately 20% of non-CpG 
containing TSS in neurons were enriched for H3K4me3 marking. However, in 6 month old 
neurons the magnitude of H3K4me3 marking at non-CpG TSS was depleted, and the 
proportion of non-CpG island containing TSS marked with H3K4me3 was slightly reduced 
(Figure 4.7d). H3K4me3 marking remained relatively constant in non-CpG TSS in 12 month 
old neurons compared to 6 month old neurons (Figure 4.7d). Finally, at 24 months of age, the 
magnitude of H3K4me3 marking at non-CpG TSS in neurons increased (Figure 4.7d).   
H3K4me3 is highly enriched at TSS in 3 month old neurons, while 6 month old neurons exhibit 
a lower magnitude of H3K4me3 marking at a similar proportion TSS. H3K4me3 enrichment 
at TSS in neurons was then partially re-established at the 12 and 24 month old time-points, 
however the magnitude of H3K4me3 enrichment did not reach the levels observed in 3 month 
old neurons. Taken together, these data demonstrate that H3K4me3 marking at TSS is dynamic 















































































































Figure 4.7: H3K4me3 is enriched in promoters in neurons during development and aging 
(a) Average enrichment plots for H3K4me3 within a 2kb window of TSS for the UCSC 
KnownGene track in neurons of 3 (light blue), 6 (blue), 12 (dark blue) and 24 (dark grey) 
months of age. (b) Heatmaps of H3K4me3 marking at TSS for UCSC KnownGene sorted by 
strongest (blue) to weakest (red) signal in neurons from 3, 6, 12 and 24 months old mice. (c) 
Heatmaps of H3K4me3 marking at CpG island containing TSS from the UCSC mm10 CpG 
island track sorted by strongest (blue) to weakest (red) signal in neurons from 3, 6, 12 and 24 
month old C57/BL6 mice. (d) Heatmaps of H3K4me3 marking at non-CpG containing TSS 
from the UCSC mm10 KnownGene track sorted by strongest (blue) to weakest (red) signal in 




4.2.8 Enhancers exhibit minimal H3K4me3 enrichment in neurons across 
ages 
In the normal mammalian genome H3K4me3 is generally not found at active enhancer 
elements (Local et al., 2018; Outchkourov et al., 2013; Rada-Iglesias et al., 2011). To determine 
if there was any alteration in the distribution of H3K4me3 marking at enhancers in aging 
neurons, average H3K4me3 marking was mapped at a 2kb region around the mid-point of 
enhancer elements marked by H3K27ac.   
First, the mean abundance of H3K4me3 marking was visualised at enhancers in neurons. There 
was some H3K4me3 enrichment at putative enhancers in neurons, which did not alter 
dramatically in 3, 6, 12 or 24 month old neurons (max:  56.33, 54.42, 63.43, 72.40, respectively; 
Figure 4.8a). Next, H3K4me3 marking was mapped against the enhancer track and visualised 
with heatmaps around a 2kb window of the mid-point of enhancers. H3K4me3 marking was 
highly enriched at a small proportion of putative enhancers in neurons. In neurons at all ages, 
the majority of enhancers displayed slight enrichment for H3K4me3 marking at the mid-point 
of enhancers, while in the small proportion of enhancers that were highly enriched for 
H3K4me3 marking, H3K4me3 was distributed across the 2kb window upstream and 
downstream of the mid-point of enhancers (Figure 4.8b). In 6 month old neurons, there was a 
slight decrease to the proportion of enhancers that were highly enriched for H3K4me3 marking 
(Figure 4.8b).  
Together these data show that the majority of enhancers have minimal H3K4me3 marking, 
however, a small subset of putative enhancers are highly enriched for H3K4me3 marking in 
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Figure 4.8 Enhancers in neurons exhibit minimal H3K4me3 marking across aging  
(a) Average enrichment plots for H3K4me3 within a 2kb window of putative enhancers at 3 
months (light blue), 6 months (blue), 12 months (dark blue) and 24 months (dark grey) of age. 
(b) Heatmaps for H3K27ac marking at putative enhancers sorted by strongest (blue) to weakest 




4.2.9 H3K4me3 is annotated to pathways involving cellular function, 
maintenance, and post-translational modifications in aging neurons 
To identify the underlying pathways of differential H3K4me3 marking, gene ontology analysis 
of bed files containing all sites of significant differential enrichment from each pairwise 
comparison was performed.  
Initially, H3K4me3 marking analysis was performed against ‘GO molecular function’. 
Between 3 and 6 month old neurons, H3K4me3 marking was annotated to pathways including 
‘unfolded protein binding’, ‘rRNA binding’, ‘endonuclease activity with RNA or DNA 
producing 5’- posphomonoesters’, and ‘translation regulator activity’ (Figure 4.9a). While 
between 6 and 12 month old neurons, differential sites of H3K4me3 enrichment were annotated 
to terms including ‘ribonucleoprotein complex binding’, ‘tRNA, rRNA and snRNA binding’, 
and ‘translation elongation factor and translation regulator activity’ (Figure 4.9c). Between 12 
and 24 month old neurons, annotations to ‘GO molecular function’ were similar to the previous 
ages, with pathways including ‘unfolded protein binding’, ‘rRNA and snRNA binding’, 
‘intramolecular transferase activity’ and ‘gamma-tubulin binding’ (Figure 4.9e). Next, 
H3K4me3 marking from neurons of the aging brain were annotated to ‘GO biological process’. 
Between 3 and 6 month old neuronsH3K4me3 marking was annotated to terms including 
‘spindle assembly’, ‘GPI anchor metabolic process’, ‘antigen processing & presentation of 
peptide antigen via MHC class I’ and ‘tRNA modification’ (Figure 4.9b).  While in neurons 
between 6 and 12 months of age, H3K4me3 marking was annotated to pathways including the 
‘GPI anchor metabolic process’, ‘regulation of gene silencing’, ‘tRNA modification’, 
‘oxidative phosphorylation’ and ‘chaperone-mediated protein folding’ (Figure 4.9d). Between 
12 and 24 months of age, H3K4me3 marking in neurons was annotated to ‘GO biological 
processes’ including ‘macroautophagy’, ‘glutathione metabolic process’, ‘tRNA modification’, 
and ‘autophagic vacuole assembly’ and gene silencing pathways (Figure 4.9f).  
Together these data demonstrate that H3K4me3 marking is altered over time in pathways that 
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Figure 4.9 In neurons differential H3K4me3 marking across aging occurs at promoters 
responsible for core molecular and post-transcriptional functions 
(a-f) The top 10 gene ontology annotations, ranked by hypergeometric observed gene hits for 
sites of significant H3K27ac differential enrichment at (a,b) 3 versus 6 months, (c,d) 6 versus 
12 months and, (e,f) 12 versus 24 months of age. Gene ontology analysis predicts annotated 
pathways in (a, c, e) molecular function and, (b, d, f) biological processes.  
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4.2.10 Sites of H3K4me3 enrichment are shared between the developing and 
aging brain 
An intersection analysis of bed files containing all sites of significant differential enrichment 
across the time-course of differential H3K4me3 marking was performed to determine whether 
enrichment of H3K4me3 occurred at similar or different loci over time.  
Initially, 24739 H3K4me3 marked sites were differentially enriched specifically in the 3 month 
versus 6 month old neuron comparison, while there were only 2683 H3K4me3 differentially 
marked sites specific to the comparison between 6 month and 12 month old neurons (Figure 
4.10a). Moreover, 11273 differentially H3K4me3 marked sites were enriched in neurons only 
between 12 and 24 months of age. Strikingly, there were 20370 H3K4me3 marked sites that 
were differentially enriched in neurons in both the 3 versus 6 month old comparison and the 
12 versus 24 month old comparison (Figure 4.10a). In contrast, only 3492 differentially 
enriched H3K4me3 sites shared between neurons in the pairwise analyses of 3 versus 6 months 
of age, and the 6 versus 12 month time-points (Figure 4.10a). Likewise, only 1037 of the 
H3K4me3 differentially enriched sites in neurons between 6 and 12 months of age were shared 
with those detected between 12 and 24 months of age (Figure 4.10a). Finally, there were 10777 
sites of differential H3K4me3 enrichment detected across all time-points examine (Figure 
4.10a).  
Next, gene ontology analysis was performed for differential H3K4me3 marking that were 
shared between developing and aging neurons. H3K4me3 marked sites were annotated to ‘GO 
biological process’. Sites that were differentially enriched for H3K4me3 specifically in neurons 
between 3 month and 6 months of age were annotated to ‘protein folding’, ‘spindle 
organisation’, ‘nuclear export’, ‘spindle assembly’, and ‘protein peptidyl-prolyl isomerisation’ 
(Figure 4.10c). Differentially enriched H3K4me3 sites in neurons specific to the 6 versus 12 
months of age comparison but were annotated to pathways such as ‘cardiac cell development’, 
‘regulation of myotube differentiation’, and ‘nephron morphogenesis’ (Figure 4.10d). Sites that 
were differentially enriched for H3K4me3 in neurons specifically between 12 and 24 months 
of age were annotated to pathways including ‘actin filament bundle assembly’, ‘GPI anchor 
metabolic process’, ‘release of cytochrome c from mitochondria’, and ‘posttranscriptional gene 
silencing by RNA’ (Figure 4.10e). Interestingly, sites of differential H3K4me3 marking in 
neurons that were shared between 3 versus 6 months of age, and the 12 versus 24 month time-
points were annotated to biological processes including ‘protein folding’, ‘tRNA processing’, 
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‘maintenance of protein location in cell’ and ‘nuclear export’. H3K4me3 differentially marked 
sites in neurons that were shared by all time-points were also annotated to biological processes 
including ‘protein folding’, ‘tRNA processing’, ‘nuclear export’, and ‘nucleotide-excision 
repair’ (Figure 4.10f). There was no annotation of any ontologies of ‘GO biological processes’ 
when the differentially marked H3K4me3 sites in neurons were compared between the 3 versus 
6 month of age and the 6 versus 12 months of age data, nor for the comparison of the 6 versus 
12 month of age and the 12 versus 24 months of age data. 
When the enrichment or depletion of H3K4me3 marking at sites was assessed for neurons 
across 3, 6 and 12 months of age almost all (99%) of the sites were enriched for H3K4me3 at 
3 and 12 months of age compared the 6 month time-point. Moreover, when the enrichment or 
depletion of H3K4me3 was assessed in neurons across 6, 12 and 24 months of age the vast 
majority (87%) of sites demonstrated a progressive increase in the enrichment of H3K4me3 
across 6-24 months of age. It should be noted that there was as small subset of sites (7.7%) that 
showed enrichment in neurons at 12 months of age compared to the 6 and 24 month time-
points. Overall, these data reveal that the majority of sites that exhibit alterations in H3K4me3 
marking in neurons across the aging time course follow a similar pattern of H3K4me3 
enrichment: enrichment of H3K4me3 at 3 months of age, depletion of H3K4me3 at 6 months 
of age followed by a progressive enrichment in H3K4me3 between 6 and 24 months of age. 
This is strikingly similar to the overall pattern of H3K37ac dynamic enrichment observed at 
sites across neuronal aging.  
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Figure 4.10 Sites of H3K4me3 enrichment are shared between the developing and aging 
neurons 
(a) Venn diagram plotting the overlap in sites that were differentially enriched for H3K4me3 
in neurons from the 3, 6, 12 and 24 month old pairwise comparisons. (b) Functional annotations 
for ‘GO biological process’ for the 10777 sites that were differentially enriched for H3K4me3 
in neurons at all time points, (c) the 24739 sites unique to the 3 versus 6 months of age 
H3K4me3 differential enrichment analysis, (d) the 2683 sites unique to neurons in the 6  versus 
12 month old comparison, (e) the 11273 H3K4me3 differentially marked sites unique to 12 
versus 24 month comparison and, (f) the 20370 sites of differential H3K4me3 enrichment 





The epigenome is integral to the regulation of transcription in the developing and aging brain. 
Studies have demonstrated the epigenome is vital for learning and memory, executive function, 
synaptic plasticity, and motor function (Feng et al., 2010b; Leighton et al., 2018; Levenson et 
al., 2006; X. Li et al., 2014; Swank & Sweatt, 2001; Widagdo et al., 2016). However, there 
have been few studies to characterise the histone landscape in the aging brain.  
This study has characterised both H3K27ac and H3K4me3 marking in neurons from the 
forebrain of C57/BL6 mice at 3, 6, 12, and 24 months of age. Interestingly, H3K27ac and 
H3K4me3 marking was enriched at promoters and enhancers in neurons from juvenile and 
aging mice. Furthermore, H3K4me3 and H3K27ac marking was predominantly enriched in 
neurons at TSS that contained CpG islands in the juvenile and aging brain. H3K4me3 marking 
was enriched in aging neurons for pathways involving lipid transport, RNA modifications, 
apoptotic signalling, centrosome cycling, oxidative phosphorylation and protein export. While 
H3K27ac marking was enriched in pathways pertaining to synaptic plasticity, ion transport, 
dephosphorylation, protein localisation, membrane depolarisation, dendrite development, 
apoptosis and oxidative phosphorylation in aging neurons. Strikingly, this study observed a 
partial recapitulation of a juvenile-like epigenetic state in aged neurons. These data demonstrate 
a complex and dynamic pattern of H3K27ac and H3K4me3 marking in neurons throughout 
life.  
 
H3K4me3 and H3K27ac are enriched in juvenile neurons in a critical period of neuronal 
plasticity as the nervous system is established 
Neurons between 3 and 6 months of age represent the transition from juvenile to young adult 
mice (Fu, Rusznak, Herculano-Houzel, Watson, & Paxinos, 2013) (review: (Semple, 
Blomgren, Gimlin, Ferriero, & Noble-Haeusslein, 2013)). Strikingly, the epigenome was 
highly dynamic in neurons between 3 and 6 months of age. H3K27ac and H3K4me3 marking 
was enriched at the TSS, and H3K27ac marking was enriched at enhancers in neurons at 3 
months of age but were depleted from neurons by 6 months of age. H3K27ac and H3K4me3 
markings are generally indicative of increased transcriptional activity (Creyghton et al., 2010b; 
Santos-Rosa et al., 2002; Z. Wang et al., 2008; Wysocka et al., 2006), and enrichment of these 
marks may reflect a critical time of neuronal plasticity during the transition from juvenile to 
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young adult mice (Handley et al., 2017).The current dogma of cortical aging suggests that 
neuronal connections are established in mice by 3 months of age (review: (Semple et al., 
2013)). Although epigenetic modifications such as DNA methylation are highly dynamic 
during development, such marks have previously been shown to stabilise in mice by 3 months 
of age (Ryan Lister et al., 2013). However, emerging evidence shows the cortex to still be 
undergoing developmental changes at 3 months of age. Widespread synaptic pruning has been 
reported in layer V pyramidal neurons in the cortex of Thy1-YFP (C57/BL6) mice at 3 months 
of age (Handley et al., 2017). Studies have also shown adult levels of neurotransmitters and 
synaptic density stabilise after 3 months of age in mice (Fu et al., 2013). Myelination and total 
brain volume also dramatically increase in mice up to 3 months of age (Fu et al., 2013). 
Moreover, the emergence of adult behavioural tendencies such as reduced risk taking and 
increased parental tendencies occurs after 3 months of age (Fu et al., 2013) (review: (Semple 
et al., 2013)). Enrichment for H3K27ac and H3K4me3 marking in neurons between 3 and 6 
months of age may also reflect the developmental plasticity critical to establishing stable gene 
expression profiles in neurons for later life (reviews: (Hochberg et al., 2011; Murgatroyd & 
Spengler, 2011)). (Fu et al., 2013; Hochberg et al., 2011). 
Gene ontology analysis further illustrated that developmental and neuronal specific pathways 
were differentially enriched in neurons between 3 and 6 months of age. For example, H3K27ac 
marking was enriched in pathways for synaptic transmission, ion transport, learning, and 
dephosphorylation in neurons between 3 and 6 months of age. While H3K4me3 marking was 
annotated to pathways involved in spindle assembly, lipid transport, RNA modifications, 
apoptotic signalling, and protein trafficking in neurons between 3 and 6 months of age. 
Synaptic plasticity is critical for learning, memory and the establishment of executive function 
in the adolescent brain (review: (Selemon, 2013)). Synaptic pruning events have been observed 
in studies of non-human primate, where enrichment of cortical synapses occurs until 2 years of 
age and then declines from adolescence until adulthood (Bourgeois, Goldman-Rakic, & Rakic, 
1994; Zecevic, Bourgeois, & Rakic, 1989). Alongside synaptic pruning, apoptotic signalling 
may be activated in the juvenile nervous system for neuronal remodelling and die-back as 
functional pathways are established in neurons (review: (Yaron & Schuldiner, 2016)). 
Neuronal die-back may be triggered through NMDA receptor hypersensitivity (Ikonomidou et 
al., 1999) (review: (Kuan, Roth, Flavell, & Rakic, 2000)). NMDA receptors are critical to 
activity dependent synaptic plasticity and have been shown to activate pathways leading to the 
reduction of plasticity during neuronal maturation in-vitro (Sala, Rudolph-Correia, & Sheng, 
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2000). Indeed, previous evidence also suggests that H3K4me3 marking is developmentally 
enriched at promoters in neurons from post-mortem human prefrontal cortex and the frontal 
pole at many developmental pathways, but is stabilised as the nervous system matures (Cheung 
et al., 2010; Shulha et al., 2013). Previous literature has also demonstrated widespread 
transcriptional activity during development that stabilised later in life in the human prefrontal 
cortex (Colantuoni et al., 2011). Therefore, enrichment of H3K27ac and H3K4me3 marking at 
promoters and enhancers may reflect the activation of pathways essential to shaping gene 
transcription for the establishment of the neuronal network at 3 months of age, while loss of 
H3K27ac and H3K4me3 marking in neurons at 6 months of age could reflect the stabilisation 
of neuronal networks in young adult mice.  
 
The neuronal epigenome dynamically regulates core molecular functions and is enriched for 
H3K4me3 and H3K27ac in pathways to combat oxidative stress and promote experience 
dependent plasticity in the adult brain 
The mammalian cortex undergoes prolonged maturation throughout life, which is associated 
with underlying transcriptional change (Colantuoni et al., 2011). The data presented in this 
study indicate that H3K4me3 marking was enriched in 12 month old neurons compared to 6 
months of age, however there was little difference in H3K27ac marking between neurons from 
6 and 12 months of age. H3K4me3 marking was enriched at the TSS in 12 month old versus 6 
month old neurons; predominantly at TSS that contained CpG islands. However, there were 
only 1333 differentially enriched sites in neurons for H3K27ac marking between 6 and 12 
months of age. Gene ontology analysis further illustrated the pathways changing in aging 
neurons between 6 and 12 months of age. Differential enrichment for H3K4me3 was annotated 
to pathways that centred around core molecular processes for cell survival including regulation 
of oxidative phosphorylation, gene silencing, anterograde transport and chaperone-mediated 
protein folding. Many of these pathways have been previously identified to alter with brain 
aging. For example, research has demonstrated an age associated impairment of oxidative 
phosphorylation in synaptic mitochondrial fractions from ~3 month and 18 month old mice 
(Ferrándiz et al., 1994). Post-mitotic neuronal cells are particularly vulnerable to the effects of 
oxidative stress, and express anti-oxidant genes to compensate for oxidative stress (Miquel, 
Economos, Fleming, & Johnson, 1980; X. Wang et al., 2005). It has also been suggested that 
different neuronal sub-types are selectively vulnerable to the effects of oxidative stress, and 
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that the vulnerability may be due to damage or loss of mitochondria from reactive oxygen 
species (Mattiasson, Friberg, Hansson, Elmer, & Wieloch, 2003; X. Wang et al., 2005) (review: 
(Xinkun Wang & Michaelis, 2010)). Axonal transport also declines in the aging brain (Milde, 
Adalbert, Elaman, & Coleman, 2015; Takihara et al., 2015). Research has shown the duration 
and distance of mitochondrial transport to decrease in retinal ganglion cells in 12-13 month old 
mice, and again in 23-25 month old mice compared to 2 months of age (Takihara et al., 2015). 
Studies have also shown a decline in heat shock protein activity in response to misfolded 
proteins in the aging brain (Hsu, Murphy, & Kenyon, 2003). Heat shock proteins act as 
molecular chaperones to repair or remove dysfunctional proteins by refolding or degrading 
them (review: (Calderwood, Murshid, & Prince, 2009)). H3K4me3 marking may be enriched 
in these pathways to compensate for molecular degradation occurring in neurons from the aging 
brain.  
Although H3K27ac marking was differentially enriched at a small number of sites, differential 
marking was annotated to pathways for the regulation of synaptic transmission and plasticity, 
ion and neurotransmitter transport, membrane depolarisation and dendrite development. These 
pathways may be activated to support experience-dependent plasticity and adaptive 
remodelling in the adult brain (Trachtenberg et al., 2002). The pathways identified in the 
current study could also be linked to the homeostasis of intrinsic excitability, necessary to 
ensure network stability as mice learn and accumulate memories over time (review: 
(Turrigiano, 2011)). Indeed, multiple studies have shown that structural plasticity is ongoing 
in the adult brain of mammals (Bergami et al., 2015; T. Xu et al., 2009) (review: (Holtmaat & 
Svoboda, 2009)). For example, motor-based learning tasks cause rapid growth of dendritic 
spines of the motor cortex and repeat training caused stabilisation of spines in adult mice (T. 
Xu et al., 2009). Mice also exhibit a range of behavioural changes between 6 and 12 months of 
age as they mature, including decreased motor function, startle response and spatial/fear 
contextual memory, and enrichment of H3K27ac marking in neuronal specific pathways may 
reflect such behavioural changes in the adult brain (Shoji, Takao, Hattori, & Miyakawa, 2016). 
In the current study H3K4me3 marking was annotated to core molecular pathways necessary 
for the function of all cell types, whereas H3K27ac marking was mostly annotated to neuron 
specific pathways. The widespread enrichment for H3K4me3, but not H3K27ac marking in 12 
month old neurons compared to those 6 months of age was unexpected, and likely reflects the 
activation of transcriptional pathways for cellular maintenance in aging neurons, however 
further research is required to confirm this hypothesis. Strikingly, pathways related to oxidative 
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stress and DNA damage were enriched for H3K4me3 in 12 month old neurons. The subtle 
enrichment of H3K27ac marking in 12 month old neurons compared to 6 month old neurons 
may reflect ongoing experience-dependent plasticity and the accumulation of memories in the 
adult brain. 
 
H3K27ac and H3K4me3 marking is enriched in aged neurons in response to the accumulation 
of reactive oxygen species and age associated cognitive decline 
Aging is commonly associated with cognitive decline, cortical atrophy, and a loss of motor 
functions (Kalpouzos, Persson, & Nyberg, 2012; Marchand et al., 2011). In the current study, 
H3K27ac and H3K4me3 marking were compared between 12 and 24 month old neurons from 
C57/BL6 mice; characterising the differences in the neuronal epigenome between adult and 
aged neurons. Differential enrichment analysis demonstrated that both H3K27ac and 
H3K4me3 marking were enriched in neurons from 24 month compared to 12 month old mice. 
Interestingly, H3K27ac marking was enriched at the TSS in 24 month old neurons, particularly 
at TSS that contained CpG islands. H3K27ac marking was also enriched at enhancers in 
neurons from 24 months of age compared to 12 months of age. While H3K4me3 marking was 
relatively stable at TSS, there was a small redistribution of H3K4me3 marking downstream of 
the TSS in 24 month old neurons compared to 12 months of age. Enrichment for H3K27ac and 
H3K4me3 marking in 24 month old neurons may reflect transcriptional changes occurring as 
a result of age associated cognitive decline. Interestingly, differential H3K27ac marking was 
annotated to pathways involved in the maintenance of protein location, regulation of apoptosis, 
oxidative phosphorylation, RNA processing, and synaptic plasticity. While differential 
H3K4me3 marking was enriched in pathways for autophagy, RNA modification and RNA 
mediated gene silencing, and oxidative phosphorylation. Many of the differentially enriched 
pathways between 12 and 24 month old neurons have been previously implicated in aging 
research. For example, oxidative stress has been implicated as a central cause for cognitive 
decline in the aging brain by multiple mechanisms including: causing synaptic function decline 
(Serrano & Klann, 2004), selectively damaging the promoters of genes associated with synaptic 
function and vesicular transport (T. Lu et al., 2004), and causing epigenetic dysfunction and 
gene silencing (Gu, Sun, Li, Wu, & Li, 2013) (review: (Bishop, Lu, & Yankner, 2010)). RNA 
processing, modification and RNA mediated gene silencing have all been implicated in the 
aging brain. Age associated changes to aspects of RNA processing such as RNA splicing occurs 
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in healthy aging, and is dysregulated in some neurodegenerative diseases (T. Raj et al., 2018) 
(review: (Tollervey et al., 2011)). MicroRNA based gene silencing is critical to many cell 
regulatory functions including cognition, inflammation, lipid metabolism, mitochondrial 
function, and are differentially expressed in the cortex and hippocampus of the aging brain 
(Danka Mohammed, Park, Nam, & Kim, 2017). There is a range of literature suggesting that 
apoptotic pathways are dysfunctional in neurodegenerative disease (review: (Moh et al., 
2011)), and apoptosis may also have a role in cellular senescence in the aging brain (Anglade, 
Vyas, Hirsch, & Agid, 1997) (review: (Caballero & Coto-Montes, 2012)). Previous research 
has demonstrated that genes associated with synaptic function, vesicular transport and 
mitochondrial activity decline in the human frontal cortex after 40 years of age (T. Lu et al., 
2004). Moreover, as previously discussed, genes involved in oxidative stress are highly 
enriched in the aging non-human primate and human prefrontal cortex (Fraser, Khaitovich, 
Plotkin, Pääbo, & Eisen, 2005; T. Lu et al., 2004). Autophagy was also differentially marked 
by H3K4me3 in 12 versus 24 month old neurons. Autophagic pathways, encompassing the 
recognition, transport and processing of lysosomes for degeneration are generally considered 
to be neuroprotective in the aging brain (Decressac et al., 2013). However, functional decline 
of autophagic pathways has been observed in the aging brain (Lipinski et al., 2010) (review: 
(Martinez-Lopez, Athonvarangkul, & Singh, 2015)). Indeed, studies have observed an age 
associated decline in transcription for key regulators of autophagy, including type III 
phosphoinositide 3-kinase in human cortex (Lipinski et al., 2010; Loerch et al., 2008).  
A wide range of mechanisms associated with synaptic plasticity have been shown to decline in 
the aging brain, including: long-term potentiation, long-term depression and alteration of 
neurotransmitter receptor expression and trafficking (Henley & Wilkinson, 2013) (reviews: 
(Bergado & Almaguer, 2002; Burke & Barnes, 2006)). These age-related changes at the 
cellular level are thought to underlie age-associated cognitive decline (review: (Bergado & 
Almaguer, 2002; Burke & Barnes, 2006)). For example, previous literature suggests that aging 
is associated with a reduction in executive function and localised neuronal activity in the aging 
human prefrontal cortex (Cabeza, 2002), and key proteins for structural remodelling, including 
debrin, GAP-43, β3-tubulin and synaptophysin decline in the axons and dendrites of aging 
neurons (Hatanpää, Rapoport, Brady, Isaacs, & Shirao, 1999). Enrichment of H3K27ac and 
H3K4me3 marking in aging neurons may be to assist in the maintenance of synaptic 
connections, but also to ensure appropriate signalling for cellular senescence (Chinta et al., 
2015), autophagic and apoptotic pathways (review: (Caballero & Coto-Montes, 2012)). Indeed, 
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studies have also hypothesised a link between autophagic pathways aiding in the regulation of 
synaptic remodelling (Liang, 2019). 
Together these data indicate that H3K27ac and H3K4me3 are enriched in neurons late in aging 
as a compensatory mechanism for the neuronal changes that underlie age associated cognitive 
decline, and likely also to try to maintain core metabolic cellular function in the presence of 
factors such as oxidative stress and protein misfolding that increase with age.  
 
A partial recapitulation of a juvenile-like epigenetic state occurs in aged neurons 
A comparison of differential enrichment of H3K27ac and H3K4me3 marking across an aging 
time-course of 3, 6, 12 and 24 months old neurons demonstrated a large number of sites to be 
shared between juvenile and aged neurons. Surprisingly, the majority of differentially enriched 
H3K4me3 sites (20370) marked sites and a large proportion of H3K27ac marked sites (7203) 
were shared in neurons between juvenile and aged mice. This posed the question of whether 
the majority of the differentially enriched H3K27ac and H3K4me3 marked sites shared 
between juvenile and aged neurons were consistently enriched in aged and juvenile neurons, 
representing a recapitulation of a juvenile-like epigenetic state in aged neurons, or whether 
there was age associated depletion of sites that were previously enriched in juvenile neurons. 
Almost all (99%) H3K4me3 differentially marked sites shared between juvenile and aged 
neurons were consistently enriched in juvenile and aged neurons, similarly 92% of shared 
H3K27ac differentially marked sites were consistently enriched in aged and juvenile neurons. 
These data suggest that there is a partial recapitulation of a juvenile-like histone landscape in 
the aging brain, possibly as a compensatory mechanism to the effects of oxidative stress and 
age associated cognitive decline. The concept of aging associated recapitulation of a juvenile-
like epigenetic state has been proposed in previous literature (Douaud et al., 2014; Oh et al., 
2016). Studies have shown that the epigenome is divergent throughout life (Cheung et al., 
2010), but cortical aging leads to a convergence of inter-individual DNA methylation states, 
suggesting cell de-differentiation in the aging human frontal cortex (Oh et al., 2016). While a 
recent structural magnetic resonance imaging study has suggested that the grey matter structure 
of the aging brain mirrors a developmental state (Douaud et al., 2014).  
H3K27ac marking between juvenile and aged neurons was annotated to similar pathways when 
compared to the time-point specific analysis (3 versus 6 month old neurons and 12 versus 24 
month old neurons); however, specific pathways including the regulation of dendrite 
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development, cerebellum development and phosphatase activity were among the top 10 
pathways shared between juvenile and aged neurons. Genes that were identified from the gene 
ontology analysis for dendrite development and cerebellum development included Cdk5, 
Camk1/2, Ache, Shank1/3, Grin1, Efna1/3, and Ngef. For example, the Ngef gene encodes a 
guanine nucleotide exchange factor that is highly expressed in the developing mouse brain and 
is thought to contribute to dendritic spine development (Yoshizawa et al., 2003) (review: 
(Tolias, Duman, & Um, 2011)). While Efna1 and Efna3 encode ephrin tyrosine kinase genes 
which are crucial for cell migration, axon guidance signalling and cellular adhesion in 
development (review: (Palmer & Klein, 2003)). Early literature suggested that neuronal aging 
encompasses a combination of both neuronal loss and dendritic growth of the surviving neurons 
to maintain neuronal networks (S. Buell & Coleman, 1979; S. J. Buell & Coleman, 1981). More 
recently, studies have shown that neurite outgrowth increases in some aged neurons from C. 
elegans, often associated with a decrease in synaptic vesicle density (Toth et al., 2012). 
Interestingly, H3K4me3 marked sites that were shared between juvenile and aged neurons were 
annotated to pathways including protein folding, maintenance of protein location, nucleotide 
excision repair, and RNA export from nucleus, all of which are necessary for appropriate 
cellular function across life. Brain development and aging require large amounts of energy, to 
establish the nervous system during development, and maintain the nervous system during 
cellular senescence and cognitive decline. As previously discussed, oxidative stress contributes 
to age related cognitive decline. Oxidative stress is also responsible for some aspects of DNA 
damage in aging neurons (review: (Cooke, Evans, Dizdaroglu, & Lunec, 2003)). Both 
development and aging lead to accumulation of reactive oxygen species and activation of 
pathways of compensation (Driver, Kodavanti, & Mundy, 2000).  Some studies have suggested 
that age related decline in DNA repair pathways may be influenced by changes to the 
epigenome (Langie et al., 2017). Alongside DNA damage, oxidative stress can also damage 
proteins and inhibit normal protein folding, leading to activation of protein refolding and 
chaperone pathways to repair or degrade misfolded proteins (review: (Kikis, Gidalevitz, & 
Morimoto, 2010)). Neuronal development and aging require high levels of energy for neuronal 
activity; in juvenile mice for synaptic development, neurite extension and synaptic pruning 
(Handley et al., 2017) (review: (Selemon, 2013)), and for appropriate regulation of dendritic 
regression and dendrite spine loss in aging (review: (Dickstein, Weaver, Luebke, & Hof, 
2013)), which may account for some of the similarity juvenile and aged neurons. It is also 
possible that developmental pathways are reactivated in aged neurons to combat dendritic loss 
in aging (Toth et al., 2012). The recapitulation of a juvenile-like epigenetic state in aging 
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neurons may be to promote developmental pathways to combat the cellular mechanisms of age 
associated cognitive decline. 
 
Histone modifications are enriched in development and aging neurons and regulate diverse 
pathways for synaptic and core molecular functions throughout life 
This study characterised both H3K27ac and H3K4me3 in neurons across a time-course of the 
aging brain. H3K4me3 and H3K27ac marking are generally associated with active promoters 
and enhancers respectively, both of which are key regulatory regions for cellular identity and 
transcription (Creyghton et al., 2010b; Santos-Rosa et al., 2002; Z. Wang et al., 2008; Wysocka 
et al., 2006). Histone modifications have previously been characterised in post-mortem human 
aging brain and rodent brain (Benito et al., 2015; Cheung et al., 2010; Shulha et al., 2013). 
Although there were differences in methodology, sample source and bioinformatic analysis, 
there are points of agreeance between the current study and others in the literature.  
Nativio and colleagues (2018) previously identified an evolution of H4K16ac marking in the 
post-mortem lateral temporal lobe of the aging brain. H4K16ac marking was enriched at 
promoters and enhancers of actively transcribed genes and presented with a bimodal 
distribution at promoters. The study demonstrated age associated enrichment of H4K16ac 
marking between adult (~52 years old) and old (~68 years old) human lateral temporal lobe 
(Nativio et al., 2018). There were ~50000 peaks unique to the adult time-point, compared to 
127000 peaks that were unique to the aged brain (~68 years old), and ~156000 peaks shared 
between the two age groups (Nativio et al., 2018). The current study also observed age 
associated enrichment in H3K27ac and H3K4me3 marking in 24 month old neurons compared 
to 12 month old neurons. Nativio, et al., (2018) observed that H4K16ac marking was enriched 
predominantly around TSS in old cases, however there was little change in H4K16ac marking 
distal to the TSS (Nativio et al., 2018). Similarly, the current study observed less H3K4me3 
(associated with active promoters) marking at the TSS of young adult neurons at 6 months of 
age than in neurons at 12 and 24 months of age. However, the current study also observed 
H3K27ac marking (also associated with transcriptionally active promoters and enhancers) 
enriched at TSS, enhancers and super enhancers in aged 24 month old neurons compared to 
adult neurons at 6 and 12 months of age. Many of the pathways that were annotated for 
H4K16ac marking in the previous literature were also annotated for H3K27ac or H3K4me3 
marking in the current study. For example, both studies identified several similar pathways to 
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be enriched for histone marking including synaptic, cytoskeletal, autophagic and apoptosis 
related pathways (Nativio et al., 2018). Pathways that were inconsistent for histone marking 
between the two studies included many pathways for molecular function such as RNA 
signalling, oxidative phosphorylation, and gene silencing, in comparison with leukocyte, 
hydrolase, hypoxia and RAS signal transduction pathways (Nativio et al., 2018). Overall, both 
studies demonstrated enrichment of histone modifications associated with active transcription 
in the aging brain, however variances in gene ontology annotations may be due to the inherent 
differences between post-mortem human lateral temporal lobe in comparison to the mouse 
forebrain, or indeed the use of brain homogenate in comparison with isolated neuronal nuclei 
for ChIP-seq. It is also possible that H3K27ac, H3K4me3 and H4K16ac are marking diverse 
subsets of TSS and enhancers, resulting in different pathways being enriched between the two 
studies.   
To date there have been three studies that have utilised FACS to isolate neuronal nuclei for 
ChIP-seq in the aging brain (Benito et al., 2015; Cheung et al., 2010; Shulha et al., 2013). 
Isolation of neuronal nuclei has allowed for an accurate characterisation of the neuronal 
epigenome and further insight to the dynamic histone landscape in the aging brain. Benito, et 
al., (2015) performed ChIP-seq for H4K12ac marking from neurons of the CA1 hippocampus 
of C57/BL6 mice at 3 and 20 months of age. H4K12ac marking was present at the TSS of 
transcriptionally active genes and correlated with gene transcription (Benito et al., 2015; 
Lopez-Atalaya, Ito, Valor, Benito, & Barco, 2013). The study demonstrated an age associated 
depletion in H4K12ac marking at the TSS in neurons, which was not observed in glial 
populations (Benito et al., 2015). In contrast, the current study identified enrichment of 
H3K27ac and H3K4me3 marking in the aging brain. The current study observed enrichment 
of H3K27ac marking at TSS and enhancers and H3K4me3 marking at TSS in 3 month old 
neurons, that was depleted throughout adulthood at 6 and 12 months of age, then re-established 
in 24 month old neurons. It may be possible that the enrichment for H3K27ac and H3K4me3 
marking between 12 and 24 month old neurons in the current study occurs after 20 months of 
age and is missed in Benito and colleagues (2015) dataset, however it may also be possible that 
H3K27ac, H3K4me3 and H4K12ac are marking different subsets of TSS. Benito, et al., (2015) 
performed RNA-seq of the CA1 hippocampus alongside their ChIP-seq analysis and identified 
age associated enrichment in pathways relating to inflammatory responses, but depletion in 
pathways linked to core metabolic processes such as gene expression, RNA splicing and 
apoptosis. Similar to Benito, et al., (2015), the current study identified RNA splicing, and 
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apoptosis to be differentially enriched in aging neurons. However, the current study also 
identified synaptic pathways, lipid transport, oxidative phosphorylation and gene silencing to 
be enriched for H3K27ac or H3K4me3 marking in the aging brain.  
Two studies have isolated neurons and performed ChIP-seq for H3K4me3 in human prefrontal 
cortex identifying developmental enrichment and age associated decline in H3K4me3 marking 
(Cheung et al., 2010; Shulha et al., 2013). Cheung, et al., (2010) demonstrated enrichment of 
H3K4me3 marking in the cortex of young brains (0-1 year old, n=3), but depletion of 
H3K4me3 marking in neurons from aged cases (65-69 years of age, n=3). Shulha, et al., (2013) 
also performed ChIP-seq for H3K4me3 in young (prenatal, n=3) and aged (1-81 years old, 
n=25) in neurons from the human rostral prefrontal cortex. The study showed a mix of 
enrichment and depletion in prenatal development and early childhood that stabilised in 
neurons in later life (Shulha et al., 2013). In contrast, the current study showed H3K4me3 and 
H3K27ac marking was enriched in neurons at 3 months of age, but also enriched in neurons 
from the aging brain. The mice utilised in the current study between 3-6 month old are generally 
considered to be equivalent to humans between 18-30 years of age, while 18-24 month old 
mice are more similar to humans between 50-70 years of age (Fox et al., 2006; Semple et al., 
2013). In contrast to the data from Cheung (2010) and Shulha (2013), the current study 
identified H3K4me3 and H3K27ac marking to be enriched in juvenile mice, and interestingly 
also enriched in 12 and 24 month old mice for H3K4me3 marking, and 24 month old mice for 
H3K27ac marking. Due to the young age of cases from Cheung (2010) and Shulha (2013), 
much of the gene ontology and pathways identified in the study were annotated to sites for 
neurogenesis, neurite development, neuron development, synaptic plasticity and the regulation 
of cell differentiation (Cheung et al., 2010; Shulha et al., 2013). The youngest time-point 
measured in the current study did not capture the early developmental epigenome, however 
H3K4me3 and H3K27ac marking was annotated to similar pathways for synaptic plasticity and 
transmission, but also pathways for molecular function such as lipid and ion transport, RNA 
processing, and oxidative phosphorylation. Differences between the current study and previous 
literature may also be due to inherent differences that may exist in H3K4me3 marking between 
aging rodent and human neurons, brain area sampled, sample size or bioinformatic methods 
for analysis (peak calling versus differential enrichment analysis with csaw). It is also possible 
that the differences may due to the wide inter-individual variation in the epigenome that can be 
seen in post-mortem human tissue (Cheung et al., 2010), where it is necessary to identify 
confounding factors due to physical health, cognitive reserve, and age.  
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Despite the strengths of the current study, there are a few caveats to consider when interpreting 
the results. The NeuN antibody, first discovered in 1992, labels neuronal nuclei expressing the 
transcription factor FOX-3, which is present in the vast majority of neuronal nuclei in 
vertebrates (K. K. Kim, R. S. Adelstein, & S. Kawamoto, 2009; Richard J Mullen, Charles R 
Buck, & Alan M Smith, 1992). Current research into the NeuN/FOX-3 antibody shows that it 
labels the vast majority of neuronal nuclei from adult mammalian brain, first detectable during 
development after neurons withdraw from the cell-cycle (Richard J Mullen et al., 1992). 
However, there has not been extensive research into differential expression of NeuN during 
aging. Although the FACS data from the current study showed no significant differences in the 
number of NeuN+ nuclei between 3, 6, 12 and 24 months of age, it is possible that the 
distribution of NeuN changes throughout aging in the mammalian brain and this is an important 
avenue for future characterisation. Independent techniques such as immunohistochemistry and 
single-cell sequencing could be utilised for verification of the findings from the current study. 
Indeed, recent research into H3K4me3 and H3K27ac marking in the aging brain suggest that 
there are global changes in the distribution of H3K4me3 and H3K27me3 marking in NF-
positive pyramidal neurons and calretinin-positive interneurons throughout aging (Dyer, 
Phipps, Mitew, Taberlay, & Woodhouse, 2019). Dyer et al., (2019) demonstrated an age 
associated loss in H3K27ac marking in NF+ pyramidal neurons between 3 and 6 months of age 
when measured with immunohistochemistry, and an age associated enrichment in H3K27ac 
between 6 and 12 months of age. The study also identified H3K27me3 marking to significantly 
increase in calretinin labelled interneurons between 3 and 12 months of age  (Dyer et al., 2019). 
This PhD study also identified enrichment for H3K27ac marking at 3 months of age compared 
to 6 months, however little change between 6 and 12 months for H3K27ac marking. However, 
this study showed that the genomic coverage of H3K27ac to remain relatively constant until 
24 months of age. Another caveat to consider in the current study is the use of pseudo-replicates 
for bioinformatic analysis. Despite many different bioinformatics pipelines being tested and 
optimised for the analysis in this study, current pipelines are not well suited for the 
heterogenous samples seen in the mammalian brain. Although the current study performed the 
analysis similarly to previously published studies (Benito et al., 2015; Gjoneska et al., 2015; 
Nativio et al., 2018), future research could develop despoke bioinformatic pipelines to analyse 
the biological replicates and inter-individual differences to determine whether histone 
enrichment across the genome becomes more or less divergent with aging. Despite the use of 
pseudoreplicates, it is still possible that technical differences may have influenced the data, 
including potential inefficiencies between ChIPs at different time-points. Inefficiencies in ChIP 
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experiments may have influenced the results, and explain some of the differences between the 
ages identified in the current study, however all ChIP experiments and library preparation was 
performed in a single batch to minimise any technical differences. These imitations should also 
be minimized due to the use of 5 biological replicates for each genotype and timepoint to 
generate the pseudoreplicates in the current study.  
  
Conclusion 
In summary, this study identified enrichment of H3K27ac and H3K4me3 marking in juvenile 
and aged neurons compared to adult neurons. This data provides the first comprehensive 
characterisation of H3K27ac and H3K4me3 at promoters, enhancers and super-enhancers 
across a time-course of aging in neurons. Strikingly, H3K27ac and H3K4me3 dynamically 
regulate neuronal processes including synaptic plasticity, ion channel binding, transporter 
activity, calcium channel activity and cellular metabolic processes across life. These data also 
point towards a partial recapitulation of a juvenile-like epigenetic state in aging neurons, which 





Chapter 5: Alteration of the neuronal epigenome occurs 
prior to pathology onset and is altered throughout 





The epigenome is dysregulated in AD, correlating with increasing Braak stage and neuritic 
plaque load (Chapter 1.13-1.14;(P. L. De Jager et al., 2014; Lunnon et al., 2014)). Despite 
increasing research effort in this space, there have been few studies that have investigated 
histone modifications in AD (Benito et al., 2015; Gjoneska et al., 2015; Klein et al., 2019; 
Marzi et al., 2018; D. Mastroeni et al., 2013; Nativio et al., 2018), and importantly, there has 
been no investigation of the core ENCODE histone modifications in neurons in AD. 
The limited literature that is available regarding histone modifications in AD points towards 
depletion of certain histone modifications at putative enhancers and promoters associated with 
synaptic plasticity along with enrichment at immune response genes (Gjoneska et al., 2015), 
and genome-wide depletion of histone 4 lysine 16 acetylation (H4K16ac) and histone 4 lysine 
12 acetylation (H4K12ac) at transcriptional start sites (TSS) (Benito et al., 2015; Nativio et al., 
2018). There have only been five studies that performed ChIP-seq in post-mortem human or 
mouse brain, and one study that examined histone modifications with immunohistochemistry 
(Benito et al., 2015; Gjoneska et al., 2015; Klein et al., 2019; Marzi et al., 2018; D. Mastroeni 
et al., 2013; Nativio et al., 2018). An earlier study by Gjoneska and colleagues (2015) was a 
significant advance in the field at the time, in that they performed genome-wide RNA-seq and 
ChIP-seq for H3K4me1, H3K4me3, H3K27ac, H3K27me3, H3K36me3, and H4K20me1 
attempting to dissect coordinate changes in the transcriptome and histone modification 
landscape in the CK-p25 inducible neurodegeneration mouse model. This study compared 
wildtype and transgenic animals at a single 3 month old time point, after either two weeks or 
six weeks induction of Cdk5 (Gjoneska et al., 2015). The results from this study demonstrated 
a depletion of histone modifications associated with promoter and enhancer activity with genes 
involved in synaptic plasticity and the immune response and increased immune-cell-specific 
signalling pathways. ChromHMM identified enhancers were found to be upregulated at known 
AD-associated loci including Picalm, Bin1, Inpp5d, Celf1 and Ptk2b  in the CK-p25 mouse 
model (Gjoneska et al., 2015). However, the use of whole brain homogenate and the CK-p25 
model, which is associated with a range of neurodegenerative diseases, means that it is difficult 
to establish the histone modification alterations that are directly related to AD pathology, or 
identify changes that are occurring in specific cell types (Cruz, Tseng, Goldman, Shih, & Tsai, 
2003). Histone modification changes may also be due to metabolic load or the rapid pathology 
accumulation in this model. More recently, a study by Nativio et al. (2018) showed that 
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H4K16ac was enriched and accumulates with increasing age in the healthy brain, however 
interestingly, H4K16ac was depleted in the lateral-temporal-lobe in post-mortem human AD 
cases compared to controls (Nativio et al., 2018). Gene ontology analysis demonstrated that 
H4K16ac depletion occurred in pathways relating to myeloid differentiation, cell death, and 
Wnt/Ras signalling (Nativio et al., 2018). Correlating these finding with accumulating AD 
pathology led to the identification of three separate classes of change in H4K16ac marking; 
age-regulated, age-dysregulated and age-independent changes (Nativio et al., 2018). This study 
also found H4K16ac dysregulation at AD-associated quantitative trait loci curated from 
previous genome-wide association studies, finding 143 age-regulated, 231 age-dysregulated 
and 220 disease specific overlaps (Nativio et al., 2018). Another recent genome-wide study of 
H3K27ac identified 4162 sites of differential enrichment between post-mortem entorhinal 
cortex from AD cases and matched control cases (Marzi et al., 2018). This study identified 
differentially enriched sites associated with Aβ and tau pathology (APP, PS1, PS2, MAPT), 
and ontology analysis showed lipoprotein-particle binding, apolipoprotein binding, response to 
hypoxia and Aβ metabolic process to be differentially enriched for H3K27ac (Marzi et al., 
2018). In accordance with other recent literature, genome-wide analysis of H3K9ac using 
ChIP-seq in the prefrontal cortex of post-mortem AD cases has shown that tau, but not Aβ 
correlates with altered H3K9ac profile (affecting 5990 H3K9ac marked sites) at promoters and 
enhancers, leading to transcriptional changes in AD as measured by RNA-seq (Klein et al., 
2019). These data also complement an analysis of global histone modifications in post-mortem 
human brain; immunohistochemistry and Western blot demonstrate global loss of nuclear 
H3K4me3, and cytoplasmic accumulation of H3K4me3 in neurons of the hippocampus and 
middle-temporal gyrus that correlated with early markers of tau pathology and Braak staging 
in AD (D. Mastroeni et al., 2015).  
The studies reported above utilised whole brain homogenate containing a mixture of cells. The 
inherent definition of the epigenome means that it is regulated in a cell type specific manner; 
however, there has been only one study that has performed ChIP-seq in neurons in AD (Benito 
et al., 2015) and no comprehensive studies across a time-course of pathology accumulation in 
an AD model. Benito, et al., (2015) performed RNA-seq, and ChIP-seq for H4K12ac in neurons 
from the CA1 hippocampal subregion and dentate gyrus in 3 month and 20 month old 
APP/PS1-21 mice (Benito et al., 2015). These data revealed a genome-wide loss of H4K12ac 
in neurons, with dysregulation of H4K12ac leading to altered epigenetic signatures at 
regulatory elements of genes associated with synaptic plasticity and subsequent changes in 
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gene expression in neurons. These alterations occurred concomitant with enrichment of 
H4K12ac in pathways associated with an immune response in non-neuronal cells (Benito et 
al., 2015). Interestingly, administration of HDACi (SAHA) restored cognitive performance, 
stabilised H4K12ac and reduced the inflammatory response in the model (Benito et al., 2015).  
This PhD study is the first to perform a time-course experiment examining H3K4me3 and 
H3K27ac alterations in neurons from APP/PS1 transgenic AD mice compared to WT control 
mice at 3, 6, and 12 months of age, representing pre-pathology, pathology onset, and pathology 
rich time-points in this AD model.  
 
5.2 Results 
5.2.1 Histone acetylation is enriched in neurons early in the APP/PS1 mouse 
model of AD 
Histone modifications contribute to the compaction of DNA into chromatin and the access of 
transcriptional machinery to chromatin. These sites of regulation can be at promoters near TSS, 
or at distal regulatory elements. Currently, it is accepted that H3K27ac marks active enhancers 
(>2kB distal to TSS) and promoters (Rada-Iglesias et al., 2011). Core ENCODE histone 
modifications have not been characterised in neurons in AD. Here, H3K27ac was analysed in 
neurons genome-wide with ChIP-seq in the APP/PS1 mouse model of AD at 3 months of age 
representing pre-pathology, 6 months of age representing pathology onset, and 12 months of 
age, which is a pathology rich time-point in APP/PS1 mice.  
An assessment of total genomic coverage can provide an indication of histone modification 
changes occurring in neurons in APP/PS1 neurons and WT control neurons on a global scale. 
At 3 months of age, APP/PS1 neurons exhibited greater total genomic coverage for H3K27ac 
marking than WT control neurons (APP/PS1 5.94% versus WT 2.23%; Figure 5.1a); however, 
by 6 months of age, H3K27ac covered a smaller percentage of the genome in APP/PS1 neurons 
compared to WT control neurons (APP/PS1 1.38% versus WT 2.46%; Figure 5.1b). At 12 
months of age, H3K27ac exhibited greater genomic coverage in APP/PS1 neurons compared 
to WT control neurons (APP/PS1 2.72% versus WT 1.86%; Figure 5.1c). Over time, WT 
control neurons sustained a relatively consistent level of H3K27ac. By contrast, APP/PS1 
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Figure 5.1: Global dysregulation of H3K27ac in neurons prior to pathology onset in 
APP/PS1 mice 
ChIP-seq was performed for 5 biological replicates for H3K27ac per genotype, then merged 
into pseudoreplicate tracks for analysis. (a-c) Percentage of 5× genomic coverage of H3K27ac 
in neurons from APP/PS1 (red) and WT control (blue) mice at (a) 3 months, (b) 6 months and 
(c), and 12 months of age. (d-f) Volcano plots show the logFC and FDR adjusted P-value of 
APP/PS1 compared to WT control neurons; positive logFC (light green) and negative logFC 
(dark green) for all differentially enriched windows of H3K27ac marking at (d) 3 months, (e) 
6 months and (f) 12 months of age. (g-i) Representative tracks of pseudoreplicates visualised 
in IGV showing the top-ranked sites of enrichment between APP/PS1 (red) and WT control 
mice (blue). (g) The Selt promoter at 3 months of age, (h) the Kbtbd11 promoter 6 months of 
age and (i) the Brsk1 promoter at 12 months of age. (j-l) Histograms showing the logFC of the 
best window within the normalised region of H3K27ac marking in APP/PS1 neurons compared 
to WT control mice at 3 months (black), 6 months (light grey) and 12 months (dark grey) of 




Next, differential enrichment of H3K27ac was assessed genome-wide in neurons from 
APP/PS1 and WT control mice. There was an evolution of H3K27ac marking in neurons 
between WT and APP/PS1 mice across disease progression (Figure 5.1d-f). There were 35745, 
7049, and 2076 H3K27ac marked sites significantly enriched in 3, 6, and 12 month old 
APP/PS1 neurons compared to WT control neurons, respectively (Figure 5.1d-f; Benjamini 
Hochberg FDR adjusted p-value <0.05). Whereas, there were 9547, 98, and 74 differentially 
enriched H3K27ac sites depleted in APP/PS1 neurons at 3, 6, and 12 months of age, 
respectively (Figure 5.1d-f; Benjamini Hochberg FDR adjusted p-value <0.05). There was a 
progressive decline in the total number of H3K27ac differentially enriched sites across disease 
progression in APP/PS1 neurons (Figure 5.1d-f). Visualisation of H3K27ac marked sites in 
IGV showed multiple regions of differential enrichment in APP/PS1 neurons compared to WT 
control neurons. For example, the promoter of the Selt gene on chromosome 3 was 
differentially enriched for H3K27ac at 3 months of age; this gene encodes selenoprotein T, 
which is known to protect against oxidative stress in dopaminergic neurons in 
neurodegenerative disease (Figure 5.1g; (Boukhzar et al., 2016)). Similarly, in 6 month old 
neurons, the Kbtbd11 promoter on chromosome 8, encoding the Kelch Repeat and BTB domain 
containing 11 protein, was enriched for H3K27ac in neurons from APP/PS1 neurons compared 
to WT control neurons (Figure 5.1h), and at 12 months of age, Brsk1, encoding the 
Serine/theonine-protein kinase 1 transmembrane protein was enriched for H3K27ac in 
APP/PS1 neurons compared to WT control neurons (Figure 5.1i). Histograms of H3K27ac 
enrichment at the promoters of Selt, Kbtbd11, and Brsk1 at 3, 6 and 12 months demonstrated 
dynamic enrichment at these sites through pathology accumulation in APP/PS1 neurons 
compared to WT control neurons (Figure 5.1j-l).  
 
5.2.2 H3K27ac is enriched at TSS in neurons prior to pathology onset in the 
APP/PS1 mice 
H3K27ac can be present at both promoters and enhancers and is indicative of gene regulatory 
element activity (Creyghton et al., 2010b; Rada-Iglesias et al., 2011). First, the average 
distribution of H3K27ac was examined by visualising the mean abundance of reads around a 
2kb region upstream and downstream of the TSS. Here, H3K27ac marking displayed a bimodal 
distribution and the mean enrichment was higher in APP/PS1 neurons compared to WT control 
neurons at 3, 6, and 12 months of age.  
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Figure 5.2: H3K27ac enrichment occurs at transcriptional start sites in neurons from 
APP/PS1 mice prior to pathology onset 
(a-c) Average enrichment plots for H3K27ac within a 2kb window of TSS of the UCSC 
KnownGene track in APP/PS1 (red) and WT control neurons (blue) at (a) 3 months of age, (b) 
6 months of age and (c) 12 months of age. (d-f) Heatmaps of H3K27ac marking for UCSC 
KnownGene sorted by strongest (blue) to weakest (red) signal in WT (left) and APP/PS1 
neurons (right) at (d) 3 months, (e) 6 months and (f) 12 months of age. (g-i) Heatmaps of 
H3K27ac marking at CpG islands from the UCSC mm10 CpG island track sorted by strongest 
(blue) to weakest (red) signal in WT (left) and APP/PS1 neurons (right) at (g) 3 months of age, 
(h) 6 months of age, and (i) 12 months of age. (j-l) Heatmaps of H3K27ac marking at non-CpG 
containing TSS from the UCSC mm10 KnownGene track sorted by strongest (blue) to weakest 
(red) signal in WT (left) and APP/PS1 (right) at (j) 3 months of age, (k) 6 months of age, and 




The difference in signal between genotypes was greatest over the highly positioned -1 
nucleosome that sits immediately 5’- to the TSS in mammalian cells (Figure 5.2a-f). 
Quantitation of the mean enrichment plots (Figure 5.2a-c) showed that H3K27ac enrichment 
at the TSS in APP/PS1 neurons was highest at 3 months, approximately 2-fold increase 
compared to WT neurons (APP/PS1 max: 4.25; WT max: 2.04; Figure 5.2a). Whereas the mean 
H3K27ac signal at the TSS was increased approximately 0.5-fold in APP/PS1 neurons 
compared to WT control neurons at 6 months of age (APP/PS1 max: 1.62; WT max: 1.13; 
Figure 5.2b), and normalised by 12 months of age (APP/PS1 max: 1.59; WT max: 1.34, 
respectively; Figure 5.2c).  
Next, H3K27ac marking was visualised with heatmaps against the UCSC KnownGene track, 
to determine the distribution of H3K27ac at a 2kb window around TSS. At 3 months of age 
H3K27ac was enriched at a greater magnitude at TSS and in a larger proportion of TSS in 
APP/PS1 neurons (approximately 50% of TSS were enriched for H3K27ac) compared to WT 
control neurons (approximately 30% of TSS were enriched for H3K27ac; Figure 5.2d). At 6 
months of age, there was a dramatic loss of enrichment and altered distribution of H3K27ac 
from both APP/PS1 and WT neurons compared to 3 months of age. However, 6 month old 
APP/PS1 neurons were marginally enriched for H3K27ac, and marking was present at a greater 
number of TSS compared to WT control neurons (Figure 5.2e). Interestingly, at 12 months of 
age there was little change in the proportion of TSS or magnitude of H3K27ac marking in 
APP/PS1 neurons compared to WT control neurons.  
CpG islands are predominantly found at TSS and are key sites for the regulation of DNA 
methylation and transcription (review: (Deaton & Bird, 2011)). To identify whether the 
enrichment seen at all TSS was predominantly at TSS containing CpG islands, H3K27ac 
marking was generated against heatmaps for TSS that contained CpG islands, and TSS that did 
not contain CpG islands (Figure 5.2g-l). At 3 months of age, the proportion of TSS and 
magnitude of H3K27ac marking at TSS that contained CpG islands were enriched in APP/PS1 
neurons compared to WT control neurons, with marking present at approximately 80% of all 
CpG island TSS (Figure 5.2g). At 6 months of age, the magnitude and proportion of TSS that 
contained CpG islands were also enriched for H3K27ac in APP/PS1 neurons, however the 
overall magnitude of enrichment was reduced when compared to 3 months of age (Figure 5.2h). 
At 12 months of age, H3K27ac marking at TSS that contained CpG islands was similar between 
APP/PS1 neurons and WT neurons (Figure 5.2i). In comparison to CpG islands, non-CpG 
island TSS exhibited less H3K27ac marking (Figure 5.2j-l). At 3 months of age, there was a 
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minor enrichment in the proportion of TSS and magnitude of H3K27ac at non-CpG island TSS 
in APP/PS1 neurons compared to WT control neurons (Figure 5.2j), however at 6 and 12 
months of age, non-CpG island TSS exhibited minimal H3K27ac enrichment in both WT and 
APP/PS1 neurons (Figure 5.2k,l).  
Together, these results show that H3K27ac marking is enriched at TSS, and is present at a 
greater number of TSS in APP/PS1 neurons compared to WT control neurons prior to 
pathology onset at 3 months of age. The enrichment of H3K27ac at TSS in APP/PS1 neurons 
is then depleted at pathology onset at 6 months of age, and there is minimal difference between 
APP/PS1 neurons and WT control neurons in pathology rich animals at 12 months of age. TSS 
that contain CpG islands are enriched for H3K27ac in APP/PS1 neurons prior to pathology 
onset, and at pathology onset, however by 12 months of age there is minimal difference in 
H3K27ac marking at TSS that contain CpG islands when comparing APP/PS1 neurons and 
WT control neurons. 
 
5.2.3 H3K27ac is reduced at enhancers genome-wide, but enriched at the 
majority of cortical super-enhancers in neurons prior to pathology onset in 
APP/PS1 mice 
Similar to Chapter 4, to identify epigenetic modifications occurring at enhancers specifically, 
a track of all H3K27ac marking outside of a 2kb window of UCSC KnownGene TSS was 
generated and used to map ‘putative enhancers’. Herein, ‘putative enhancers’ as defined above 
will be referred to as enhancers.  
Initially the average proportion of enhancers that contained H3K27ac marking was measured 
with by visualising the mean abundance of reads around a 2kb region upstream and 
downstream of enhancer elements. At 3 months of age, average H3K27ac marking was 
depleted at enhancers in neurons from APP/PS1 animals (max: 26.96) compared to WT control 
neurons (max: 37.98) (Figure 5.3a). The mean enrichment for H3K27ac marking at enhancers 
increased in APP/PS1 neurons compared to WT control neurons at 6 months (APP/PS1 max: 
38.17; WT max: 31.32; Figure 5.3b) but was less at 12 months of age compared to WT control 
neurons (APP/PS1 max: 43.86; WT max: 45.60; Figure 5.3c). Interestingly, the average 
H3K27ac enrichment at enhancers gradually increased across the time-course in neurons from 
APP/PS1 animals up to 12 months of age; however, neurons from WT animals exhibited stable 
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H3K27ac marking at enhancers at 3 and 6 months of age, followed by enrichment at 12 months 
of age compared to 3 and 6 month time-points.  
Next, H3K27ac was visualised with heatmaps within a 2kb window of enhancers to determine 
the magnitude and proportion of enhancers containing H3K27ac marking. At 3 months of age 
H3K27ac marking and magnitude was depleted at enhancers in APP/PS1 neurons compared to 
WT control neurons, while the proportion of enhancers containing H3K27ac marking remained 
constant with the vast majority of enhancers showing H3K27ac marking in APP/PS1 and WT 
neurons (Figure 5.3d). At 6 months of age, both the magnitude and proportion of enhancers 
containing H3K27ac marking was depleted from enhancers in both APP/PS1 and WT neurons 
compared to 3 months of age. Interestingly, H3K27ac was enriched to a greater magnitude in 
APP/PS1 neurons at 6 months of age compared to WT control neurons, however the 
distribution of H3K27ac marking remained the same between APP/PS1 neurons and WT 
control neurons. Whereas at 12 months of age, there was a slight increase in the magnitude and 
no difference in the distribution of H3K27ac marking between APP/PS1 neurons and WT 
neurons (Figure 5.3f). Visualisation of differential enrichment of H3K27ac marking at 
enhancers demonstrated multiple regions of enrichment in APP/PS1 neurons compared to WT 
control neurons (Figure 5.3g-i). 
Super-enhancers are genomic regions responsible for the majority of cell-type specific gene 
expression and allow for appropriate cellular identity ((Hnisz et al., 2013; Whyte et al., 
2013);chapter 1.10). A cortical super-enhancer track was obtained from dbSUPER, a database 
of known super-enhancers to map changes in H3K27ac enrichment around known cortical 
super-enhancers (Khan & Zhang, 2016). Interestingly, H3K27ac enrichment was identified at 
the majority of cortical super-enhancers in neurons from 3, 6, and 12 month old APP/PS1 
neurons in comparison to WT controls (Figure 5.4a-f). Heatmaps for known cortical super-
enhancers showed enrichment in the magnitude and proportion of enhancers containing 
H3K27ac marking in APP/PS1 compared to WT neurons at 3 months of age (Figure 5.4a). 
Enrichment for H3K27ac at cortical super-enhancers was also present in 6 month old APP/PS1 
neurons compared to WT control neurons (Figure 5.4b). Interestingly, there was an overall 
depletion of H3K27ac marking at super-enhancers at 6 months of age compared to the 3 month 
time-point (Figure 5.4a,b). At 12 months of age, there was slight enrichment of the proportion 
and magnitude of H3K27ac marking at cortical super-enhancers in APP/PS1 neurons compared 
to WT control neurons (Figure 5.4c). At 3 months of age there were 1389 sites of differential 
H3K27ac enrichment that overlapped cortical super-enhancers; 871 sites were enriched, and 
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488 super-enhancers were depleted for H3K27ac in APP/PS1 compared to WT control neurons. 
For example, at 3 months of age, H3K27ac was enriched in APP/PS1 neurons at the super-
enhancer overlapping the Cpeb2 gene (2.23 logFC versus WT control neurons; Figure 5.4d). 
At 6 months of age, there were 697 super-enhancers enriched and 7 super-enhancer sites 
depleted of H3K27ac in APP/PS1 neurons versus WT control neurons, with the highest 
enrichment of H3K27ac in APP/PS1 neurons observed at the super-enhancer overlapping the 
Arhgef10 and Kbtbd11 genes (3.51 logFC; Figure 5.4e). Whereas at 12 months, there were only 
276 super-enhancer sites enriched for H3K27ac, and 10 sites depleted, in APP/PS1 neurons 
compared to WT neurons, with the top site of enrichment overlapping the Sept8 gene (1.91 
logFC; Figure 5.4f).  
Taken together, the proportion of enhancers and super-enhancers containing H3K27ac marking 
illustrates an inverse pattern in APP/PS1 neurons compared to WT control neurons. Prior to 
pathology onset there is an overall loss of H3K27ac marking at enhancers, but interestingly, 
enrichment of H3K27ac in cortical super-enhancers in APP/PS1 compared to WT neurons. 
However, by 12 months of age there was minimal change in H3K27ac at both enhancers and 
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Figure 5.3: H3K27ac is depleted from putative enhancers in APP/PS1 neurons prior to 
pathology onset 
(a-c) Average enrichment plots for H3K27ac within a 2kb window of putative enhancers in 
APP/PS1 (red) or WT control neurons (blue) at (a) 3 months, (b) 6 months and (c) 12 months. 
(d-f) Heatmaps for H3K27ac signal at enhancers sorted by strongest (blue) to weakest (red) 
signal in WT (left) and APP/PS1 (right) at (d) 3 months, (e) 6 months and (f) 12 months of age. 
(g-i) Representative tracks of pseudoreplicates visualised in IGV showing example enhancer 
sites of enrichment between APP/PS1 (red) and WT control mice (blue). (g) The Tbr1 enhancer 
at 3 months of age, (h) the Map7d1 enhancer at 6 months of age and (i) the Arhgef25 enhancer 
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Figure 5.4: A subset of cortical super-enhancers are enriched for H3K27ac in APP/PS1 
neurons at 3 months 
Heatmaps for the Super-Enhancer Database (dbSUPER) track were sorted by strongest (blue) 
to weakest (red) signal in WT (left) and APP/PS1 (right) mice at (a) 3 months, (b) 6 months 
and (c) 12 months of age. Representative tracks visualised using the IGV browser are shown. 
H3K27ac signal overlap was evident between APP/PS1 neurons (red) and WT control mice 
(blue) at super enhancers overlapping the top ranked differentially enriched sites including (d) 




5.2.4 H3K27ac marking of the epigenome changes in neurons at sites 
associated with synaptic plasticity and post-translational modification 
pathways 
Next, the molecular pathways and biological processes associated with differential enrichment 
of H3K27ac in neurons from APP/PS1 and WT mice was assessed using the Genomic Regions 
Enrichment of Annotations Tool (GREAT) (C. Y. McLean et al., 2010).  
This analysis revealed that several key cellular networks were disrupted in APP/PS1 neurons 
compared to WT neurons. At 3 months of age, this encompassed annotations of differential 
H3K27ac enrichment to ‘GO molecular functions’ such as ‘SNARE binding’, ‘syntaxin 
binding’, ‘polyubiquitin binding’, and ‘cholesterol binding’ (Figure 5.5a), and annotations to 
‘GO biological processes’ including ‘regulation of synaptic plasticity’, ‘regulation of mRNA 
processing’ and ‘learning’ (Figure 5.5d). These terms were mostly associated with neuronal 
specific functions and core cellular processes. At 6 months of age, differential H3K27ac 
marking in APP/PS1 neurons were annotated to ‘GO molecular function’ pathways for ‘ion 
channel binding’, ‘glutamate receptor binding’, and ‘death domain protein binding’ (Figure 
5.5b). While H3K27ac marking for ‘GO biological processes’ was annotated to ‘regulation of 
synaptic plasticity’, ‘regulation of protein complex disassembly’, ‘regulation of mRNA 
processing’ and ‘regulation of RNA splicing’ (Figure 5.5e). At 12 months of age, ‘GO 
molecular function’ terms from differential H3K27ac enrichment in APP/PS1 neurons included 
terms such as ‘glutamate receptor binding’, ‘clathrin binding’, ‘spectrin binding’ and ‘ion 
channel binding’, while differential H3K27ac annotations for ‘GO biological processes’ 
encompassed the ‘maintenance of protein location’ as well as developmental pathways such as 
the ‘regulation of dendrite development’. As an interesting proof of principal, gene ontology 
analysis was able to predict mouse phenotypes from differential H3K27ac enrichment that 
included well known characteristics of the APP/PS1 mouse model such as abnormal object 
recognition memory, abnormal dendritic spine and cell morphology, axonal transport, 
abnormal NMDA and AMPA mediated synaptic currents and synaptic plasticity (Figure 5.5g). 
Taken together, these analyses illustrated changes in H3K27ac marking at gene loci involved 
in synaptic plasticity, core cellular processes and post-translational modifications, while 
pathology burden led to altered H3K27ac marking in pathways involved in protein location 
and axonal development, possibly as a result of diminished synaptic plasticity seen in the 
APP/PS1 mouse model (Figure 5.5a-f).   
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Figure 5.5: H3K27ac alterations affects synaptic plasticity and post-translational 
modification regulatory pathways in neurons in APP/PS1 neurons 
(a-i) The top 10 gene ontology annotations, ranked by hypergeometric observed gene hits for 
sites of significant H3K27ac differential enrichment in neurons from APP/PS1 and WT control 
neurons at (a, d, g) 3 months (pre-pathology), (b, e, h) 6 months (pathology onset), and (c, f, i) 
12 month (pathology rich) time-points. Gene ontology analysis predicts dysregulated pathways 
in (a, b, c) molecular function, (d, e, f) biological processes and, (g, h, i) mouse phenotype. 
Pathways involved in synaptic function are highlighted in red, developmental GO terms are 




5.2.5 H3K27ac reprogramming occurs early and changes over time in 
APP/PS1 neurons 
To determine whether the sites of differential H3K27ac enrichment between APP/PS1 and WT 
neurons occurred at similar or different loci at each time-point, an intersection analysis of bed 
files containing all sites of significant differential enrichment at each time-point was 
performed.  
By identifying overlaps between differentially enriched sites in APP/PS1 versus WT neurons 
from the 3, 6 and 12 month time-points (5.2.1), a change of H3K27ac marking in neurons was 
observed across pathology accumulation in APP/PS1 mice (Figure 5.6). There were 50440 
H3K27ac sites of differential enrichment specific to 3 month old APP/PS1 neurons, while 2404 
sites were unique to 6 month old, and 39 sites unique to 12 month old APP/PS1 neurons (Figure 
5.6a). Interestingly, the majority of H3K27ac differentially enriched sites at the 6 and 12 month 
old time-points overlapped with those found in 3 month old neurons (5852 and 3530 sites, 
respectively; Figure 5.6a). These overlaps also included 1176 H3K27ac sites that were 
consistently differentially enriched across all timepoints examined (Figure 5.6a).  
To determine the functional pathways that shared differential H3K27ac marking over time in 
APP/PS1 neurons, functional annotation with GREAT ‘GO biological process’ was performed 
(Figure 5.6b-f). Sites of differential enrichment that were consistently altered across all time-
points were annotated to pathways including ‘regulation of dephosphorylation’, ‘protein 
acetylation’, ‘regulation of phosphatase activity’ and ‘regulation of RNA splicing’ (Figure 
5.6b). Differentially enriched sites unique to 3 month old APP/PS1 neurons were annotated to 
‘GO biological process’ pathways involved in ‘calcium ion transmembrane transport’, 
‘regulation of synaptic plasticity’, ‘membrane depolarisation’, ‘regulation of mRNA 
processing’ and ‘regulation of receptor activity’ (Figure 5.6c), while sites that were shared 
between 3 month and 6 month old neurons included ‘regulation of protein complex 
disassembly’, ‘regulation of ARF signal transduction’, ‘protein stabilisation’ and ‘regulation 
of RNA splicing’ (Figure 5.6d). Interestingly, differentially enriched sites in APP/PS1 and WT 
neurons that were common to both 3 and 12 month old timepoints included functional 
annotations for ‘protein localisation to membrane’, ‘regulation of synaptic plasticity’, 
‘regulation of dephosphorylation’, ‘calcium ion transmembrane transport’, and ‘regulation of 
dendrite development’ (Figure 5.6e). Functional annotation of sites unique to 6 month old 
APP/PS1 neurons revealed terms including the ‘negative regulation of cell projection 
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organisation’, and ‘protein deubiquitination’ (Figure 5.6f). There were no annotations for 
comparisons between 6 and 12 month old neurons, or specific to 12 month old neurons. 
Differentially enriched pathways unique to 3 and 12 month old neurons were mostly shared 
with their relative time-point specific analysis, however pathways unique to 6 months of age 
were novel compared to the time-point specific analysis. 
Next, analysis was performed to determine whether sites of differential H3K27ac marking 
shared enrichment or depletion between timepoints. Differential enrichment data from csaw 
was separated into subsets of H3K27ac sites that were enriched or depleted in APP/PS1 
compared to WT neurons, then analysed with BEDTools intersect to determine the number and 
direction of overlapping differentially H3K27ac marked sites. Comparisons between 3 and 6 
months of age showed that 75% of shared differentially marked H3K27ac sites were enriched 
in APP/PS1 neurons compared to wild-type neurons at both time-points, while less than 1% of 
differentially marked H3K27ac sites were depleted in APP/PS1 neurons at both time-points. 
24% of differentially marked H3K27ac sites were depleted in neurons at 3 months of age, but 
enriched at 6 months of age; and less than 1% differentially marked H3K27ac sites were 
enriched at 3 months of age and depleted at 6 months of age in APP/PS1 neurons. Comparisons 
between 6 months of age and 12 months of age showed that 95% of differentially marked 
H3K27ac sites were enriched in neurons at both time-points, while only less than 1% of 
differentially marked H3K27ac sites were depleted at both time-points, or depleted in 6 month 
old neurons and enriched in 12 month old neurons, but 3.7% of differentially marked H3K27ac 
sites were enriched in 6 month old neurons and depleted in 12 month old neurons.  Interestingly 
when comparing 3 months of age with 12 months of age, 70% of shared H3K27ac marked sites 
were consistently enriched in neurons at both time-points, while 2% of differentially marked 
H3K27ac sites were consistently depleted in neurons at both time-points. 27% differentially 
marked H3K27ac sites were depleted in neurons at 3 months of age, but enriched at 12 months 
of age in APP/PS1 neurons, and 2% of differentially marked H3K27ac sites were enriched in 
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Figure 5.6: Alteration of H3K27ac marking in neurons across pathology accumulation in 
APP/PS1 neurons  
(a) Venn diagram plotting the overlap in sites that were differentially enriched in APP/PS1 
versus WT neurons from 3 month, 6 month, and 12 month old pairwise comparisons. (b) 
Functional annotations for biological process for the 1176 sites that were differentially enriched 
at all time-points, (c) the 50440 sites unique to the 3 month differential enrichment analysis, 
(d) sites shared between 3 and 6 month time-points and (e) 3 and 12 months of age. (f) 
Functional annotation of biological processes from the 2404 sites unique to 6 months of age.  
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Table 5.1: H3K27ac marking is consistently enriched in pre-pathology and pathology rich 
neurons 
 Consistently Enriched Depleted 
 Enriched Depleted depleted enriched 
3 vs 6 month 3826 (75%) 20 (<1%) 31 (<1%) 1238 (24%) 
6 vs 12 month 1129 (94.9%) 9 (<1%) 45 (3.7%) 7 (<1%) 
3 vs 12 month 1501 (69.6%) 35 (1.6%) 37 (1.7%) 582 (27%) 
 
Taken together, these data demonstrate a complex pattern of H3K27ac marking across the time-
course of pathology accumulation. H3K27ac marking was highly specific at individual time-
points with over 50000 sites unique to neurons from 3 month old APP/PS1 mice. Interestingly, 
over 75% of differentially enriched H3K27ac sites were consistently enriched throughout 
pathology accumulation. These data demonstrate a partial recapitulation of a juvenile histone 
landscape in 12 month old APP/PS1 neurons.  
 
5.2.6 Differential enrichment of H3K4me3 marking prior to pathology onset, 
and with increasing age in APP/PS1 neurons  
Histone modifications contribute to the compaction of DNA into chromatin and the access of 
transcriptional machinery to chromatin. These sites of regulation can be at promoters near TSS, 
or at distal regulatory elements. Currently, it is accepted that H3K27ac marks active enhancers 
(>2kB distal to TSS) and promoters, and H3K4me3 is consistently indicative of active 
promoters (Rada-Iglesias et al., 2011). Here, H3K4me3 was analysed genome-wide with ChIP-
seq in neurons from APP/PS1 and WT mice at 3 months of age (pre-pathology), 6 months of 
age (pathology onset), and 12 months of age (pathology rich). 
Total genomic coverage assessments were performed to provide an indication of H3K4me3 
changes in APP/PS1 and WT neurons at a global scale. At 3 months of age, APP/PS1 neurons 
exhibited reduced genomic coverage of H3K4me3 compared to WT control neurons (APP/PS1 
mean: 1.98% versus WT mean: 2.94%; Figure 5.7a). However, by 6 months of age, H3K4me3 
marking increased in APP/PS1 neurons compared to WT control neurons (APP/PS1 mean: 
2.51% versus WT mean: 1.85%; Figure 5.7b), and by 12 months of age, the difference in total 
genomic coverage between APP/PS1 and WT control neurons further increased (APP/PS1 
mean: 2.71% versus WT mean: 1.91%; Figure 5.7c). WT control neurons were initially 
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enriched for H3K4me3 at 3 months of age, but marking was depleted at 6 months of age which 
was sustained until 12 months of age. Whereas APP/PS1 neurons gradually gained H3K4me3 
marking over time (Figure 5.7a-c).  
Next, differential enrichment of H3K4me3 was assessed genome-wide in neurons from 
APP/PS1 and WT control mice. There was a change in H3K4me3 marking in APP/PS1 neurons 
compared to WT control neurons across disease progression (Figure 5.7d-f). A total of 20368 
H3K4me3 sites were enriched and 3198 sites depleted in APP/PS1 neurons compared to WT 
control neurons at 3 months of age (Benjamini Hochberg FDR adjusted p-value <0.05; Figure 
5.7d). However, by 6 months of age, there were 1,171 sites enriched for H3K4me3, and 1323 
sites that were H3K4me3 depleted in APP/PS1 compared to WT neurons (Benjamini Hochberg 
FDR adjusted p-value <0.05; Figure 5.7e). Interestingly at 12 months of age, there were 26,616 
H3K4me3 marked sites differentially enriched, and 6545 sites depleted in APP/PS1 versus WT 
neurons at 12 months of age (Benjamini Hochberg FDR adjusted p-value <0.05; Figure 5.7f). 
There was widespread enrichment of H3K4me3 marking prior to pathology onset in neurons 
from APP/PS1 mice. While there was a decline in the total number of H3K4me3 marked sites 
at pathology onset, that was reversed by 12 months of age, where plaque pathology is 
widespread in the APP/PS1 mouse model. This contrasted with the reported genomic coverage 
of H3K4me3 in APP/PS1 neurons between 3 and 6 months of age (Figure 5.7a-f).  
Visualisation of H3K4me3 marked sites in IGV showed that the majority of H3K4me3 signal 
was located around the transcriptional start sites (Figure 5.7g-i). For example, the top 
differentially enriched site for H3K4me3 in 3 month old neurons was at the promoter for the 
Ncdn gene encoding Neurochondrin; this protein has known roles in neurite outgrowth and 
CaMKII phosphorylation ((Dateki et al., 2005); Figure 5.7g). At 6 months of age Csgalnact2 
was depleted in APP/PS1 neurons compared to WT control neurons. Csgalnact2a encodes the 
Chondroitin Sulfate N-Acetylgalactosaminyltransferase 2 protein, which is involved in 
chondroitin sulfate synthesis, which in turn is a component of brain extracellular matrix 
((Kwok, Warren, & Fawcett, 2012);Figure 5.7h). Interestingly, the Mark4 gene promoter was 
enriched in 12 month old APP/PS1 neurons compared to WT control neurons. Mark4 encodes 
the Microtubule Affinity Regulating Kinase 4 protein, which is known to phosphorylate 
Microtubule-Associated Protein Tau (MAPT), and is associated with early MAPT 
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Figure 5.7: H3K4me3 is dysregulated prior to pathology onset, and with increasing age 
in APP/PS1 neurons  
(a-c) Percentage 5× genomic coverage of H3K4me3 in neurons from APP/PS1 (red) and WT 
control mice (blue) at (a) 3 months, (b) 6 months and, (c) 12 months of age. (d-f) Volcano plots 
show the logFC and FDR adjusted P-value of APP/PS1 neurons compared to WT control 
neurons; positive logFC (light green), and negative logFC (dark green) for all differentially 
enriched windows of H3K4me3 marking at (d) 3 months, (e) 6 months and (f) 12 months of 
age. (g-i) Representative tracks visualised in IGV showing the top-ranked sites of enrichment 
between pseudoreplicates of APP/PS1 (red) and WT control neurons (blue). (g) The Ncdn 
promoter at 3 months of age, (h) the Csgalnact2a promoter at 6 months of age and, (i) the 
Mark4 promoter at 12 months of age. Histograms showing the logFC of the best window within 
the normalised region of H3K4me3 marking in APP/PS1 neurons compared to WT controls at 
3 months (black), 6 months (light grey) and 12 months (dark grey) for (j) the Ncdn promoter, 




Histograms of H3K4me3 enrichment at the promoters of Ncdn, Csgalnact2a, and Mark4 
demonstrated dynamic enrichment at these sites throughout pathology accumulation in 
APP/PS1 neurons compared to WT control neurons (Figure 5.7j-l) 
Taken together, these data demonstrate a dynamic pattern of differential enrichment in 
APP/PS1 compared to WT neurons across a time-course of Aβ pathology accumulation (Figure 
5.7j-l).  
 
5.2.7 H3K4me3 is enriched at TSS at pre-pathology and pathology-rich time-
points in APP/PS1 neurons 
H3K4me3 is present at promoter elements of active genes (B. E. Bernstein et al., 2005; 
Nathaniel D. Heintzman et al., 2007; Rada-Iglesias et al., 2011). Initially, the mean distribution 
of H3K4me3 was examined by visualising the mean abundance of reads around a 2kb region 
upstream and downstream of the TSS. Here, similar to H3K27ac, H3K4me3 presented with a 
bimodal distribution around the TSS of UCSC KnownGenes (Figure 5.8a-f). The average 
enrichment for H3K4me3 was greatest over the -1 nucleosome 5’- to the TSS, and H3K4me3 
marking extended 1kb into gene bodies (Figure 5.8a-c). Quantitation of the average enrichment 
plots showed that H3K4me3 enrichment was highest at 3 months in APP/PS1 neurons with an 
approximately 1.6-fold increase in signal compared to WT controls (APP/PS1 max: 11.02, WT 
max: 7.12; Figure 5.8a). Whereas at 6 months of age, H3K4me3 marking was depleted 
compared to 3 month old neurons, and H3K4me3 marking was lower in APP/PS1 neurons 
compared to WT neurons (APP/PS1 max: 2.97, WT max: 3.24; Figure 5.8b). Interestingly, by 
12 months of age, APP/PS1 neurons were enriched ~1.6-fold for H3K4me3 at the TSS 
compared to WT neurons (APP/PS1 max: 8.11, WT max: 5.17; Figure 5.8c).  
Next, H3K4me3 marking was visualised with heatmaps around a 2kb region from TSS of the 
UCSC KnownGene track. H3K4me3 marking was prominent around the TSS of approximately 
half of all sites identified by the UCSC KnownGene track. H3K4me3 marking was present up 
to 1kb upstream of the TSS and to 2kb downstream (Figure 5.8d-f). At 3 months of age 
H3K4me3 marking exhibited an increase in magnitude with similar proportion of TSS in 
APP/PS1 compared to WT neurons (Figure 5.8d). However, at 6 months of age, H3K4me3 
marking covered a similar proportion of TSS, but the magnitude was depleted in APP/PS1 
compared to WT neurons (Figure 5.8e). By 12 months of age, the magnitude and distribution 
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of H3K4me3 marking was increased in APP/PS1 neurons compared to WT control neurons, 
similar to the 3 month time-point (Figure 5.8f).  
Similar to the analysis performed for H3K27ac enrichment at TSS, H3K4me3 was mapped to 
CpG island containing TSS, and non-CpG island containing TSS to identify if there was a 
difference in H3K4me3 marking at these two types of TSS in the APP/PS1 mouse model of 
AD (Figure 5.8g-l). At 3 months of age, the distribution and magnitude H3K4me3 marking 
were enriched to a small degree in APP/PS1 neurons compared to WT controls, with marking 
present at approximately 75% of all CpG islands (Figure 5.8g). At 6 months of age, the 
magnitude and distribution H3K4me3 marking was similar between APP/PS1 and WT 
neurons, but interestingly, the overall magnitude of H3K4me3 marking was lower than in 3 
month old neurons (Figure 5.8h). At 12 months of age, the magnitude of H3K4me3 marking at 
CpG islands was enriched in APP/PS1 neurons compared to WT neurons (Figure 5.8i). In 
comparison, H3K4me3 marking at non-CpG island TSS covered approximately 20% of non-
CpG island TSS (Figure 5.8j-l). At 3 months of age, there was no difference in the distribution 
and magnitude of H3K4me3 at non-CpG island TSS in APP/PS1versus control neurons (Figure 
5.8j), which was maintained at 6 months of age (Figure 5.8k). At 12 months of age both the 
magnitude and distribution of H3K4me3 marking was slightly enriched in APP/PS1 compared 
to WT neurons (Figure 5.8l).  
Together, these results show that although there is little difference in the proportion of TSS 
containing H3K4me3 over time in APP/PS1 neurons, the marking is present in neurons at a 
greater magnitude in APP/PS1 neurons prior to pathology onset and in pathology rich neurons 
compared to WT control neurons. The majority of the differences in H3K4me3 marking are 
driven by differential enrichment found at TSS containing CpG islands. These data demonstrate 
the dynamic nature of H3K4me3 marking around TSS in APP/PS1 neurons through pathology 
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Figure 5.8: H3K4me3 is enriched at TSS at pre-pathology and pathology-rich timepoints 
in APP/PS1 neurons 
(a-c) Average enrichment plots for H3K4me3 within a 2kb window of TSS for the UCSC 
KnownGene track in APP/PS1 neurons (red) compared to WT control neurons (blue) at (a) 3 
months, (b) 6 months and (c), 12 months of age. Heatmaps of H3K4me3 marking at TSS for 
UCSC KnownGene sorted by strongest (blue) to weakest (red) signal in WT control neurons 
(left) and APP/PS1 neurons (right) at (d) 3 months, (e) 6 months and, (f) 12 months of age.  
Heatmaps of H3K4me3 marking at CpG islands from the UCSC mm10 CpG island track sorted 
by strongest (blue) to weakest (red) signal in WT (left) and APP/PS1 neurons (right) at (g) 3 
months of age, (h) 6 months of age, and (i) 12 months of age. (j-l) Heatmaps of H3K4me3 
marking at non-CpG containing TSS from the UCSC mm10 KnownGene track sorted by 
strongest (blue) to weakest (red) signal in WT (left) and APP/PS1 (right) at (j) 3 months of age, 




5.2.8 H3K4me3 is not dysregulated at enhancers in APP/PS1 neurons 
In the normal mammalian genome, H3K4me3 is generally not found at active enhancer 
elements (Local et al., 2018; Outchkourov et al., 2013; Rada-Iglesias et al., 2011). To determine 
if there was an aberrant change in the distribution of H3K4me3 marking from promoters to 
enhancers in APP/PS1 neurons, average H3K4me3 marking was mapped at a 2kb region 
around all enhancer elements marked by H3K27ac. 
Initially, the average signal for H3K4me3 showed a single peak of enrichment just downstream 
of the mid-point of enhancers that was consistent between APP/PS1 and wild type neurons 
(Figure 5.9a-c). At 3 months, there was ~0.84-fold enrichment of H3K4me3 at enhancers in 
APP/PS1 neurons compared to WT controls (APP/PS1 max: 67.05, WT max: 56.33; Figure 
5.9a). While at 6 months of age, APP/PS1 and WT neurons had similar levels of H3K4me3 
marking at enhancers (APP/PS1 max: 55.46, WT max: 54.42; Figure 5.9c). At 12 months of 
age, APP/PS1 neurons were ~0.81-fold depleted for H3K4me3 at enhancers compared to WT 
neurons (APP/PS1 max: 51.27, WT max: 63.43; Figure 5.9c).  
Next, H3K4me3 was mapped against enhancers and visualised with heatmaps within a 2kb 
window of the mid-point of enhancers. The magnitude of H3K4me3 marking was highly 
enriched at a small proportion of enhancers in both APP/PS1 neurons and WT neurons at all 
time-points (Figure 5.9d-f). The magnitude of H3K4me3 enrichment at enhancers was also 
similar between APP/PS1 and WT neurons at 3, 6 and 12 months of age (Figure 5.9d-f). 
Taken together, these data demonstrate that H3K4me3 marking is not dysregulated at 
enhancers in APP/PS1 neurons, and there is a small subset of enhancers highly enriched for 
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Figure 5.9: H3K4me3 marking is not dysregulated at enhancers in APP/PS1 neurons 
(a-c) Average enrichment plots for H3K4me3 within a 2kb window of putative enhancers in 
APP/PS1 (red) or WT (blue) at (a) 3 months, (b) 6 months and (c), 12 months of age. Heatmaps 
for H3K4me3 signal in putative enhancers sorted by strongest to weakest signal in WT control 
neurons (left) and APP/PS1 neurons (right) at (d) 3 months, (e) 6 months and, (f) 12 months of 




5.2.9 H3K4me3 marking is enriched at sites associated with core molecular 
processes in APP/PS1 neurons 
Gene ontology allows for the prediction of molecular pathways changing as a result of altered 
transcriptional regulation. Here, the ‘GO molecular function’ and the ‘GO biological process’ 
were assessed for the sites of differential H3K4me3 enrichment in APP/PS1 neurons and WT 
control neurons at 3, 6, and 12 months of age using GREAT as previously described (Chapter 
2.23).  
Gene ontology analysis demonstrated that differential enrichment of H3K4me3 in APP/PS1 
neurons was annotated to pathways pertaining to core metabolic processes such as RNA 
modifications and post-translational modifications (Figure 5.10a-e). For example, at 3 months 
of age, ‘GO molecular function’ annotation of H3K4me3 differential enrichment was annotated 
to molecular pathways for ‘unfolded protein binding’, ‘rRNA binding’ and ‘RNA polymerase 
II carboy-terminal domain kinase activity’ among others, and interestingly, ‘histone 
methyltransferase activity (H3K4 specific)’ was also annotated (Figure 5.10a). Whereas at 12 
months of age, the top pathways identified by ‘GO molecular function’ also included ‘RNA 
polymerase II carboxy-terminal domain kinase activity’, ‘mannosyltransferase activity’ and 
‘glutathione peroxidase activity’, but also included ‘TBP-class protein binding’, and ‘protein 
transmembrane transporter activity’ (Figure 5.10b). Analysis of ‘GO biological process’ for 
differentially enriched H3K4me3 sites in 3 month old APP/PS1 neurons identified processes 
including ‘GPI anchor metabolic process’, ‘regulation of gene silencing’, ‘tRNA modification’ 
and interestingly, ‘mRNA stabilisation’ and ‘regulation of protein dephosphorylation’ (Figure 
5.10c). Meanwhile at 12 months of age, pathways identified by ‘GO biological process’ 
included ‘antigen processing and presentation of exogenous peptide antigen’, ‘de novo post-
translational protein folding’ and ‘protein refolding’ (Figure 5.10d). At 6 months of age, gene 
ontology analysis could not be performed due to the small number of differentially enriched 
sites, however a summary of the top sites of differential enrichment demonstrated overlap with 
genes involved in protein modification, ion channel maintenance, and core cell regulatory 
pathways (Figure 5.10e). 
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Chr Start position End position FDR Direction Gene Function (Entrez)
chr6 118138101 118139800 8.12E-6 down Csgalnact2
Involved in elongation during chondroitin sulfate 
synthesis.
chr13 113614751 113618700 1.28E-5 up Snx18
Member of sorting nexin family. Phosphoinositide 
binding domain, involved in intracellular trafficiking.
chr9 27790201 27794850 6.89E-5 up Opcml
Products include opioid binding-cell adhesion mole-
cule. Member of immunoglobulin protein superfamily.
chr11 29718401 29720800 7.28E-5 up Rtn4
Associated with endoplasmic retiuculum, invoved in 
neuroendocrine secretion and membrane trafficiking. 
May block neurite outgrowth
chr10 107271251 107273550 7.28E-5 down Lin7a
Generation and maintenance of channels and recep-
tors in the membrane. Protein products assist with 
channel localisation and synaptic vesicle exocytosis.
chr9 106477201 106478400 8.79E-5 down Parp3
Poly-ADP-ribosylation producing gene. Products 
required for DNA repair and regulation of apoptosis. 
chr15 95524951 95529200 8.79E-5 down Nell2
Encodes for a glycoprotein. Homotrimer found in 
the cytoplasm. May regulate neural cell growth and 
differentiation.
chr2 25316201 25319250 8.79E-5 up Grin1
Encodes a critical subunit for NMDA receptors and 
complexes to form ligand-gated ion channels. Assists 
in the regulation of synaptic plasticity.
chr19 10895101 10897000 9.23E-5 down Prpf19
Gene products are essential for cell survival and DNA 
repair. 
chr3 84951501 84958300 9.26E-5 up Fbxw7
F-box protein - subunit for ubiquitin protein ligase 
complex. 
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Figure 5.10: H3K4me3 marking occurs at promoters responsible for core molecular and 
post-transcriptional modification pathways 
(a-e) The top 10 gene ontology predictions ranked by hypergeometric observed gene hits for 
sites of significant H3K4me3 differential enrichment in neurons from APP/PS1 and WT 
control neurons at (a,c) 3 months (pre-pathology) and, (b,d) 12 month (pathology rich) time-
points. Gene ontology annotates differentially enriched H3K4me3 sites in APP/PS1 neurons 
compared to WT control neurons to (a,b) molecular function and, (c,d) biological processes. 
(e) The top 10 differentially enriched sites between APP/PS1 and WT neurons at 6 months of 




5.2.10 H3K4me3 differential enrichment peaks at pre-pathology and 
pathology rich time-points in APP/PS1 neurons 
A comparison of sites that were differentially enriched for H3K4me3 between APP/PS1 and 
WT neurons at 3, 6, and 12 months of age was performed to determine if there are sites that 
overlap. This analysis demonstrated altered H3K4me3 binding through pathology onset and 
progression in APP/PS1 neurons. Initially, there were 35864 sites of H3K4me3 differential 
enrichment specific to 3 month old APP/PS1 neurons, while 572 sites were unique to 6 month 
old, and 19207 sites unique to 12 month old APP/PS1 neurons (Figure 5.11a). Interestingly, 
the majority of H3K4me3 differentially marked sites at 12 months of age overlapped with those 
at 3 months of age (16890 sites; Figure 5.11a), while there were 1833 sites that were 
differentially enriched at all time-points in APP/PS1 neurons compared to WT neurons (Figure 
5.11a).  
Gene ontology analysis was performed for all overlapping H3K4me3 marked sites. Gene 
ontology analysis for ‘GO biological process’ identified H3K4me3 marked sites unique to 3 
months of age were annotated to pathways such as ‘unfolded protein binding’, ‘nuclear export’ 
and ‘spindle assembly’ (Figure 5.11b). Whereas H3K4me3 marked sites unique to 12 months 
of age were annotated to pathways involved in ‘chemosensory behaviour’, ‘regulation of B cell 
receptor signalling pathway’ and ‘mitochondrial calcium ion homeostasis’. H3K4me3 marked 
sites shared between 3 and 12 months of age were annotated to biological processes including 
‘protein folding’, ‘porphyrin-containing compound metabolic process’, ‘macroautophagy’, and 
interestingly ‘tRNA modification’ and the ‘regulation of gene silencing’ (Figure 5.11c). There 
were no pathways annotated for H3K4me3 marking from the remaining overlap comparisons 
between 3 and 6 months, 6 and 12 months, and shared between all time-points. Next, an 
assessment of the overlapping H3K4me3 differentially enriched sites was performed to 
determine whether the shared sites were indicating a recapitulation of the juvenile epigenome 
or dysregulation at sites from the juvenile epigenome. H3K4me3 differential enrichment data 
was subset into enrichment or depletion and an overlap analysis was performed with 
BEDTools. At 3 months of age, 35% of H3K4me3 differentially marked sites that were also 
enriched in 6 month old APP/PS1 neurons compared to wild-type neurons, and less than 1% 
of shared sites were depleted in both 3 month and 6 month old APP/PS1 neurons.  
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Figure 5.11: H3K4me3 differential enrichment peaks at pre-pathology and pathology-
rich time-points in APP/PS1 neurons 
(a) Venn diagram plotting the overlap for differentially enriched H3K4me3 sites in APP/PS1 
versus WT neurons from 3, 6, and 12 months of age. (b) Functional annotations for ‘GO 
biological process’ for the 35864 sites unique to 3 months differential enrichment analysis, (c) 
the 19207 sites unique to 12 month differential binding analysis and, (d) sites shared between 




Approximately 62% of differentially marked H3K4me3 sites shared between 3 and 6 months 
of age were enriched in 3 month old APP/PS1 neurons compared to wild-type neurons, but 
depleted in 6 month old APP/PS1 neurons. 28% of H3K4me3 differentially marked sites were 
enriched in both 6 month, and 12 month old APP/PS1 neurons. While ~10% of H3K4me3 
differentially marked sites were enriched at 6 months of age but depleted at 12 months of age, 
and 60% of H3K4me3 differentially marked sites were depleted at 6 months of age but enriched 
at 12 months of age in APP/PS1 neurons. There were far more sites overlapping between 3 
months of age and 12 months of age: ~90% H3K4me3 differentially marked sites were enriched 
in both 3 month and 12 months old APP/PS1 neurons (including sites identified to be shared 
between all time-points), while only 1.4% of sites were depleted at both time-points in 
APP/PS1 neurons.  
Table 5.2: H3K4me3 marking is consistently enriched in pre-pathology and pathology 
rich neurons 
 Consistently Enriched Depleted 
 Enriched Depleted depleted enriched 
3 vs 6 month 693 (35.4%)  7 (<1%) 1220 (62.4%) 36 (1.8%) 
6 vs 12 month 567 (28.6%) 15 (<1%) 206 (10.4%) 1195 (60.3%) 
3 vs 12 month 14104 (89.5%) 222 (1.4%) 1220 (7.7%) 205 (1.3%) 
 
Taken together, these data demonstrate that H3K4me3 enrichment peaked in neurons prior to 
pathology onset and in pathology rich neurons. H3K4me3 marking was highly specific at 3 and 
12 months of age, although more than 15000 sites were shared between 3 and 12 month old 
neurons, of which the vast majority were consistently enriched in both time points. These data 





5.2.11 H3K27ac and H3K4me3 are enriched in known AD risk variants  
Previous studies have shown that histone modifications are dysregulated at known AD risk loci 
in mouse models and post-mortem human entorhinal cortex from AD cases (Gjoneska et al., 
2015; Marzi et al., 2018). To determine whether H3K27ac or H3K4me3 marking was 
dysregulated at sites of known AD risk variants, differentially enriched H3K27ac and 
H3K4me3 marked sites from APP/PS1 neurons were annotated to known AD risk variants 
(Giri, Zhang, & Lü, 2016). H3K4me3 and H3K27ac marking were enriched at 22 AD risk 
variant loci in neurons from APP/PS1 mice, including well-established loci from previous 
genome-wide association studies; Bin1, Clu and Picalm (Table 5.3) (Harold et al., 2009; 
Seshadri et al., 2010). Risk loci including Clu, Cr1, Bin1, Cd2ap, Picalm, Mef2c, Cass4, 
Zcwpw1, Celf1, Fermt2, Slc24a4, Pld3, Unc5c, Akap9, Adam10 were enriched for H3K27ac 
marking in APP/PS1 neurons at 3 months of age (Table 5.3). While Clu, Sorl1, Cr1, Bin1, 
Cd2ap, Picalm, Epha1, Inpp5d, Ptk2b, Zcwpw1, Celf1, Fermt2, Slc24a4, Pld3, Unc5c, Akap9 
and Adam10 were enriched for H3K4me3 marking in 3 month old APP/PS1 neurons. 
Interestingly Clu, Sorl1, Bin1, Cd2ap, Mef2c, Ptk2b, Celf1, Fermt2, Scl24a4, and Unc5c were 
enriched for H3K27ac marking in 6 month old APP/PS1 neurons, while Sorl1 was the only risk 
loci that was enriched for H3K4me3 marking in APP/PS1 neurons at 6 months of age. At 12 
months of age, H3K27ac marking was enriched in neurons at Bin1, Cd2ap, Picalm, Ptk2b, 
Celf1, and Unc5c loci. While Bin1, Cd2ap, Picalm, Mef2c, Ptk2b, Zcwpw1, Celf1, Fermt2, 
Slc24a4, Pld3 and Unc5c were enriched for H3K4me3 marking in 12 month old APP/PS1 
neurons. 7 of the 22 annotated AD risk alleles were depleted for H3K4me3 or H3K27ac 
marking in APP/PS1 neurons. At 3 months of age, Mef2c was depleted for H3K4me3 marking, 
while Sorl1, Inpp5d, and Ptk2b were depleted for H3K27ac marking in APP/PS1 neurons. At 
6 months of age, H3K4me3 marking was depleted from Picalm, Celf1, and Pld3 risk loci in 
APP/PS1 neurons, and no risk loci were depleted for H3K27ac marking, similar to 12 months 
of age, where no AD risk loci were depleted for H3K4me3 or H3K27ac marking in APP/PS1 
neurons.  
In summary, known AD risk loci are dysregulated in neurons from APP/PS1 mice, including 
well established risk loci from genome-wide association studies such as Clu, Picalm and Bin1. 
The majority of AD risk loci were significantly enriched for H3K27ac and H3K4me3 marking 
in APP/PS1 neurons, while few risk loci were depleted for H3K27ac and H3K4me3 marking 
in APP/PS1 neurons. Surprisingly, AD risk loci were enriched for H3K27ac and H3K4me3 
prior to pathology onset.  
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Table 5.3: H3K4me3 and H3K27ac are differentially enriched at AD risk loci 












Clu Synapse turnover, 
chaperone protein 
Enriched - Enriched Enriched Enriched - 
Abca7 Phagocytosis, lipid 
homeostasis 
- - Enriched - - - 
Sorl1 Endocytosis, receptor for 
APOE, processing of 
APP 
Enriched Enriched Enriched Depleted Enriched - 
Cr1 Amyloid β clearance, 
complement activation 
Enriched - Enriched Enriched - - 
Ms4a Signal transduction, 
immune function 
- - Enriched - - - 
Bin1 Synaptic vesicle, APP 
trafficking, cytoskeletal 
dynamics 




Enriched - Enriched Enriched Enriched Enriched 
Picalm Clathrin-mediated 
endocytosis 
Enriched Depleted Enriched Enriched - Enriched 
Epha1 Synaptic development, 
immune function, neural 
development 
Enriched - - - - - 
Inpp5d Cytokine signaling, 
immune function 
Enriched - - Depleted - - 
Mef2c Myogenesis, synapse 
formation 
Depleted - Enriched Enriched Enriched - 
Cass4 Cell migration, cell 
adhesion 
- - - Enriched - - 
Ptk2b Calcium homeostasis, 
MAP kinase signalling 
Enriched - Enriched Depleted Enriched Enriched 
Zcwpw1 Epigenetic regulation, 
neural development 
Enriched - Enriched Enriched - - 
Celf1 mRNA editing, pre-
mRNA splicing 
Enriched Depleted Enriched Enriched Enriched Enriched 
Fermt2 Cell–cell adhesion, 
angiogenesis 
Enriched - Enriched Enriched Enriched - 
Slc24a4 Cell signalling, neural 
development 
Enriched - Enriched Enriched Enriched - 
Pld3 Signal transduction, 
epigenetic modification 
Enriched Depleted Enriched Enriched - - 
Unc5c Neural development Enriched - Enriched Enriched Enriched Enriched 




Enriched - Enriched Enriched - - 
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5.2.12 H3K27ac and H3K4me3 enriched sites are transcribed in human AD 
cases 
Recently, studies have utilised single cell sequencing techniques to show differential 
expression of RNA transcripts in numerous cell-types between age matched controls and AD 
cases, demonstrating cell-type specific transcriptional dysregulation in AD (Mathys et al., 
2019). To validate the data in the current study, a comparison between the neuronal 
transcriptomic data from Mathys, et al., (2019) and the genes that were differentially enriched 
for H3K27ac and H3K4me3 marking in 12 month APP/PS1 neurons was performed. 5802 of 
the 6550 genes that were differentially expressed (88%) in human neurons between control and 
AD cases identified by Mathys, et al., (2019) were identified as having differential enrichment 
of H3K4me3 between wild-type and APP/PS1 neurons (Figure 5.12a). Furthermore 5793 of 
the 6557 (88.3%) genes that were differentially expressed in neurons between human control 
and early AD cases (Mathys et al., 2019) were differentially enriched for H3K4me3 marking 
between wild-type and APP/PS1 neurons (Figure 5.12b). However, 872 of 6550 genes (13.3%) 
that were differentially expressed between neurons from control versus AD cases were 
identified as having differential enrichment for H3K27ac marking in APP/PS1 neurons versus 
wild-type neurons (Figure 5.12c). Finally, 876 of 6557 genes (13.3%) that were differentially 
expressed between neurons from human control versus early AD cases also exhibited 
differential enrichment for H3K27ac marking in wild-type neurons versus APP/PS1 neurons 
(Figure 5.12d). Of note, as the number of genes that were differentially enriched for H3K4me3 
and H3K27ac marking between wild-type and APP/PS1 neurons in this study were 15228 and 
1854, respectively, this represents ~38% and ~47% overlap of the mouse data with 
differentially expressed genes between human control and AD neurons.  
Taken together, these data validate the differential enrichment from H3K4me3 and H3K27ac 
ChIP-seq experiments and demonstrate that H3K4me3 and H3K27ac marking from APP/PS1 
neurons can somewhat predict changes in gene expression in human neurons in AD. 
Furthermore, these data suggest that the changes in chromatin structure identified in the current 


















Figure 5.12: Genes differentially enriched for H3K27ac and H3K4me3 marking are also 
differentially expressed in human AD 
(a) Venn diagram plotting the overlap of genes differentially enriched for H3K4me3 marking 
in 12 month old wild-type versus APP/PS1 neurons (blue) compared to differentially expressed 
genes in neurons from human control versus AD cases (purple). (b) Venn diagram plotting the 
overlap for genes with differential H3K4me3 marking in 12 month old wild-type versus 
APP/PS1 neurons (blue) compared to differentially expressed genes from human control 
neurons versus those in early-AD cases (purple). (c) Venn diagram plotting the overlap of genes 
differentially enriched for H3K27ac marking in neurons from 12 month old wild-type versus 
APP/PS1 mice (blue) compared to differentially expressed genes in human neurons in aged 
controls versus AD cases (purple). (d) Venn diagram plotting the overlap for genes 
differentially enriched for H3K27ac in 12 month old wild-type neurons versus APP/PS1 
neurons (blue) compared to differentially expressed genes from human neurons in controls 




This study was the first to characterise both H3K27ac and H3K4me3 marking in neurons from 
APP/PS1 transgenic AD mice and WT control mice at 3, 6, and 12 months of age, representing 
pre-pathology, pathology onset, and pathology rich time-points in this amyloidosis model 
(Garcia-Alloza et al., 2006; Jankowsky et al., 2004). These data demonstrated widespread 
enrichment for H3K4me3 marking prior to pathology onset and in pathology rich cases in 
APP/PS1 neurons, while the majority of differential H3K27ac marking in APP/PS1 neurons 
occurred prior to or at pathology onset with few changes in pathology rich cases compared to 
WT control neurons. Furthermore, gene ontology analysis showed epigenetic dysregulation to 
be occurring at the promoters for key neuronal pathways implicated in the regulation of 
synaptic plasticity, as well as core molecular pathways for post-transcriptional modifications 
in APP/PS1 neurons compared to WT control neurons. Strikingly, a partial recapitulation of 
the juvenile epigenome was observed in APP/PS1 neurons in pathology rich cases.  
 
Soluble Aβ may contribute to dysregulation of the neuronal epigenetic landscape pre-
pathology in APP/PS1 mice 
APP/PS1 mice at 3 months of age represents a pre-pathology time-point (Garcia-Alloza et al., 
2006; Jankowsky et al., 2004). Surprisingly, the epigenome was highly dynamic in neurons 
from 3 month old APP/PS1 mice compared to WT control mice. Widespread enrichment of 
H3K27ac and H3K4me3 marking was observed across the genome in APP/PS1 neurons 
compared to WT control neurons. The enrichment of H3K27ac and H3K4me3 marking is 
generally associated with increased transcriptional activity (Creyghton et al., 2010b; Santos-
Rosa et al., 2002; Z. Wang et al., 2008; Wysocka et al., 2006). Differential H3K4me3 marking 
was concentrated at the TSS of 3 month old APP/PS1 neurons, and specifically at CpG island 
containing TSS, and was not abnormally located at enhancer elements. Alongside enrichment 
at promoters at 3 months of age, H3K27ac marking was also depleted from enhancers, and 
interestingly, enriched at known cortical super enhancers in neurons from APP/PS1 mice. 
Super enhancers are large clusters of transcriptional enhancers that drive expression of genes 
that regulate cellular identity, maintain pluripotent state, and control differentiation from 
pluripotent stem-cells to terminally differentiated cell-types (Hnisz et al., 2013; Whyte et al., 
2013). There have been 389 cortical super enhancers identified to date that regulate cell-type 
specific gene expression in the cortex (Khan & Zhang, 2016). The redistribution of neuronal 
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H3K27ac marking in APP/PS1 mice from enhancers to super-enhancers in the current study 
may indicate a loss of normal neuronal gene function. This was further illustrated by 
differential H3K27ac marking in neurons from APP/PS1 mice being annotated to pathways for 
the regulation of synaptic plasticity, membrane depolarisation, neurotransmitter secretion and 
calcium ion transmembrane transport at 3 months of age. Dysregulation of super-enhancers has 
also been previously identified in Huntington’s disease, altering genes involved in neuronal 
identity (Achour et al., 2015; Le Gras et al., 2017), and a single study has identified a range of 
AD associated single nucleotide polymorphisms to overlap known super-enhancers, including 
super enhancers for BIN1, which was identified to be differentially enriched for histone 
marking in the current study and has been previously implicated in AD (Chapuis et al., 2013; 
Hnisz et al., 2013). However, as super-enhancers have only recently been discovered this is the 
first study of the epigenetic regulation around super-enhancers in AD to date.  
Strikingly, there was widespread disruption of histone marking in neurons from APP/PS1 mice 
at 3 months of age. APP/PS1 mice harbour familial AD transgenes that are over-expressed 
from birth (Garcia-Alloza et al., 2006). Although Aβ plaque accumulation does not occur until 
approximately 6 months of age in APP/PS1 mice, soluble oligomeric Aβ can be detected as 
early as 1-2 months of age (Garcia-Alloza et al., 2006; Trinchese et al., 2004). Previous 
literature has demonstrated soluble oligomeric Aβ to be neurotoxic in mouse brain slice 
cultures at nanomolar doses, disrupt cognitive function and learned behaviour, and disrupt 
long-term potentiation in mice and rat hippocampal slices (James P. Cleary et al., 2004; Koffie 
et al., 2009a; Mota, Ferreira, Pereira, Oliveira, & Rego, 2012; Walsh et al., 2002; H. W. Wang 
et al., 2002) (review:(John Hardy & Selkoe, 2002)). Thus, the altered distribution of H3K27ac 
and H3K4me3 in APP/PS1 neurons at 3 months of age is likely due, at least in part, to the 
accumulation of soluble Aβ. This current study (including data in Chapter 4 and Chapter 5) has 
demonstrated that the epigenome is highly dynamic in neurons at 3 months of age. Thus, an 
alternate, but not mutually exclusive hypothesis is that the accumulation of soluble Aβ may 
have disrupted the maturation of the neuronal epigenome at 3 months of age. This is also 
supported by emerging literature that has shown that pyramidal neurons in the cortex are still 
undergoing synaptic pruning at 3 months of age (Handley et al., 2017). It is likely that some of 
the differences between 3 and 6 month old neurons represent an age of transition between 
juvenile and young adult mice. Total brain volume dramatically increases up to 3 months of 
age, though myelination is still occurring between 3 and 6 months of age (Fu et al., 2013). 
Adult levels of neurotransmitters and synaptic density stabilise after 3 months of age in mice, 
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which is associated with the emergence of adult behavioural tendencies such as reduced risk 
taking and increased parental tendencies (Fu et al., 2013) (review: (Semple et al., 2013). 
Differential enrichment of H3K27ac in 3 month old APP/PS1 neurons was annotated to 
pathways involved in synaptic plasticity, calcium ion transport, membrane depolarisation, and 
mRNA processing. These findings are supported by previous AD literature. Alterations to 
synaptic transmission have been observed in APP/PS1 mice prior to pathology onset (Trinchese 
et al., 2004; Unger et al., 2016). Interestingly, exposure of soluble oligomeric Aβ also impaired 
long-term potentiation in hippocampal slices of 2-3 month old C57/BL6 mice (Puzzo et al., 
2005; Shankar et al., 2008). Intracellular calcium homeostasis and calcium signalling have also 
been implicated in AD (reviews: (Demuro, Parker, & Stutzmann, 2010; Magi et al., 2016)). In 
line with the gene ontology data presented in the current study, it has been previously suggested 
that Aβ oligomers can form calcium-permeable channels in membranes that reduce synaptic 
plasticity and cause cytotoxicity in APPswe, and 3xTg mouse models of AD (Arispe, Pollard, 
& Rojas, 1993; Lopez et al., 2008). However, previous literature has also reported that 3 month 
old APP/PS1 mice do not show elevated calcium levels (Kuchibhotla et al., 2008). Taken 
together, these data indicate that soluble Aβ may be causing disruption to the neuronal 
epigenome prior to pathology onset in neurons from APP/PS1 mice.  
Interestingly, gene ontology analysis of differential H3K4me3 marking indicated that pathways 
associated with RNA modification and stabilisation, gene silencing, protein localisation, and 
dephosphorylation were disrupted in 3 month old APP/PS1 neurons. Many of these pathways 
identified in the current study have been implicated in the AD literature. Indeed, some aspects 
of RNA processing, such as RNA splicing are dysregulated in AD, with accumulation of 
unspliced RNA products accumulating in the post-mortem human frontal cortex (Bing Bai et 
al., 2013). Hyperphosphorylation is widely implicated in AD literature. For example, paired 
helical filaments of hyperphosphorylated tau is a pathological hallmark of AD, resulting in 
disruption to microtubules and altered cytoskeletal integrity (Arriagada et al., 1992; Berg et al., 
1998; M. E. Murray et al., 2015). While NFTs are not observed in APP/PS1 mice, neuritic 
processes containing hyperphosphorylated tau have been reported in 8 month old APP/PS1 
mice (Maia et al., 2013; Radde et al., 2006). It is possible that soluble Aβ dysregulates common 
phosphorylation pathways, resulting in altered histone phosphorylation and epigenetic 
regulation of the transcriptome, or alternatively acetylation and aceylation of proteins is 
disrupted in AD (reviews: (Banerjee & Chakravarti, 2011; Rossetto, Avvakumov, & Côté, 
2012)). Gene ontology data for differential H3K4me3 marking in 3 month old APP/PS1 
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neurons also identified gene silencing pathways as disrupted in AD. The genes associated with 
this term included Tet1, Sirt1, Cdk2, Apobec1, Sin3a, Phf2/8, Tnrc6c and the Hist1h family, 
many of which are involved in epigenetic regulation of transcription. Interestingly, epigenetic 
silencing of pathways involved in Aβ production have been implicated as an intervention to 
slow amyloid deposition (Scarpa, Fuso, D'Anselmi, & Cavallaro, 2003). It is possible that gene 
silencing pathways are altered in 3 month old APP/PS1 neurons, potentially to compensate for 
the overexpression of familial AD transgenes from birth in APP/PS1 mice. Alternatively, it is 
also possible that the change in histone marking that was observed in 3 month old neurons is a 
consequence of other epigenetic and chromatin changes that were not examined in the current 
study.  
 
Pathology onset is associated with enrichment of H3K27ac marking in APP/PS1 neurons at 
enhancers and neuronal super-enhancers, potentially to promote neuronal function 
6 month old APP/PS1 mice exhibit the appearance of Aβ plaque pathology, and represent 
pathology onset in this amyloidosis model (Garcia-Alloza et al., 2006; Jankowsky et al., 2004). 
Differential enrichment analysis showed that H3K27ac marked sites were enriched in APP/PS1 
neurons compared to WT control neurons at 6 months of age, however there was minimal 
change in H3K4me3 marking in 6 month old APP/PS1 neurons. At 6 months of age H3K27ac 
marking was slightly enriched at TSS in APP/PS1 neurons compared to WT controls, while 
there was no change in H3K4me3 enrichment at TSS in APP/PS1 neurons. Interestingly, at 6 
months of age H3K27ac marking was enriched at enhancers and super-enhancers in APP/PS1 
neurons compared to WT control neurons. Enrichment of H3K27ac at TSS, enhancers, and 
super enhancers in APP/PS1 neurons at 6 months of age may be due to the activation of 
neuronal specific functions, potentially as a compensatory mechanism to Aβ plaque 
accumulation (Hnisz et al., 2013; Whyte et al., 2013). The enrichment of H3K27ac marking in 
pathways from neuronal specific functions at 6 months of age could be associated with Aβ 
plaque deposition and the associated disruption to the neuropil, including plaque-associated 
synapse loss and dystrophic neurites (Garcia-Alloza et al., 2006; Jankowsky et al., 2004; Mitew 
et al., 2013a, 2013b). Furthermore, soluble Aβ would still be present in the brain at 6 months 
of age leading to disruption to neuronal connections. For instance, dendritic spine loss is known 
to begin in the presence of soluble Aβ prior to plaque formation, and dendritic spines loss 
persists in pathology rich APP/PS1 brains (Bittner et al., 2012).  
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Differential H3K27ac marking in 6 month old APP/PS1 neurons was enriched at sites 
pertaining to synaptic plasticity, protein depolymerisation, RNA processing and the regulation 
of protein complex disassembly. As previously discussed, deficits in synaptic plasticity have 
been identified in APP/PS1 mice as early as 3 months of age, and have been shown to increase 
with Aβ plaque deposition (Trinchese et al., 2004; Unger et al., 2016). While studies of synaptic 
deficits in human AD have also observed cholinergic dysfunction to occur in early-AD and be 
proportional to Aβ plaque load (Potter et al., 2011). Furthermore, Aβ induced protein 
depolymerisation has been previously shown to occur in hippocampal cultures, causing DNA 
fragmentation and microtubule deregulation, possibly due to disruption of NMDA receptor 
function (Mota et al., 2012). It may also be possible that hyperphosphorylation of tau leads to 
depolymerisation of microtubules, or alternatively that microtubules depolymerise leading to 
excess tau in the soma of neurons that may be prone to hyperphosphorylation and aggregation 
(reviews: (Brandt & Bakota, 2017; Jean & Baas, 2013)). In the current study, RNA processing 
was annotated to genes including Ago2, Ahcyl1, Btg2, Celf3/4/6, Cnot1/7, and Cpeb3 which 
regulate RNA splicing, RNA mediated gene silencing and mRNA deadenylation. Intracellular 
inclusions of RNA splicing products have been described in AD brains, accumulating in some 
cases around intracellular tau tangles (B. Bai et al., 2013). Moreover, aberrant pre-mRNA 
splicing is dysregulated in the dorsolateral prefrontal cortex of AD brains (Towfique Raj et al., 
2018) (review: (Koch, 2018)). 
Although gene ontology analysis was not possible for H3K4me3 marking at 6 months of age 
due to the low number of differentially marked sites, individual sites of H3K4me3 enrichment 
were at genes related to intracellular trafficking, ion channel maintenance, synaptic plasticity, 
and cell survival and DNA repair, which align with the previous literature (Mota et al., 2012; 
Potter et al., 2011). Literature suggests that impairment of axonal retrograde transporters 
contributes to aberrant Aβ production and clearance, possibly due to accumulation of axonal 
lysosomes (Gowrishankar et al., 2015). Moreover, a range of studies have implicated 
hyperphosphorylation of tau in AD to cause impairment of axonal transport, leading to the 
decay of synapses and subsequent neurodegeneration (review: (Mandelkow, Thies, Konzack, 
& Mandelkow, 2009)). Post-mitotic neuronal cells are particularly vulnerable to the effects of 
oxidative stress in the aging brain, which is further exacerbated in AD (Miquel et al., 1980; X. 
Wang et al., 2005) (review: (Xinkun Wang & Michaelis, 2010)). The accumulation of reactive 
oxygen species has been linked with subsequent DNA damage in AD and is suggested to be 
one of the earliest detectable events in AD (review: (Coppede & Migliore, 2009)). Recent 
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studies have suggested that the DNA damage response is compromised in the AD brain 
(review: (Wezyk & Zekanowski, 2018). Furthermore, core proteins in the DNA damage 
response such as BRCA1 are depleted from the AD brain, inhibiting DNA repair pathways and 
leading to downstream neuronal dysfunction and cell death (Suberbielle et al., 2015). 
Interestingly, ion channel maintenance was among the pathways enriched for H3K4me3 
marking. Appropriate maintenance of synaptic ion channels is essential to proper synaptic 
transmission and plasticity. Dysfunction of NMDA channels have been shown to disrupt cell 
membrane potential and lead to cell death in AD (review: (Yan Zhang, Li, Feng, & Wu, 2016)). 
Post-synaptic AMPA receptor function is also reduced in hippocampal neurons of APP/PS1 
mice (Chang et al., 2006). Alongside AMPA and NMDA receptors, a range of other ion 
channels contribute to neuronal excitability, including voltage-gated ion channels, many of 
which have been reported in AD literature (Boda, Hoxha, Pini, Montarolo, & Tempia, 2012; 
Poulopoulou et al., 2010) (review: (Cochran, Hall, & Roberson, 2014)).  
It is likely that a combination of both soluble Aβ accumulation and Aβ plaque deposition and 
its sequelae contribute to the disruption of the neuronal epigenome at pathology onset in 
APP/PS1 mice.   
 
Aβ plaque accumulation is associated with H3K4me3 enrichment that promotes inflammatory, 
protein refolding, and developmental pathways in neurons from pathology rich APP/PS1 mice 
Aβ plaque pathology is considered one of the key pathological hallmarks of AD (review: (John 
Hardy & Selkoe, 2002)). 12 month old APP/PS1 mice exhibit extensive Aβ plaque deposition 
and recapitulate the Aβ plaque-associated neuronal pathology in human early sporadic AD 
cases (Garcia-Alloza et al., 2006; Jankowsky et al., 2004; Mitew et al., 2013a, 2013b; A. 
Woodhouse et al., 2009). The data presented in this study demonstrated enrichment of 
H3K4me3 marking, but minimal enrichment of H3K27ac marking in neurons from APP/PS1 
mice at 12 months of age. H3K4me3 marking was enriched predominantly around TSS that 
contained CpG islands in APP/PS1 neurons compared to WT control neurons, but not in 
enhancers. Whereas there was slight enrichment for H3K27ac at the TSS, but no change at 
enhancers in 12 month old APP/PS1 neurons compared to WT control neurons. The enrichment 
of H3K4me3 in pathology rich neurons may act as a compensatory mechanism to Aβ plaque 
formation, soluble Aβ and synaptic loss, or as a downstream consequence of Aβ accumulation.  
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Gene ontology analysis further illustrated the effects of differential H3K4me3 marking from 
APP/PS1 neurons at 12 months of age, which were annotated to pathways including immune 
response, protein refolding, and antigen processing and presentation. There is strong evidence 
to suggest that misfolded Aβ intermediates, such as Aβ fibrils, act as precursors to core Aβ 
plaque pathology (review: (Fink, 1998)). Indeed, there are a number of pathways for correcting 
misfolded proteins with chaperones to destabilise abnormal conformations or promote 
refolding through heat shock protein complexes that are activated in AD (review: (Hartl, 
Bracher, & Hayer-Hartl, 2011; Koren et al., 2009)). H3K4me3 may be enriched to increase the 
activation of protein folding complexes in response to severe Aβ pathology in 12 month old 
APP/PS1 brains. Activation of the innate immune system and inflammation are other hallmarks 
of AD and have been widely implicated to be a driving force in the neurodegeneration seen in 
the disease (review: (Tony Wyss-Coray, 2006)). In particular, activated microglia and reactive 
astrocytes are observed around Aβ plaques (Ansoleaga et al., 2015; Itagaki et al., 1989). 
Widespread activation of microglia occurs in AD, and microglia can internalise and degrade 
Aβ (review: (C. Y. D. Lee & Landreth, 2010)). Studies have shown that the immune response 
increases between 6 and 12 months of age in APP/PS1 mice (Ansoleaga et al., 2015). Several 
immune response risk alleles have also been implicated in AD pathogenesis and progression 
(Giri et al., 2016). However, it was surprising that the current study identified immune response 
and antigen processing and response pathways to be differentially enriched for H3K4me3 
marking in neurons from 12 month old APP/PS1 mice. It may be possible that neurons are also 
activating immune response pathways to further illicit an immune response as a result of Aβ 
accumulation in the pathology rich brain (Peltier, Simms, Farmer, & Miller, 2010) (review: 
(Veiga-Fernandes & Artis, 2018)).   
Interestingly, there was minimal change to H3K27ac marking in neurons from 12 month old 
APP/PS1 mice. There was a total of 2150 differentially enriched H3K27ac marked sites in 
APP/PS1 neurons at 12 months of age. There was also little difference in H3K27ac marking 
between APP/PS1 neurons and WT control neurons at 12 months of age at enhancers and super-
enhancers. Interestingly, the number of differentially enriched H3K27ac marked sites 
decreased in neurons across the time-course of Aβ accumulation. Meanwhile, gene ontology 
terms annotated by differential H3K27ac marking in 12 month old APP/PS1 neurons included 
pathways involved in synaptic plasticity, protein localisation, dephosphorylation, dendrite 
development, maintenance of location, and cerebellum development. Literature has suggested 
that dendritic sprouting occurs in AD (Masliah et al., 1991). Growth associated protein 43 
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(GAP-43) is critical to dendritic growth in developing neurons, and is associated with 
regenerating dendrites (review: (Benowitz & Routtenberg, 1997)). Interestingly, GAP-43 is 
present in coiled fibres in dystrophic neurites, pathology may be involved in synaptic pathology 
in AD cortex (Masliah et al., 1991). While studies have shown a reduction of GAP-43 in the 
frontal cortex, CA1 and CA4 regions of the hippocampus (Ansoleaga et al., 2015). 
Furthermore, the use of HDAC inhibitors to increase histone acetylation has resulted in 
increased dendritic sprouting and synaptogenesis in pathology rich CK-p25 mice (Fischer, 
Sananbenesi, Wang, Dobbin, & Tsai, 2007b) (review:(Arendt, 2009)).  
The dense pathology burden seen in 12 month old APP/PS1 animals may cause enrichment for 
neuronal H3K4me3 marking at the TSS for metabolic processes such as protein refolding, and 
immune system responses, possibly to compensate for Aβ aggregation and its sequelae. 
However it is important to note that disruption of the epigenome may also contribute to the 
pathology onset and progression seen in AD.  
 
A partial recapitulation of a juvenile-like epigenetic signature occurs in neurons from 
pathology rich APP/PS1 mice 
By comparing differential enrichment of H3K27ac and H3K4me3 marking across 3, 6, and 12 
months of age, this study observed sites that were shared across the time-course of Aβ 
pathology accumulation. Unexpectedly, the majority of differentially enriched H3K27ac and 
H3K4me3 marked sites in APP/PS1 neurons at 3 and 12 months of age were shared between 
these time-points. This posed the question of whether the shared differentially enriched sites 
were consistently enriched, demonstrating a recapitulation of a juvenile-like epigenetic state, 
or whether dysregulation in neurons from pathology rich APP/PS1 neurons was occurring at 
previously enriched sites of H3K27ac and H3K4me3 marking from juvenile mice. Strikingly, 
the majority of enriched H3K27ac marked sites (69.6%) and the vast majority of differentially 
enriched H3K4me3 marked sites (89.5%) that were shared between 3 and 12 month old 
APP/PS1 neurons were consistently enriched at both time-points. These data indicate that 
APP/PS1 neurons from a pathology rich environment partially recapitulate a juvenile-like 
histone landscape. Differentially enriched H3K27ac marked sites shared between 3 and 12 
month old APP/PS1 neurons were annotated to pathways including protein localisation, 
synaptic plasticity, calcium ion transport, and dendrite development. Similar pathways were 
identified in the gene ontology analysis of all H3K27ac differentially enriched sites in APP/PS1 
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neurons when the 3 and 12 month old time points were analysed individually. Whereas 
differentially enriched H3K4me3 marked sites that were shared between APP/PS1 neurons 
from 3 and 12 months of age were mostly from pathways implicated in protein folding (review: 
(Soto & Pritzkow, 2018)), glycosylphosphatidylinositol (GPI) anchoring and autophagic 
pathways (review: (Uddin et al., 2018)). GPI anchoring and lipid based transport has been 
previously implicated in APP processing in-vitro, and is thought to be involved in APP and Aβ 
trafficking and key to the regulation of Aβ processing (Cordy, Hussain, Dingwall, Hooper, & 
Turner, 2003) (review:(Cordy, Hooper, & Turner, 2006)).  
Interestingly, previous literature has also identified a recapitulation of juvenile pathways in 
AD. Several regulators for initiating and arresting the cell cycle have been implicated in AD, 
suggesting that reactivation of the cell cycle may occur in terminally differentiated neurons in 
the AD brain. For example, P16, CDK4, and hyperphosphorylated retinoblastoma protein, 
which are all key proteins in the regulation of cell cycle are disrupted in pyramidal neurons 
from human AD hippocampus and in the 3xTg mouse model of AD (Hradek et al., 2015; 
McShea, Harris, Webster, Wahl, & Smith, 1997). It is possible that reactivation of these 
pathways inhibits normal neuronal function and apoptotic pathways in impaired neurons, 
exacerbating AD progression (review: (Moh et al., 2011)). Studies have also shown that 
markers of synaptic and dendritic growth are upregulated as a result of Aβ pathology in CK-
p25 mice and neurons from post-mortem AD hippocampus (Fischer et al., 2007b; McKee, 
Kowall, & Kosik, 1989). Growth associated proteins have also been identified to be 
upregulated in the AD brain and CSF of AD patients as a result of Aβ and tau accumulation 
(Masliah et al., 1991; Sandelius et al., 2019).  
Together these data demonstrate a partial recapitulation of a juvenile-like epigenome in 
neurons from pathology rich APP/PS1 mice. The disruption to the normal epigenome may be 
driving mechanism, or occur as a downstream consequence of Aβ accumulation, or indeed may 
act as a compensatory mechanism against pathology accumulation. 
 
Enrichment of H3K27ac and H3K4me3 at known AD risk variants in neurons from APP/PS1 
mice 
Genome-wide association studies have established a number of gene variants to be associated 
with AD (Harold et al., 2009; Seshadri et al., 2010). A wide array of research has identified 
that these AD risk loci have roles in synaptic plasticity, protein trafficking, cytoskeletal 
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dynamics, immune function and other neuronal processes (review: (Giri et al., 2016)). The 
current study demonstrated H3K27ac and H3K4me3 marking was differentially enriched in 
APP/PS1 neurons at 22 known AD risk loci, including Clu, Abca7, Sorl1, Cr1, Ms4a, Bin1, 
Cd2ap, Picalm, Epha1, Inpp5d, Mef2c, Cass4, Ptk2b, Zcwpw1, Celf1, Fermt2, Slc24a4, Pld3, 
Unc5c, Akap9, and Adam10. Unexpectedly, the majority of the identified AD risk variants were 
enriched for H3K27ac and H3K4me3 marking in APP/PS1 neurons prior to pathology onset, 
however there were few AD risk loci that were differentially enriched for H3K27ac and 
H3K4me3 marking at pathology onset in 6 month old neurons. Several AD risk variants have 
been differentially enriched for histone modifications in AD. Gjoneska and colleagues (2015) 
also observed differential enrichment of histone modifications at the Abca1, Slc39a13, Picalm, 
Bin1, Inpp5d, and Rrbp1 AD risk loci in the CK-p25 mouse model of neurodegeneration. While 
Marzi, et al., (2018) determined that APOE, CR1, APP, PS1, PS2 and MAPT to be differentially 
enriched for H3K27ac marking in the post-mortem human entorhinal cortex from AD cases. 
Indeed, CpG islands within AD risk variants including ANK1, BIN1, RHBDF2, ABCA7 have 
also been shown to be hypermethylated in AD, implicating epigenome wide alterations to AD 
risk alleles in the disease (P. L. De Jager et al., 2014; Lunnon et al., 2014). From the data 
presented here and previous literature, it is plausible that early- and late onset AD share similar 
pathogenic pathways, of which many are impacted by epigenetic dysregulation.   
 
Genome-wide analysis of isolated neuronal nuclei demonstrate a distinct pattern of histone 
modification marking in AD  
This was the first study to characterise both H3K4me3 and H3K27ac in neurons across a time-
course of amyloidosis. H3K4me3 and H3K27ac are generally associated with active promoters 
and enhancers respectively (Creyghton et al., 2010b; Santos-Rosa et al., 2002; Z. Wang et al., 
2008; Wysocka et al., 2006). There have been 5 studies to date that have performed ChIP-seq 
in human AD cases or animal models of AD (Benito et al., 2015; Gjoneska et al., 2015; Klein 
et al., 2019; Marzi et al., 2018; Nativio et al., 2018). Despite the differences in methodology, 
tissue source and bioinformatic analyses performed, there are several points of agreeance 
between this study and others in the literature.  
Nativio et al. (2018) measured H4K16ac marking in the lateral temporal lobe genome-wide in 
young control cases, age matched control cases and AD subjects. H4K16ac marking is 
generally enriched at promoters and enhancers of actively transcribed genes, and displayed a 
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bimodal distribution at the TSS and a single peak at intergenic regions (including enhancers) 
(Nativio et al., 2018; Rai et al., 2014; Taylor, Eskeland, Hekimoglu-Balkan, Pradeepa, & 
Bickmore, 2013). Interestingly, Nativio, et al., (2018) identified depletion of H4K16ac marking 
in the lateral temporal lobe of AD cases, which was concentrated around the TSS. However, 
Nativio et al. (2018) showed no significant depletion from enhancers in AD cases. In contrast, 
the current study identified a slight enrichment of H3K27ac marking and widespread 
enrichment of H3K4me3 marking at promoters in neurons, but little change at enhancers in 
neurons from pathology rich APP/PS1 mice. The current study also observed that neurons from 
APP/PS1 mice were enriched for H3K4me3 and H3K27ac marking prior to pathology onset, 
with the magnitude of differential enrichment for H3K27ac marking decreased over the time-
course of amyloidosis. In comparison, Nativio et al. (2018) identified age associated 
enrichment of H4K16ac marking, but depletion of H4K16 marking in AD cases (Nativio et al., 
2018). GO analysis of H4K16ac marking demonstrated that pathways involved in myeloid 
differentiation, cell death, Wnt signalling, and Ras signal transduction were disrupted in the 
lateral temporal lobe of AD cases. Whereas the current study identified pathways associated 
with protein folding, GPI lipid processing and RNA modifications to be enriched for H3K4me3 
marking in 12 month old APP/PS1 neurons; and synaptic plasticity, ion transport, dendrite 
development, and protein dephosphorylation to be enriched for H3K27ac in neurons from 12 
month old APP/PS1 mice.  
Another recent study has performed genome-wide assessment of H3K27ac marking in post-
mortem entorhinal cortex from AD cases and age matched control cases (Marzi et al., 2018). 
Marzi and colleagues (2018) identified 4162 differentially enriched H3K27ac marked sites in 
AD cases, of which 35% were enriched for H3K27ac marking, while 65% were depleted for 
H3K27ac marking, however there was no report on the global levels of H3K27ac marking at 
promoters or enhancers in the AD cases (Marzi et al., 2018). In contrast, the current study found 
the vast majority of H3K27ac marking was enriched in APP/PS1 neurons, however H3K27ac 
marking peaked prior to pathology onset, with only 2076 significantly enriched H3K27ac 
marked sites in pathology rich neurons from APP/PS1 mice. Interestingly, Marzi et al. (2018) 
observed that H3K27ac differentially marked sites were associated with pathways for 
lipoprotein-particle binding, apolipoprotein binding, response to hypoxia, cardiac muscle cell 
development, GABA-receptor activity, synaptic plasticity, and Aβ metabolic process (Marzi et 
al., 2018). Several of these gene ontology terms were also present in the current study, 
including lipoprotein-particle binding, synaptic plasticity, and receptor activity. Interestingly, 
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another recently published study performed genome-wide assessment of H3K9ac marking in 
the post-mortem human AD prefrontal cortex has identified that tau, but not Aβ correlated with 
an altered H3K9ac marking in AD, and that tau regulates aspects of chromosomal and nuclear 
structure (Klein et al., 2019). H3K9ac is a marker of transcriptionally active chromatin and is 
often present around active transcriptional start sites (~41%) and enhancer elements (~27%), 
marking bivalently around the TSS (Klein et al., 2019). Enrichment of H3K9ac marking 
correlated with tau pathology at 5990 out of 26384 identified peaks, and interestingly, 
chromatin restructuring occurred prior to tangle formation when measured in a tau transgenic 
mouse model (Klein et al., 2019). Early enrichment of H3K9ac marking aligns with the 
findings of the current study, where H3K4me3 and H3K27ac were highly enriched in APP/PS1 
neurons prior to the onset of pathology. It is possible that epigenetic dysregulation is one of the 
earliest changes in the pathogenesis of AD and occurs prior to both Aβ and tau pathology.  
Differences between the previous literature and the current study could be due to the use of the 
APP/PS1 mouse model of amyloidosis, compared to the use of post-mortem human lateral 
temporal lobe, entorhinal cortex, and prefrontal cortex from AD cases, or different mouse 
models of neurodegeneration (Klein et al., 2019; Marzi et al., 2018; Nativio et al., 2018). 
Differences may also be due to different histone modifications measured (Klein et al., 2019; 
Nativio et al., 2018). Additionally, different populations of cells were measured between the 
studies, as the previous literature performed genome-wide ChIP-seq analysis on neurons and 
glia, whereas the current study used purified neurons across a time-course of amyloidosis from 
the forebrain of APP/PS1 mice (Klein et al., 2019; Marzi et al., 2018; Nativio et al., 2018). 
There have been two studies of histone modifications in mouse models of AD. Gjoneska and 
colleagues (2015) provided one of the most comprehensive studies of histone modifications at 
two time-points in the CK-p25 mouse model of neurodegeneration; 2 weeks and 6 weeks post-
induction of p25, representing low pathology, and pathology rich cases respectively. Gjoneska 
et al. (2015) performed ChIP-seq on several histone modifications including H3K4me1, 
H3K4me3, H3K27ac, H3K27me3, H3K36me3, and H4K20me1, alongside RNA-seq for 
transcriptomic analysis, then used ChromHMM to build a chromatin state model for active 
promoter and enhancer regions (Gjoneska et al., 2015). Gjoneska et al. (2015) identified 
chromatin states analogous with depletion of promoters and enhancers at genes associated with 
synaptic plasticity, but enrichment of promoters and enhancers associated with an immune 
response. Interestingly, the study found far fewer differentially enriched peaks compared to the 
current study: 3667 enriched and 5056 depleted for H3K4me3 marking, and 2456 enriched and 
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2154 depleted for H3K27ac marking, however, it may be due to differences in analysis 
(Gjoneska et al., 2015). Interestingly, gene ontology analysis revealed pathways such as 
immune system response, cell cycle, cell adhesion, establishment of location, neuron projection 
development, learning and memory, neurogenesis, which were orthologous with gene 
expression data from post-mortem human hippocampal grey matter (Gjoneska et al., 2015). 
Many of the gene ontology pathways identified in Gjoneska et al. (2015) were similar to the 
pathways identified by gene ontology analysis in the current study, which included protein 
folding, GPI lipid processing and RNA modifications, synaptic plasticity, ion transport, 
dendrite development, and protein dephosphorylation (Gjoneska et al., 2015). As CK-p25 mice 
are an inducible model that rapidly accumulate plaque pathology, widespread enrichment of 
immune responses is likely a consequence of the model, and differences between the two 
models may account for the disparity in the number of sites of enrichment of histone marks 
detected between the two studies, however differences may also be due the selective isolation 
of neuronal nuclei from the forebrain of APP/PS1 neurons in the current study (Gjoneska et 
al., 2015).  
Benito et al. (2015) also performed genome-wide assessment of histone modifications in a 
mouse model of AD. To date it is the only study to isolate neuronal nuclei from the brain for 
genome-wide ChiP-seq analysis, characterising H4K12ac marking in neurons from the 
hippocampus and dentate gyrus 10 month old APP/PS1-21 AD mice (Benito et al., 2015). 
H4K12ac is a histone modification that generally correlates with gene expression, is a marker 
of active chromatin, and presents with a bimodal distribution across the TSS (Benito et al., 
2015; Lopez-Atalaya et al., 2013). H4K12ac marking was depleted from the TSS in neurons 
and glia from AD mice (Benito et al., 2015). In contrast, the current study found enrichment of 
H3K27ac and H3K4me3 at the TSS in neurons from pathology rich APP/PS1 mice, however 
enrichment of H3K27ac decreased across disease progression in APP/PS1 neurons. H3K4me3 
marking was also enriched in APP/PS1 neurons prior to pathology onset. Gene ontology 
analysis demonstrated that H4K12ac marking was depleted from pathways involved in protein 
localisation in the cell and synaptic organisation and transmission, and enriched in pathways 
associated with cytotoxicity, cell death, and inflammation (Benito et al., 2015). Many of the 
pathways implicated in Benito, et al., (2015) were similar to the pathways enriched for 
H3K27ac marking in neurons from APP/PS1 mice, including synaptic plasticity, inflammation, 
and apoptosis. Strikingly, HDAC inhibitors were able to restore neuronal H4K12ac marking in 
APP/PS1-21 mice to WT control levels. The differences between the current study and 
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previously published literature may be due to the pathology levels seen in the mouse models, 
or indeed different time-points analysed (Gjoneska et al., 2015). In the current study, isolating 
neuronal nuclei has allowed for accurate determination of the effects of Aβ accumulation on 
the neuronal epigenome, however future research needs to incorporate cell-type specific 
characterisation of the neuronal and glial epigenome in aging and AD (Mo et al., 2015).  
Similar to the findings from Chapter 4, some caveats should be considered when interpreting 
the results of this study. NeuN labels neuronal nuclei and encodes for the transcription factor 
FOX-3, which is present in the vast majority of neuronal nuclei in vertebrates, with the 
exception of cerebellar Purkinje cells, olfactory bulb mitral cells, and retinal photoreceptor 
cells (K. K. Kim et al., 2009; Richard J Mullen et al., 1992). Current research shows that NeuN 
labels the vast majority of neuronal nuclei from adult mammalian brain, first detectable during 
development after neurons withdraw from the cell-cycle (Richard J Mullen et al., 1992). 
However, it is possible that the distribution of NeuN changes throughout aging and AD in the 
mammalian brain, which maintains to be an important avenue for future characterisation. 
Future research could incorporate independent techniques such as immunohistochemistry and 
single-cell sequencing to confirm the findings from the current study, and further examine 
inter-individual differences in H3K4me3 and H3K27ac marking in AD. Despite the advantages 
of using APP/PS1 neurons, the use of pseudoreplicates in the current study is another limitation 
to consider. The established bioinformatics pipelines are not well suited for the heterogenous 
samples seen in the mammalian brain. As such, the current study performed the analysis 
similarly to previously published studies by merging biological replicates together (Benito et 
al., 2015; Gjoneska et al., 2015; Nativio et al., 2018). Future research could further expand and 
utilise the biological replicates to identify inter-individual differences and perform more 
rigorous statistical analysis to further elucidate the mechanisms of epigenetic dysregulation in 
AD. 
As a validation of the findings of the current study, an overlap analysis between genes enriched 
for H3K27ac and H3K4me3 marking between wild-type and APP/PS1 neurons, and neuronal 
RNA-seq data from human AD cases generated by Mathys and colleagues (2019) was 
performed. This analysis showed that approximately 88% of the genes that were differentially 
expressed in neurons from human control versus AD cases were differentially enriched for 
H3K4me3 between wild-type and APP/PS1 neurons. While approximately 47% of H3K27ac 
differentially marked sites between wild-type and APP/PS1 neurons were also differentially 
expressed between neurons from human control versus AD cases. Interestingly, this 
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demonstrated that APP/PS1 neurons reflect many of the changes occurring in neurons in human 
AD cases. Although post-mortem human tissue is a valuable resource, the inherent variability 
of NGS data may limit the analysis of such data. An advantage of using APP/PS1 mice in the 
current study is that the mice used are an inbred strain enabling the detection of differential 
enrichment with low background noise, which may contribute to the large number of sites 
identified in the current study compared to the number of differentially expressed genes 
detectable in the human neuron transcriptomic data (which would have heterogenous genetics). 
 
Conclusions 
In summary, this study is the first to characterise H3K4me3 and H3K27ac in neurons across a 
time-course of amyloidosis. Unexpectedly, this study demonstrated substantial enrichment for 
H3K27ac and H3K4me3 marking in neurons prior to pathology onset in APP/PS1 mice at 
promoters and TSS, in pathways involved in synaptic plasticity, ion channel maintenance, lipid 
transport and RNA modifications. This study has also identified widespread depletion of 
H3K27ac marking at enhancers and enrichment in cortical super enhancers in neurons prior to 
pathology onset in APP/PS1 mice. A major restructuring of the neuronal histone landscape 
occurred with dense Aβ pathology, with widespread enrichment for H3K4me3 marking, but 
minimal change in H3K27ac in 12 month old APP/PS1 neurons. Differential enrichment of 
histone marking in 12 month old APP/PS1 neurons was annotated to pathways involved in 
dephosphorylation, synaptic plasticity, maintenance of location and other juvenile pathways. 
Strikingly, this study has also demonstrated a partial recapitulation of a juvenile-like 
epigenome at pathology-rich time-points. Characterising the neuronal epigenome is pivotal to 











Alzheimer’s disease is the most common form of dementia and is a terminal, progressive, 
neurodegenerative disorder. Pathological hallmarks of AD include extracellular Aβ plaques, 
intraneuronal NFTs of tau protein, dystrophic neurites, and neuropil threads (Braak & Braak, 
1991; G. Perry et al., 1991). The cause of 90% of AD cases is unknown, and in the absence of 
highly penetrant risk alleles, changes to the regulatory elements controlling transcription could 
contribute to the pathogenesis and progression of AD. The number of published papers 
characterising the epigenome in AD is growing rapidly and most have identified epigenetic 
dysregulation present in human AD cases and in AD mouse models, which provide support for 
the notion of epigenetic dysregulation occurring in AD. However, it is not known whether 
epigenetic dysregulation is critical to the onset of AD, contributes to disease progression or 
acts as a downstream consequence of the disease (Benito et al., 2015; P. L. De Jager et al., 
2014; Gasparoni et al., 2018; Lunnon et al., 2014). Seminal studies have demonstrated 
dysregulation of DNA methylation to occur at the earliest detectable stages of AD in human 
tissue (P. L. De Jager et al., 2014; Lunnon et al., 2014). Considering the key role of neurons in 
both AD and age-related cognitive decline there have been relatively few studies that have 
characterised the epigenome in neurons, neither in the healthy aging brain nor in AD (Benito 
et al., 2015; Cheung et al., 2010; Gasparoni et al., 2018; Shulha et al., 2013). To address this 
gap in knowledge, this thesis sought to characterise the neuronal epigenome in aging and AD, 
both globally and at a genome-wide level across a time-course of healthy aging and 
pathological progression.  
Characterisation of DNA methylation was performed at a global level in a cell-type specific 
manner in human inferior temporal gyrus from early-AD, late-AD, and age matched control 
cases. Previous analyses of global DNA methylation in AD was contentious, showing global 
hypermethylation (Bradley-Whitman & Lovell, 2013; Coppieters et al., 2013; Lardenoije et al., 
2018), global hypomethylation (Chouliaras et al., 2013; A. Fuso et al., 2005; D. Mastroeni et 
al., 2010; S.-C. Wang et al., 2008; West et al., 1995), or no change to global DNA methylation 
in AD (Lashley et al., 2014). Much of the previous literature performed qualitative analysis in 
all cell-types or in neurons and glia and few studies have examined epigenetic alterations in 
NFT-bearing neurons or in cells adjacent to Aβ plaques. To address these gaps in the literature 
and determine whether global dysregulation of the epigenome was occurring in NF-positive 
pyramidal neurons, calretinin-labelled interneurons, astrocytes and microglia in AD, this study 
quantitatively measured 5mC and 5hmC in human control, early-AD, and late-AD cases. This 
study demonstrated that astrocytes were deficient in nuclear 5mC and 5hmC in AD cases, and 
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a lower proportion of NF-positive pyramidal neurons displayed extranuclear 5mC in AD cases 
compared to controls. However, no global differences in 5mC or 5hnC were detected in 
calretinin-labelled interneurons and microglia in AD. Interestingly, there was also no robust 
alterations in 5mC and 5hmC in cells adjacent to Aβ plaques, nor any detectable change in 
5mC or 5hmC in tangle-bearing neurons. These data demonstrated global dysregulation DNA 
methylation marks to occur in a cell-type specific manner in AD. 
Although global measurements of the epigenome can provide an indication of overall changes 
occurring in the brain, epigenetic regulation of the genome is finely controlled at promoters 
and enhancers to regulate gene expression with exquisite precision. While DNA methylation 
alters the accessibility for transcription factors to bind to DNA and initiate transcription, other 
regulatory elements act in consort to alter accessibility to chromatin, including histone 
modifications (review: (Bannister & Kouzarides, 2011)). After identifying changes occurring 
to the epigenome at a global level in the AD brain, this study sought to characterise key histone 
modifications in neurons across a time-course of the aging and AD brain. By utilising a mouse 
model of AD it was possible to observe the earliest changes occurring to the epigenome in 
neurons due to the accumulation of Aβ (Garcia-Alloza et al., 2006; Jankowsky et al., 2004). 
Specifically, this enabled analysis of pre-pathology and pathology-onset time points, both of 
which are extremely difficult to assess in human AD cases. 
To date, three studies have investigated histone modifications in neurons from the aging brain 
(Benito et al., 2015; Cheung et al., 2010; Shulha et al., 2013). One study has reported a loss of 
H4K12ac in neurons of the aging brain (Benito et al., 2015). However, the two other studies 
have reported developmental enrichment of H3K4me3 in neurons, that stabilise in the aging 
brain (Cheung et al., 2010; Shulha et al., 2013). To further expand the literature of histone 
modifications in the aging brain, this thesis characterised H3K27ac and H3K4me3 marking in 
neurons from the forebrain of C57/BL6 mice at 3, 6, 12, and 24 months of age (Chapter 4). The 
data from this study demonstrated a redistribution H3K4me3 and H3K27ac marking across the 
neuronal epigenome in juvenile, adult and aging brain. Interestingly, H3K27ac and H3K4me3 
marking was enriched at promoters and enhancers in neurons from juvenile (3 month old) and 
aging (24 months old) mice in comparison to neurons from adult mice (6 and 12 months of 
age). H3K27ac and H3K4me3 marking was predominant in many synaptic and core molecular 
processes across life (Table 6.1). However, ontologies that were unique to juvenile neurons 
included developmental processes such as the centrosome cycle and spindle assembly. 
Ontologies that were unique to adult neurons included axonal transport, protein folding and 
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membrane depolarisation pathways (Table 6.1). Furthermore, pathways that were unique to 
aging neurons included a range of cellular functions such as apoptotic and autophagic 
pathways, receptor regulation pathways, and RNA processing pathways (Table 6.1). 
Table 6.1: Pathways of H3K27ac and H3K4me3 enrichment in aging neurons 
Shared across life Unique to 
juvenile 
neurons 
Unique to adult 
neurons 
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This study observed a partial recapitulation of a juvenile-like epigenetic state in aged neurons. 
The differences in histone marking observed throughout the aging time-course demonstrated 
the dynamic nature of the epigenome in neurons throughout life. 
As the epigenome is dynamic throughout life, it is possible that dysregulation of the epigenome 
contributes to the pathogenesis and progression of AD, or is a sequela of AD pathology. There 
have been five studies to date to investigate histone modifications in AD in a genome-wide 
manner (Benito et al., 2015; Gjoneska et al., 2015; Klein et al., 2019; Marzi et al., 2018; Nativio 
et al., 2018); however, only one study has isolated neuronal nuclei for its analysis, 
demonstrating genome wide loss of H4K12ac in neurons from APP/PS1-21 mice (Benito et 
al., 2015). To characterise the disruption of the neuronal epigenome occurring in AD, ChIP-
seq was performed for H3K4me3 and H3K27ac marking on neuronal nuclei from 3, 6 and 12 
month old wild-type and APP/PS1 mice, representing pre-pathology, pathology onset and 
pathology rich time-points in this amyloidosis model (Garcia-Alloza et al., 2006; Jankowsky 
et al., 2004) (Chapter 5). Interestingly, widespread differential enrichment of H3K27ac and 
H3K4me3 marking occurred in neurons from APP/PS1 mice across the amyloidosis time-
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course. H3K4me3 marking was enriched at the TSS in APP/PS1 neurons pre-pathology 
compared to WT controls, however there was little difference in H3K4me3 marking between 
genotypes at pathology onset. By 12 months of age H3K4me3 marking was enriched again in 
12 month old APP/PS1 neurons compared to WT control neurons. Whereas, H3K27ac marking 
was enriched at the TSS in APP/PS1 neurons prior to pathology onset, but depleted from 
enhancers. H3K27ac marking was enriched in APP/PS1 neurons at super-enhancers at 3 and 6 
months of age, then proceeded to normalise to WT control levels in 12 month old APP/PS1 
neurons. Differential enrichment for H3K27ac and H3K4me3 marking was annotated to a wide 
range of neuronal specific pathways and core metabolic pathways in APP/PS1 neurons that 
were shared across pre-pathology, pathology onset and pathology rich time-points (Table 6.2). 
However, there were a range of core molecular pathways that were differentially enriched in 
APP/PS1 neurons prior to pathology onset, such as lipid and ion transport and pathways 
involved in gene silencing. Furthermore, pathways unique to APP/PS1 neurons at pathology 
onset included cell survival pathways and protein depolymerisation and disassembly pathways. 
Furthermore, H3K27ac and H3K4me3 were enriched in APP/PS1 neurons from the pathology 
rich time-point in developmental pathways, and core molecular processes such as protein 
modification and protein refolding pathways, as well as dendrite and cerebellum development. 
Strikingly, when comparing differential enrichment from APP/PS1 neurons across 3, 6, and 12 
months of age, a partial recapitulation of the epigenome from pre-pathology neurons was 
observed in pathology rich APP/PS1 neurons.  
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Table 6.2: Pathways enriched for H3K27ac and H3K4me3 marking in APP/PS1 neurons 






Unique to pathology rich 
Antigen processing Gene silencing Protein complex 
disassembly 
Cerebellum development 
ARF protein signal transduction GPI anchor process Protein 
depolymerisation 
Dendrite development 
Maintenance of protein location Ion transport Apoptosis Mitochondrial fission 





Negative regulation of 
megakaryocyte differentiation 
RNA processing Neurotransmitter 
secretion 
 Non-ribosomal peptide 
biosynthetic process 
Synaptic plasticity Protein 
dephosphorylation 
 Protein acylation 
   Protein acetylation 
   Protein folding 
   Type 1 interferon production 
  
After characterising histone modifications in aging and AD neurons, some interesting points 
of comparison can be raised between the two studies. In both the aging and AD data generated 
in this thesis, there were distinct patterns of histone marking that were observed over the time-
course. In the healthy aging brain, H3K27ac and H3K4me3 marking were enriched in juvenile 
neurons, depleted in young adult, then re-established with age. Similarly, in APP/PS1 neurons 
H3K4me3 marking was enriched in comparison to wild-type neurons at 3 months of age, with 
minimal difference at pathology onset, before being enriched in 12 month old APP/PS1 
neurons compared to WT control neurons. In contrast, H3K27ac marking was differentially 
enriched in APP/PS1 neurons prior to pathology onset and was enriched in enhancers and 
super-enhancers in 6 month old APP/PS1 neurons compared to WT control neurons. However, 
differences in H3K27ac marking between APP/PS1 and WT control neurons stabilised in 12 
month old neurons. Furthermore, it appeared as though amyloidosis caused a disruption to age 
associated enrichment of H3K27ac and H3K4me3 marking at specific regulatory elements.  
This PhD thesis detailed differences in H3K4me3 and H3K27ac marking in a pairwise fashion 
in APP/PS1 and WT control neurons across a time-course of healthy aging and Aβ pathology 
accumulation. Despite there being significant differences between the APP/PS1 and WT 
neurons at each time-point (discussed in Chapter 5 and above), H3K27ac and H3K4me3 
marking in APP/PS1 neurons followed a similar pattern of enrichment when compared to WT 
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neurons across the time-course of healthy aging, with the clear exception of H3K27ac marking 
at super-enhancers in APP/PS1 neurons. For example, when H3K27ac marking at the TSS and 
enhancers in aging neurons were examined across time, H3K27ac marking was enriched (“up”) 
at 3 months of age, before being depleted at 6 months of age (“down”), then stabilised at 12 
months of age (“same”; Figure 5.2). Likewise, the pattern of H3K4me3 marking over time was 
enriched at 3 months of age (“up”), depleted at 6 months of age (“down”), and enriched again 
at 12 months of age (“up”; Figure 5.7) for both APP/PS1 and WT neurons. There was one clear 
exception where the pattern of H3K27ac marking across the time-points differed between wild-
type and APP/PS1 neurons. H3K27ac marking at super-enhancers in APP/PS1 neurons was 
enriched in WT control neurons at 3 months of age (“up”), then was depleted at 6 months of 
age (“down”), before being re-established at 12 months of age (“up”). In contrast, H3K27ac 
marking was enriched in APP/PS1 neurons at 3 months of age (“up”), before being reduced at 
6 months of age (“down”), then further depleted at 12 months of age (“down”) (Figure 5.4; 
Appendix 2: Supplementary Figure 3). The differential enrichment of super-enhancers was 
unexpected, as all other patterns of enrichment followed similar trends in marking in both the 
amyloidosis and aging time-course. The depletion of H3K27ac at super-enhancers in APP/PS1 
neurons implies that there is a continuous loss of super-enhancer activity with the accumulation 
of Aβ pathology, and possible dysregulation of neuronal identity in AD in comparison to 
neurons from the healthy aging brain (Hnisz et al., 2013). 
Next, this PhD thesis sought to determine whether the alterations in histone landscape occurred 
in pathways that are altered across the course of healthy aging brain that become dysregulated 
in AD, and/or whether epigenetic dysregulation was occurring in pathways in AD mice that 
were not usually altered in healthy aging. Gene ontology annotations of differential H3K4me3 
and H3K27ac marking in neurons were compared between the aging and AD datasets and GO 
terms were categorised into: 1) Shared: pathways that were altered in the course of healthy 
aging and were dysregulated in AD; 2) AD specific: pathways that were present only in AD 
gene ontology analysis; 3) Aging specific: pathways that were altered across healthy aging and 
remain unperturbed in AD (Table 6.3). In the ‘Shared’ category H3K27ac and H3K4me3 
differential marking was annotated to many pathways related to synaptic plasticity, neuronal 
activity, RNA processing and protein folding and localisation (Table 6.3). Gene ontology 
pathways that were in the ‘AD specific’ category included protein modification and processing 
and neurotransmitter pathways that were differentially enriched for H3K27ac marking and 
transcriptional and inflammatory-related pathways were specifically enriched for H3K4me3 
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marking (Table 6.3). In the unperturbed aging category H3K27ac and H3K4me3 differential 
marking was present in apoptotic, oxidative phosphorylation, autophagic, axon transport and 
oxidative phosphorylation pathways (Table 6.3). Although many of the enriched pathways 
observed in this PhD thesis were annotated to specific categories of ‘Shared’, ‘Aging specific’ 
and ‘AD specific’, the ontologies presented were not an exhaustive list, with only the top ten 
pathways being compared between the groups. However, there was a similar distribution of 
pathways enriched for H3K27ac and H3K4me3 marking across all three categories. Previous 
research has also identified ‘Shared’, ‘AD specific’ and ‘Aging specific’ pathways to be 
enriched for H4K16ac marking in human AD (Nativio et al., 2018). Nativio, et al., (2018) and 
this PhD thesis identified many similar “Shared” pathways for histone modifications including 
protein phosphorylation, synaptic pathways, and neuron development pathways (Nativio et al., 
2018). There were some “Aging specific” pathways shared between the two studies, which 
included apoptosis, autophagy and hypoxia (which may be related to oxidative phosphorylation 
from the current study), however the current study was also enriched for many core molecular 
pathways that were not observed in previous studies (Nativio et al., 2018). “AD specific” 
pathways shared between the two studies included metabolic processes, however there were 
many pathways that were independent between the two studies such as hormone stimulus, 
neuron projection and signal transduction pathways (Nativio et al., 2018). The differences 
between the two studies may be due to the use of human brain homogenate compared to isolated 
neuronal nuclei in the current study, and also may due to differences as a result of tau related 
pathology present in human AD that does not occur in APP/PS1 mice.  It has been suggested 
that AD results in dysregulation of chromatin restructuring that occurs as a part of normal 
healthy aging (Nativio et al., 2018). Indeed, some age-associated epigenetic modifications that 
are normally protective against disease may become dysregulated, leading to AD pathogenesis 




Table 6.3: Many pathways of H3K27ac and H3K4me3 marking are shared between aging 
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This thesis also observed a partial recapitulation of a juvenile-like state in aging neurons, and 
a partial recapitulation the pre-pathology epigenome in aged APP/PS1 neurons. In healthy 
aging more than 28% of H3K27ac and H3K4me3 differentially marked sites were shared 
between juvenile and aged neurons. When the direction of change of these shared sites was 
analysed, more than 87% of H3K4me3 and H3K27ac marked sites were consistently enriched 
in juvenile and aged neurons. Similarly approximately 23% of differentially H3K4me3 marked 
sites were shared between 3 and 12 month old APP/PS1 neurons, and more than 89% of the 
shared sites were consistently enriched in both time-points. In contrast, approximately 65% 
H3K27ac marked sites from 12 month old APP/PS1 neurons were shared with the 3 month old 
pre-pathology time-point, and approximately 70% of the shared sites were consistently 
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enriched at pre-pathology and pathology rich time-points. Due to the pairwise analysis 
performed for the aging data across the time-course (for example: 3 month time-point versus 6 
month time-point) in comparison to time-point specific analysis in APP/PS1 neurons (for 
example: 3 month WT versus 3 month APP/PS1), this thesis has demonstrated that there are 
two independent pathways of recapitulation of juvenile-like epigenetic state in neurons; 1) A 
partial recapitulation of the juvenile-like H3K27ac and H3K4me3 landscape in aging neurons 
from the healthy brain; and 2) a partial  recapitulation of  the pre-pathology H3K4me3 neuronal 
signature in APP/PS1 neurons from the pathology rich environment. The data presented in this 
thesis support previous studies that have identified a partial recapitulation of the developmental 
DNA methylation profiles in the aging nervous system, and a recapitulation of the 
developmental cortical landscape in the aging brain when measured via structural magnetic 
resonance imaging (Douaud et al., 2014; Oh et al., 2016).  
 
6.1 Strengths, limitations and future directions 
There are several strengths and limitations to consider when interpreting the data from this 
thesis, and to take into consideration for future studies. This thesis was the first to characterise 
H3K27ac and H3K4me3 in neurons across a time-course of healthy aging and AD, and also 
quantitated cell-type specific differences in DNA methylation in AD.  
The use of global measurements of DNA methylation and hydroxymethylation via 
immunohistochemistry allowed the current study to measure these marks in post-mortem 
human AD tissue in a cell-type specific manner, to analyse intracellular localization and to 
assess 5mC and 5hmC alterations in cells that contained or were adjacent to AD pathology. 
Currently, analysing neuronal and glial subtypes, intracellular localization, and spatial 
relationships between DNA methylation changes and AD pathology are not feasible with 
molecular techniques, including next-generation sequencing. While global measurements 
allow for cell-type specific and spatial analysis of the epigenome, they do not provide base-
pair specific resolution of DNA methylation. The findings of the current study, alongside 
previous literature, provide compelling evidence supporting cell-type specific changes to DNA 
methylation in AD. However, genome-wide and cell-type specific analyses of DNA 
methylation and histone modifications in the same samples need to be performed to provide a 
comprehensive characterisation of the epigenome in AD. Recently, studies have isolated 
neuronal and glial nuclei in AD and demonstrated differential DNA methylation signatures 
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between neurons and glia in human AD (Gasparoni et al., 2018). A logical step for future 
research would be to develop protocols for the isolation of neuronal and glial subtypes for 
genome-wide analysis, however, it is currently difficult to identify markers of the nuclei from 
these cellular sub-types. An alternative strategy would be to use single-cell sequencing and a 
bioinformatics approach to cluster similar cell-types, however, such methodologies still yield 
low sequencing depth which may mask key aspects of differential methylation in AD (Luo et 
al., 2017). 
To date, there have only been three previous studies of histone modifications in neurons in 
aging and AD (Benito et al., 2015; Cheung et al., 2010; Shulha et al., 2013). The isolation of 
neuronal nuclei for genome-wide analysis of H3K27ac and H3K4me3 marking was a major 
strength of the current study in comparison to using whole brain homogenate. It is important 
to note that the NeuN antibody (transcription factor FOX-3) labels a wide range of neuronal 
sub-types, but does not mark some subsets of neurons including Purkinje cells, Golgi cells and 
gamma motor neurons (Kee K. Kim et al., 2009; R. J. Mullen et al., 1992). Moreover, NeuN is 
not specific to excitatory or inhibitory neurons, which are known to have different epigenetic 
profiles (Luo et al., 2017; Mo et al., 2015), and different vulnerability to degeneration and death 
in AD (P. R. Hof et al., 1990; Patrick R. Hof & Morrison, 1990; Koffie et al., 2009b; Mitew et 
al., 2013b; Sampson et al., 1997; Thangavel et al., 2009; J. C. Vickers et al., 1994). Recent 
studies have demonstrated that 70-85% of neurons in the cortex are excitatory (Lake et al., 
2016; Mo et al., 2015). Thus, the data presented in the current study is an approximation of the 
histone landscape of the vast majority of neurons, however, only four different histone 
modifications have been measured genome-wide in neurons in aging or AD, out of a wide 
range of regulatory elements that act collectively to regulate transcription (review: (M. Tan et 
al., 2011)). The data generated in this thesis will be a valuable resource for future research, and 
in conjunction with future studies of DNA methylation and nucleosome occupancy, histone 
modifications and RNA-seq can contribute to characterising the complete epigenetic signature 
of neurons in the aging and AD brain. Due to the limited number of histone modifications 
measured in the current study, it was not possible to confirm the putative enhancers that were 
identified from H3K27ac marking. It is common to identify putative enhancers by annotating 
H3K27ac marking outside (>2kB distal) of promoter regions, however, such a definition is 
limited for the accurate identification of either poised or active distal regulatory elements. 
Future studies should incorporate ChIP-seq for H3K4me1 marking to more accurately identify 
enhancers defined by H3K27ac marking, and/or incorporate functional testing of putative 
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enhancer regions with Hi-C and reporter assays (Jin et al., 2013; Mifsud et al., 2015). 
Moreover, utilising multiple histone modifications and other epigenetic readouts will allow for 
the creation of regulatory maps of the genome with software such as ChromHMM (Ernst & 
Kellis, 2017).  
Another consideration when interpreting the data from this thesis is the use of the APP/PS1 
mouse model of amyloidosis. Mice do not naturally develop AD related pathology. The 
APP/PS1 mice utilised in this thesis over-express familial AD mutations of human APPswe 
(KM670/671NL) and PS1 (dE9) mutations under the Pnrp promoter (Jankowsky et al., 2004; 
Spanopoulou et al., 1991). These mice accumulate Aβ associated pathology, with plaque 
accumulation beginning at 6 months, dense plaque pathology by 12 months of age, and Aβ 
plaque-associated neuronal pathology similar to human early-AD cases (Garcia-Alloza et al., 
2006; Jankowsky et al., 2004; Mitew et al., 2013a, 2013b; A. Woodhouse et al., 2009). 
APP/PS1 mice also have behavioural deficits in cognitive awareness and memory by 6 months 
of age (Gallagher et al., 2013; Serneels et al., 2009). However, these mice do not exhibit all 
aspects of human AD pathology, with no overt neuronal loss or NFT accumulation (Garcia-
Alloza et al., 2006; Jankowsky et al., 2004). It is highly likely that NFT associated pathology 
would impact the epigenome in AD, which is not assessed in the current study. Recent studies 
have suggested that NFT pathology is the major contributing factor to epigenetic dysregulation 
in human AD (Klein et al., 2019), however, by using the APP/PS1 mouse model this thesis has 
clearly demonstrated that Aβ pathology also contributes to epigenetic dysregulation seen in 
AD in the absence of NFT pathology. It is also possible that metabolic stress would impact the 
epigenome in APP/PS1 mice, which over-express the familial AD mutations from birth. It 
would be difficult to isolate the impact of APP or the PS1 transgenes, or indeed the impact of 
Aβ accumulation without the associated metabolic load from over-expression (Sasaguri et al., 
2017). Several new models of AD have been designed to account for the limitations of the 
APP/PS1 and other over-expression models. Knock-in models that express mutant human APP 
at the mouse App locus, recapitulate some aspects of AD pathology without the phenotypes of 
over-expression, which would be useful to incorporate into future studies of AD pathogenesis 
and progression (T. Saito et al., 2014) (review: (Sasaguri et al., 2017)). Despite the many 
advances in new model organisms it is difficult to generate models that fully recapitulate 
human AD. Future studies could incorporate Tau or APP/Tau transgenic models to investigate 
the effects of NFT pathology on the epigenome, and should also consider isolating neuronal 
nuclei from human tissue for genome-wide analysis of histone modifications in AD. 
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A range of different types of bioinformatic analyses have been performed for ChIP-seq in the 
AD literature. Many bioinformatic workflows for ChIP-seq analysis have focussed around the 
use of highly similar technical replicates, or samples with low variability such as those seen in 
cell lines. Biologically variable in vivo datasets with large sample size are difficult to analyse 
as there are limited tools that can accommodate for highly variable datasets (A. T. L. Lun & 
Smyth, 2016; M. D. Robinson et al., 2010). For example, social hierarchy and other 
environmental stimuli could all cause variation to the epigenome. Current ENCODE guidelines 
suggest peak-calling for the analysis of histone modifications in ChIP-seq, however many peak 
calling tools have statistical limitations as a result of the modelling, resulting in the loss of type-
1 error control (Consortium, 2012; A. T. Lun & Smyth, 2014). To account for inter-individual 
differences and minimise technical error, the .bam files from biological replicates were merged 
into a single file, then reads were randomly shuffled and split into technical replicates for 
processing with window based differential enrichment analysis with csaw and EdgeR, which 
are more statistically rigorous than peak calling methods (A. T. Lun & Smyth, 2014; A. T. L. 
Lun & Smyth, 2016). However, as a result of the bioinformatics approach utilised in the current 
study and others in the field (Benito et al., 2015; Gjoneska et al., 2015; Nativio et al., 2018), it 
was not possible to investigate the potential inter-individual variability of the epigenome in 
aging or AD. New bioinformatics pipelines are needed to account for variability in biological 
data present both in the current study and others in the field. Characterising the inter-induvial 
variability in the neuronal epigenome would be fascinating to address in future studies after 
new bioinformatics pipelines are generated.  
There are still many aspects of the epigenome that could be characterised with the data 
generated from this study, and indeed many questions to address in future studies. One 
interesting aspect of these data was that H3K27ac and H3K4me3 marked categorically 
different TSS, with H3K27ac marking pathways generally involved in neuronal function, while 
H3K4me3 marked pathways that generally were integral to core cellular function. Future work 
could perform peak calling for the H3K4me3 and H3K27ac data and determine whether these 
two histone modifications mark distinct subsets of TSS in neurons. Furthermore, the current 
study isolated neuronal nuclei for ChIP-seq and demonstrated a range of differential 
enrichment patterns in neurons of the aging and AD brain. However, literature suggests that 
glial cells may contribute to the pathology progression in AD (Benito et al., 2015; Gasparoni 
et al., 2018; Gjoneska et al., 2015) (review: (C. Y. D. Lee & Landreth, 2010)). Indeed, recent 
studies have demonstrated differential DNA methylation patterns exist between neurons and 
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glia in human aging and AD (Gasparoni et al., 2018), and ChIP-seq analysis in neurons and 
glia identified differential H4K12ac marking in glia, which were enriched at pathways for 
immune and inflammatory responses in CK-p25 mice (Benito et al., 2015). Glial nuclei were 
isolated from each sample via FACS and collected in the current study, but it was outside of 
the scope of the current project to perform ChIP-seq on these glial samples. Future work should 
incorporate ChIP-seq and analysis of glia to compare with the neuronal epigenome. Ideally, 
future studies will also incorporate post-mortem human tissue, and characterise multiple 
aspects of the epigenome from the same samples with experiments such as nucleosome 
occupancy and DNA methylation sequencing, RNA-seq, ChIP-seq and Hi-C to generate a 
complete reference for the neuronal and glial epigenome in the aging and AD brain. This PhD 
thesis has demonstrated that epigenetic dysregulation is likely occurring in the earliest stages 
of AD which cannot be captured in studies of human AD. It has also demonstrated the dynamic 
nature of the epigenome in aging, and of the impact of Aβ accumulation on the epigenome in 
an AD model. The data generated in this study will be a useful resource for comparison with 
human AD cases in future studies. 
 
6.2 Conclusions 
In summary this PhD thesis has substantially contributed to the field of neuroepigenetics in 
aging and AD. The key contributions of this study are:  
- There was a global loss of DNA methylation in neurofilament-positive pyramidal 
neurons and astrocytes in sporadic human AD. 
- The neuronal epigenome was dynamic throughout life, with widespread changes in 
differential enrichment for H3K27ac and H3K4me3 marking with the greatest changes 
occurring in 3 month old and 24 month old neurons. Strikingly, there was a partial 
recapitulation of a juvenile-like epigenetic state in aging neurons.  
- There was an increase in H3K27ac and H3K4me3 marking at promoters prior to 
pathology onset in APP/PS1 neurons. 
- Enhancers and super-enhancers were differentially enriched for H3K27ac marking in 
APP/PS1 neurons between 3 and 6 months of age.  
- Unlike TSS and enhancers, super-enhancers followed a different pattern of enrichment 
in neurons over the time-course of amyloidosis. 
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- H3K27ac marking was mostly annotated to neuron specific pathways, while H3K4me3 
marking was annotated to core metabolic and cellular functions in aging and AD. There 
was a partial recapitulation of a pre-pathology like state of H3K4me3 and H3K27ac 
marking in APP/PS1 neurons from pathology rich brains.  
An improved understanding of the neuronal epigenome is crucial to understanding the 
pathogenesis and progression of AD, however, without understanding the nature of the 
neuronal epigenome in the aging brain it will not be possible to identify the dysregulation 
occurring in AD. This PhD thesis has substantially contributed to the growing knowledge of 
the neuronal epigenome in both aging and AD, by characterising H3K27ac and H3K4me3 
marking in neurons across a time-course of healthy aging and AD in a mouse model, and 
identifying cell-type specific differences in DNA methylation in post-mortem human AD. This 
PhD thesis demonstrated that the epigenome is dynamic throughout life, and partially 
recapitulates a juvenile-like epigenetic state in aged neurons. Strikingly, this thesis has also 
observed wide-spread enrichment for H3K27ac and H3K4me3 in APP/PS1 neurons prior to 
pathology onset and at pathology rich time-points, in pathways critical for neuronal function 
and cellular senescence, and revealed that APP/PS1 neurons from pathology rich time-points 
partially recapitulated a juvenile-like epigenetic state. The data presented in this study is an 
important step towards developing a complete reference epigenome for neurons in aging and 
AD. This thesis has provided insight into the epigenetic dysregulation occurring in neurons in 
a milieu of amyloidosis. A better understanding of the dynamic epigenetic landscape in neurons 
will add to our accumulated knowledge of the molecular pathways involved in AD 
pathogenesis and progression, and likely contribute to the identification of novel therapeutic 





Aagaard, L., Laible, G., Selenko, P., Schmid, M., Dorn, R., Schotta, G., . . . Jenuwein, T. 
(1999). Functional mammalian homologues of the Drosophila PEV-modifier Su(var)3-
9 encode centromere-associated proteins which complex with the heterochromatin 
component M31. Embo j, 18(7), 1923-1938. doi:10.1093/emboj/18.7.1923 
Achour, M., Merienne, K., Keime, C., Le Gras, S., Davidson, I., Néri, C., . . . Boutillier, A.-L. 
(2015). Neuronal identity genes regulated by super-enhancers are preferentially down-
regulated in the striatum of Huntington's disease mice. Human molecular genetics, 
24(12), 3481-3496. doi:10.1093/hmg/ddv099 
Ahmadian, S. S., Rezvanian, A., Peterson, M., Weintraub, S., Bigio, E. H., Mesulam, M.-M., 
& Geula, C. (2015). Loss of calbindin-D28K is associated with the full range of tangle 
pathology within basal forebrain cholinergic neurons in Alzheimer's disease. Neurobiol 
Aging, 36(12), 3163-3170. doi:10.1016/j.neurobiolaging.2015.09.001 
Akiyama, H., Schwab, C., Kondo, H., Mori, H., Kametani, F., Ikeda, K., & McGeer, P. L. 
(1996). Granules in glial cells of patients with Alzheimer's disease are immunopositive 
for C-terminal sequences of β-amyloid protein. Neurosci Lett, 206(2–3), 169-172. 
doi:http://dx.doi.org/10.1016/S0304-3940(96)12474-5 
Aleksic, B., Kushima, I., Hashimoto, R., Ohi, K., Ikeda, M., Yoshimi, A., . . . Ozaki, N. (2013). 
Analysis of the VAV3 as candidate gene for schizophrenia: evidences from voxel-based 
morphometry and mutation screening. Schizophr Bull, 39(3), 720-728. 
doi:10.1093/schbul/sbs038 
Alelú-Paz, R., Carmona, F. J., Sanchez-Mut, J. V., Cariaga-Martínez, A., González-Corpas, 
A., Ashour, N., . . . Ropero, S. (2016). Epigenetics in Schizophrenia: A Pilot Study of 
Global DNA Methylation in Different Brain Regions Associated with Higher Cognitive 
Functions. Frontiers in Psychology, 7, 1496. doi:10.3389/fpsyg.2016.01496 
Allen, B., Ingram, E., Takao, M., Smith, M. J., Jakes, R., Virdee, K., . . . Goedert, M. (2002). 
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice 
expressing human P301S tau protein. J Neurosci, 22(21), 9340-9351.  
Allfrey, V. G., Faulkner, R., & Mirsky, A. E. (1964). ACETYLATION AND 
METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE 
REGULATION OF RNA SYNTHESIS. Proc Natl Acad Sci U S A, 51(5), 786-794.  
Allfrey, V. G., & Mirsky, A. E. (1964). Structural Modifications of Histones and their Possible 
Role in the Regulation of RNA Synthesis. Science, 144(3618), 559. 
doi:10.1126/science.144.3618.559 
Allis, C. D., Berger, S. L., Cote, J., Dent, S., Jenuwien, T., Kouzarides, T., . . . Zhang, Y. 
(2007). New Nomenclature for Chromatin-Modifying Enzymes. Cell, 131(4), 633-636. 
doi:https://doi.org/10.1016/j.cell.2007.10.039 
Allis, C. D., & Jenuwein, T. (2016). The molecular hallmarks of epigenetic control. Nature 
Reviews Genetics, 17, 487. doi:10.1038/nrg.2016.59 
Alzheimer's Disease International. (2015). World Alzheimer Report 2015: The Global Impact 
of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends Retrieved from 
http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf 
Ambigapathy, G., Zheng, Z., & Keifer, J. (2015). Regulation of BDNF chromatin status and 
promoter accessibility in a neural correlate of associative learning. Epigenetics, 10(10), 
981-993. doi:10.1080/15592294.2015.1090072 
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999). 
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-
binding protein 2. Nat Genet, 23, 185. doi:10.1038/13810 
227 
 
Andersson, R. (2015). Promoter or enhancer, what's the difference? Deconstruction of 
established distinctions and presentation of a unifying model. Bioessays, 37(3), 314-
323. doi:10.1002/bies.201400162 
Andorfer, C., Kress, Y., Espinoza, M., de Silva, R., Tucker, K. L., Barde, Y. A., . . . Davies, P. 
(2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human 
tau isoforms. J Neurochem, 86(3), 582-590.  
Andrews, S. (2010). FastQC: A quality control tool for high throughput sequence data. 
Retrieved from http://www.bioinformatics.babraham.ac.uk/projects/fastqc 
Anglade, P., Vyas, S., Hirsch, E. C., & Agid, Y. (1997). Apoptosis in dopaminergic neurons 
of the human substantia nigra during normal aging. Histol Histopathol, 12(3), 603-610.  
Ansoleaga, B., López-González, I., Garcia-Esparcia, P., Aso, E., LLorens, F., Moreno, J., . . . 
Fuso, A. (2015). Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 
Transgenic Mice: Correlations With Plaques, Tangles, and Oligomeric Species. Journal 
of Neuropathology & Experimental Neurology, 74(4), 319-344. 
doi:10.1097/nen.0000000000000176 
Antequera, F., Boyes, J., & Bird, A. (1990). High levels of De Novo methylation and altered 
chromatin structure at CpG islands in cell lines. Cell, 62(3), 503-514. 
doi:https://doi.org/10.1016/0092-8674(90)90015-7 
Anttila, T., Helkala, E. L., Viitanen, M., Kareholt, I., Fratiglioni, L., Winblad, B., . . . Kivipelto, 
M. (2004). Alcohol drinking in middle age and subsequent risk of mild cognitive 
impairment and dementia in old age: a prospective population based study. Bmj, 
329(7465), 539. doi:10.1136/bmj.38181.418958.BE 
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999). Tripartite synapses: glia, the 
unacknowledged partner. Trends in Neurosciences, 22(5), 208-215. 
doi:https://doi.org/10.1016/S0166-2236(98)01349-6 
Arendt, T. (2009). Synaptic degeneration in Alzheimer’s disease. Acta Neuropathol, 118(1), 
167-179.  
Arispe, N., Pollard, H. B., & Rojas, E. (1993). Giant multilevel cation channels formed by 
Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc 
Natl Acad Sci U S A, 90(22), 10573-10577.  
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992). 
Neurofibrillary tangles but not senile plaques parallel duration and severity of 
Alzheimer's disease. Neurology, 42(3), 631. doi:10.1212/wnl.42.3.631 
Ashford, J. W. (2004). APOE genotype effects on Alzheimer’s disease onset and epidemiology. 
Journal of Molecular Neuroscience, 23(3), 157-165.  
Atti, A. R., Palmer, K., Volpato, S., Winblad, B., De Ronchi, D., & Fratiglioni, L. (2008). Late-
life body mass index and dementia incidence: nine-year follow-up data from the 
Kungsholmen Project. J Am Geriatr Soc, 56(1), 111-116. doi:10.1111/j.1532-
5415.2007.01458.x 
Avery, O. T., Macleod, C. M., & McCarty, M. (1944). STUDIES ON THE CHEMICAL 
NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF 
PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A 
DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM 
PNEUMOCOCCUS TYPE III. J Exp Med, 79(2), 137-158.  
Azuara, V., Perry, P., Sauer, S., Spivakov, M., Jørgensen, H. F., John, R. M., . . . Fisher, A. G. 





Bai, B., Hales, C. M., Chen, P.-C., Gozal, Y., Dammer, E. B., Fritz, J. J., . . . Peng, J. (2013). 
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in 
Alzheimer’s disease. Proceedings of the National Academy of Sciences, 110(41), 
16562-16567. doi:10.1073/pnas.1310249110 
Bai, B., Hales, C. M., Chen, P. C., Gozal, Y., Dammer, E. B., Fritz, J. J., . . . Peng, J. (2013). 
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in 
Alzheimer's disease. Proc Natl Acad Sci U S A, 110(41), 16562-16567. 
doi:10.1073/pnas.1310249110 
Bakulski, K. M., Dolinoy, D. C., Sartor, M. A., Paulson, H. L., Konen, J. R., Lieberman, A. P., 
. . . Rozek, L. S. (2012). Genome-wide DNA methylation differences between late-
onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J 
Alzheimers Dis, 29(3), 571-588. doi:10.3233/JAD-2012-111223 
Ballatore, C., Lee, V. M., & Trojanowski, J. Q. (2007). Tau-mediated neurodegeneration in 
Alzheimer's disease and related disorders. Nat Rev Neurosci, 8(9), 663-672. 
doi:10.1038/nrn2194 
Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., & Landreth, G. E. (2003). 
A cell surface receptor complex for fibrillar beta-amyloid mediates microglial 
activation. J Neurosci, 23(7), 2665-2674.  
Banerjee, T., & Chakravarti, D. (2011). A Peek into the Complex Realm of Histone 
Phosphorylation. Mol Cell Biol, 31(24), 4858-4873. doi:10.1128/mcb.05631-11 
Banerji, J., Olson, L., & Schaffner, W. (1983). A lymphocyte-specific cellular enhancer is 
located downstream of the joining region in immunoglobulin heavy chain genes. Cell, 
33(3), 729-740.  
Banerji, J., Rusconi, S., & Schaffner, W. (1981). Expression of a beta-globin gene is enhanced 
by remote SV40 DNA sequences. Cell, 27(2 Pt 1), 299-308.  
Bannister, A. J., & Kouzarides, T. (2011). Regulation of chromatin by histone modifications. 
Cell Research, 21(3), 381-395. doi:10.1038/cr.2011.22 
Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D. E., Wang, Z., . . . Zhao, K. (2007). 
High-Resolution Profiling of Histone Methylations in the Human Genome. Cell, 
129(4), 823-837. doi:http://dx.doi.org/10.1016/j.cell.2007.05.009 
Barulli, D., & Stern, Y. (2013). Efficiency, capacity, compensation, maintenance, plasticity: 
emerging concepts in cognitive reserve. Trends Cogn Sci, 17(10), 502-509. 
doi:10.1016/j.tics.2013.08.012 
Belikoff, E., Wong, L. J., & Alberts, B. M. (1980). Extensive purification of histone acetylase 
A, the major histone N-acetyl transferase activity detected in mammalian cell nuclei. J 
Biol Chem, 255(23), 11448-11453.  
Benito, E., Urbanke, H., Ramachandran, B., Barth, J., Halder, R., Awasthi, A., . . . Fischer, A. 
(2015). HDAC inhibitor–dependent transcriptome and memory reinstatement in 
cognitive decline models. J Clin Invest, 125(9), 3572-3584. doi:10.1172/JCI79942 
Benjamini, Y., & Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and 
Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series 
B (Methodological), 57(1), 289-300.  
Benowitz, L. I., & Routtenberg, A. (1997). GAP-43: an intrinsic determinant of neuronal 
development and plasticity. Trends in Neurosciences, 20(2), 84-91. 
doi:https://doi.org/10.1016/S0166-2236(96)10072-2 
Berg, L., McKeel, D. W., Jr, Miller, J., & et al. (1998). Clinicopathologic studies in cognitively 
healthy aging and alzheimer disease: Relation of histologic markers to dementia 




Bergado, J. A., & Almaguer, W. (2002). Aging and synaptic plasticity: a review. Neural Plast, 
9(4), 217-232. doi:10.1155/np.2002.217 
Bergami, M., Masserdotti, G., Temprana, Silvio G., Motori, E., Eriksson, Therese M., Göbel, 
J., . . . Berninger, B. (2015). A Critical Period for Experience-Dependent Remodeling 
of Adult-Born Neuron Connectivity. Neuron, 85(4), 710-717. 
doi:https://doi.org/10.1016/j.neuron.2015.01.001 
Bernstein, A. I., Lin, Y., Street, R. C., Lin, L., Dai, Q., Yu, L., . . . Jin, P. (2016). 5-
Hydroxymethylation-associated epigenetic modifiers of Alzheimer's disease modulate 
Tau-induced neurotoxicity. Hum Mol Genet, 25(12), 2437-2450. 
doi:10.1093/hmg/ddw109 
Bernstein, B. E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D. K., Huebert, D. J., . 
. . Lander, E. S. (2005). Genomic Maps and Comparative Analysis of Histone 
Modifications in Human and Mouse. Cell, 120(2), 169-181. 
doi:http://dx.doi.org/10.1016/j.cell.2005.01.001 
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., . . . Lander, E. 
S. (2006). A Bivalent Chromatin Structure Marks Key Developmental Genes in 
Embryonic Stem Cells. Cell, 125(2), 315-326. 
doi:https://doi.org/10.1016/j.cell.2006.02.041 
Beydoun, M. A., Lhotsky, A., Wang, Y., Dal Forno, G., An, Y., Metter, E. J., . . . Zonderman, 
A. B. (2008). Association of adiposity status and changes in early to mid-adulthood 
with incidence of Alzheimer's disease. Am J Epidemiol, 168(10), 1179-1189. 
doi:10.1093/aje/kwn229 
Bihaqi, S. W., Bahmani, A., Adem, A., & Zawia, N. H. (2014). Infantile Postnatal Exposure to 
Lead (Pb) Enhances Tau Expression in the Cerebral Cortex of Aged Mice: Relevance 
to AD. Neurotoxicology, 0, 114-120. doi:10.1016/j.neuro.2014.06.008 
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005). Intraneuronal 
Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in 
transgenic mice. Neuron, 45(5), 675-688. doi:10.1016/j.neuron.2005.01.040 
Bird, A., Taggart, M., Frommer, M., Miller, O. J., & Macleod, D. (1985). A fraction of the 
mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell, 
40(1), 91-99.  
Bishop, N. A., Lu, T., & Yankner, B. A. (2010). Neural mechanisms of ageing and cognitive 
decline. Nature, 464, 529. doi:10.1038/nature08983 
Bittner, T., Burgold, S., Dorostkar, M. M., Fuhrmann, M., Wegenast-Braun, B. M., Schmidt, 
B., . . . Herms, J. (2012). Amyloid plaque formation precedes dendritic spine loss. Acta 
Neuropathol, 124(6), 797-807. doi:10.1007/s00401-012-1047-8 
Blizzard, C. A., Chuckowree, J. A., King, A. E., Hosie, K. A., McCormack, G. H., Chapman, 
J. A., . . . Dickson, T. C. (2011). Focal Damage to the Adult Rat Neocortex Induces 
Wound Healing Accompanied by Axonal Sprouting and Dendritic Structural Plasticity. 
Cerebral Cortex, 21(2), 281-291. doi:10.1093/cercor/bhq091 
Boda, E., Hoxha, E., Pini, A., Montarolo, F., & Tempia, F. (2012). Brain expression of Kv3 
subunits during development, adulthood and aging and in a murine model of 
Alzheimer's disease. Journal of Molecular Neuroscience, 46(3), 606-615. 
doi:10.1007/s12031-011-9648-6 
Bornemann, K. D., Wiederhold, K. H., Pauli, C., Ermini, F., Stalder, M., Schnell, L., . . . 
Staufenbiel, M. (2001). Abeta-induced inflammatory processes in microglia cells of 
APP23 transgenic mice. Am J Pathol, 158(1), 63-73.  
Boukhzar, L., Hamieh, A., Cartier, D., Tanguy, Y., Alsharif, I., Castex, M., . . . Anouar, Y. 
(2016). Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects 
230 
 
Dopaminergic Neurons in Mouse Models of Parkinson's Disease. Antioxid Redox 
Signal, 24(11), 557-574. doi:10.1089/ars.2015.6478 
Bourgeois, J. P., Goldman-Rakic, P. S., & Rakic, P. (1994). Synaptogenesis in the prefrontal 
cortex of rhesus monkeys. Cereb Cortex, 4(1), 78-96.  
Braak, H., & Braak, E. (1985). On areas of transition between entorhinal allocortex and 
temporal isocortex in the human brain. Normal morphology and lamina-specific 
pathology in Alzheimer's disease. Acta Neuropathol, 68(4), 325-332. 
doi:10.1007/bf00690836 
Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathol, 82(4), 239-259.  
Bradley-Whitman, M. A., & Lovell, M. A. (2013). Epigenetic changes in the progression of 
Alzheimer's disease. Mech Ageing Dev, 134(10), 486-495. 
doi:10.1016/j.mad.2013.08.005 
Bramham, C. R., & Messaoudi, E. (2005). BDNF function in adult synaptic plasticity: the 
synaptic consolidation hypothesis. Prog Neurobiol, 76(2), 99-125. 
doi:10.1016/j.pneurobio.2005.06.003 
Brandt, R., & Bakota, L. (2017). Microtubule dynamics and the neurodegenerative triad of 
Alzheimer's disease: The hidden connection. Journal of Neurochemistry, 143(4), 409-
417. doi:10.1111/jnc.14011 
Brayne, C., Ince, P. G., Keage, H. A., McKeith, I. G., Matthews, F. E., Polvikoski, T., & 
Sulkava, R. (2010). Education, the brain and dementia: neuroprotection or 
compensation? Brain, 133(Pt 8), 2210-2216. doi:10.1093/brain/awq185 
Bredy, T. W., Wu, H., Crego, C., Zellhoefer, J., Sun, Y. E., & Barad, M. (2007). Histone 
modifications around individual BDNF gene promoters in prefrontal cortex are 
associated with extinction of conditioned fear. Learn Mem, 14(4), 268-276. 
doi:10.1101/lm.500907 
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., . . . Ances, 
B. M. (2016). Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s 
disease. Science Translational Medicine, 8(338), 338ra366-338ra366. 
doi:10.1126/scitranslmed.aaf2362 
Britten, R. J., & Davidson, E. H. (1969). Gene regulation for higher cells: a theory. Science, 
165(3891), 349-357.  
Brookmeyer, R., Johnson, E., Ziegler-Graham, K., & Arrighi, H. M. (2007). Forecasting the 
global burden of Alzheimer&#x2019;s disease. Alzheimer's & Dementia: The Journal 
of the Alzheimer's Association, 3(3), 186-191. doi:10.1016/j.jalz.2007.04.381 
Brown, L., Hansnata, E., & La, H. A. (2017). Economic Cost of Dementia in Australia.  
Brownell, J. E., Zhou, J., Ranalli, T., Kobayashi, R., Edmondson, D. G., Roth, S. Y., & Allis, 
C. D. (1996). Tetrahymena Histone Acetyltransferase A: A Homolog to Yeast Gcn5p 
Linking Histone Acetylation to Gene Activation. Cell, 84(6), 843-851. 
doi:https://doi.org/10.1016/S0092-8674(00)81063-6 
Brun, A., & Englund, E. (1981). Regional pattern of degeneration in Alzheimer's disease: 
neuronal loss and histopathological grading. Histopathology, 5(5), 549-564. 
doi:10.1111/j.1365-2559.1981.tb01818.x 
Buell, S., & Coleman, P. (1979). Dendritic growth in the aged human brain and failure of 
growth in senile dementia. Science, 206(4420), 854-856. doi:10.1126/science.493989 
Buell, S. J., & Coleman, P. D. (1981). Quantitative evidence for selective dendritic growth in 
normal human aging but not in senile dementia. Brain Research, 214(1), 23-41.  
Buenrostro, J. D., Wu, B., Litzenburger, U. M., Ruff, D., Gonzales, M. L., Snyder, M. P., . . . 
Greenleaf, W. J. (2015). Single-cell chromatin accessibility reveals principles of 
regulatory variation. Nature, 523(7561), 486-490. doi:10.1038/nature14590 
231 
 
Burke, S. N., & Barnes, C. A. (2006). Neural plasticity in the ageing brain. Nature Reviews 
Neuroscience, 7, 30. doi:10.1038/nrn1809 
Caballero, B., & Coto-Montes, A. (2012). An insight into the role of autophagy in cell 
responses in the aging and neurodegenerative brain. Histol Histopathol, 27(3), 263-275. 
doi:10.14670/hh-27.263 
Cabeza, R. (2002). Hemispheric asymmetry reduction in older adults: the HAROLD model. 
Psychol Aging, 17(1), 85-100.  
Cajal, R.-y. (1909). Histologie du système nerveux de l'homme & des vertébrés. Paris : 
Maloine: Paris : Maloine. 
Calderwood, S. K., Murshid, A., & Prince, T. (2009). The Shock of Aging: Molecular 
Chaperones and the Heat Shock Response in Longevity and Aging – A Mini-Review. 
Gerontology, 55(5), 550-558. doi:10.1159/000225957 
Calfa, G., Chapleau, C. A., Campbell, S., Inoue, T., Morse, S. J., Lubin, F. D., & Pozzo-Miller, 
L. (2012). HDAC activity is required for BDNF to increase quantal neurotransmitter 
release and dendritic spine density in CA1 pyramidal neurons. Hippocampus, 22(7), 
1493-1500. doi:10.1002/hipo.20990 
Calhoun, M. E., Wiederhold, K.-H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-
Pierrat, C., . . . Jucker, M. (1998). Neuron loss in APP transgenic mice. Nature, 
395(6704), 755-756.  
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., . . . Zhang, Y. 
(2002). Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing. 
Science, 298(5595), 1039-1043. doi:10.1126/science.1076997 
Carter, C. W. (1978). Histone packing in the nucleosome core particle of chromatin. Proc Natl 
Acad Sci U S A, 75(8), 3649-3653.  
Cedar, H., & Bergman, Y. (2009). Linking DNA methylation and histone modification: 
patterns and paradigms. Nature Reviews Genetics, 10(5), 295-304.  
Chang, E. H., Savage, M. J., Flood, D. G., Thomas, J. M., Levy, R. B., Mahadomrongkul, V., 
. . . Huerta, P. T. (2006). AMPA receptor downscaling at the onset of Alzheimer's 
disease pathology in double knockin mice. Proc Natl Acad Sci U S A, 103(9), 3410-
3415. doi:10.1073/pnas.0507313103 
Chapuis, J., Hansmannel, F., Gistelinck, M., Mounier, A., Van Cauwenberghe, C., Kolen, K. 
V., . . . Lambert, J. C. (2013). Increased expression of BIN1 mediates Alzheimer genetic 
risk by modulating tau pathology. Mol Psychiatry, 18(11), 1225-1234. 
doi:10.1038/mp.2013.1 
Charles, A. C., Merrill, J. E., Dirksen, E. R., & Sanderson, M. J. (1991). Intercellular signaling 
in glial cells: calcium waves and oscillations in response to mechanical stimulation and 
glutamate. Neuron, 6(6), 983-992.  
Chartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., . . . 
Mullan, M. (1991). Early-onset Alzheimer&#39;s disease caused by mutations at codon 
717 of the β-amyloid precursor protein gene. Nature, 353, 844. doi:10.1038/353844a0 
Chen, H., Dzitoyeva, S., & Manev, H. (2012). Effect of aging on 5-hydroxymethylcytosine in 
the mouse hippocampus. Restorative Neurology and Neuroscience, 30(3), 237-245. 
doi:10.3233/RNN-2012-110223 
Chen, L., MacMillan, A. M., Chang, W., Ezaz-Nikpay, K., Lane, W. S., & Verdine, G. L. 
(1991). Direct identification of the active-site nucleophile in a DNA (cytosine-5)-
methyltransferase. Biochemistry, 30(46), 11018-11025.  
Chen, W., Shieh, C., Swanger, S. A., Tankovic, A., Au, M., McGuire, M., . . . Pierson, T. M. 
(2017). GRIN1 mutation associated with intellectual disability alters NMDA receptor 




Cheng, T.-L., Chen, J., Wan, H., Tang, B., Tian, W., Liao, L., & Qiu, Z. (2017). Regulation of 
mRNA splicing by MeCP2 via epigenetic modifications in the brain. Scientific Reports, 
7, 42790. doi:10.1038/srep42790 
Cheung, I., Shulha, H. P., Jiang, Y., Matevossian, A., Wang, J., Weng, Z., & Akbarian, S. 
(2010). Developmental regulation and individual differences of neuronal H3K4me3 
epigenomes in the prefrontal cortex. Proc Natl Acad Sci U S A, 107(19), 8824-8829. 
doi:10.1073/pnas.1001702107 
Chibnik, L. B., Yu, L., Eaton, M. L., Srivastava, G., Schneider, J. A., Kellis, M., . . . De Jager, 
P. L. (2015). Alzheimer’s loci: epigenetic associations and interaction with genetic 
factors. Annals of Clinical and Translational Neurology, 2(6), 636-647. 
doi:10.1002/acn3.201 
Chinta, S. J., Woods, G., Rane, A., Demaria, M., Campisi, J., & Andersen, J. K. (2015). Cellular 
senescence and the aging brain. Experimental Gerontology, 68, 3-7. 
doi:https://doi.org/10.1016/j.exger.2014.09.018 
Chouliaras, L., Mastroeni, D., Delvaux, E., Grover, A., Kenis, G., Hof, P. R., . . . van den Hove, 
D. L. (2013). Consistent decrease in global DNA methylation and hydroxymethylation 
in the hippocampus of Alzheimer's disease patients. Neurobiol Aging, 34(9), 2091-
2099. doi:10.1016/j.neurobiolaging.2013.02.021 
Choy, J. S., Wei, S., Lee, J. Y., Tan, S., Chu, S., & Lee, T. H. (2010). DNA methylation 
increases nucleosome compaction and rigidity. J Am Chem Soc, 132(6), 1782-1783. 
doi:10.1021/ja910264z 
Christensen, B. C., Houseman, E. A., Marsit, C. J., Zheng, S., Wrensch, M. R., Wiemels, J. L., 
. . . Kelsey, K. T. (2009). Aging and environmental exposures alter tissue-specific DNA 
methylation dependent upon CpG island context. PLoS Genet, 5(8), e1000602. 
doi:10.1371/journal.pgen.1000602 
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., . . . Selkoe, D. 
J. (1992). Mutation of the [beta]-amyloid precursor protein in familial Alzheimer's 
disease increases [beta]-protein production. Nature, 360(6405), 672-674.  
Clark, S. J., Smallwood, S. A., Lee, H. J., Krueger, F., Reik, W., & Kelsey, G. (2017). Genome-
wide base-resolution mapping of DNA methylation in single cells using single-cell 
bisulfite sequencing (scBS-seq). Nature Protocols, 12, 534. 
doi:10.1038/nprot.2016.187 
https://www.nature.com/articles/nprot.2016.187#supplementary-information 
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. 
J., & Ashe, K. H. (2004). Natural oligomers of the amyloid-β protein specifically 
disrupt cognitive function. Nature neuroscience, 8, 79. doi:10.1038/nn1372 
https://www.nature.com/articles/nn1372#supplementary-information 
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. 
J., & Ashe, K. H. (2005). Natural oligomers of the amyloid-β protein specifically 
disrupt cognitive function. Nature neuroscience, 8(1), 79-84.  
Cleveland, D. W., Hwo, S. Y., & Kirschner, M. W. (1977). Purification of tau, a microtubule-
associated protein that induces assembly of microtubules from purified tubulin. J Mol 
Biol, 116(2), 207-225.  
Cochran, J. N., Hall, A. M., & Roberson, E. D. (2014). The dendritic hypothesis for Alzheimer's 
disease pathophysiology. Brain Research Bulletin, 103, 18-28. 
doi:10.1016/j.brainresbull.2013.12.004 
Colantuoni, C., Lipska, B. K., Ye, T., Hyde, T. M., Tao, R., Leek, J. T., . . . Kleinman, J. E. 
(2011). Temporal dynamics and genetic control of transcription in the human prefrontal 
cortex. Nature, 478(7370), 519-523. doi:10.1038/nature10524 
233 
 
Collins, J. M., King, A. E., Woodhouse, A., Kirkcaldie, M. T. K., & Vickers, J. C. (2015). The 
effect of focal brain injury on beta-amyloid plaque deposition, inflammation and 
synapses in the APP/PS1 mouse model of Alzheimer's disease. Exp Neurol, 267, 219-
229. doi:http://dx.doi.org/10.1016/j.expneurol.2015.02.034 
Connor, J. R., Menzies, S. L., St Martin, S. M., & Mufson, E. J. (1992). A histochemical study 
of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res, 31(1), 
75-83. doi:10.1002/jnr.490310111 
Connor, J. R., Snyder, B. S., Beard, J. L., Fine, R. E., & Mufson, E. J. (1992). Regional 
distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's 
disease. J Neurosci Res, 31(2), 327-335. doi:10.1002/jnr.490310214 
Consortium, E. P. (2012). An integrated encyclopedia of DNA elements in the human genome. 
Nature, 489(7414), 57-74. doi:10.1038/nature11247 
Cooke, M. S., Evans, M. D., Dizdaroglu, M., & Lunec, J. (2003). Oxidative DNA damage: 
mechanisms, mutation, and disease. Faseb j, 17(10), 1195-1214. doi:10.1096/fj.02-
0752rev 
Coppede, F., & Migliore, L. (2009). DNA damage and repair in Alzheimer's disease. Curr 
Alzheimer Res, 6(1), 36-47.  
Coppieters, N., Dieriks, B. V., Lill, C., Faull, R. L., Curtis, M. A., & Dragunow, M. (2013). 
Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease 
human brain. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2013.11.031 
Corder, E., Saunders, A., Strittmatter, W., Schmechel, D., Gaskell, P., Small, G. a., . . . Pericak-
Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of 
Alzheimer’s disease in late onset families. Science, 261(5123), 921-923.  
Cordy, J. M., Hooper, N. M., & Turner, A. J. (2006). The involvement of lipid rafts in 
Alzheimer's disease (Review) AU - Cordy, Joanna M. Molecular Membrane Biology, 
23(1), 111-122. doi:10.1080/09687860500496417 
Cordy, J. M., Hussain, I., Dingwall, C., Hooper, N. M., & Turner, A. J. (2003). Exclusively 
targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site 
processing of the amyloid precursor protein. Proc Natl Acad Sci U S A, 100(20), 11735-
11740. doi:10.1073/pnas.1635130100 
Council, N. H. a. M. R. (2013). Australian code for the care and use of animals for scientific 
purposes, 8th edition. . Retrieved from  
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., . . 
. Jaenisch, R. (2010a). Histone H3K27ac separates active from poised enhancers and 
predicts developmental state. Proc Natl Acad Sci U S A, 107(50), 21931-21936. 
doi:10.1073/pnas.1016071107 
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., . . 
. Jaenisch, R. (2010b). Histone H3K27ac separates active from poised enhancers and 
predicts developmental state. Proceedings of the National Academy of Sciences, 
107(50), 21931-21936. doi:10.1073/pnas.1016071107 
Cruz, J. C., Tseng, H. C., Goldman, J. A., Shih, H., & Tsai, L. H. (2003). Aberrant Cdk5 
activation by p25 triggers pathological events leading to neurodegeneration and 
neurofibrillary tangles. Neuron, 40(3), 471-483.  
Crystal, H., Dickson, D., Fuld, P., Masur, D., Scott, R., Mehler, M., . . . Wolfson, L. (1988). 
Clinico-pathologic studies in dementia: nondemented subjects with pathologically 
confirmed Alzheimer's disease. Neurology, 38(11), 1682-1687.  
Cummings, B. J., & Cotman, C. W. (1995). Image analysis of beta-amyloid load in Alzheimer's 
disease and relation to dementia severity. Lancet, 346(8989), 1524-1528.  
Czech, C., Tremp, G., & Pradier, L. (2000). Presenilins and Alzheimer's disease: biological 
functions and pathogenic mechanisms. Prog Neurobiol, 60(4), 363-384.  
234 
 
Dagnas, M., Guillou, J.-L., Prévôt, T., & Mons, N. (2013). HDAC Inhibition Facilitates the 
Switch between Memory Systems in Young But Not Aged Mice. The Journal of 
Neuroscience, 33(5), 1954-1963. doi:10.1523/jneurosci.3453-12.2013 
Danka Mohammed, C. P., Park, J. S., Nam, H. G., & Kim, K. (2017). MicroRNAs in brain 
aging. Mech Ageing Dev, 168, 3-9. doi:10.1016/j.mad.2017.01.007 
Dateki, M., Horii, T., Kasuya, Y., Mochizuki, R., Nagao, Y., Ishida, J., . . . Fukamizu, A. 
(2005). Neurochondrin Negatively Regulates CaMKII Phosphorylation, and Nervous 
System-specific Gene Disruption Results in Epileptic Seizure. Journal of Biological 
Chemistry, 280(21), 20503-20508. doi:10.1074/jbc.M414033200 
Davies, M. N., Volta, M., Pidsley, R., Lunnon, K., Dixit, A., Lovestone, S., . . . Mill, J. (2012). 
Functional annotation of the human brain methylome identifies tissue-specific 
epigenetic variation across brain and blood. Genome Biol, 13(6), R43. doi:10.1186/gb-
2012-13-6-r43 
Dawkins, E., & Small, D. H. (2014). Insights into the physiological function of the β-amyloid 
precursor protein: beyond Alzheimer's disease. Journal of Neurochemistry, 129(5), 
756-769. doi:10.1111/jnc.12675 
Day, J. J., Childs, D., Guzman-Karlsson, M. C., Kibe, M., Moulden, J., Song, E., . . . Sweatt, 
J. D. (2013). DNA methylation regulates associative reward learning. Nat Neurosci, 
16(10), 1445-1452. doi:10.1038/nn.3504 
de Castro, F., López-Mascaraque, L., & De Carlos, J. A. (2007). Cajal: lessons on brain 
development. Brain research reviews, 55(2), 481-489.  
De Jager, P. L., Ma, Y., McCabe, C., Xu, J., Vardarajan, B. N., Felsky, D., . . . Bennett, D. A. 
(2018). A multi-omic atlas of the human frontal cortex for aging and Alzheimer’s 
disease research. Scientific Data, 5, 180142. doi:10.1038/sdata.2018.142 
De Jager, P. L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L. C., Yu, L., . . . Bennett, 
D. A. (2014). Alzheimer's disease: early alterations in brain DNA methylation at 
ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci, 17(9), 1156-1163. 
doi:10.1038/nn.3786 
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., . . . 
Van Leuven, F. (1998). Deficiency of presenilin-1 inhibits the normal cleavage of 
amyloid precursor protein. Nature, 391, 387. doi:10.1038/34910 
Deaton, A. M., & Bird, A. (2011). CpG islands and the regulation of transcription. Genes Dev, 
25(10), 1010-1022. doi:10.1101/gad.2037511 
Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., & Björklund, A. (2013). 
TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein 
toxicity. Proc Natl Acad Sci U S A, 110(19), E1817-E1826. 
doi:10.1073/pnas.1305623110 
Demuro, A., Parker, I., & Stutzmann, G. E. (2010). Calcium signaling and amyloid toxicity in 
Alzheimer disease. J Biol Chem, 285(17), 12463-12468. doi:10.1074/jbc.R109.080895 
Dhayalan, A., Rajavelu, A., Rathert, P., Tamas, R., Jurkowska, R. Z., Ragozin, S., & Jeltsch, 
A. (2010). The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and 
guides DNA methylation. J Biol Chem, 285(34), 26114-26120. 
doi:10.1074/jbc.M109.089433 
Diaz, A., Nellore, A., & Song, J. S. (2012). CHANCE: comprehensive software for quality 
control and validation of ChIP-seq data. Genome Biol, 13(10), R98. doi:10.1186/gb-
2012-13-10-r98 
Dickey, C. A., Loring, J. F., Montgomery, J., Gordon, M. N., Eastman, P. S., & Morgan, D. 
(2003). Selectively reduced expression of synaptic plasticity-related genes in amyloid 
precursor protein + presenilin-1 transgenic mice. J Neurosci, 23(12), 5219-5226.  
235 
 
Dickson, T. C., King, C. E., McCormack, G. H., & Vickers, J. C. (1999). Neurochemical 
Diversity of Dystrophic Neurites in the Early and Late Stages of Alzheimer's Disease. 
Exp Neurol, 156(1), 100-110. doi:http://dx.doi.org/10.1006/exnr.1998.7010 
Dickson, T. C., & Vickers, J. C. (2001). The morphological phenotype of β-amyloid plaques 
and associated neuritic changes in Alzheimer’s disease. Neuroscience, 105(1), 99-107. 
doi:http://dx.doi.org/10.1016/S0306-4522(01)00169-5 
Dickstein, D. L., Weaver, C. M., Luebke, J. I., & Hof, P. R. (2013). Dendritic spine changes 
associated with normal aging. Neuroscience, 251, 21-32. 
doi:10.1016/j.neuroscience.2012.09.077 
Dion, M. F., Altschuler, S. J., Wu, L. F., & Rando, O. J. (2005). Genomic characterization 
reveals a simple histone H4 acetylation code. Proc Natl Acad Sci U S A, 102(15), 5501-
5506. doi:10.1073/pnas.0500136102 
Douaud, G., Groves, A. R., Tamnes, C. K., Westlye, L. T., Duff, E. P., Engvig, A., . . . 
Johansen-Berg, H. (2014). A common brain network links development, aging, and 
vulnerability to disease. Proceedings of the National Academy of Sciences, 111(49), 
17648. doi:10.1073/pnas.1410378111 
Doyle, J. P., Dougherty, J. D., Heiman, M., Schmidt, E. F., Stevens, T. R., Ma, G., . . . Heintz, 
N. (2008). Application of a Translational Profiling Approach for the Comparative 
Analysis of CNS Cell Types. Cell, 135(4), 749-762. 
doi:https://doi.org/10.1016/j.cell.2008.10.029 
Driver, A. S., Kodavanti, P. R. S., & Mundy, W. R. (2000). Age-related changes in reactive 
oxygen species production in rat brain homogenates. Neurotoxicology and Teratology, 
22(2), 175-181. doi:https://doi.org/10.1016/S0892-0362(99)00069-0 
Du, J., Johnson, L. M., Jacobsen, S. E., & Patel, D. J. (2015). DNA methylation pathways and 
their crosstalk with histone methylation. Nature reviews. Molecular cell biology, 16(9), 
519-532. doi:10.1038/nrm4043 
Dyer, M., Phipps, A. J., Mitew, S., Taberlay, P. C., & Woodhouse, A. (2019). Age, but Not 
Amyloidosis, Induced Changes in Global Levels of Histone Modifications in 
Susceptible and Disease-Resistant Neurons in Alzheimer’s Disease Model Mice. 
Frontiers in aging neuroscience, 11(68). doi:10.3389/fnagi.2019.00068 
Eid, A., Bihaqi, S. W., Renehan, W. E., & Zawia, N. H. (2016). Developmental lead exposure 
and lifespan alterations in epigenetic regulators and their correspondence to biomarkers 
of Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease 
Monitoring, 2, 123-131. doi:http://dx.doi.org/10.1016/j.dadm.2016.02.002 
Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010). Transgenic Mouse Models of 
Alzheimer’s Disease. The Mount Sinai journal of medicine, New York, 77(1), 69-81. 
doi:10.1002/msj.20159 
Erlandsson, A., Enarsson, M., & Forsberg-Nilsson, K. (2001). Immature neurons from CNS 
stem cells proliferate in response to platelet-derived growth factor. J Neurosci, 21(10), 
3483-3491.  
Ernst, J., & Kellis, M. (2017). Chromatin-state discovery and genome annotation with 
ChromHMM. Nature Protocols, 12, 2478. doi:10.1038/nprot.2017.124 
Ewels, P., Magnusson, M., Lundin, S., & Kaller, M. (2016). MultiQC: summarize analysis 
results for multiple tools and samples in a single report. Bioinformatics, 32(19), 3047-
3048. doi:10.1093/bioinformatics/btw354 
Farlik, M., Sheffield, N. C., Nuzzo, A., Datlinger, P., Schonegger, A., Klughammer, J., & 
Bock, C. (2015). Single-cell DNA methylome sequencing and bioinformatic inference 




Fasolino, M., Liu, S., Wang, Y., & Zhou, Z. (2017). Distinct cellular and molecular 
environments support aging-related DNA methylation changes in the substantia nigra. 
Epigenomics, 9(1), 21-31. doi:10.2217/epi-2016-0084 
Feng, J., Zhou, Y., Campbell, S. L., Le, T., Li, E., Sweatt, J. D., . . . Fan, G. (2010a). Dnmt1 
and Dnmt3a maintain DNA methylation and regulate synaptic function in adult 
forebrain neurons. Nature neuroscience, 13(4), 423-430.  
Feng, J., Zhou, Y., Campbell, S. L., Le, T., Li, E., Sweatt, J. D., . . . Fan, G. (2010b). Dnmt1 
and Dnmt3a maintain DNA methylation and regulate synaptic function in adult 
forebrain neurons. Nature neuroscience, 13, 423. doi:10.1038/nn.2514 
https://www.nature.com/articles/nn.2514#supplementary-information 
Fernandez-Martos, C. M., King, A. E., Atkinson, R. A. K., Woodhouse, A., & Vickers, J. C. 
Neurofilament light gene deletion exacerbates amyloid, dystrophic neurite, and 
synaptic pathology in the APP/PS1 transgenic model of Alzheimer's disease. Neurobiol 
Aging, 36(10), 2757-2767. doi:10.1016/j.neurobiolaging.2015.07.003 
Ferrándiz, M. L., Martínez, M., De Juan, E., Díez, A., Bustos, G., & Miquel, J. (1994). 
Impairment of mitochondrial oxidative phosphorylation in the brain of aged mice. 
Brain Research, 644(2), 335-338. doi:https://doi.org/10.1016/0006-8993(94)91699-3 
Ferrari, K. J., Scelfo, A., Jammula, S., Cuomo, A., Barozzi, I., Stutzer, A., . . . Pasini, D. (2014). 
Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and 
enhancer fidelity. Mol Cell, 53(1), 49-62. doi:10.1016/j.molcel.2013.10.030 
Finch, J. T., & Klug, A. (1976). Solenoidal model for superstructure in chromatin. Proc Natl 
Acad Sci U S A, 73(6), 1897-1901.  
Fink, A. L. (1998). Protein aggregation: folding aggregates, inclusion bodies and amyloid. 
Folding and Design, 3(1), R9-R23. doi:https://doi.org/10.1016/S1359-0278(98)00002-
9 
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007a). Recovery of 
learning and memory is associated with chromatin remodelling. Nature, 447(7141), 
178-182.  
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007b). Recovery of 
learning and memory is associated with chromatin remodelling. Nature, 447, 178. 
doi:10.1038/nature05772 
https://www.nature.com/articles/nature05772#supplementary-information 
Fischle, W., Tseng, B. S., Dormann, H. L., Ueberheide, B. M., Garcia, B. A., Shabanowitz, J., 
. . . Allis, C. D. (2005). Regulation of HP1–chromatin binding by histone H3 
methylation and phosphorylation. Nature, 438, 1116. doi:10.1038/nature04219 
https://www.nature.com/articles/nature04219#supplementary-information 
Fleminger, S., Oliver, D., Lovestone, S., Rabe-Hesketh, S., & Giora, A. (2003). Head injury as 
a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. 
Journal of Neurology, Neurosurgery, and Psychiatry, 74(7), 857-862. 
doi:10.1136/jnnp.74.7.857 
Fonseca, M., & Soriano, E. (1995). Calretinin-immunoreactive neurons in the normal human 
temporal cortex and in Alzheimer's disease. Brain Res, 691(1-2), 83-91.  
Ford, E. E., Grimmer, M. R., Stolzenburg, S., Bogdanovic, O., de Mendoza, A., Farnham, P. 
J., . . . Lister, R. (2017). Frequent lack of repressive capacity of promoter DNA 
methylation identified through genome-wide epigenomic manipulation. bioRxiv.  
Förstl, H., & Kurz, A. (1999). Clinical features of Alzheimer’s disease. European Archives of 
Psychiatry and Clinical Neuroscience, 249(6), 288-290. doi:10.1007/s004060050101 
237 
 
Fox, J. G., Barthold, S., Davisson, M., Newcomer, C. E., Quimby, F. W., & Smith, A. (2006). 
The mouse in biomedical research: normative biology, husbandry, and models (Vol. 
3): Elsevier. 
Francis, Y. I., Fà, M., Ashraf, H., Zhang, H., Staniszewski, A., Latchman, D. S., & Arancio, 
O. (2009). Dysregulation of histone acetylation in the APP/PS1 mouse model of 
Alzheimer's disease. J Alzheimers Dis, 18(1), 131-139. doi:10.3233/jad-2009-1134 
Fraser, H. B., Khaitovich, P., Plotkin, J. B., Pääbo, S., & Eisen, M. B. (2005). Aging and Gene 
Expression in the Primate Brain. PLoS Biology, 3(9), e274. 
doi:10.1371/journal.pbio.0030274 
Fu, Y., Rusznak, Z., Herculano-Houzel, S., Watson, C., & Paxinos, G. (2013). Cellular 
composition characterizing postnatal development and maturation of the mouse brain 
and spinal cord. Brain Struct Funct, 218(5), 1337-1354. doi:10.1007/s00429-012-0462-
x 
Fuks, F., Hurd, P. J., Wolf, D., Nan, X., Bird, A. P., & Kouzarides, T. (2003). The methyl-
CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol 
Chem, 278(6), 4035-4040. doi:10.1074/jbc.M210256200 
Fuso, A., Nicolia, V., Cavallaro, R. A., Ricceri, L., D'Anselmi, F., Coluccia, P., . . . Scarpa, S. 
(2008). B-vitamin deprivation induces hyperhomocysteinemia and brain S-
adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and 
BACE expression and amyloid-β deposition in mice. Molecular and Cellular 
Neuroscience, 37(4), 731-746. doi:https://doi.org/10.1016/j.mcn.2007.12.018 
Fuso, A., Seminara, L., Cavallaro, R. A., D'Anselmi, F., & Scarpa, S. (2005). S-
adenosylmethionine/homocysteine cycle alterations modify DNA methylation status 
with consequent deregulation of PS1 and BACE and beta-amyloid production. 
Molecular and Cellular Neuroscience, 28(1), 195-204. doi:10.1016/j.mcn.2004.09.007 
Gallagher, J. J., Minogue, A. M., & Lynch, M. A. (2013). Impaired performance of female 
APP/PS1 mice in the Morris water maze is coupled with increased Abeta accumulation 
and microglial activation. Neurodegener Dis, 11(1), 33-41. doi:10.1159/000337458 
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, 
S., . . . Frosch, M. P. (2006). Characterization of amyloid deposition in the 
APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis, 24(3), 516-524. 
doi:http://dx.doi.org/10.1016/j.nbd.2006.08.017 
Gasparoni, G., Bultmann, S., Lutsik, P., Kraus, T. F. J., Sordon, S., Vlcek, J., . . . Walter, J. 
(2018). DNA methylation analysis on purified neurons and glia dissects age and 
Alzheimer’s disease-specific changes in the human cortex. Epigenetics Chromatin, 
11(1), 41. doi:10.1186/s13072-018-0211-3 
Gates, L. A., Shi, J., Rohira, A. D., Feng, Q., Zhu, B., Bedford, M. T., . . . O'Malley, B. W. 
(2017). Acetylation on histone H3 lysine 9 mediates a switch from transcription 
initiation to elongation. Journal of Biological Chemistry. 
doi:10.1074/jbc.M117.802074 
Ghosh, K., Agarwal, P., & Haggerty, G. (2011). Alzheimer's Disease – Not an Exaggeration of 
Healthy Aging. Indian Journal of Psychological Medicine, 33(2), 106-114. 
doi:10.4103/0253-7176.92047 
Giri, M., Zhang, M., & Lü, Y. (2016). Genes associated with Alzheimer's disease: an overview 
and current status. Clinical interventions in aging, 11, 665-681. 
doi:10.2147/CIA.S105769 
Gjoneska, E., Pfenning, A. R., Mathys, H., Quon, G., Kundaje, A., Tsai, L.-H., & Kellis, M. 
(2015). Conserved epigenomic signals in mice and humans reveal immune basis of 





Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., . . . Hardy, 
J. (1991). Segregation of a missense mutation in the amyloid precursor protein gene 
with familial Alzheimer's disease. Nature, 349(6311), 704-706.  
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989). Multiple 
isoforms of human microtubule-associated protein tau: sequences and localization in 
neurofibrillary tangles of Alzheimer's disease. Neuron, 3(4), 519-526.  
Gomez-Arboledas, A., Davila, J. C., Sanchez-Mejias, E., Navarro, V., Nunez-Diaz, C., 
Sanchez-Varo, R., . . . Gutierrez, A. (2018). Phagocytic clearance of presynaptic 
dystrophies by reactive astrocytes in Alzheimer's disease. Glia, 66(3), 637-653. 
doi:10.1002/glia.23270 
Govindarajan, N., Rao, P., Burkhardt, S., Sananbenesi, F., Schluter, O. M., Bradke, F., . . . 
Fischer, A. (2013). Reducing HDAC6 ameliorates cognitive deficits in a mouse model 
for Alzheimer's disease. EMBO Mol Med, 5(1), 52-63. doi:10.1002/emmm.201201923 
Gowrishankar, S., Yuan, P., Wu, Y., Schrag, M., Paradise, S., Grutzendler, J., . . . Ferguson, S. 
M. (2015). Massive accumulation of luminal protease-deficient axonal lysosomes at 
Alzheimer’s disease amyloid plaques. Proceedings of the National Academy of 
Sciences, 112(28), E3699-E3708. doi:10.1073/pnas.1510329112 
Graff, J., Rei, D., Guan, J. S., Wang, W. Y., Seo, J., Hennig, K. M., . . . Tsai, L. H. (2012). An 
epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature, 
483(7388), 222-226. doi:10.1038/nature10849 
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., & Teipel, S. J. (2017). In vivo 
staging of regional amyloid deposition. Neurology, 89(20), 2031-2038. 
doi:10.1212/wnl.0000000000004643 
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. 
(1986). Microtubule-associated protein tau. A component of Alzheimer paired helical 
filaments. J Biol Chem, 261(13), 6084-6089.  
Gu, G. J., Lund, H., Wu, D., Blokzijl, A., Classon, C., von Euler, G., . . . Kamali-Moghaddam, 
M. (2013). Role of individual MARK isoforms in phosphorylation of tau at Ser(2)(6)(2) 
in Alzheimer's disease. Neuromolecular Med, 15(3), 458-469. doi:10.1007/s12017-
013-8232-3 
Gu, X., Sun, J., Li, S., Wu, X., & Li, L. (2013). Oxidative stress induces DNA demethylation 
and histone acetylation in SH-SY5Y cells: potential epigenetic mechanisms in gene 
transcription in Aβ production. Neurobiol Aging, 34(4), 1069-1079. 
doi:https://doi.org/10.1016/j.neurobiolaging.2012.10.013 
Guo, J. U., Ma, D. K., Mo, H., Ball, M. P., Jang, M.-H., Bonaguidi, M. A., . . . Song, H. (2011). 
Neuronal activity modifies the DNA methylation landscape in the adult brain. Nature 
neuroscience, 14, 1345. doi:10.1038/nn.2900 
https://www.nature.com/articles/nn.2900#supplementary-information 
Guo, J. U., Su, Y., Shin, J. H., Shin, J., Li, H., Xie, B., . . . Song, H. (2013). Distribution, 
recognition and regulation of non-CpG methylation in the adult mammalian brain. 
Nature neuroscience, 17, 215. doi:10.1038/nn.3607 
https://www.nature.com/articles/nn.3607#supplementary-information 
Hampton, D. W., Webber, D. J., Bilican, B., Goedert, M., Spillantini, M. G., & Chandran, S. 
(2010). Cell-mediated neuroprotection in a mouse model of human tauopathy. J 
Neurosci, 30(30), 9973-9983. doi:10.1523/jneurosci.0834-10.2010 
Handley, E. E., Pitman, K. A., Dawkins, E., Young, K. M., Clark, R. M., Jiang, T. C., . . . 
Blizzard, C. A. (2017). Synapse Dysfunction of Layer V Pyramidal Neurons Precedes 
239 
 
Neurodegeneration in a Mouse Model of TDP-43 Proteinopathies. Cereb Cortex, 27(7), 
3630-3647. doi:10.1093/cercor/bhw185 
Hardy, J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on 
the road to therapeutics. Science (New York, N.Y.), 297(5580), 353-356. 
doi:10.1126/science.1072994 
Hardy, J., & Selkoe, D. J. (2002). The Amyloid Hypothesis of Alzheimer's Disease: Progress 
and Problems on the Road to Therapeutics. Science, 297(5580), 353-356. 
doi:10.1126/science.1072994 
Hardy, J. A., & Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. 
Science, 256(5054), 184.  
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., . . . 
Williams, J. (2009). Genome-wide association study identifies variants at CLU and 
PICALM associated with Alzheimer&#39;s disease. Nat Genet, 41, 1088. 
doi:10.1038/ng.440 
https://www.nature.com/articles/ng.440#supplementary-information 
Hartl, F. U., Bracher, A., & Hayer-Hartl, M. (2011). Molecular chaperones in protein folding 
and proteostasis. Nature, 475, 324. doi:10.1038/nature10317 
Hatanpää, K., Rapoport, S. I., Brady, D. R., Isaacs, K. R., & Shirao, T. (1999). Loss of Proteins 
Regulating Synaptic Plasticity in Normal Aging of the Human Brain and in Alzheimer 
Disease. Journal of Neuropathology & Experimental Neurology, 58(6), 637-643. 
doi:10.1097/00005072-199906000-00008 
Heintzman, N. D., Hon, G. C., Hawkins, R. D., Kheradpour, P., Stark, A., Harp, L. F., . . . 
Ching, C. W. (2009). Histone modifications at human enhancers reflect global cell-
type-specific gene expression. Nature, 459. doi:10.1038/nature07829 
Heintzman, N. D., Stuart, R. K., Hon, G., Fu, Y., Ching, C. W., Hawkins, R. D., . . . Ren, B. 
(2007). Distinct and predictive chromatin signatures of transcriptional promoters and 
enhancers in the human genome. Nat Genet, 39(3), 311-318. 
doi:http://www.nature.com/ng/journal/v39/n3/suppinfo/ng1966_S1.html 
Heitz, E. (1928). Das Heterochromatin der Moose. I. Jahrb Wiss Bot, 1(69), 762-818.  
Henley, J. M., & Wilkinson, K. A. (2013). AMPA receptor trafficking and the mechanisms 
underlying synaptic plasticity and cognitive aging. Dialogues Clin Neurosci, 15(1), 11-
27.  
Hernandez, D. G., Nalls, M. A., Gibbs, J. R., Arepalli, S., van der Brug, M., Chong, S., . . . 
Traynor, B. J. (2011). Distinct DNA methylation changes highly correlated with 
chronological age in the human brain. Human molecular genetics, 20(6), 1164-1172.  
Hirabayashi, Y., & Gotoh, Y. (2005). Stage-dependent fate determination of neural precursor 
cells in mouse forebrain. Neuroscience Research, 51(4), 331-336. 
doi:https://doi.org/10.1016/j.neures.2005.01.004 
Hirabayashi, Y., Itoh, Y., Tabata, H., Nakajima, K., Akiyama, T., Masuyama, N., & Gotoh, Y. 
(2004). The Wnt/beta-catenin pathway directs neuronal differentiation of cortical 
neural precursor cells. Development, 131(12), 2791-2801. doi:10.1242/dev.01165 
Hirschhorn, J. N., Brown, S. A., Clark, C. D., & Winston, F. (1992). Evidence that SNF2/SWI2 
and SNF5 activate transcription in yeast by altering chromatin structure. Genes Dev, 
6(12a), 2288-2298.  
Hnisz, D., Abraham, Brian J., Lee, Tong I., Lau, A., Saint-André, V., Sigova, Alla A., . . . 
Young, Richard A. (2013). Super-Enhancers in the Control of Cell Identity and 
Disease. Cell, 155(4), 934-947. doi:10.1016/j.cell.2013.09.053 
240 
 
Ho, P. I., Ashline, D., Dhitavat, S., Ortiz, D., Collins, S. C., Shea, T. B., & Rogers, E. (2003). 
Folate deprivation induces neurodegeneration: roles of oxidative stress and increased 
homocysteine. Neurobiol Dis, 14(1), 32-42.  
Hochberg, Z., Feil, R., Constancia, M., Fraga, M., Junien, C., Carel, J. C., . . . Albertsson-
Wikland, K. (2011). Child health, developmental plasticity, and epigenetic 
programming. Endocr Rev, 32(2), 159-224. doi:10.1210/er.2009-0039 
Hof, P. R., Cox, K., & Morrison, J. H. (1990). Quantitative analysis of a vulnerable subset of 
pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal 
cortex. J Comp Neurol, 301(1), 44-54. doi:10.1002/cne.903010105 
Hof, P. R., & Morrison, J. H. (1990). Quantitative analysis of a vulnerable subset of pyramidal 
neurons in Alzheimer's disease: II. Primary and secondary visual cortex. J Comp 
Neurol, 301(1), 55-64. doi:10.1002/cne.903010106 
Hof, P. R., Nimchinsky, E. A., Celio, M. R., Bouras, C., & Morrison, J. H. (1993). Calretinin-
immunoreactive neocortical interneurons are unaffected in Alzheimer's disease. 
Neurosci Lett, 152(1-2), 145-148.  
Holliday, R., & Pugh, J. (1975). DNA modification mechanisms and gene activity during 
development. Science, 187(4173), 226-232. doi:10.1126/science.187.4173.226 
Holtmaat, A., & Svoboda, K. (2009). Experience-dependent structural synaptic plasticity in the 
mammalian brain. Nature Reviews Neuroscience, 10, 647. doi:10.1038/nrn2699 
https://www.nature.com/articles/nrn2699#supplementary-information 
Hong, L., Schroth, G. P., Matthews, H. R., Yau, P., & Bradbury, E. M. (1993). Studies of the 
DNA binding properties of histone H4 amino terminus. Thermal denaturation studies 
reveal that acetylation markedly reduces the binding constant of the H4 "tail" to DNA. 
J Biol Chem, 268(1), 305-314.  
Hotchkiss, R. D. (1948). The quantitative separation of purines, pyrimidines, and nucleosides 
by paper chromatography. J Biol Chem, 175(1), 315-332.  
Houtman, S. H., Rutteman, M., De Zeeuw, C. I., & French, P. J. (2007). Echinoderm 
microtubule-associated protein like protein 4, a member of the echinoderm 
microtubule-associated protein family, stabilizes microtubules. Neuroscience, 144(4), 
1373-1382. doi:10.1016/j.neuroscience.2006.11.015 
Hradek, A. C., Lee, H.-P., Siedlak, S. L., Torres, S. L., Jung, W., Han, A. H., & Lee, H.-g. 
(2015). Distinct chronology of neuronal cell cycle re-entry and tau pathology in the 
3xTg-AD mouse model and Alzheimer's disease patients. J Alzheimers Dis, 43(1), 57-
65. doi:10.3233/JAD-141083 
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., . . . Cole, G. (1996). 
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. 
Science, 274(5284), 99-102.  
Hsu, A. L., Murphy, C. T., & Kenyon, C. (2003). Regulation of aging and age-related disease 
by DAF-16 and heat-shock factor. Science, 300(5622), 1142-1145. 
doi:10.1126/science.1083701 
Hu, X., Pickering, E., Liu, Y. C., Hall, S., Fournier, H., Katz, E., . . . Soares, H. (2011). Meta-
analysis for genome-wide association study identifies multiple variants at the BIN1 
locus associated with late-onset Alzheimer's disease. PLoS One, 6(2), e16616. 
doi:10.1371/journal.pone.0016616 
Huang, Y., Fang, J., Bedford, M. T., Zhang, Y., & Xu, R.-M. (2006). Recognition of Histone 
H3 Lysine-4 Methylation by the Double Tudor Domain of JMJD2A. Science, 
312(5774), 748-751. doi:10.1126/science.1125162 
241 
 
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., . . . Olney, J. 
W. (1999). Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the 
Developing Brain. Science, 283(5398), 70-74. doi:10.1126/science.283.5398.70 
Ioshikhes, I. P., & Zhang, M. Q. (2000). Large-scale human promoter mapping using CpG 
islands. Nat Genet, 26, 61. doi:10.1038/79189 
Irizarry, M. C., McNamara, M., Fedorchak, K., Hsiao, K., & Hyman, B. T. (1997). APPSw 
transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no 
neuronal loss in CA1. J Neuropathol Exp Neurol, 56(9), 965-973.  
Irizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D., & Hyman, B. 
T. (1997). Abeta deposition is associated with neuropil changes, but not with overt 
neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic 
mouse. J Neurosci, 17(18), 7053-7059.  
Islam, S., Zeisel, A., Joost, S., La Manno, G., Zajac, P., Kasper, M., . . . Linnarsson, S. (2014). 
Quantitative single-cell RNA-seq with unique molecular identifiers. Nat Methods, 
11(2), 163-166. doi:10.1038/nmeth.2772 
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989). Relationship of 
microglia and astrocytes to amyloid deposits of Alzheimer disease. Journal of 
Neuroimmunology, 24(3), 173-182. doi:10.1016/0165-5728(89)90115-X 
Ito, S., D'Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010). Role 
of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass 
specification. Nature, 466(7310), 1129-1133. doi:10.1038/nature09303 
Jaenisch, R., & Bird, A. (2003). Epigenetic regulation of gene expression: how the genome 
integrates intrinsic and environmental signals. Nat Genet, 33 Suppl, 245-254. 
doi:10.1038/ng1089 
Jaenisch, R., & Bird, A. (2003). Epigenetic regulation of gene expression: how the genome 
integrates intrinsic and environmental signals. Nat Genet, 33, 245. doi:10.1038/ng1089 
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., . . . 
Borchelt, D. R. (2004). Mutant presenilins specifically elevate the levels of the 42 
residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific 
gamma secretase. Hum Mol Genet, 13(2), 159-170. doi:10.1093/hmg/ddh019 
Jean, D. C., & Baas, P. W. (2013). It cuts two ways: microtubule loss during Alzheimer disease. 
Embo j, 32(22), 2900-2902. doi:10.1038/emboj.2013.219 
Jenuwein, T., & Allis, C. D. (2001). Translating the histone code. Science, 293(5532), 1074-
1080. doi:10.1126/science.1063127 
Jia, D., Jurkowska, R. Z., Zhang, X., Jeltsch, A., & Cheng, X. (2007). Structure of Dnmt3a 
bound to Dnmt3L suggests a model for de novo DNA methylation. Nature, 449(7159), 
248-251. doi:10.1038/nature06146 
Jiang, Y., Matevossian, A., Huang, H.-S., Straubhaar, J., & Akbarian, S. (2008). Isolation of 
neuronal chromatin from brain tissue. BMC neuroscience, 9(1), 42.  
Jin, F., Li, Y., Dixon, J. R., Selvaraj, S., Ye, Z., Lee, A. Y., . . . Ren, B. (2013). A high-
resolution map of the three-dimensional chromatin interactome in human cells. Nature, 
503(7475), 290-294. doi:10.1038/nature12644 
Jjingo, D., Conley, A. B., Yi, S. V., Lunyak, V. V., & Jordan, I. K. (2012). On the presence 
and role of human gene-body DNA methylation. Oncotarget, 3(4), 462-474.  
Johnson, D. S., Mortazavi, A., Myers, R. M., & Wold, B. (2007). Genome-wide mapping of in 
vivo protein-DNA interactions. Science, 316(5830), 1497-1502. 
doi:10.1126/science.1141319 
Jones, P. A. (2012). Functions of DNA methylation: islands, start sites, gene bodies and 
beyond. Nat Rev Genet, 13(7), 484-492.  
242 
 
Jones, P. A., & Liang, G. (2009). Rethinking how DNA Methylation Patterns are Maintained. 
Nature reviews. Genetics, 10(11), 805-811. doi:10.1038/nrg2651 
Jones, P. A., & Taylor, S. M. (1980). Cellular differentiation, cytidine analogs and DNA 
methylation. Cell, 20(1), 85-93.  
Jones, P. L., Jan Veenstra, G. C., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., . . . 
Wolffe, A. P. (1998). Methylated DNA and MeCP2 recruit histone deacetylase to 
repress transcription. Nat Genet, 19, 187. doi:10.1038/561 
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., . . . 
Stefansson, K. (2012). A mutation in APP protects against Alzheimer’s disease and 
age-related cognitive decline. Nature, 488, 96. doi:10.1038/nature11283 
https://www.nature.com/articles/nature11283#supplementary-information 
Kalinowska, M., Chávez, A. E., Lutzu, S., Castillo, P. E., Bukauskas, F. F., & Francesconi, A. 
(2015). Actinin-4 Governs Dendritic Spine Dynamics and Promotes Their Remodeling 
by Metabotropic Glutamate Receptors. J Biol Chem, 290(26), 15909-15920. 
doi:10.1074/jbc.M115.640136 
Kalpouzos, G., Persson, J., & Nyberg, L. (2012). Local brain atrophy accounts for functional 
activity differences in normal aging. Neurobiol Aging, 33(3), 623.e621-623.e613. 
doi:10.1016/j.neurobiolaging.2011.02.021 
Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., . . . 
Muller-Hill, B. (1987). The precursor of Alzheimer's disease amyloid A4 protein 
resembles a cell-surface receptor. Nature, 325(6106), 733-736. doi:10.1038/325733a0 
Karch, C. M., & Goate, A. M. (2015). Alzheimer's disease risk genes and mechanisms of 
disease pathogenesis. Biol Psychiatry, 77(1), 43-51. 
doi:10.1016/j.biopsych.2014.05.006 
Karp, A., Andel, R., Parker, M. G., Wang, H. X., Winblad, B., & Fratiglioni, L. (2009). 
Mentally stimulating activities at work during midlife and dementia risk after age 75: 
follow-up study from the Kungsholmen Project. Am J Geriatr Psychiatry, 17(3), 227-
236. doi:10.1097/JGP.0b013e318190b691 
Kelly, P. H., Bondolfi, L., Hunziker, D., Schlecht, H. P., Carver, K., Maguire, E., . . . Sommer, 
B. (2003). Progressive age-related impairment of cognitive behavior in APP23 
transgenic mice. Neurobiol Aging, 24(2), 365-378.  
Kelly, T. K., Liu, Y., Lay, F. D., Liang, G., Berman, B. P., & Jones, P. A. (2012). Genome-
wide mapping of nucleosome positioning and DNA methylation within individual DNA 
molecules. Genome Res, 22(12), 2497-2506. doi:10.1101/gr.143008.112 
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, 
T. K., . . . Amit, I. (2017). A Unique Microglia Type Associated with Restricting 
Development of Alzheimer’s Disease. Cell, 169(7), 1276-1290.e1217. 
doi:https://doi.org/10.1016/j.cell.2017.05.018 
Khan, A., & Zhang, X. (2016). dbSUPER: a database of super-enhancers in mouse and human 
genome. Nucleic Acids Res, 44(D1), D164-171. doi:10.1093/nar/gkv1002 
Khandelwal, P. J., Herman, A. M., & Moussa, C. E. H. (2011). Inflammation in the early stages 
of neurodegenerative pathology. Journal of Neuroimmunology, 238(1-2), 1-11. 
doi:10.1016/j.jneuroim.2011.07.002 
Kidder, B. L., Hu, G., & Zhao, K. (2011). ChIP-Seq: Technical Considerations for Obtaining 
High Quality Data. Nature immunology, 12(10), 918-922. doi:10.1038/ni.2117 
Kikis, E. A., Gidalevitz, T., & Morimoto, R. I. (2010). Protein homeostasis in models of aging 
and age-related conformational disease. Adv Exp Med Biol, 694, 138-159.  
Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & 
Rumbaugh, G. (2009). Inhibitors of Class 1 Histone Deacetylases Reverse Contextual 
243 
 
Memory Deficits in a Mouse Model of Alzheimer's Disease. 
Neuropsychopharmacology, 35(4), 870-880. 
doi:http://www.nature.com/npp/journal/v35/n4/suppinfo/npp2009197s1.html 
Kim, K. K., Adelstein, R. S., & Kawamoto, S. (2009). Identification of neuronal nuclei (NeuN) 
as Fox-3, a new member of the Fox-1 gene family of splicing factors. J Biol Chem, 
284(45), 31052-31061. doi:10.1074/jbc.M109.052969 
Kim, K. K., Adelstein, R. S., & Kawamoto, S. (2009). Identification of Neuronal Nuclei 
(NeuN) as Fox-3, a New Member of the Fox-1 Gene Family of Splicing Factors. J Biol 
Chem, 284(45), 31052-31061. doi:10.1074/jbc.M109.052969 
Kleff, S., Andrulis, E. D., Anderson, C. W., & Sternglanz, R. (1995). Identification of a gene 
encoding a yeast histone H4 acetyltransferase. J Biol Chem, 270(42), 24674-24677.  
Klein, H.-U., McCabe, C., Gjoneska, E., Sullivan, S. E., Kaskow, B. J., Tang, A., . . . De Jager, 
P. L. (2019). Epigenome-wide study uncovers large-scale changes in histone 
acetylation driven by tau pathology in aging and Alzheimer’s human brains. Nature 
neuroscience, 22(1), 37-46. doi:10.1038/s41593-018-0291-1 
Klimasauskas, S., Kumar, S., Roberts, R. J., & Cheng, X. (1994). Hhal methyltransferase flips 
its target base out of the DNA helix. Cell, 76(2), 357-369. 
doi:https://doi.org/10.1016/0092-8674(94)90342-5 
Koch, L. (2018). Altered splicing in Alzheimer transcriptomes. Nature Reviews Genetics, 
19(12), 738-739. doi:10.1038/s41576-018-0064-4 
Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-
Alloza, M., . . . Spires-Jones, T. L. (2009a). Oligomeric amyloid β associates with 
postsynaptic densities and correlates with excitatory synapse loss near senile plaques. 
Proceedings of the National Academy of Sciences, 106(10), 4012-4017. 
doi:10.1073/pnas.0811698106 
Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-
Alloza, M., . . . Spires-Jones, T. L. (2009b). Oligomeric amyloid β associates with 
postsynaptic densities and correlates with excitatory synapse loss near senile plaques. 
Proc Natl Acad Sci U S A, 106(10), 4012-4017. doi:10.1073/pnas.0811698106 
Kok, E., Haikonen, S., Luoto, T., Huhtala, H., Goebeler, S., Haapasalo, H., & Karhunen, P. J. 
(2009). Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions 
begins in middle age. Ann Neurol, 65(6), 650-657. doi:10.1002/ana.21696 
Koldamova, R., Schug, J., Lefterova, M., Cronican, A. A., Fitz, N. F., Davenport, F. A., . . . 
Lefterov, I. (2014). Genome-wide approaches reveal EGR1-controlled regulatory 
networks associated with neurodegeneration. Neurobiol Dis, 63, 107-114. 
doi:10.1016/j.nbd.2013.11.005 
Koren, J., 3rd, Jinwal, U. K., Lee, D. C., Jones, J. R., Shults, C. L., Johnson, A. G., . . . Dickey, 
C. A. (2009). Chaperone signalling complexes in Alzheimer's disease. Journal of 
cellular and molecular medicine, 13(4), 619-630. doi:10.1111/j.1582-
4934.2008.00557.x 
Kornberg, R. D. (1974). Chromatin structure: a repeating unit of histones and DNA. Science, 
184(4139), 868-871.  
Kouzarides, T. (2007). Chromatin Modifications and Their Function. Cell, 128(4), 693-705. 
doi:https://doi.org/10.1016/j.cell.2007.02.005 
Kozlenkov, A., Roussos, P., Timashpolsky, A., Barbu, M., Rudchenko, S., Bibikova, M., . . . 
Dracheva, S. (2014). Differences in DNA methylation between human neuronal and 
glial cells are concentrated in enhancers and non-CpG sites. Nucleic Acids Res, 42(1), 
109-127. doi:10.1093/nar/gkt838 
Kozlenkov, A., Wang, M., Roussos, P., Rudchenko, S., Barbu, M., Bibikova, M., . . . Dracheva, 
S. (2016). Substantial DNA methylation differences between two major neuronal 
244 
 
subtypes in human brain. Nucleic Acids Res, 44(6), 2593-2612. 
doi:10.1093/nar/gkv1304 
Kraus, T. F., Guibourt, V., & Kretzschmar, H. A. (2015). 5-Hydroxymethylcytosine, the "Sixth 
Base", during brain development and ageing. J Neural Transm (Vienna), 122(7), 1035-
1043. doi:10.1007/s00702-014-1346-4 
Kraus, T. F. J., Kilinc, S., Steinmaurer, M., Stieglitz, M., Guibourt, V., & Kretzschmar, H. A. 
(2016). Profiling of methylation and demethylation pathways during brain development 
and ageing. Journal of Neural Transmission, 123(3), 189-203. doi:10.1007/s00702-
015-1469-2 
Kuan, C. Y., Roth, K. A., Flavell, R. A., & Rakic, P. (2000). Mechanisms of programmed cell 
death in the developing brain. Trends Neurosci, 23(7), 291-297.  
Kuchibhotla, K. V., Goldman, S. T., Lattarulo, C. R., Wu, H.-Y., Hyman, B. T., & Bacskai, B. 
J. (2008). Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo 
resulting in structural and functional disruption of neuronal networks. Neuron, 59(2), 
214-225. doi:10.1016/j.neuron.2008.06.008 
Kwok, J. C., Warren, P., & Fawcett, J. W. (2012). Chondroitin sulfate: a key molecule in the 
brain matrix. Int J Biochem Cell Biol, 44(4), 582-586. doi:10.1016/j.biocel.2012.01.004 
Lake, B. B., Ai, R., Kaeser, G. E., Salathia, N. S., Yung, Y. C., Liu, R., . . . Zhang, K. (2016). 
Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the 
human brain. Science, 352(6293), 1586-1590. doi:10.1126/science.aaf1204 
Lambert, J. C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., . . . Amouyel, P. 
(2009). Genome-wide association study identifies variants at CLU and CR1 associated 
with Alzheimer's disease. Nat Genet, 41(10), 1094-1099. doi:10.1038/ng.439 
Landt, S. G., Marinov, G. K., Kundaje, A., Kheradpour, P., Pauli, F., Batzoglou, S., . . . Snyder, 
M. (2012). ChIP-seq guidelines and practices of the ENCODE and modENCODE 
consortia. Genome Res, 22(9), 1813-1831. doi:10.1101/gr.136184.111 
Langie, S. A. S., Cameron, K. M., Ficz, G., Oxley, D., Tomaszewski, B., Gorniak, J. P., . . . 
Mathers, J. C. (2017). The Ageing Brain: Effects on DNA Repair and DNA Methylation 
in Mice. Genes, 8(2), 75. doi:10.3390/genes8020075 
Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. Nat Meth, 
9(4), 357-359. doi:10.1038/nmeth.1923 
http://www.nature.com/nmeth/journal/v9/n4/abs/nmeth.1923.html#supplementary-
information 
Lardenoije, R., van den Hove, D. L. A., Havermans, M., van Casteren, A., Le, K. X., Palmour, 
R., . . . Rutten, B. P. F. (2018). Age-related epigenetic changes in hippocampal 
subregions of four animal models of Alzheimer's disease. Molecular and Cellular 
Neuroscience, 86, 1-15. doi:https://doi.org/10.1016/j.mcn.2017.11.002 
Lashley, T., Gami, P., Valizadeh, N., Li, A., Revesz, T., & Balazs, R. (2014). Alterations in 
global DNA methylation and hydroxymethylation are not detected in Alzheimer's 
disease. Neuropathol Appl Neurobiol. doi:10.1111/nan.12183 
Laurin, D., Verreault, R., Lindsay, J., MacPherson, K., & Rockwood, K. (2001). Physical 
activity and risk of cognitive impairment and dementia in elderly persons. Archives of 
Neurology, 58(3), 498-504. doi:10.1001/archneur.58.3.498 
Lawrence, M., Gentleman, R., & Carey, V. (2009). rtracklayer: an R package for interfacing 
with genome browsers. Bioinformatics, 25(14), 1841-1842. 
doi:10.1093/bioinformatics/btp328 
Le Gras, S., Keime, C., Anthony, A., Lotz, C., De Longprez, L., Brouillet, E., . . . Merienne, 
K. (2017). Altered enhancer transcription underlies Huntington's disease striatal 
transcriptional signature. Scientific Reports, 7, 42875-42875. doi:10.1038/srep42875 
245 
 
Lee, C. Y. D., & Landreth, G. E. (2010). The role of microglia in amyloid clearance from the 
AD brain. J Neural Transm (Vienna), 117(8), 949-960. doi:10.1007/s00702-010-0433-
4 
Lee, J. Y., & Lee, T.-H. (2012). Effects of DNA methylation on the structure of nucleosomes. 
J Am Chem Soc, 134(1), 173-175. doi:10.1021/ja210273w 
Lee, M. K., & Cleveland, D. W. (1996). Neuronal intermediate filaments. Annu Rev Neurosci, 
19, 187-217. doi:10.1146/annurev.ne.19.030196.001155 
Lehnertz, B., Ueda, Y., Derijck, A. A. H. A., Braunschweig, U., Perez-Burgos, L., Kubicek, 
S., . . . Peters, A. H. F. M. (2003). Suv39h-Mediated Histone H3 Lysine 9 Methylation 
Directs DNA Methylation to Major Satellite Repeats at Pericentric Heterochromatin. 
Current Biology, 13(14), 1192-1200. doi:https://doi.org/10.1016/S0960-
9822(03)00432-9 
Leighton, L. J., Zhao, Q., Li, X., Dai, C., Marshall, P. R., Liu, S., . . . Wei, W. (2018). A 
Functional Role for the Epigenetic Regulator ING1 in Activity-induced Gene 
Expression in Primary Cortical Neurons. Neuroscience, 369, 248-260. 
doi:https://doi.org/10.1016/j.neuroscience.2017.11.018 
Levenson, J. M., Roth, T. L., Lubin, F. D., Miller, C. A., Huang, I.-C., Desai, P., . . . Sweatt, J. 
D. (2006). Evidence that DNA (cytosine-5) methyltransferase regulates synaptic 
plasticity in the hippocampus. Journal of Biological Chemistry, 281(23), 15763-15773.  
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D., Oshima, J., Pettingell, W., . . . al., e. 
(1995). Candidate gene for the chromosome 1 familial Alzheimer's disease locus. 
Science, 269(5226), 973-977. doi:10.1126/science.7638622 
Lewis, J. D., Meehan, R. R., Henzel, W. J., Maurer-Fogy, I., Jeppesen, P., Klein, F., & Bird, 
A. (1992). Purification, sequence, and cellular localization of a novel chromosomal 
protein that binds to methylated DNA. Cell, 69(6), 905-914.  
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., . . . Durbin, R. (2009). 
The Sequence Alignment/Map format and SAMtools. Bioinformatics, 25(16), 2078-
2079. doi:10.1093/bioinformatics/btp352 
Li, X., Wei, W., Zhao, Q.-Y., Widagdo, J., Baker-Andresen, D., Flavell, C. R., . . . Bredy, T. 
W. (2014). Neocortical Tet3-mediated accumulation of 5-hydroxymethylcytosine 
promotes rapid behavioral adaptation. Proceedings of the National Academy of 
Sciences, 111(19), 7120-7125. doi:10.1073/pnas.1318906111 
Li, Y., Sun, H., Chen, Z., Xu, H., Bu, G., & Zheng, H. (2016). Implications of GABAergic 
Neurotransmission in Alzheimer’s Disease. Frontiers in aging neuroscience, 8, 31. 
doi:10.3389/fnagi.2016.00031 
Liang, Y. (2019). Emerging Concepts and Functions of Autophagy as a Regulator of Synaptic 
Components and Plasticity. Cells, 8(1). doi:10.3390/cells8010034 
Lindroth, A. M., Cao, X., Jackson, J. P., Zilberman, D., McCallum, C. M., Henikoff, S., & 
Jacobsen, S. E. (2001). Requirement of CHROMOMETHYLASE3 for maintenance of 
CpXpG methylation. Science, 292(5524), 2077-2080. doi:10.1126/science.1059745 
Lipinski, M. M., Zheng, B., Lu, T., Yan, Z., Py, B. F., Ng, A., . . . Yuan, J. (2010). Genome-
wide analysis reveals mechanisms modulating autophagy in normal brain aging and in 
Alzheimer's disease. Proc Natl Acad Sci U S A, 107(32), 14164-14169. 
doi:10.1073/pnas.1009485107 
Lister, R., Mukamel, E. A., Nery, J. R., Urich, M., Puddifoot, C. A., Johnson, N. D., . . . Ecker, 
J. R. (2013). Global Epigenomic Reconfiguration During Mammalian Brain 
Development. Science, 341(6146). doi:10.1126/science.1237905 
Lister, R., Pelizzola, M., Dowen, R. H., Hawkins, R. D., Hon, G., Tonti-Filippini, J., . . . Ecker, 
J. R. (2009). Human DNA methylomes at base resolution show widespread epigenomic 
differences. Nature, 462(7271), 315-322. doi:10.1038/nature08514 
246 
 
Liu, C. L., Kaplan, T., Kim, M., Buratowski, S., Schreiber, S. L., Friedman, N., & Rando, O. 
J. (2005). Single-Nucleosome Mapping of Histone Modifications in S. cerevisiae. PLoS 
Biology, 3(10), e328. doi:10.1371/journal.pbio.0030328 
Liu, J., & Jia, G. (2014). Methylation modifications in eukaryotic messenger RNA. J Genet 
Genomics, 41(1), 21-33. doi:10.1016/j.jgg.2013.10.002 
Local, A., Huang, H., Albuquerque, C. P., Singh, N., Lee, A. Y., Wang, W., . . . Ren, B. (2018). 
Identification of H3K4me1-associated proteins at mammalian enhancers. Nat Genet, 
50(1), 73-82. doi:10.1038/s41588-017-0015-6 
Loerch, P. M., Lu, T., Dakin, K. A., Vann, J. M., Isaacs, A., Geula, C., . . . Yankner, B. A. 
(2008). Evolution of the aging brain transcriptome and synaptic regulation. PLoS One, 
3(10), e3329-e3329. doi:10.1371/journal.pone.0003329 
Lonskaya, I., Hebron, M., Chen, W., Schachter, J., & Moussa, C. (2014). Tau deletion impairs 
intracellular beta-amyloid-42 clearance and leads to more extracellular plaque 
deposition in gene transfer models. Mol Neurodegener, 9, 46. doi:10.1186/1750-1326-
9-46 
Lopez-Atalaya, J. P., Ito, S., Valor, L. M., Benito, E., & Barco, A. (2013). Genomic targets, 
and histone acetylation and gene expression profiling of neural HDAC inhibition. 
Nucleic Acids Res, 41(17), 8072-8084. doi:10.1093/nar/gkt590 
López-Muñoz, F., Boya, J., & Alamo, C. (2006). Neuron theory, the cornerstone of 
neuroscience, on the centenary of the Nobel Prize award to Santiago Ramón y Cajal. 
Brain Research Bulletin, 70(4), 391-405. 
doi:https://doi.org/10.1016/j.brainresbull.2006.07.010 
Lopez, J. R., Lyckman, A., Oddo, S., Laferla, F. M., Querfurth, H. W., & Shtifman, A. (2008). 
Increased intraneuronal resting [Ca2+] in adult Alzheimer's disease mice. J Neurochem, 
105(1), 262-271. doi:10.1111/j.1471-4159.2007.05135.x 
Lord, J., & Cruchaga, C. (2014a). The epigenetic landscape of Alzheimer's disease. Nat 
Neurosci, 17(9), 1138-1140. doi:10.1038/nn.3792 
Lord, J., & Cruchaga, C. (2014b). THE EPIGENETIC LANDSCAPE OF ALZHEIMER’S 
DISEASE. Nature neuroscience, 17(9), 1138-1140. doi:10.1038/nn.3792 
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998). 
Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci, 158(1), 47-
52.  
Lu, T., Pan, Y., Kao, S.-Y., Li, C., Kohane, I., Chan, J., & Yankner, B. A. (2004). Gene 
regulation and DNA damage in the ageing human brain. Nature, 429, 883. 
doi:10.1038/nature02661 
https://www.nature.com/articles/nature02661#supplementary-information 
Lu, T., Pan, Y., Kao, S. Y., Li, C., Kohane, I., Chan, J., & Yankner, B. A. (2004). Gene 
regulation and DNA damage in the ageing human brain. Nature, 429(6994), 883-891. 
doi:10.1038/nature02661 
Lubin, F. D., Roth, T. L., & Sweatt, J. D. (2008). EPIGENETIC REGULATION OF BDNF 
GENE TRANSCRIPTION IN THE CONSOLIDATION OF FEAR MEMORY. The 
Journal of Neuroscience, 28(42), 10576-10586. doi:10.1523/JNEUROSCI.1786-
08.2008 
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., . . . Rogers, J. (1999). 
Soluble Amyloid &#x3b2; Peptide Concentration as a Predictor of Synaptic Change in 




Lue, L. F., Brachova, L., Civin, W. H., & Rogers, J. (1996). Inflammation, A beta deposition, 
and neurofibrillary tangle formation as correlates of Alzheimer's disease 
neurodegeneration. J Neuropathol Exp Neurol, 55(10), 1083-1088.  
Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997). Crystal 
structure of the nucleosome core particle at 2.8 A resolution. Nature, 389(6648), 251-
260. doi:10.1038/38444 
Lukas, W., & Jones, K. A. (1994). Cortical neurons containing calretinin are selectively 
resistant to calcium overload and excitotoxicity in vitro. Neuroscience, 61(2), 307-316.  
Lun, A. T., & Smyth, G. K. (2014). De novo detection of differentially bound regions for ChIP-
seq data using peaks and windows: controlling error rates correctly. Nucleic Acids Res, 
42(11), e95. doi:10.1093/nar/gku351 
Lun, A. T. L., & Smyth, G. K. (2016). csaw: a Bioconductor package for differential binding 
analysis of ChIP-seq data using sliding windows. Nucleic Acids Res, 44(5), e45. 
doi:10.1093/nar/gkv1191 
Lund, H., Gustafsson, E., Svensson, A., Nilsson, M., Berg, M., Sunnemark, D., & von Euler, 
G. (2014). MARK4 and MARK3 associate with early tau phosphorylation in 
Alzheimer's disease granulovacuolar degeneration bodies. Acta Neuropathol Commun, 
2, 22. doi:10.1186/2051-5960-2-22 
Lunnon, K., Smith, R., Hannon, E., De Jager, P. L., Srivastava, G., Volta, M., . . . Mill, J. 
(2014). Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's 
disease. Nat Neurosci, 17(9), 1164-1170. doi:10.1038/nn.3782 
http://www.nature.com/neuro/journal/v17/n9/abs/nn.3782.html#supplementary-information 
Luo, C., Keown, C. L., Kurihara, L., Zhou, J., He, Y., Li, J., . . . Ecker, J. R. (2017). Single-
cell methylomes identify neuronal subtypes and regulatory elements in mammalian 
cortex. Science, 357(6351), 600.  
Ma, D. K., Jang, M.-H., Guo, J. U., Kitabatake, Y., Chang, M.-l., Pow-anpongkul, N., . . . Song, 
H. (2009). Neuronal Activity–Induced Gadd45b Promotes Epigenetic DNA 
Demethylation and Adult Neurogenesis. Science, 323(5917), 1074-1077. 
doi:10.1126/science.1166859 
Maeda, S., Djukic, B., Taneja, P., Yu, G. Q., Lo, I., Davis, A., . . . Mucke, L. (2016). Expression 
of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic 
mice. EMBO Rep, 17(4), 530-551. doi:10.15252/embr.201541438 
Magi, S., Castaldo, P., Macrì, M. L., Maiolino, M., Matteucci, A., Bastioli, G., . . . Lariccia, V. 
(2016). Intracellular Calcium Dysregulation: Implications for Alzheimer's Disease. 
BioMed Research International, 2016, 6701324-6701324. doi:10.1155/2016/6701324 
Magistri, M., Khoury, N., Mazza, E. M. C., Velmeshev, D., Lee, J. K., Bicciato, S., . . . Faghihi, 
M. A. (2016). A comparative transcriptomic analysis of astrocytes differentiation from 
human neural progenitor cells. The European journal of neuroscience, 44(10), 2858-
2870. doi:10.1111/ejn.13382 
Maia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, 
M. (2013). Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic 
mice overexpressing amyloid precursor protein. Sci Transl Med, 5(194), 194re192. 
doi:10.1126/scitranslmed.3006446 
Mandelkow, E. M., Thies, E., Konzack, S., & Mandelkow, E. (2009). Tau and Intracellular 
Transport in Neurons. In P. H. S. George-Hyslop, W. C. C. Mobley, & Y. Christen 
(Eds.), Intracellular Traffic and Neurodegenerative Disorders (pp. 59-70). Berlin, 
Heidelberg: Springer Berlin Heidelberg. 
Marchand, W. R., Lee, J. N., Suchy, Y., Garn, C., Johnson, S., Wood, N., & Chelune, G. (2011). 
Age-related changes of the functional architecture of the cortico-basal ganglia circuitry 
248 
 
during motor task execution. Neuroimage, 55(1), 194-203. 
doi:10.1016/j.neuroimage.2010.12.030 
Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing 
reads. 2011, 17(1). doi:10.14806/ej.17.1.200 
pp. 10-12 
Martinez-Lopez, N., Athonvarangkul, D., & Singh, R. (2015). Autophagy and aging. Adv Exp 
Med Biol, 847, 73-87. doi:10.1007/978-1-4939-2404-2_3 
Martinowich, K., Hattori, D., Wu, H., Fouse, S., He, F., Hu, Y., . . . Sun, Y. E. (2003). DNA 
Methylation-Related Chromatin Remodeling in Activity-Dependent <em>Bdnf</em> 
Gene Regulation. Science, 302(5646), 890-893. doi:10.1126/science.1090842 
Maruyama, R., Choudhury, S., Kowalczyk, A., Bessarabova, M., Beresford-Smith, B., 
Conway, T., . . . Polyak, K. (2011). Epigenetic Regulation of Cell Type–Specific 
Expression Patterns in the Human Mammary Epithelium. PLoS Genet, 7(4), e1001369. 
doi:10.1371/journal.pgen.1001369 
Marzi, S. J., Leung, S. K., Ribarska, T., Hannon, E., Smith, A. R., Pishva, E., . . . Mill, J. (2018). 
A histone acetylome-wide association study of Alzheimer’s disease identifies disease-
associated H3K27ac differences in the entorhinal cortex. Nature neuroscience, 21(11), 
1618-1627. doi:10.1038/s41593-018-0253-7 
Masliah, E., Mallory, M., Hansen, L., Alford, M., Albright, T., DeTeresa, R., . . . Saitoh, T. 
(1991). Patterns of aberrant sprouting in alzheimer's disease. Neuron, 6(5), 729-739. 
doi:https://doi.org/10.1016/0896-6273(91)90170-5 
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, 
K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. 
Proceedings of the National Academy of Sciences, 82(12), 4245.  
Mastroeni, D., Chouliaras, L., Grover, A., Liang, W. S., Hauns, K., Rogers, J., & Coleman, P. 
D. (2013). Reduced RAN expression and disrupted transport between cytoplasm and 
nucleus; a key event in Alzheimer's disease pathophysiology. PLoS One, 8(1), e53349. 
doi:10.1371/journal.pone.0053349 
Mastroeni, D., Delvaux, E., Nolz, J., Tan, Y., Grover, A., Oddo, S., & Coleman, P. D. (2015). 
Aberrant intracellular localization of H3k4me3 demonstrates an early epigenetic 
phenomenon in Alzheimer's disease. Neurobiol Aging, 36(12), 3121-3129. 
doi:10.1016/j.neurobiolaging.2015.08.017 
Mastroeni, D., Grover, A., Delvaux, E., Whiteside, C., Coleman, P. D., & Rogers, J. (2010). 
Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol 
Aging, 31(12), 2025-2037. doi:10.1016/j.neurobiolaging.2008.12.005 
Mastroeni, D., McKee, A., Grover, A., Rogers, J., & Coleman, P. D. (2009). Epigenetic 
Differences in Cortical Neurons from a Pair of Monozygotic Twins Discordant for 
Alzheimer's Disease. PLoS One, 4(8), e6617. doi:10.1371/journal.pone.0006617 
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., . . . Tsai, 
L. H. (2019). Single-cell transcriptomic analysis of Alzheimer's disease. Nature, 
570(7761), 332-337. doi:10.1038/s41586-019-1195-2 
Mattiasson, G., Friberg, H., Hansson, M., Elmer, E., & Wieloch, T. (2003). Flow cytometric 
analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals 
differences in permeability transition pore activation. J Neurochem, 87(2), 532-544.  
McGhee, J. D., & Felsenfeld, G. (1980). Nucleosome structure. Annu Rev Biochem, 49, 1115-
1156. doi:10.1146/annurev.bi.49.070180.005343 
McKee, A. C., Kowall, N. W., & Kosik, K. S. (1989). Microtubular reorganization and 




McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Vbeyreuther, K., . . . 
Masters, C. L. (1999). Soluble pool of Aβ amyloid as a determinant of severity of 
neurodegeneration in Alzheimer's disease. Ann Neurol, 46(6), 860-866.  
McLean, C. Y., Bristor, D., Hiller, M., Clarke, S. L., Schaar, B. T., Lowe, C. B., . . . Bejerano, 
G. (2010). GREAT improves functional interpretation of cis-regulatory regions. Nature 
Biotechnology, 28, 495. doi:10.1038/nbt.1630 
https://www.nature.com/articles/nbt.1630#supplementary-information 
McShea, A., Harris, P. L., Webster, K. R., Wahl, A. F., & Smith, M. A. (1997). Abnormal 
expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. The 
American Journal of Pathology, 150(6), 1933-1939.  
Megee, P. C., Morgan, B. A., & Smith, M. M. (1995). Histone H4 and the maintenance of 
genome integrity. Genes Dev, 9(14), 1716-1727.  
Meissner, A., Mikkelsen, T. S., Gu, H., Wernig, M., Hanna, J., Sivachenko, A., . . . Lander, E. 
S. (2008). Genome-scale DNA methylation maps of pluripotent and differentiated cells. 
Nature, 454(7205), 766-770. doi:10.1038/nature07107 
Mellen, M., Ayata, P., Dewell, S., Kriaucionis, S., & Heintz, N. (2012). MeCP2 binds to 5hmC 
enriched within active genes and accessible chromatin in the nervous system. Cell, 
151(7), 1417-1430. doi:10.1016/j.cell.2012.11.022 
Mendizabal, I., & Yi, S. V. (2016). Whole-genome bisulfite sequencing maps from multiple 
human tissues reveal novel CpG islands associated with tissue-specific regulation. 
Human molecular genetics, 25(1), 69-82. doi:10.1093/hmg/ddv449 
Mifsud, B., Tavares-Cadete, F., Young, A. N., Sugar, R., Schoenfelder, S., Ferreira, L., . . . 
Osborne, C. S. (2015). Mapping long-range promoter contacts in human cells with 
high-resolution capture Hi-C. Nat Genet, 47, 598. doi:10.1038/ng.3286 
https://www.nature.com/articles/ng.3286#supplementary-information 
Milde, S., Adalbert, R., Elaman, M. H., & Coleman, M. P. (2015). Axonal transport declines 
with age in two distinct phases separated by a period of relative stability. Neurobiol 
Aging, 36(2), 971-981. doi:10.1016/j.neurobiolaging.2014.09.018 
Miquel, J., Economos, A. C., Fleming, J., & Johnson, J. E. (1980). Mitochondrial role in cell 
aging. Experimental Gerontology, 15(6), 575-591. doi:https://doi.org/10.1016/0531-
5565(80)90010-8 
Mirsky, A. E., & Silverman, B. (1972). Blocking by Histones of Accessibility to DNA in 
Chromatin. Proc Natl Acad Sci U S A, 69(8), 2115-2119.  
Mitew, S., Kirkcaldie, M. T., Dickson, T. C., & Vickers, J. C. (2013a). Altered synapses and 
gliotransmission in Alzheimer's disease and AD model mice. Neurobiol Aging, 34(10), 
2341-2351. doi:10.1016/j.neurobiolaging.2013.04.010 
Mitew, S., Kirkcaldie, M. T., Dickson, T. C., & Vickers, J. C. (2013b). Neurites containing the 
neurofilament-triplet proteins are selectively vulnerable to cytoskeletal pathology in 
Alzheimer's disease and transgenic mouse models. Front Neuroanat, 7, 30. 
doi:10.3389/fnana.2013.00030 
Mo, A., Mukamel, Eran A., Davis, Fred P., Luo, C., Henry, Gilbert L., Picard, S., . . . Nathans, 
J. (2015). Epigenomic Signatures of Neuronal Diversity in the Mammalian Brain. 
Neuron, 86(6), 1369-1384. doi:10.1016/j.neuron.2015.05.018 
Moh, C., Kubiak, J. Z., Bajic, V. P., Zhu, X., Smith, M. A., & Lee, H.-G. (2011). Cell cycle 
deregulation in the neurons of Alzheimer's disease. Results and problems in cell 
differentiation, 53, 565-576. doi:10.1007/978-3-642-19065-0_23 
Molyneaux, B. J., Arlotta, P., Menezes, J. R., & Macklis, J. D. (2007). Neuronal subtype 




Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., . . . Clark, 
C. (1989). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). 
Part I. Clinical and neuropsychological assesment of Alzheimer's disease. Neurology, 
39(9), 1159. doi:10.1212/wnl.39.9.1159 
Morris, M. C., Tangney, C. C., Wang, Y., Sacks, F. M., Bennett, D. A., & Aggarwal, N. T. 
(2015). MIND diet associated with reduced incidence of Alzheimer's disease. 
Alzheimers Dement, 11(9), 1007-1014. doi:10.1016/j.jalz.2014.11.009 
Morris, S. A., Rao, B., Garcia, B. A., Hake, S. B., Diaz, R. L., Shabanowitz, J., . . . Strahl, B. 
D. (2007). Identification of histone H3 lysine 36 acetylation as a highly conserved 
histone modification. J Biol Chem, 282(10), 7632-7640. doi:10.1074/jbc.M607909200 
Morrison, J. H., Lewis, D. A., Campbell, M. J., Huntley, G. W., Benson, D. L., & Bouras, C. 
(1987). A monoclonal antibody to non-phosphorylated neurofilament protein marks the 
vulnerable cortical neurons in Alzheimer's disease. Brain Research, 416(2), 331-336.  
Mortimer, J., Van Duijn, C., Chandra, V., Fratiglioni, L., Graves, A., Heyman, A., . . . Rocca, 
W. A. (1991). Head trauma as a risk factor for Alzheimer's disease: a collaborative re-
analysis of case-control studies. International Journal of Epidemiology, 
20(Supplement_2), S28-S35.  
Mosher, K. I., & Wyss-Coray, T. (2014). Microglial Dysfunction in Brain Aging and 
Alzheimer’s Disease. Biochemical pharmacology, 88(4), 594-604. 
doi:10.1016/j.bcp.2014.01.008 
Mota, S. I., Ferreira, I. L., Pereira, C., Oliveira, C. R., & Rego, A. C. (2012). Amyloid-beta 
peptide 1-42 causes microtubule deregulation through N-methyl-D-aspartate receptors 
in mature hippocampal cultures. Curr Alzheimer Res, 9(7), 844-856.  
Mullen, R. J., Buck, C. R., & Smith, A. M. (1992). NeuN, a neuronal specific nuclear protein 
in vertebrates. Development, 116(1), 201-211.  
Mullen, R. J., Buck, C. R., & Smith, A. M. (1992). NeuN, a neuronal specific nuclear protein 
in vertebrates. Development, 116(1), 201-211.  
Murayama, S., & Saito, Y. (2004). Neuropathological diagnostic criteria for Alzheimer's 
disease. Neuropathology, 24(3), 254-260.  
Murgatroyd, C., & Spengler, D. (2011). Epigenetics of early child development. Frontiers in 
psychiatry, 2, 16-16. doi:10.3389/fpsyt.2011.00016 
Murray, A. J., Sauer, J. F., Riedel, G., McClure, C., Ansel, L., Cheyne, L., . . . Wulff, P. (2011). 
Parvalbumin-positive CA1 interneurons are required for spatial working but not for 
reference memory. Nat Neurosci, 14(3), 297-299. doi:10.1038/nn.2751 
Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, 
S. A., . . . Dickson, D. W. (2015). Clinicopathologic and 11C-Pittsburgh compound B 
implications of Thal amyloid phase across the Alzheimer’s disease spectrum. Brain, 
138(5), 1370-1381. doi:10.1093/brain/awv050 
Nan, X., Ng, H.-H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., & Bird, 
A. (1998). Transcriptional repression by the methyl-CpG-binding protein MeCP2 
involves a histone deacetylase complex. Nature, 393, 386. doi:10.1038/30764 
Nan, X., Ng, H. H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., & Bird, 
A. (1998). Transcriptional repression by the methyl-CpG-binding protein MeCP2 
involves a histone deacetylase complex. Nature, 393(6683), 386-389. 
doi:10.1038/30764 
Narayan, P. J., Lill, C., Faull, R., Curtis, M. A., & Dragunow, M. (2015). Increased acetyl and 




Näslund, J., Haroutunian, V., Mohs, R., & et al. (2000). COrrelation between elevated levels 
of amyloid β-peptide in the brain and cognitive decline. JAMA, 283(12), 1571-1577. 
doi:10.1001/jama.283.12.1571 
Nativio, R., Donahue, G., Berson, A., Lan, Y., Amlie-Wolf, A., Tuzer, F., . . . Berger, S. L. 
(2018). Dysregulation of the epigenetic landscape of normal aging in Alzheimer’s 
disease. Nature neuroscience. doi:10.1038/s41593-018-0101-9 
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005). Resting Microglial Cells Are Highly 
Dynamic Surveillants of Brain Parenchyma in Vivo. Science, 308(5726), 1314-1318. 
doi:10.1126/science.1110647 
Numata, S., Ye, T., Hyde, T. M., Guitart-Navarro, X., Tao, R., Wininger, M., . . . Lipska, B. 
K. (2012). DNA methylation signatures in development and aging of the human 
prefrontal cortex. Am J Hum Genet, 90(2), 260-272. doi:10.1016/j.ajhg.2011.12.020 
O'Carroll, D., Scherthan, H., Peters, A. H., Opravil, S., Haynes, A. R., Laible, G., . . . Jenuwein, 
T. (2000). Isolation and characterization of Suv39h2, a second histone H3 
methyltransferase gene that displays testis-specific expression. Mol Cell Biol, 20(24), 
9423-9433.  
Oakford, P. C., James, S. R., Qadi, A., West, A. C., Ray, S. N., Bert, A. G., . . . Holloway, A. 
F. (2010). Transcriptional and epigenetic regulation of the GM-CSF promoter by 
RUNX1. Leuk Res, 34(9), 1203-1213. doi:10.1016/j.leukres.2010.03.029 
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., . . . Vassar, R. (2006). 
Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in 
transgenic mice with five familial Alzheimer's disease mutations: potential factors in 
amyloid plaque formation. J Neurosci, 26(40), 10129-10140. 
doi:10.1523/jneurosci.1202-06.2006 
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., . . . LaFerla, 
F. M. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: 
intracellular Abeta and synaptic dysfunction. Neuron, 39(3), 409-421.  
Oh, G., Ebrahimi, S., Wang, S.-C., Cortese, R., Kaminsky, Z. A., Gottesman, I. I., . . . Petronis, 
A. (2016). Epigenetic assimilation in the aging human brain. Genome Biol, 17(1), 76. 
doi:10.1186/s13059-016-0946-8 
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999). DNA methyltransferases Dnmt3a and 
Dnmt3b are essential for de novo methylation and mammalian development. Cell, 
99(3), 247-257.  
Olins, A. L., & Olins, D. E. (1974). Spheroid Chromatin Units (ν Bodies). Science, 183(4122), 
330-332. doi:10.1126/science.183.4122.330 
Ooi, S. K., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., . . . Bestor, T. H. (2007). DNMT3L 
connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature, 
448(7154), 714-717. doi:10.1038/nature05987 
Outchkourov, N. S., Muino, J. M., Kaufmann, K., van Ijcken, W. F., Groot Koerkamp, M. J., 
van Leenen, D., . . . Timmers, H. T. (2013). Balancing of histone H3K4 methylation 
states by the Kdm5c/SMCX histone demethylase modulates promoter and enhancer 
function. Cell Rep, 3(4), 1071-1079. doi:10.1016/j.celrep.2013.02.030 
Palmer, A., & Klein, R. (2003). Multiple roles of ephrins in morphogenesis, neuronal 
networking, and brain function. Genes Dev, 17(12), 1429-1450. 
doi:10.1101/gad.1093703 
Parodi, J., Sepulveda, F. J., Roa, J., Opazo, C., Inestrosa, N. C., & Aguayo, L. G. (2010). Beta-
amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J 
Biol Chem, 285(4), 2506-2514. doi:10.1074/jbc.M109.030023 
Pavlopoulos, E., Jones, S., Kosmidis, S., Close, M., Kim, C., Kovalerchik, O., . . . Kandel, E. 
R. (2013). Molecular Mechanism for Age-Related Memory Loss: The Histone-Binding 
252 
 
Protein RbAp48. Science Translational Medicine, 5(200), 200ra115. 
doi:10.1126/scitranslmed.3006373 
Peleg, S., Sananbenesi, F., Zovoilis, A., Burkhardt, S., Bahari-Javan, S., Agis-Balboa, R. C., . 
. . Fischer, A. (2010). Altered histone acetylation is associated with age-dependent 
memory impairment in mice. Science, 328(5979), 753-756. 
doi:10.1126/science.1186088 
Peltier, D. C., Simms, A., Farmer, J. R., & Miller, D. J. (2010). Human neuronal cells possess 
functional cytoplasmic and TLR-mediated innate immune pathways influenced by 
phosphatidylinositol-3 kinase signaling. J Immunol, 184(12), 7010-7021. 
doi:10.4049/jimmunol.0904133 
Peng, S., Garzon, D. J., Marchese, M., Klein, W., Ginsberg, S. D., Francis, B. M., . . . 
Fahnestock, M. (2009). Decreased Brain-Derived Neurotrophic Factor Depends on 
Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer&#039;s 
Disease. The Journal of Neuroscience, 29(29), 9321.  
Penner, M. R., Roth, T. L., Chawla, M. K., Hoang, L. T., Roth, E. D., Lubin, F. D., . . . Barnes, 
C. A. (2011). Age-related changes in Arc transcription and DNA methylation within 
the hippocampus. Neurobiol Aging, 32(12), 2198-2210. 
doi:https://doi.org/10.1016/j.neurobiolaging.2010.01.009 
Perea, G., Navarrete, M., & Araque, A. (2009). Tripartite synapses: astrocytes process and 
control synaptic information. Trends Neurosci, 32(8), 421-431. 
doi:10.1016/j.tins.2009.05.001 
Perry, G., Cash, A. D., Srinivas, R., & Smith, M. A. (2002). Metals and oxidative homeostasis 
in Alzheimer's disease. Drug Development Research, 56(3), 293-299. 
doi:10.1002/ddr.10099 
Perry, G., Kawai, M., Tabaton, M., Onorato, M., Mulvihill, P., Richey, P., . . . Gambetti, P. 
(1991). Neuropil threads of Alzheimer's disease show a marked alteration of the normal 
cytoskeleton. J Neurosci, 11(6), 1748-1755.  
Peters, D. G., Connor, J. R., & Meadowcroft, M. D. (2015). The Relationship between Iron 
Dyshomeostasis and Amyloidogenesis in Alzheimer’s Disease: Two Sides of the Same 
Coin. Neurobiol Dis, 81, 49-65. doi:10.1016/j.nbd.2015.08.007 
Phillips, H. S., Hains, J. M., Armanini, M., Laramee, G. R., Johnson, S. A., & Winslow, J. W. 
(1991). BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's 
disease. Neuron, 7(5), 695-702.  
Pike, C. J., & Cotman, C. W. (1995). Calretinin-immunoreactive neurons are resistant to β-
amyloid toxicity in vitro. Brain Research, 671(2), 293-298. 
doi:https://doi.org/10.1016/0006-8993(94)01354-K 
Plassman, B. L., Havlik, R., Steffens, D., Helms, M., Newman, T., Drosdick, D., . . . Burke, J. 
(2000). Documented head injury in early adulthood and risk of Alzheimer’s disease and 
other dementias. Neurology, 55(8), 1158-1166.  
Polydoro, M., Acker, C. M., Duff, K., Castillo, P. E., & Davies, P. (2009). Age-dependent 
impairment of cognitive and synaptic function in the htau mouse model of tau 
pathology. J Neurosci, 29(34), 10741-10749. doi:10.1523/jneurosci.1065-09.2009 
Pott, S. (2017). Simultaneous measurement of chromatin accessibility, DNA methylation, and 
nucleosome phasing in single cells. eLife, 6, e23203. doi:10.7554/eLife.23203 
Pott, S., & Lieb, J. D. (2014). What are super-enhancers? Nat Genet, 47, 8. 
doi:10.1038/ng.3167 
Potter, P. E., Rauschkolb, P. K., Pandya, Y., Sue, L. I., Sabbagh, M. N., Walker, D. G., & 
Beach, T. G. (2011). Pre- and post-synaptic cortical cholinergic deficits are proportional 
to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease. 
Acta Neuropathol, 122(1), 49-60. doi:10.1007/s00401-011-0831-1 
253 
 
Poulopoulou, C., Markakis, I., Davaki, P., Tsaltas, E., Rombos, A., Hatzimanolis, A., & 
Vassilopoulos, D. (2010). Aberrant modulation of a delayed rectifier potassium channel 
by glutamate in Alzheimer's disease. Neurobiol Dis, 37(2), 339-348. 
doi:10.1016/j.nbd.2009.10.012 
Puzzo, D., Vitolo, O., Trinchese, F., Jacob, J. P., Palmeri, A., & Arancio, O. (2005). Amyloid-
β Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-
Binding Protein Pathway during Hippocampal Synaptic Plasticity. The Journal of 
Neuroscience, 25(29), 6887-6897. doi:10.1523/jneurosci.5291-04.2005 
Quinlan, A. R. (2014). BEDTools: The Swiss-Army Tool for Genome Feature Analysis. 
Current protocols in bioinformatics, 47, 11.12.11-11.12.34. 
doi:10.1002/0471250953.bi1112s47 
Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S. A., Flynn, R. A., & Wysocka, J. (2011). 
A unique chromatin signature uncovers early developmental enhancers in humans. 
Nature, 470(7333), 279-283. doi:10.1038/nature09692 
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., . . . Jucker, 
M. (2006). Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and 
robust pathology. EMBO Rep, 7(9), 940-946. doi:10.1038/sj.embor.7400784 
Raff, M. C., Miller, R. H., & Noble, M. (1983). A glial progenitor cell that develops in vitro 
into an astrocyte or an oligodendrocyte depending on culture medium. Nature, 303, 
390. doi:10.1038/303390a0 
Rai, T. S., Cole, J. J., Nelson, D. M., Dikovskaya, D., Faller, W. J., Vizioli, M. G., . . . Adams, 
P. D. (2014). HIRA orchestrates a dynamic chromatin landscape in senescence and is 
required for suppression of neoplasia. Genes Dev, 28(24), 2712-2725. 
doi:10.1101/gad.247528.114 
Raj, T., Li, Y. I., Wong, G., Humphrey, J., Wang, M., Ramdhani, S., . . . De Jager, P. L. (2018). 
Integrative transcriptome analyses of the aging brain implicate altered splicing in 
Alzheimer’s disease susceptibility. Nat Genet, 50(11), 1584-1592. 
doi:10.1038/s41588-018-0238-1 
Raj, T., Li, Y. I., Wong, G., Humphrey, J., Wang, M., Ramdhani, S., . . . De Jager, P. L. (2018). 
Integrative transcriptome analyses of the aging brain implicate altered splicing in 
Alzheimer's disease susceptibility. Nat Genet, 50(11), 1584-1592. doi:10.1038/s41588-
018-0238-1 
Rajendran, L., & Annaert, W. (2012). Membrane trafficking pathways in Alzheimer's disease. 
Traffic, 13(6), 759-770.  
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., . . . Manke, T. 
(2016). deepTools2: a next generation web server for deep-sequencing data analysis. 
Nucleic Acids Res, 44(Web Server issue), W160-W165. doi:10.1093/nar/gkw257 
Ramsahoye, B. H., Biniszkiewicz, D., Lyko, F., Clark, V., Bird, A. P., & Jaenisch, R. (2000). 
Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by 
DNA methyltransferase 3a. Proceedings of the National Academy of Sciences, 97(10), 
5237-5242. doi:10.1073/pnas.97.10.5237 
Rao, J. S., Keleshian, V. L., Klein, S., & Rapoport, S. I. (2012). Epigenetic modifications in 
frontal cortex from Alzheimer's disease and bipolar disorder patients. Transl 
Psychiatry, 2, e132. doi:10.1038/tp.2012.55 
Razin, A., & Riggs, A. (1980). DNA methylation and gene function. Science, 210(4470), 604-
610. doi:10.1126/science.6254144 
Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., & Landreth, G. E. (2009). CD14 and toll-like 
receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J 
Neurosci, 29(38), 11982-11992. doi:10.1523/jneurosci.3158-09.2009 
254 
 
Ridge, P. G., Ebbert, M. T. W., & Kauwe, J. S. K. (2013). Genetics of Alzheimer's Disease. 
BioMed Research International, 2013, 254954. doi:10.1155/2013/254954 
Rizzardi, L., Hickey, P., Rodriguez, V., Tryggvadottir, R., Callahan, C., Idrizi, A., . . . Feinberg, 
A. P. (2017). Neuronal brain region-specific DNA methylation and chromatin 
accessibility are associated with neuropsychiatric disease heritability. bioRxiv.  
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., . . . Mucke, L. 
(2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an 
Alzheimer's disease mouse model. Science, 316(5825), 750-754. 
doi:10.1126/science.1141736 
Robertson, G., Hirst, M., Bainbridge, M., Bilenky, M., Zhao, Y., Zeng, T., . . . Jones, S. (2007). 
Genome-wide profiles of STAT1 DNA association using chromatin 
immunoprecipitation and massively parallel sequencing. Nature Methods, 4, 651. 
doi:10.1038/nmeth1068 
https://www.nature.com/articles/nmeth1068#supplementary-information 
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010). edgeR: a Bioconductor package for 
differential expression analysis of digital gene expression data. Bioinformatics, 26(1), 
139-140. doi:10.1093/bioinformatics/btp616 
Robinson, M. D., & Oshlack, A. (2010). A scaling normalization method for differential 
expression analysis of RNA-seq data. Genome Biol, 11(3), R25. doi:10.1186/gb-2010-
11-3-r25 
Rodrigues, H. F., Souza, T. A., Ghiraldini, F. G., Mello, M. L., & Moraes, A. S. (2014). 
Increased age is associated with epigenetic and structural changes in chromatin from 
neuronal nuclei. J Cell Biochem, 115(4), 659-665. doi:10.1002/jcb.24705 
Rodriguez-Vieitez, E., Saint-Aubert, L., Carter, S. F., Almkvist, O., Farid, K., Schöll, M., . . . 
Nordberg, A. (2016). Diverging longitudinal changes in astrocytosis and amyloid PET 
in autosomal dominant Alzheimer’s disease. Brain, 139(3), 922-936. 
doi:10.1093/brain/awv404 
Rossetto, D., Avvakumov, N., & Côté, J. (2012). Histone phosphorylation: a chromatin 
modification involved in diverse nuclear events. Epigenetics, 7(10), 1098-1108. 
doi:10.4161/epi.21975 
Rotem, A., Ram, O., Shoresh, N., Sperling, R. A., Goren, A., Weitz, D. A., & Bernstein, B. E. 
(2015). Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. 
Nature Biotechnology, 33, 1165. doi:10.1038/nbt.3383 
https://www.nature.com/articles/nbt.3383#supplementary-information 
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., . . . Saido, T. C. (2014). 
Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci, 17(5), 661-
663. doi:10.1038/nn.3697 
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., . . . Saido, T. C. (2014). 
Single App knock-in mouse models of Alzheimer&#39;s disease. Nature neuroscience, 
17, 661. doi:10.1038/nn.3697 
https://www.nature.com/articles/nn.3697#supplementary-information 
Saito, T., Matsuba, Y., Yamazaki, N., Hashimoto, S., & Saido, T. C. (2016). Calpain Activation 
in Alzheimer's Model Mice Is an Artifact of APP and Presenilin Overexpression. J 
Neurosci, 36(38), 9933-9936. doi:10.1523/jneurosci.1907-16.2016 
Sala, C., Rudolph-Correia, S., & Sheng, M. (2000). Developmentally Regulated NMDA 
Receptor-Dependent Dephosphorylation of cAMP Response Element-Binding Protein 




Sambrook, J., & Russell, D. W. (2006). Purification of Nucleic Acids by Extraction with 
Phenol:Chloroform. Cold Spring Harbor Protocols, 2006(1), pdb.prot4455. 
doi:10.1101/pdb.prot4455 
Sample, V., Ramamurthy, S., Gorshkov, K., Ronnett, G. V., & Zhang, J. (2015). Polarized 
activities of AMPK and BRSK in primary hippocampal neurons. Mol Biol Cell, 26(10), 
1935-1946. doi:10.1091/mbc.E14-02-0764 
Sampson, V. L., Morrison, J. H., & Vickers, J. C. (1997). The cellular basis for the relative 
resistance of parvalbumin and calretinin immunoreactive neocortical neurons to the 
pathology of Alzheimer's disease. Exp Neurol, 145(1), 295-302. 
doi:10.1006/exnr.1997.6433 
Sanchez-Mut, J. V., Aso, E., Heyn, H., Matsuda, T., Bock, C., Ferrer, I., & Esteller, M. (2014). 
Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent 
TAU phosphorylation and CREB activation in Alzheimer's disease. Hippocampus. 
doi:10.1002/hipo.22245 
Sanchez-Mut, J. V., Aso, E., Panayotis, N., Lott, I., Dierssen, M., Rabano, A., . . . Esteller, M. 
(2013). DNA methylation map of mouse and human brain identifies target genes in 
Alzheimer's disease. Brain, 136(Pt 10), 3018-3027. doi:10.1093/brain/awt237 
Sanchez-Mut, J. V., Heyn, H., Vidal, E., Moran, S., Sayols, S., Delgado-Morales, R., . . . 
Esteller, M. (2016). Human DNA methylomes of neurodegenerative diseases show 
common epigenomic patterns. Translational psychiatry, 6(1), e718. 
doi:10.1038/tp.2015.214 
Sandelius, A., Portelius, E., Kallen, A., Zetterberg, H., Rot, U., Olsson, B., . . . Blennow, K. 
(2019). Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau 
and amyloid pathology. Alzheimers Dement, 15(1), 55-64. 
doi:10.1016/j.jalz.2018.08.006 
Santos-Rosa, H., Schneider, R., Bannister, A. J., Sherriff, J., Bernstein, B. E., Emre, N. C., . . . 
Kouzarides, T. (2002). Active genes are tri-methylated at K4 of histone H3. Nature, 
419(6905), 407-411. doi:10.1038/nature01080 
Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., . . . Saido, T. 
C. (2017). APP mouse models for Alzheimer's disease preclinical studies. Embo j, 
36(17), 2473-2487. doi:10.15252/embj.201797397 
Sasaki, A., Yamaguchi, H., Ogawa, A., Sugihara, S., & Nakazato, Y. (1997). Microglial 
activation in early stages of amyloid beta protein deposition. Acta Neuropathol, 94(4), 
316-322.  
Sauzeau, V., Horta-Junior, J. A., Riolobos, A. S., Fernandez, G., Sevilla, M. A., Lopez, D. E., 
. . . Bustelo, X. R. (2010). Vav3 is involved in GABAergic axon guidance events 
important for the proper function of brainstem neurons controlling cardiovascular, 
respiratory, and renal parameters. Mol Biol Cell, 21(23), 4251-4263. 
doi:10.1091/mbc.E10-07-0639 
Scarmeas, N., Stern, Y., Tang, M.-X., Mayeux, R., & Luchsinger, J. A. (2006). Mediterranean 
Diet and Risk for Alzheimer’s Disease. Ann Neurol, 59(6), 912-921. 
doi:10.1002/ana.20854 
Scarpa, S., Fuso, A., D'Anselmi, F., & Cavallaro, R. A. (2003). Presenilin 1 gene silencing by 
S-adenosylmethionine: a treatment for Alzheimer disease? FEBS Letters, 541(1-3), 
145-148. doi:doi:10.1016/S0014-5793(03)00277-1 
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., . . . Younkin, S. (1996). 
Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer&#39;s 
disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to 
familial Alzheimer&#39;s disease. Nature medicine, 2, 864. doi:10.1038/nm0896-864 
256 
 
Schmid, C. D., & Bucher, P. (2007). ChIP-Seq Data Reveal Nucleosome Architecture of 
Human Promoters. Cell, 131(5), 831-832. 
doi:https://doi.org/10.1016/j.cell.2007.11.017 
Selemon, L. D. (2013). A role for synaptic plasticity in the adolescent development of 
executive function. Translational psychiatry, 3, e238. doi:10.1038/tp.2013.7 
Selkoe, D. J. (2008). Soluble oligomers of the amyloid β-protein impair synaptic plasticity and 
behavior. Behav Brain Res, 192(1), 106-113. 
doi:http://dx.doi.org/10.1016/j.bbr.2008.02.016 
Semple, B. D., Blomgren, K., Gimlin, K., Ferriero, D. M., & Noble-Haeusslein, L. J. (2013). 
Brain development in rodents and humans: Identifying benchmarks of maturation and 
vulnerability to injury across species. Prog Neurobiol, 106-107, 1-16. 
doi:10.1016/j.pneurobio.2013.04.001 
Sen, A., Nelson, T. J., & Alkon, D. L. (2015). ApoE4 and Aβ Oligomers Reduce BDNF 
Expression via HDAC Nuclear Translocation. The Journal of Neuroscience, 35(19), 
7538-7551. doi:10.1523/jneurosci.0260-15.2015 
Sen, A., Nelson, T. J., & Alkon, D. L. (2017). ApoE isoforms differentially regulates cleavage 
and secretion of BDNF. Molecular Brain, 10, 19. doi:10.1186/s13041-017-0301-3 
Serneels, L., Van Biervliet, J., Craessaerts, K., Dejaegere, T., Horre, K., Van Houtvin, T., . . . 
De Strooper, B. (2009). gamma-Secretase heterogeneity in the Aph1 subunit: relevance 
for Alzheimer's disease. Science, 324(5927), 639-642. doi:10.1126/science.1171176 
Serrano, F., & Klann, E. (2004). Reactive oxygen species and synaptic plasticity in the aging 
hippocampus. Ageing Research Reviews, 3(4), 431-443. 
doi:https://doi.org/10.1016/j.arr.2004.05.002 
Seshadri, S., Fitzpatrick, A. L., Ikram, M. A., DeStefano, A. L., Gudnason, V., Boada, M., . . . 
EADI1 Consortia, f. t. (2010). Genome-wide Analysis of Genetic Loci Associated With 
Alzheimer Disease. JAMA, 303(18), 1832-1840. doi:10.1001/jama.2010.574 
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., . . . 
Selkoe, D. J. (2008). Amyloid-β protein dimers isolated directly from Alzheimer&#39;s 
brains impair synaptic plasticity and memory. Nature medicine, 14, 837. 
doi:10.1038/nm1782 
https://www.nature.com/articles/nm1782#supplementary-information 
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., . . . St 
  George-Hyslop, P. H. (1995). Cloning of a gene bearing missense 
mutations in early-onset familial   Alzheimer's disease. Nature, 375(6534), 
754-760.  
Shogren-Knaak, M., Ishii, H., Sun, J.-M., Pazin, M. J., Davie, J. R., & Peterson, C. L. (2006a). 
Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions. 
Science, 311(5762), 844.  
Shogren-Knaak, M., Ishii, H., Sun, J.-M., Pazin, M. J., Davie, J. R., & Peterson, C. L. (2006b). 
Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions. 
Science, 311(5762), 844-847. doi:10.1126/science.1124000 
Shoji, H., Takao, K., Hattori, S., & Miyakawa, T. (2016). Age-related changes in behavior in 
C57BL/6J mice from young adulthood to middle age. Molecular Brain, 9, 11-11. 
doi:10.1186/s13041-016-0191-9 
Shulha, H. P., Cheung, I., Guo, Y., Akbarian, S., & Weng, Z. (2013). Coordinated cell type-
specific epigenetic remodeling in prefrontal cortex begins before birth and continues 




Siegmund, K. D., Connor, C. M., Campan, M., Long, T. I., Weisenberger, D. J., Biniszkiewicz, 
D., . . . Akbarian, S. (2007). DNA methylation in the human cerebral cortex is 
dynamically regulated throughout the life span and involves differentiated neurons. 
PLoS One, 2(9), e895. doi:10.1371/journal.pone.0000895 
Singh, R. P., Shiue, K., Schomberg, D., & Zhou, F. C. (2009). Cellular epigenetic modifications 
of neural stem cell differentiation. Cell Transplant, 18(10), 1197-1211. 
doi:10.3727/096368909x12483162197204 
Skene, P. J., Illingworth, R. S., Webb, S., Kerr, A., James, K. D., Turner, D. J., . . . Bird, A. P. 
(2010). Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters 
the chromatin state. Mol Cell, 37(4), 457-468. doi:10.1016/j.molcel.2010.01.030 
Smallwood, S. A., Lee, H. J., Angermueller, C., Krueger, F., Saadeh, H., Peat, J., . . . Kelsey, 
G. (2014). Single-cell genome-wide bisulfite sequencing for assessing epigenetic 
heterogeneity. Nat Methods, 11(8), 817-820. doi:10.1038/nmeth.3035 
Smith, A. R., Smith, R. G., Condliffe, D., Hannon, E., Schalkwyk, L., Mill, J., & Lunnon, K. 
(2016). Increased DNA methylation near TREM2 is consistently seen in the superior 
temporal gyrus in Alzheimer's disease brain. Neurobiol Aging, 47, 35-40. 
doi:https://doi.org/10.1016/j.neurobiolaging.2016.07.008 
Soreq, L., Rose, J., Soreq, E., Hardy, J., Trabzuni, D., Cookson, M. R., . . . Ule, J. (2017). 
Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of Human Brain 
Aging. Cell Rep, 18(2), 557-570. doi:10.1016/j.celrep.2016.12.011 
Soto, C., & Pritzkow, S. (2018). Protein misfolding, aggregation, and conformational strains 
in neurodegenerative diseases. Nat Neurosci, 21(10), 1332-1340. doi:10.1038/s41593-
018-0235-9 
Spanopoulou, E., Giguere, V., & Grosveld, F. (1991). The functional domains of the murine 
Thy-1 gene promoter. Mol Cell Biol, 11(4), 2216-2228.  
Squires, J. E., Patel, H. R., Nousch, M., Sibbritt, T., Humphreys, D. T., Parker, B. J., . . . Preiss, 
T. (2012). Widespread occurrence of 5-methylcytosine in human coding and non-
coding RNA. Nucleic Acids Res, 40(11), 5023-5033. doi:10.1093/nar/gks144 
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., . 
. . et al. (1987). The genetic defect causing familial Alzheimer's disease maps on 
chromosome 21. Science, 235(4791), 885-890.  
Stadler, M. B., Murr, R., Burger, L., Ivanek, R., Lienert, F., Schöler, A., . . . Schübeler, D. 
(2011). DNA-binding factors shape the mouse methylome at distal regulatory regions. 
Nature, 480, 490. doi:10.1038/nature10716 
https://www.nature.com/articles/nature10716#supplementary-information 
Stedman, E., & Stedman, E. (1950). Cell Specificity of Histones. Nature, 166, 780. 
doi:10.1038/166780a0 
Stempor, P., & Ahringer, J. (2016). SeqPlots - Interactive software for exploratory data 
analyses, pattern discovery and visualization in genomics. Wellcome Open Research, 
1, 14. doi:10.12688/wellcomeopenres.10004.1 
Stern, Y., Gurland, B., Tatemichi, T. K., Tang, M. X., Wilder, D., & Mayeux, R. (1994). 
Influence of education and occupation on the incidence of Alzheimer's disease. JAMA, 
271(13), 1004-1010.  
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, 
G. S., & Roses, A. D. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid 
and increased frequency of type 4 allele in late-onset familial Alzheimer disease. 




Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., 
. . . Sommer, B. (1997). Two amyloid precursor protein transgenic mouse models with 
Alzheimer disease-like pathology. Proc Natl Acad Sci U S A, 94(24), 13287-13292.  
Suberbielle, E., Djukic, B., Evans, M., Kim, D. H., Taneja, P., Wang, X., . . . Mucke, L. (2015). 
DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive 
function in mice. Nature Communications, 6, 8897. doi:10.1038/ncomms9897 
https://www.nature.com/articles/ncomms9897#supplementary-information 
Suzuki, M. M., & Bird, A. (2008). DNA methylation landscapes: provocative insights from 
epigenomics. Nature Reviews Genetics, 9, 465. doi:10.1038/nrg2341 
Swank, M. W., & Sweatt, J. D. (2001). Increased histone acetyltransferase and lysine 
acetyltransferase activity and biphasic activation of the ERK/RSK cascade in insular 
cortex during novel taste learning. J Neurosci, 21(10), 3383-3391.  
Szulwach, K. E., Li, X., Li, Y., Song, C.-X., Wu, H., Dai, Q., . . . Levey, A. I. (2011). 5-hmC-
mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nature 
neuroscience, 14(12), 1607-1616.  
Taberlay, P. C., Kelly, T. K., Liu, C. C., You, J. S., De Carvalho, D. D., Miranda, T. B., . . . 
Jones, P. A. (2011). Polycomb-repressed genes have permissive enhancers that initiate 
reprogramming. Cell, 147(6), 1283-1294. doi:10.1016/j.cell.2011.10.040 
Taberlay, P. C., Statham, A. L., Kelly, T. K., Clark, S. J., & Jones, P. A. (2014). 
Reconfiguration of nucleosome-depleted regions at distal regulatory elements 
accompanies DNA methylation of enhancers and insulators in cancer. Genome Res, 
24(9), 1421-1432. doi:10.1101/gr.163485.113 
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., . . . Rao, A. 
(2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian 
DNA by MLL partner TET1. Science, 324(5929), 930-935. 
doi:10.1126/science.1170116 
Takahashi, H., Brasnjevic, I., Rutten, B. P., Van Der Kolk, N., Perl, D. P., Bouras, C., . . . 
Dickstein, D. L. (2010). Hippocampal interneuron loss in an APP/PS1 double mutant 
mouse and in Alzheimer's disease. Brain Struct Funct, 214(2-3), 145-160. 
doi:10.1007/s00429-010-0242-4 
Takihara, Y., Inatani, M., Eto, K., Inoue, T., Kreymerman, A., Miyake, S., . . . Tanihara, H. 
(2015). In vivo imaging of axonal transport of mitochondria in the diseased and aged 
mammalian CNS. Proc Natl Acad Sci U S A, 112(33), 10515-10520. 
doi:10.1073/pnas.1509879112 
Takizawa, T., Nakashima, K., Namihira, M., Ochiai, W., Uemura, A., Yanagisawa, M., . . . 
Taga, T. (2001). DNA methylation is a critical cell-intrinsic determinant of astrocyte 
differentiation in the fetal brain. Dev Cell, 1(6), 749-758.  
Tamaru, H., & Selker, E. U. (2001). A histone H3 methyltransferase controls DNA methylation 
in Neurospora crassa. Nature, 414, 277. doi:10.1038/35104508 
https://www.nature.com/articles/35104508#supplementary-information 
Tamaru, H., Zhang, X., McMillen, D., Singh, P. B., Nakayama, J., Grewal, S. I., . . . Selker, E. 
U. (2003). Trimethylated lysine 9 of histone H3 is a mark for DNA methylation in 
Neurospora crassa. Nat Genet, 34(1), 75-79. doi:10.1038/ng1143 
Tan, M., Luo, H., Lee, S., Jin, F., Yang, J. S., Montellier, E., . . . Zhao, Y. (2011). Identification 
of 67 histone marks and histone lysine crotonylation as a new type of histone 
modification. Cell, 146(6), 1016-1028. doi:10.1016/j.cell.2011.08.008 
Tan, S.-L., Nishi, M., Ohtsuka, T., Matsui, T., Takemoto, K., Kamio-Miura, A., . . . Kageyama, 
R. (2012). Essential roles of the histone methyltransferase ESET in the epigenetic 
control of neural progenitor cells during development. Development, 139(20), 3806.  
259 
 
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996). A mammalian histone deacetylase related 
to the yeast transcriptional regulator Rpd3p. Science, 272(5260), 408-411.  
Taylor, G. C., Eskeland, R., Hekimoglu-Balkan, B., Pradeepa, M. M., & Bickmore, W. A. 
(2013). H4K16 acetylation marks active genes and enhancers of embryonic stem cells, 
but does not alter chromatin compaction. Genome Res, 23(12), 2053-2065. 
doi:10.1101/gr.155028.113 
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., . . . Katzman, R. 
(1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is 
the major correlate of cognitive impairment. Ann Neurol, 30(4), 572-580. 
doi:10.1002/ana.410300410 
Thangavel, R., Sahu, S. K., Van Hoesen, G. W., & Zaheer, A. (2009). Loss of 
nonphosphorylated neurofilament immunoreactivity in temporal cortical areas in 
Alzheimer's disease. Neuroscience, 160(2), 427-433. 
doi:10.1016/j.neuroscience.2009.02.037 
The, E. P. C. (2012). An integrated encyclopedia of DNA elements in the human genome. 
Nature, 489, 57. doi:10.1038/nature11247 
https://www.nature.com/articles/nature11247#supplementary-information 
Thinakaran, G., & Koo, E. H. (2008). Amyloid Precursor Protein Trafficking, Processing, and 
Function. Journal of Biological Chemistry, 283(44), 29615-29619. 
doi:10.1074/jbc.R800019200 
Thoma, F., & Koller, T. (1977). Influence of histone H1 on chromatin structure. Cell, 12(1), 
101-107.  
Tohgi, H., Utsugisawa, K., Nagane, Y., Yoshimura, M., Ukitsu, M., & Genda, Y. (1999). The 
methylation status of cytosines in a tau gene promoter region alters with age to 
downregulate transcriptional activity in human cerebral cortex. Neurosci Lett, 275(2), 
89-92.  
Tokuda, T., Calero, M., Matsubara, E., Vidal, R., Kumar, A., Permanne, B., . . . Ghiso, J. 
(2000). Lipidation of apolipoprotein E influences its isoform-specific interaction with 
Alzheimer's amyloid beta peptides. Biochemical Journal, 348(Pt 2), 359-365.  
Tolias, K. F., Duman, J. G., & Um, K. (2011). Control of synapse development and plasticity 
by Rho GTPase regulatory proteins. Prog Neurobiol, 94(2), 133-148. 
doi:https://doi.org/10.1016/j.pneurobio.2011.04.011 
Tollervey, J. R., Wang, Z., Hortobágyi, T., Witten, J. T., Zarnack, K., Kayikci, M., . . . Ule, J. 
(2011). Analysis of alternative splicing associated with aging and neurodegeneration in 
the human brain. Genome Res, 21(10), 1572-1582. doi:10.1101/gr.122226.111 
Toth, M. L., Melentijevic, I., Shah, L., Bhatia, A., Lu, K., Talwar, A., . . . Driscoll, M. (2012). 
Neurite Sprouting and Synapse Deterioration in the Aging &lt;em&gt;Caenorhabditis 
elegans&lt;/em&gt; Nervous System. The Journal of Neuroscience, 32(26), 8778. 
doi:10.1523/JNEUROSCI.1494-11.2012 
Trachtenberg, J. T., Chen, B. E., Knott, G. W., Feng, G., Sanes, J. R., Welker, E., & Svoboda, 
K. (2002). Long-term in vivo imaging of experience-dependent synaptic plasticity in 
adult cortex. Nature, 420, 788. doi:10.1038/nature01273 
https://www.nature.com/articles/nature01273#supplementary-information 
Trinchese, F., Liu, S., Battaglia, F., Walter, S., Mathews, P. M., & Arancio, O. (2004). 
Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. 
Ann Neurol, 55(6), 801-814. doi:10.1002/ana.20101 
Turrigiano, G. (2011). Too Many Cooks? Intrinsic and Synaptic Homeostatic Mechanisms in 




Uddin, M. S., Stachowiak, A., Mamun, A. A., Tzvetkov, N. T., Takeda, S., Atanasov, A. G., . 
. . Stankiewicz, A. M. (2018). Autophagy and Alzheimer's Disease: From Molecular 
Mechanisms to Therapeutic Implications. Frontiers in aging neuroscience, 10, 04-04. 
doi:10.3389/fnagi.2018.00004 
Unger, M. S., Marschallinger, J., Kaindl, J., Höfling, C., Rossner, S., Heneka, M. T., . . . Aigner, 
L. (2016). Early Changes in Hippocampal Neurogenesis in Transgenic Mouse Models 
for Alzheimer's Disease. Molecular neurobiology, 53(8), 5796-5806. 
doi:10.1007/s12035-016-0018-9 
Van Dam, D., D'Hooge, R., Staufenbiel, M., Van Ginneken, C., Van Meir, F., & De Deyn, P. 
P. (2003). Age-dependent cognitive decline in the APP23 model precedes amyloid 
deposition. European Journal of Neuroscience, 17(2), 388-396. doi:10.1046/j.1460-
9568.2003.02444.x 
van Duijn, C. M., de Knijff, P., Cruts, M., Wehnert, A., Havekes, L. M., Hofman, A., & 
Broeckhoven, C. V. (1994). Apolipoprotein E4 allele in a population–based study of 
early–onset Alzheimer&#39;s disease. Nat Genet, 7, 74. doi:10.1038/ng0594-74 
van Galen, P., Viny, A. D., Ram, O., Ryan, R. J. H., Cotton, M. J., Donohue, L., . . . Bernstein, 
B. E. (2015). A Multiplexed System for Quantitative Comparisons of Chromatin 
Landscapes. Mol Cell, 61(1), 170-180. doi:10.1016/j.molcel.2015.11.003 
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., . . . Citron, M. 
(1999). β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the 
Transmembrane Aspartic Protease BACE. Science, 286(5440), 735-741. 
doi:10.1126/science.286.5440.735 
Vecsey, C. G., Hawk, J. D., Lattal, K. M., Stein, J. M., Fabian, S. A., Attner, M. A., . . . Wood, 
M. A. (2007). Histone Deacetylase Inhibitors Enhance Memory and Synaptic Plasticity 
via CREB: CBP-Dependent Transcriptional Activation. The Journal of Neuroscience, 
27(23), 6128-6140. doi:10.1523/jneurosci.0296-07.2007 
Veiga-Fernandes, H., & Artis, D. (2018). Neuronal–immune system cross-talk in homeostasis. 
Science, 359(6383), 1465. doi:10.1126/science.aap9598 
Viana, J., Hannon, E., Dempster, E., Pidsley, R., Macdonald, R., Knox, O., . . . Turecki, G. 
(2016). Schizophrenia-associated methylomic variation: molecular signatures of 
disease and polygenic risk burden across multiple brain regions. Human molecular 
genetics, 26(1), 210-225.  
Vickers, J. C., Chin, D., Edwards, A. M., Sampson, V., Harper, C., & Morrison, J. (1996). 
Dystrophic neurite formation associated with age-related beta amyloid deposition in the 
neocortex: clues to the genesis of neurofibrillary pathology. Exp Neurol, 141(1), 1-11. 
doi:10.1006/exnr.1996.0133 
Vickers, J. C., Kirkcaldie, M. T., Phipps, A., & King, A. E. (2016). Alterations in 
neurofilaments and the transformation of the cytoskeleton in axons may provide insight 
into the aberrant neuronal changes of Alzheimer's disease. Brain Res Bull, 126(Pt 3), 
324-333. doi:10.1016/j.brainresbull.2016.07.012 
Vickers, J. C., Riederer, B. M., Marugg, R. A., Buee-Scherrer, V., Buee, L., Delacourte, A., & 
Morrison, J. H. (1994). Alterations in neurofilament protein immunoreactivity in 
human hippocampal neurons related to normal aging and Alzheimer's disease. 
Neuroscience, 62(1), 1-13.  
Vickers, J. C., Tan, A., & Dickson, T. C. (2003). Direct determination of the proportion of 
intra- and extra-cellular neocortical neurofibrillary tangles in Alzheimer’s disease. 




Waddington, C. H. (1942a). CANALIZATION OF DEVELOPMENT AND THE 
INHERITANCE OF ACQUIRED CHARACTERS. Nature, 150, 563. 
doi:10.1038/150563a0 
Waddington, C. H. (1942b). The Epigenotype. Endeavour, 1, 18-20.  
Wagner, M., Steinbacher, J., Kraus, T. F. J., Michalakis, S., Hackner, B., Pfaffeneder, T., . . . 
Carell, T. (2015). Age-Dependent Levels of 5-Methyl-, 5-Hydroxymethyl-, and 5-
Formylcytosine in Human and Mouse Brain Tissues. Angewandte Chemie International 
Edition, 54(42), 12511-12514. doi:10.1002/anie.201502722 
Walker, M., LaFerla, F., Oddo, S., & Brewer, G. (2013). Reversible epigenetic histone 
modifications and Bdnf expression in neurons with aging and from a mouse model of 
Alzheimer’s disease. AGE, 35(3), 519-531. doi:10.1007/s11357-011-9375-5 
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., . . . Selkoe, 
D. J. (2002). Naturally secreted oligomers of amyloid β protein potently inhibit 
hippocampal long-term potentiation in vivo. Nature, 416, 535. doi:10.1038/416535a 
Wang, C., JeBailey, L., & Ridgway, N. D. (2002). Oxysterol-binding-protein (OSBP)-related 
protein 4 binds 25-hydroxycholesterol and interacts with vimentin intermediate 
filaments. Biochem J, 361(Pt 3), 461-472.  
Wang, H. W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., . . . Trommer, 
B. L. (2002). Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation 
but not long-term depression in rat dentate gyrus. Brain Res, 924(2), 133-140.  
Wang, H. X., Wahlin, Å., Basun, H., Fastbom, J., Winblad, B., & Fratiglioni, L. (2001). 
Vitamin B&lt;sub&gt;12&lt;/sub&gt; and folate in relation to the development of 
Alzheimer’s disease. Neurology, 56(9), 1188.  
Wang, S.-C., Oelze, B., & Schumacher, A. (2008). Age-Specific Epigenetic Drift in Late-Onset 
Alzheimer's Disease. PLoS One, 3(7), e2698. doi:10.1371/journal.pone.0002698 
Wang, X., & Michaelis, E. K. (2010). Selective neuronal vulnerability to oxidative stress in the 
brain. Frontiers in aging neuroscience, 2, 12-12. doi:10.3389/fnagi.2010.00012 
Wang, X., Pal, R., Chen, X. W., Limpeanchob, N., Kumar, K. N., & Michaelis, E. K. (2005). 
High intrinsic oxidative stress may underlie selective vulnerability of the hippocampal 
CA1 region. Brain Res Mol Brain Res, 140(1-2), 120-126. 
doi:10.1016/j.molbrainres.2005.07.018 
Wang, Z., Zang, C., Cui, K., Schones, D. E., Barski, A., Peng, W., & Zhao, K. (2009). Genome-
wide mapping of HATs and HDACs reveals distinct functions in active and inactive 
genes. Cell, 138(5), 1019-1031. doi:10.1016/j.cell.2009.06.049 
Wang, Z., Zang, C., Rosenfeld, J. A., Schones, D. E., Barski, A., Cuddapah, S., . . . Zhao, K. 
(2008). Combinatorial patterns of histone acetylations and methylations in the human 
genome. Nat Genet, 40(7), 897-903. doi:10.1038/ng.154 
Ward, D. D., Andel, R., Saunders, N. L., Thow, M. E., Klekociuk, S. Z., Bindoff, A. D., & 
Vickers, J. C. (2017). The BDNF Val66Met polymorphism moderates the effect of 
cognitive reserve on 36-month cognitive change in healthy older adults. Alzheimer's & 
Dementia : Translational Research & Clinical Interventions, 3(3), 323-331. 
doi:10.1016/j.trci.2017.04.006 
Waterston, R. H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J. F., Agarwal, P., . . . Lander, 
E. S. (2002). Initial sequencing and comparative analysis of the mouse genome. Nature, 
420(6915), 520-562. doi:10.1038/nature01262 
Watson, C. T., Roussos, P., Garg, P., Ho, D. J., Azam, N., Katsel, P. L., . . . Sharp, A. J. (2016). 
Genome-wide DNA methylation profiling in the superior temporal gyrus reveals 




Watt, F., & Molloy, P. L. (1988). Cytosine methylation prevents binding to DNA of a HeLa 
cell transcription factor required for optimal expression of the adenovirus major late 
promoter. Genes Dev, 2(9), 1136-1143.  
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975). A protein factor 
essential for microtubule assembly. Proc Natl Acad Sci U S A, 72(5), 1858-1862.  
West, R., Lee, J., & Maroun, L. (1995). Hypomethylation of the amyloid precursor protein 
gene in the brain of an alzheimer’s disease patient. Journal of Molecular Neuroscience, 
6(2), 141-146. doi:10.1007/BF02736773 
Wezyk, M., & Zekanowski, C. (2018). Role of BRCA1 in Neuronal Death in Alzheimer's 
Disease. ACS Chem Neurosci, 9(5), 870-872. doi:10.1021/acschemneuro.8b00149 
Whitehouse, I., Flaus, A., Cairns, B. R., White, M. F., Workman, J. L., & Owen-Hughes, T. 
(1999). Nucleosome mobilization catalysed by the yeast SWI/SNF complex. Nature, 
400, 784. doi:10.1038/23506 
Whyte, Warren A., Orlando, David A., Hnisz, D., Abraham, Brian J., Lin, Charles Y., Kagey, 
Michael H., . . . Young, Richard A. (2013). Master Transcription Factors and Mediator 
Establish Super-Enhancers at Key Cell Identity Genes. Cell, 153(2), 307-319. 
doi:10.1016/j.cell.2013.03.035 
Widagdo, J., Zhao, Q.-Y., Kempen, M.-J., Tan, M. C., Ratnu, V. S., Wei, W., . . . Bredy, T. W. 
(2016). Experience-Dependent Accumulation of <em>N</em><sup>6</sup>-
Methyladenosine in the Prefrontal Cortex Is Associated with Memory Processes in 
Mice. The Journal of Neuroscience, 36(25), 6771-6777. doi:10.1523/jneurosci.4053-
15.2016 
Woodhouse, A., Vickers, J. C., Adlard, P. A., & Dickson, T. C. (2009). Dystrophic neurites in 
TgCRND8 and Tg2576 mice mimic human pathological brain aging. Neurobiol Aging, 
30(6), 864-874. doi:10.1016/j.neurobiolaging.2007.09.003 
Woodhouse, A., Vickers, J. C., Adlard, P. A., & Dickson, T. C. (2009). Dystrophic neurites in 
TgCRND8 and Tg2576 mice mimic human pathological brain aging. Neurobiol Aging, 
30(6), 864-874. doi:http://dx.doi.org/10.1016/j.neurobiolaging.2007.09.003 
Wysocka, J., Swigut, T., Xiao, H., Milne, T. A., Kwon, S. Y., Landry, J., . . . Allis, C. D. (2006). 
A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin 
remodelling. Nature, 442, 86. doi:10.1038/nature04815 
https://www.nature.com/articles/nature04815#supplementary-information 
Wyss-Coray, T. (2006). Inflammation in Alzheimer disease: driving force, bystander or 
beneficial response? Nature medicine, 12, 1005. doi:10.1038/nm1484 
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., . . . Husemann, J. 
(2003). Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med, 
9(4), 453-457. doi:10.1038/nm838 
Xu, T., Yu, X., Perlik, A. J., Tobin, W. F., Zweig, J. A., Tennant, K., . . . Zuo, Y. (2009). Rapid 
formation and selective stabilization of synapses for enduring motor memories. Nature, 
462, 915. doi:10.1038/nature08389 
https://www.nature.com/articles/nature08389#supplementary-information 
Xu, W. L., Atti, A. R., Gatz, M., Pedersen, N. L., Johansson, B., & Fratiglioni, L. (2011). 
Midlife overweight and obesity increase late-life dementia risk: a population-based 
twin study. Neurology, 76(18), 1568-1574. doi:10.1212/WNL.0b013e3182190d09 
Yanagisawa, M., Nakashima, K., Arakawa, H., Ikenaka, K., Yoshida, K., Kishimoto, T., . . . 
Taga, T. (2000). Astrocyte differentiation of fetal neuroepithelial cells by interleukin-
11 via activation of a common cytokine signal transducer, gp130, and a transcription 
factor, STAT3. J Neurochem, 74(4), 1498-1504.  
263 
 
Yankner, B. A. (2000). A century of cognitive decline. Nature, 404, 125. 
doi:10.1038/35004673 
Yaron, A., & Schuldiner, O. (2016). Common and Divergent Mechanisms in Developmental 
Neuronal Remodeling and Dying Back Neurodegeneration. Curr Biol, 26(13), R628-
R639. doi:10.1016/j.cub.2016.05.025 
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., . . . Lee, V. M. 
(2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy 
mouse model. Neuron, 53(3), 337-351. doi:10.1016/j.neuron.2007.01.010 
Yoshizawa, M., Sone, M., Matsuo, N., Nagase, T., Ohara, O., Nabeshima, Y.-i., & Hoshino, 
M. (2003). Dynamic and coordinated expression profile of dbl-family guanine 
nucleotide exchange factors in the developing mouse brain. Gene Expression Patterns, 
3(3), 375-381. doi:https://doi.org/10.1016/S1567-133X(03)00002-4 
Young, M. D., Willson, T. A., Wakefield, M. J., Trounson, E., Hilton, D. J., Blewitt, M. E., . . 
. Majewski, I. J. (2011). ChIP-seq analysis reveals distinct H3K27me3 profiles that 
correlate with transcriptional activity. Nucleic Acids Res, 39(17), 7415-7427. 
doi:10.1093/nar/gkr416 
Yu, M., Hon, G. C., Szulwach, K. E., Song, C. X., Zhang, L., Kim, A., . . . He, C. (2012). Base-
resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell, 
149(6), 1368-1380. doi:10.1016/j.cell.2012.04.027 
Zamanian, J. L., Xu, L., Foo, L. C., Nouri, N., Zhou, L., Giffard, R. G., & Barres, B. A. (2012). 
Genomic Analysis of Reactive Astrogliosis. J Neurosci, 32(18), 6391-6410. 
doi:10.1523/JNEUROSCI.6221-11.2012 
Zecevic, N., Bourgeois, J.-P., & Rakic, P. (1989). Changes in synaptic density in motor cortex 
of rhesus monkey during fetal and postnatal life. Developmental Brain Research, 50(1), 
11-32. doi:https://doi.org/10.1016/0165-3806(89)90124-7 
Zeisel, A., Muñoz-Manchado, A. B., Codeluppi, S., Lönnerberg, P., La Manno, G., Juréus, A., 
. . . Linnarsson, S. (2015). Cell types in the mouse cortex and hippocampus revealed by 
single-cell RNA-seq. Science, 347(6226), 1138-1142. doi:10.1126/science.aaa1934 
Zentner, G. E., & Henikoff, S. (2013). Regulation of nucleosome dynamics by histone 
modifications. Nature Structural &Amp; Molecular Biology, 20, 259. 
doi:10.1038/nsmb.2470 
Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., . . . Brunden, K. R. 
(2012). The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal 
Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an 
Interventional Study with Aged Tau Transgenic Mice. The Journal of Neuroscience, 
32(11), 3601.  
Zhang, Y., Iratni, R., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (1997). Histone 
Deacetylases and SAP18, a Novel Polypeptide, Are Components of a Human Sin3 
Complex. Cell, 89(3), 357-364. doi:https://doi.org/10.1016/S0092-8674(00)80216-0 
Zhang, Y., Li, P., Feng, J., & Wu, M. (2016). Dysfunction of NMDA receptors in Alzheimer's 
disease. Neurological sciences : official journal of the Italian Neurological Society and 
of the Italian Society of Clinical Neurophysiology, 37(7), 1039-1047. 
doi:10.1007/s10072-016-2546-5 
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., . . . Liu, X. S. 
(2008). Model-based Analysis of ChIP-Seq (MACS). Genome Biol, 9(9), R137-R137. 
doi:10.1186/gb-2008-9-9-r137 
Zhao, J., Zhu, Y., Yang, J., Li, L., Wu, H., De Jager, P. L., . . . Bennett, D. A. (2017). A genome-
wide profiling of brain DNA hydroxymethylation in Alzheimer's disease. Alzheimers 
Dement, 13(6), 674-688. doi:10.1016/j.jalz.2016.10.004 
264 
 
Zhao, Q., Zhang, J., Chen, R., Wang, L., Li, B., Cheng, H., . . . Wong, J. (2016). Dissecting the 
precise role of H3K9 methylation in crosstalk with DNA maintenance methylation in 
mammals. Nature Communications, 7, 12464. doi:10.1038/ncomms12464 
https://www.nature.com/articles/ncomms12464#supplementary-information 
Zhou, Y., & Grummt, I. (2005). The PHD finger/bromodomain of NoRC interacts with 
acetylated histone H4K16 and is sufficient for rDNA silencing. Curr Biol, 15(15), 
1434-1438. doi:10.1016/j.cub.2005.06.057 
Ziller, M. J., Gu, H., Müller, F., Donaghey, J., Tsai, L. T.-Y., Kohlbacher, O., . . . Bernstein, 
B. E. (2013). Charting a dynamic DNA methylation landscape of the human genome. 
Nature, 500(7463), 477-481.  
Ziller, M. J., Gu, H., Muller, F., Donaghey, J., Tsai, L. T., Kohlbacher, O., . . . Meissner, A. 
(2013). Charting a dynamic DNA methylation landscape of the human genome. Nature, 





Appendix 1  
General solutions 
Stock solutions 
90.0g sodium chloride (NaCl) (BDH, USA) was dissolved in 1L milliQ water 
28.0g di-sodium hydrogen orthophosphate (Na2HPO) (BDH, USA) was dissolved in 
1L milliQ water 
31.2g sodium di-hydrogen orthophosphate (NaH2PO4.2H2O) (Ajax, Australia) was 
dissolved in 1L milliQ water. 
Stock solutions were prepared by dissolving reagents in one litre of milliQ water using 
a magnetic stirrer. All stock solutions were stored at RT. 
 
0.01 M Phosphate buffered saline (PBS): 
10mL NaH2PO4.2H2O stock solution  
40mL Na2HPO stock solution  
100mL NaCl stock solution  
850mL milliQ water  
0.01M PBS solution was mixed briefly then stored at RT.  
 
For molecular and flow cytometry-based experiments, fresh 0.01M PBS was sterilised 












600μL Triton-X-100 (0.3%) (Sigma-Aldrich, Missouri, USA) was dissolved in 
199.4mL 0.01M PBS. 
Solutions were dissolved together with a magnetic stirrer then stored at 4oC.  
 
0.01M Citrate Buffer 
2.94g trisodium citrate (Sigma-Aldrich, Missouri, USA) was dissolved in 800mL 
MilliQ water  
Solutions were dissolved and adjusted to pH 6 with 0.1M citric acid, then made up to 
1L with MilliQ water. 
 
18.0% Sucrose Solution 
180g sucrose (Sigma-Aldrich, Missouri, USA) was dissolved in 1L 0.01M PBS-0.01% 
Sodium azide (Sigma) 
18% sucrose solution was stored at 4oC. 
 
30.0% Sucrose Solution 
300g sucrose (Sigma-Aldrich, Missouri, USA) was dissolved in 1L 0.01M PBS with 
0.01% Sodium azide (Sigma-Aldrich, Missouri, USA)  
30% sucrose solution was stored at 4oC. 
 
Tissue Storage Solution 
0.1% sodium azide (Sigma-Aldrich, Missouri, USA)  
500mL 0.01M PBS 
0.5g sodium azide was dissolved in 500mL 0.01M PBS 
Tissue storage solution was stored at 4oC 
 
4% paraformaldehyde (PFA) 
40g granulated paraformaldehyde (PFA) 
500mL MilliQ® water 
400mL 28.0g/L Na2HPO 
100mL 31.2g/L NaH2PO4.2H2O 
267 
 
1.0M NaOH & 1.0M HCl to pH 
MilliQ water was heated to 80oC, then granulated PFA was added with 5 drops of 
NaOH with heat until dissolved. NaH2PO4.H2O and Na2HPO was added then filtered 
and pH to 7.4. Stored at -20oC 
 
Nuclei extraction solutions 
All stock solutions are kept at 4oC unless otherwise stated. 
Stock solutions 
1M glycine 25mL  
1.8765g glycine (Sigma-Aldrich, Missouri, USA) was dissolved in 25mL MilliQ water. 
 
0.5M EDTA pH8 10mL 
1.461g EDTA (Sigma-Aldrich, Missouri, USA) was dissolved in 8mL MilliQ water, 
then pH adjusted to 8.0 with sodium hydroxide then made up to 10mL with MilliQ 
water. 
 
100mM Mg(Ac).4H2O 10mL 
0.2145g Mg(Ac).4H2O (Sigma-Aldrich, Missouri, USA) was dissolved in 10mL MilliQ 
water. 
 
1M Tris-HCl pH8 10mL 
1.576g Tris HCl (Sigma-Aldrich, Missouri, USA) was dissolved in 8mL MilliQ water, 
then pH adjusted to 8.0 with sodium hydroxide and made to 10mL with MilliQ water. 
 
100mM PMSF 10mL 
0.1742g PMSF (Sigma-Aldrich, Missouri, USA) was dissolved in 10mL 2-Propanol, 





1000μL Triton-X100 (Sigma-Aldrich, Missouri, USA) was dissolved in 10mL MilliQ 
water. 
1M CaCl2 10mL 
1.1098g CaCl2 (Sigma-Aldrich, Missouri, USA) was dissolved in 10mL MilliQ water. 
 
Nuclei Extraction Buffer (NEB): 
Nuclei extraction buffer was made fresh for each experiment performed. Approximately 5mL 
was required per sample, however a minimum 10mL was made up to ensure accuracy of 
measurements. 
Appendix table 1: Nuclei extraction buffer solution 
Total 10mL volume Final conc 
Sucrose 1.095g 0.32M 
1M CaCl 50uL 5mM 
100mM Mg(Ac).4H2O 300uL 3mM 
0.5M EDTA pH8 2uL 0.1mM 
1M Tris-HCl pH8 100uL 10mM 
Roche mini protease inhibitor 1 tablet per 10mL 
 
100mM PMSF 10uL 0.1mM 
Trion-X100 (if Immunostaining) 100uL 0.10% 









Chromatin Immunoprecipitation buffers 
Stock solutions were made up and stored at room temperature apart from Low Salt, High Salt 
LiCl and TE buffers.  
Appendix table 2: Chromatin immunoprecipitation buffers 
Stock Solutions 
Final Concentration 





0.5M EDTA, pH8.0   1.2mM 2mM 2mM 1mM 1mM 10mM - 
10% SDS 0.01% 0.1% 0.1% - - 1% 1% 
10% Triton-X-100  1% 1% 1% - - - - 
1M Tris-HCl pH8.1   16.7mM 20mM 20mM 10mM 10mM 50mM - 
5M NaCl  167mM 150mM 500mM - - - - 
5M LiCl - - - 250mM - - - 
10% IgePal  - - - 1% - - - 
10% Sodium 
Deoxycholate  
- - - 1% - - - 
1M Sodium 
bicarbonate1 
- - - - - - 100mM 
 
Stock Solutions 

















0.5M EDTA, pH8.0   120µl 200µl 200µl 100µl 100µl 200µl - 
10% SDS 50µl 500µl 500µl - - 1000µl 300µl 
10% Triton-X-100  5000µl 5000µl 5000µl - - - - 
1M Tris-HCl pH8.1   835µl 1000µl 1000µl 500µl 500µl 500µl - 
5M NaCl  1670µl 1500µl 5000µl - - - - 
5M LiCl - - - 2500µl - - - 








- -  - - 300µl 
dH2O 41907.5µl 41800µl 38300µl 36900µl 49400µl 8300µl 2400µl 
1To be made fresh each time  
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Appendix 2: Supplementary Figure 1: Polyclonal 5hmC antibody versus mouse 
monoclonal 5hmC antibody labelling 
Representative flattened image stacks of rabbit polyclonal 5hmC (A), and mouse monoclonal 
5hmC (B), demonstrating analogous extranuclear immunoreactivity (C) in human post-mortem 





Appendix 2: Supplementary Figure 2: Correlations detected between cell-type specific 
DNA methylation data and PMI or Age 
Scatter plot of the percentage NF-positive pyramidal neurons with nuclear 5mC in layer 2/3 
versus PMI (A). Scatter plot of the percentage NF-positive pyramidal neurons with 
extranuclear 5mC in layer 2/3 versus PMI (B). Scatter plot of the percentage microglia with 
nuclear 5hmC in layer 2/3 versus Age (C). Filled circles represent control cases, open circles 
represent Early-AD cases, and filled triangles represent Late-AD cases. Lines represent linear 
regression of plot.   
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Appendix 2: Supplementary Figure 3: Dysregulation of H3K27ac marking at enhancers 
and super-enhancers in APP/PS1 neurons 
(a-c) Heatmaps for H3K27ac signal at enhancers sorted by strongest (blue) to weakest (red) 
signal in WT (left) and APP/PS1 (right) at (a) 3 months, (b) 6 months and (c) 12 months of 
age. (d-f) Heatmaps for the Super-Enhancer Database (dbSUPER) track were sorted by 
strongest (blue) to weakest (red) signal in WT (left) and APP/PS1 (right) mice at (d) 3 months, 
(e) 6 months and (f) 12 months of age. 
 
